ERIC J. TOPOL, M.D. - Scripps Translational Science Institute
ERIC J. TOPOL, M.D. - Scripps Translational Science Institute
ERIC J. TOPOL, M.D. - Scripps Translational Science Institute
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Bibliography | Eric J. Topol, M.D. | June 2011<br />
<strong>ERIC</strong> J. <strong>TOPOL</strong>, M.D.<br />
BIBLIOGRAPHY<br />
Original Publications in Scientific Journals<br />
1. Moss AJ, Glaser W, Topol EJ: Atrial tachypacing in the treatment of a patient with primary orthostatic<br />
hypotension. New England Journal of Medicine 302:1456-1457, 1980. [PMID 7374710]<br />
2. Topol EJ, Brodows RD: Effect of indomethacin on acute insulin release in man. Diabetes 29:379-383,<br />
1980. [PMID 6769727]<br />
3. Topol EJ, Goldschlager N, Ports T, DiCarlo L, Schiller N, Botvinick E, Chatterjee K: Hemodynamic<br />
benefit of atrial pacing in right ventricular myocardial infarction. Annals of Internal Medicine 96:594-597,<br />
1982. [PMID 7073152]<br />
4. Topol EJ, Lerman BB: Hypomagnesemic torsade de pointes. American Journal of Cardiology 52:1367-<br />
1368, 1983. [PMID 6650429]<br />
5. Lerman BB, Topol EJ, Platia EV, Baughman KL: Orthostatic atrial tachy-cardia: Autonomic influence on<br />
atrial pacemakers. American Journal of Cardiology 54:1406-1408, 1984. [PMID 6711447]<br />
6. Topol EJ, Fortuin NJ: Cardiac tumors and carcinoid heart disease. American -Journal of Medicine<br />
77:950-952, 1984. [PMID 6496552]<br />
7. Topol EJ, Weiss JL, Guzman PA, Dorsey Lima S, Blanck TJJ, Humphrey LJ, Baumgartner WA, Flaherty<br />
JT, Reitz BA: Immediate improvement of dysfunc-tional myocardial segments after coronary revascularization:<br />
detection by intraoperative transesophageal echocardi-ography. Journal of American College of<br />
Cardiology 4:1123-1134, 1984. [PMID 6334108]<br />
8. Collen D, Topol EJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML, Sobel BE, Leinbach RC, Brinker JA,<br />
Ludbrook PA, Yasuda T, Bulkley BH, Robinson AK, Hutter AM, Bell WR, Spadaro JJ, Khaw BA,<br />
Grossbard EB: Coronary thrombo-lysis with -recombinant human tissue type plasminogen activator: a<br />
prospective, randomized, placebo-controlled trial. Circulation 70: 1012-1017, 1984. [PMID 6388898]<br />
9. Topol EJ, Traill TA, Fortuin NJ: Hypertensive hypertrophic cardio-myopathy of the elderly. New England<br />
Journal of Medicine 312:277-283, 1985. [PMID 2857050]<br />
10. Topol EJ, Ciuffo AA, Pearson TA, Dillman JJ, Builder S, Grossbard E, Weisfeldt ML, Bulkley BH:<br />
Thrombolysis with recombinant tissue plasminogen activator in atheroscle-rotic, thrombotic occlusion.<br />
Journal of American College of Cardiology 5:85-91, 1985. [PMID 4038373]<br />
11. Topol EJ, Biern R, Reitz B: Cardiac papillary fibroelastoma and stroke: Echo-cardio-graphic diagnosis<br />
and guide to excision. American Journal of Medicine 80:129-132, 1986. [PMID 3942145]<br />
12. Topol EJ, Humphrey LS, Borkon MA, Baumgartner WA, Reitz BA, Weiss JL: Value of intraoperative left<br />
ventricular microbubbles detected by transesophageal two dimensional echocardiography in predicting<br />
neurologic outcome after cardiac operations. American Journal of Cardiology 56:773-775, 1985. [PMID<br />
4061300]<br />
13. Topol EJ, Weiss JL, Brinker JA, Bulkley BH, Brin KP, Gottlieb SO, Gerstenblith G, Guerci AD, Flaherty<br />
JF, Chandra N, Ouyang P, Gottlieb SH, Becker LB, Weisfeldt ML, Shapiro EP: Regional wall motion<br />
improvement after coronary thrombolysis with recombinant tissue plasminogen activator: importance of<br />
coronary angioplasty. Journal of American College of Cardiology 6:426-433, 1985. [PMID 3160757]<br />
14. Topol EJ, Eha J, Brin KP, Shapiro EP, Weiss JL, Riegel MB, Gottlieb SO, Brinker JB: Applicability of<br />
percutaneous trans-luminal coronary angioplasty to patients with recombinant tissue plasminogen activator<br />
mediated thrombo-lysis. Catheterization and Cardiovascular Diagnosis 11:337-348, 1985. [PMID<br />
2931176]<br />
15. Topol EJ, Myler RK, Stertzer SH: Selection of dilatation hardware for PTCA –1985. Catheterization<br />
and Cardiovascular Diagnosis 11:629-637, 1985. [PMID 2936462]<br />
Page 1
16. Topol EJ, Lerman BB, Baughman KL, Platia EV, Griffith LSC: De novo refrac-tory ventricular<br />
tachyarrhythmias after coronary revascu-larization. American Journal of Cardiology 57:57-59, 1986.<br />
[PMID 3484603]<br />
17. Topol EJ, Bell WR, Weisfeldt ML: Coronary thrombolysis with recombinant tissue-type plasminogen<br />
activator: A hematologic and pharmacologic study. -Annals of Internal Medicine 103:837-843, 1985.<br />
[PMID 3933395]<br />
18. Topol EJ, Fung AY, Kline E, Kaplan L, Landis D, Strozeski M, Burney RE, Pitt B, O’Neill WW: Safety of<br />
helicopter transport and out of--hospital intra-venous fibrinolytic therapy in patients with evolving<br />
myocardial infarc-tion. Catheterization and Cardio-vascular Diagnosis 13:151-155, 1986. [PMID<br />
3089627]<br />
19. Topol EJ, Herskowitz A, Hutchins G: Massive hemorrhagic myo-cardial infarction after coronary<br />
thrombolysis. American Journal of Medicine 81:339-343, 1986. [PMID 3090880]<br />
20. Fung AY, Lai P, Topol EJ, Bates ER, Bourdillon PDV, Walton JA Jr, Mancini GBJ, Kryski T, Pitt B, O’Neill<br />
WW: Value of percutaneous transluminal coronary angio-plasty after unsuccessful intravenous<br />
streptokinase therapy in acute myocardial infarction. American Journal of- -Cardiology 58:686-691, 1986.<br />
[PMID 2945418]<br />
21. Wind BE, Snider RA, Buda AJ, O’Neill WW, Topol EJ, Dilworth LR: Pulsed doppler assessment of left<br />
ventricular diastolic filling in coronary artery disease -before and immediately after coronary angioplasty.<br />
American Journal of Cardiology 59:1041-1046, 1987. [PMID 2953227]<br />
22. Myler RK, Topol EJ, Shaw RE, Stertzer SH, Clark DA, Fishman-Rosen J, Murphy MC: Multiple vessel<br />
coronary angioplasty: classifica-tion, results and patterns of restenosis in 494 consecutive patients.<br />
Catheterization and Cardiovascular Diagnosis 13:1-15, 1987. [PMID 2949849]<br />
23. Topol EJ, Morris D, Smalling R, Schumacher R, Taylor CR, Nishikawa A, Liberman HA, Collen D, Tufte<br />
ME, Grossbard E, O’Neill WW: A multicenter, randomized, placebo controlled trial of a new form of<br />
intravenous recombi-nant tissue type plasmino-gen activator (Activase) in acute myocardial<br />
24.<br />
infarction. Journal of American College of Cardiology 9:1205-1213, 1987. [PMID 2953770]<br />
Kircher BE, Topol EJ, O’Neill WW, Pitt B: Prediction of coronary artery recanalization after intra-venous<br />
thrombolytic therapy. American Journal of Cardiology 59:513-515, 1987. [PMID 3825886]<br />
25. Topol EJ, O’Neill WW, Langburd AB, Walton JA, Bourdillon PVD, Bates ER, Grines CL, Schork MA, Kline<br />
E, Pitt B: A randomized, placebo-controlled trial of intra-venous recombinant tissue type plasminogen<br />
activator and emergency coronary angioplasty in patients with acute myocardial infarction. Circulation<br />
75:420-428, 1987. [PMID 2948735]<br />
26. Walsh DG, Kaplan LR, Burney RE, Topol EJ, O’Neill WW: Use of tissue plas-minogen activator in the<br />
emergency department for acute myocardial infarction. Annals of Emergency Medicine 16:243-247, 1987.<br />
[PMID 2949679]<br />
27. Topol EJ, Ellis S, Fishman-Rosen J, Leimgruber P, Myler RK, Stertzer SH, O’Neill WW, Douglas JS,<br />
Roubin G, King SE: Multi-center study of percu-taneous trans-luminal angioplasty for right coronary<br />
artery ostial stenosis. Journal of American College of Cardiology 9:1214-1218, 1987. [PMID 2953771]<br />
28. O’Neill WW, Topol EJ, Fung AY, Bourdillon PDV, Nicklas JM, Walton JA, Bates ER, Pitt B: Coronary<br />
angioplasty as therapy for acute myocardial infarc-tion: University of Michigan experience. Circulation<br />
76(Suppl II):II-79-87, 1987. [PMID 2955959]<br />
29. Pitt B, Topol EJ, O’Neill WW: Role of percutaneous transluminal coronary angioplasty in acute<br />
myocardial infarction. American Journal of Cardiology 60:185-187, 1987. [PMID 2955691]<br />
30. Bates ER, Topol EJ, Kline EM, Langburd AB, Fung AY, Walton JA Jr, Bourdillon PDV, Vogel RA, Pitt B,<br />
O’Neill WW: Early reperfusion therapy improves left -ventricular function after acute inferior myocardial<br />
infarction associated with right coronary artery disease. American Heart Journal 114:261-267, 1987.<br />
[PMID 2955688]<br />
31. Sanz ML, Mancini J, LeFree MT, Mickelson JK, Starling MR, Vogel RA, Topol EJ: Variability of<br />
quantitative digital subtraction coronary angiography before and -after percutaneous transluminal<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 2
coronary angioplasty. American Journal of Cardiology 60:55-60, 1987. [PMID 2955693]<br />
32. Topol EJ: Acute intervention for myocardial infarction. Chest 92:929-932, 1987. [PMID 2959455]<br />
33. Topol EJ, Califf RM, Kereiakes DJ, George BS: Thrombolysis and Angio-plasty in Myo-cardial Infarction<br />
(TAMI) trial. Journal of the American College of Cardiology 10:65B-74B, 1987. [PMID 2959716]<br />
34. Topol EJ: Clinical use of streptokinase and urokinase therapy for acute myocardial infarction. Heart and<br />
Lung 16:760-774, 1987. [PMID 3316129]<br />
35. Papadopoulos SM, Chandler WF, Salamat MS, Topol EJ, Sackellares JC: Recom-binant human tissuetype<br />
plasminogen activator therapy in acute thrombotic stroke. Journal of Neurosurgery 67:394-398,<br />
1987. [PMID 3112328]<br />
36. Topol EJ, Califf RM, George BS, Kereiakes DJ, Abbottsmith CW, Candela RJ, Lee KL, Pitt B, Stack RS,<br />
O’Neill WW and the Thrombo-lysis and Angioplasty in Myocardial Infarction (TAMI) Study Group: A<br />
random-ized trial of immediate -versus delayed elective angio-plasty after intravenous tissue<br />
plasminogen activator in acute myo-cardial infarction. New England Journal of Medicine 317:581-588,<br />
1987. [PMID 2956516]<br />
37. Topol EJ, Juni JE, O’Neill WW, Nicklas JM, Shea MJ, Burek K, Pitt B: Exercise testing three days after<br />
onset of acute myocardial infarc-tion. American Journal of Cardiology 60:958-962, 1987. [PMID<br />
2960230]<br />
38. Topol EJ, Bates ER, Walton JA Jr, Baumann G, Wolfe S, Maino J, Bayer L, Gorman L, Kline EM, O’Neill<br />
WW: Community hospital administration of intra-venous tissue plasminogen acti-vator in acute<br />
myocardial infarction: improved -timing, thrombo-lytic efficacy and ventricular function. Journal of the<br />
American College of Cardiology 10:1173-1177, 1987. [PMID 3119685]<br />
39. Topol EJ: Advances in thrombolytic therapy for acute myocardial infarction. Journal of Clinical<br />
Pharmacology 27:735-745, 1987. [PMID 3123526]<br />
40. Guerci AD, Gerstenblith G, Brinker JA, Chandra NC, Gottlieb SO, Bahr RD, Weiss JL, Shapiro EP,<br />
Flaherty JT, Bush DE, Chew PH, Gottlieb SH, Halperin HR, Ouyang P, Walford GD, Bell WR, Fatterpaker<br />
AK, Llewellyn M, Topol EJ, Healy B, Siu C, Becker LC, Weisfeldt ML: A randomized trial of intravenous<br />
tissue plasminogen activator for acute myocardial infarction with subsequent randomi-zation to elective<br />
coronary angioplasty. New England Journal of Medicine 317:1613-1617, 1987. [PMID 2960897]<br />
41. Topol EJ, George BS, Kereiakes DJ, Candela RJ, Abbottsmith CW, Stump DC, Boswick J, O’Neill WW,<br />
Stack RS, Califf RM, and the TAMI Study Group: Comparison of two dose regimens of intra-venous<br />
tissue plasminogen activator for acute myocardial infarction. American Journal of Cardiology 61:723-728,<br />
1988. [PMID 2965504]<br />
42. Grines CL, Topol EJ, Bates ER, Juni JE, O’Neill WW: Infarct vessel status after intravenous tissue<br />
plasminogen activator and acute coronary angio-plasty: Prediction of clinical outcome. American Heart<br />
Journal 115:1-7, 1988. [PMID 2962478]<br />
43. O’Neill WW, Topol EJ, Pitt B: Reperfusion therapy of acute myocardial infarction. Progress in<br />
Cardiovascular Diseases 30:235-266, 1988. [PMID 3275989]<br />
44. Humphrey LS, Topol EJ, Rosenfeld GI, Borkon AM, Baumgartner WA, Gardner TJ, Maruschak G, Weiss<br />
JL: Immediate enhancement of left ventricular relaxation by coronary artery bypass grafting:<br />
intraoperative assessment. Circulation 77:886-896, 1988. [PMID 3258195]<br />
45. Topol EJ, Burek K, O’Neill WW, Kewman DG, Kander NH, Shea MJ, Schork A, Kirscht J, Juni JE, Pitt B:<br />
A randomized controlled trial of hospital discharge three days after myocardial infarction in the era of<br />
reperfusion. New England Journal of Medicine 318:1083-1088, 1988. [PMID 3281014]<br />
46. Kereiakes DJ, Topol EJ, George BS, Abbottsmith CW, Stack RS, Candela RJ, O’Neill WW, Martin LH,<br />
Califf RM, and the TAMI Study Group: Emergency coronary artery bypass surgery preserves global and<br />
regional left ventricular function after intravenous tissue plasminogen activator therapy for acute<br />
myocardial infarction. Journal of the American College of Cardiology 11:899-907, 1988. [PMID 2965716]<br />
47. Califf RM, Topol EJ, George BS, Boswick J, Lee KL, Stump D, Dillon J, Abbottsmith C, Candela R,<br />
Kereiakes D, O’Neill W, Stack RS, and the TAMI Study Group: Characteris-tics and outcome of patients<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 3
in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis<br />
and Angioplasty in Myocardial Infarction (TAMI) I trial. Circulation 77:1090-1099, 1988. [PMID 2966016]<br />
48. Topol EJ, Califf RM, George BS, Kereiakes DJ, Rothbaum D, Candela RJ, Abbottsmith CW, Pinkerton<br />
CA, Stump DC, Collen D, Lee KL, Pitt B, Kline EM, Boswick J, O’Neill WW, Stack RS, and the TAMI<br />
Study Group: Coronary arterial thrombolysis with combined infusion of recombinant tissue-type<br />
plasminogen -activator and urokinase in patients with acute myocardial infarction. Circulation 77:1100-<br />
1107, 1988. [PMID 2966017]<br />
49. Califf RM, O’Neill W, Stack RS, Aronson L, Mark DB, Mantell S, George BS, Candela RJ, Kereiakes DJ,<br />
Abbottsmith C, Topol EJ and the TAMI Study Group: Failure of simple clinical measurements to predict<br />
perfusion status after intravenous thrombo-lysis. Annals of Internal Medicine 108:658-662, 1988. [PMID<br />
3128953]<br />
50. Topol EJ, Nicklas JM, Kander N, Walton JA, Ellis SG, Gorman L, Pitt B: Coronary revasculariza-tion after<br />
intravenous tissue plasmino-gen activator for unstable angina pectoris: results of a randomized, doubleblind,<br />
placebo-controlled trial. American Journal of Cardiology 62:368-371, 1988. [PMID 2970776]<br />
51. Stump DC, Topol EJ, Chen AB, Hopkins A, Collen D: Monitoring of hemostasis parameters during<br />
coronary thrombolysis with recombi-nant tissue-type plasminogen activator. Thrombosis and<br />
Haemostasis 59:133-137, 1988. [PMID 2455358]<br />
52. Topol EJ: The long-term investment of coronary angioplasty for acute myocardial infarction. Journal of<br />
the American College of Cardiology 11:1150-1152, 1988. [PMID 2966835]<br />
53. Grines CL, O’Neill WW, Anselmo EG, Juni JE, Topol EJ: Compari-son of left -ventricular function and<br />
contractile reserve after successful recanalization by thrombolysis versus rescue percutaneous<br />
transluminal coronary angioplasty for acute myocardial infarction. American Journal of Cardiology<br />
62:352-357, 1988. [PMID 2970774]<br />
54. Topol EJ: An overview of the Thrombolysis and Angioplasty in acute Myo-cardial Infarction (TAMI) trials.<br />
Archives des Maladies du Coeur et des Vaisseaux 81(Suppl I):45-49, 1988. [PMID 2973302]<br />
55. Carlson SE, Aldrich MS, Greenberg HS, Topol EJ: Intracerebral hemorrhage complicat-ing intravenous<br />
tissue plasminogen activator treatment. Archives of -Neurology 45:1070-1073, 1988. [PMID 3140769]<br />
56. Ellis SG, Topol EJ, Gallison L, Grines CL, Langburd AB, Bates ER, Walton JA Jr, O’Neill WW: Predictors<br />
of success for coronary angioplasty performed for acute myocardial infarction. Journal of the American<br />
College of Cardiology 12:1407-1415, 1988. [PMID 2973481]<br />
57. Califf RM, Topol EJ, Stump D, George BS, Boswick JM, Abbottsmith C, Candela R, Kereiakes D, O’Neill<br />
W, Stack RS and the TAMI Study Group: Hemorrhagic complica-tions associated with the use of<br />
intravenous tissue plasminogen activator in treatment of acute myocardial infarction. American Journal of<br />
Medicine 85:353-359, 1988. [PMID 3137818]<br />
58. Werns SW, Topol EJ: Review of hardware for PTCA. Journal of Interventional Cardiology 1:209-219,<br />
1988.<br />
59. Topol EJ, Califf RM, George BS, Kereiakes DJ, Lee KL, for the TAMI Study Group: Insights derived from<br />
the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trials. Journal of the American College<br />
of Cardiology 12(Suppl A):24A-31A, 1988. [PMID 2973486]<br />
60. Steinberg EP, Topol EJ, Sakin JW, Kahane SN, Appel LJ, Powe, Anderson GF, Erickson JE, Guerci AD:<br />
Cost and procedure implica-tions of thrombo-lytic treatment for acute myocardial infarction. Journal of<br />
the American College of Cardiology 12(Suppl A):58A-68A, 1988. [PMID 3057037]<br />
61. Langburd AB, Topol EJ, Sereika SM, Bates ER, Walton JA Jr, Schork MA, Pitt B, O’Neill WW:<br />
Determinants of left ventricular functional recovery after thrombolytic therapy and/or immediate coronary<br />
angioplasty in acute myocardial infarction. Journal of Interven-tional Cardiology 2:167-174, 1988.<br />
62. Bates ER, O’Neill WW, Topol EJ: Percutaneous atherectomy catheters. Cardiology Clinics 6:373-382,<br />
1988. [PMID 3073007]<br />
63. Topol EJ: Coronary angioplasty for acute myocardial infarction. Annals of Internal Medicine 109:970-<br />
980, 1988. [PMID 2973762]<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 4
64. Bates ER, Califf RM, Stack RS, Aronson L, George BS, Candela RJ, Kereiakes DJ, Abbottsmith CW,<br />
Anderson L, Pitt B, O’Neill WW, Topol EJ, and the Thrombolysis and Angioplasty in Myocardial Infarction<br />
Study Group: Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) Trial: Influence of infarct<br />
location on arterial patency, left ventricular func-tion, and mortality after intravenous tissue plasminogen<br />
activator. Journal of the American College of Cardiology 13:12-18, 1989. [PMID 2521226]<br />
65. Topol EJ: Emerging strategies for failed percutaneous transluminal coronary angioplasty. American<br />
Journal of Cardiology 63:249-250, 1989. [PMID 2521274]<br />
66. Topol EJ, George BS, Kereiakes DJ, Stump DC, Candela RJ, Abbottsmith CW, Aronson L, Pickel A,<br />
Boswick JM, Lee KL, Ellis SG, Califf RM and the TAMI Study Group: A randomized controlled trial of<br />
intra-venous tissue plasminogen -activator and early intravenous heparin in acute myo-cardial infarction.<br />
Circulation 79:281-286, 1989. [PMID 2492454]<br />
67. Ellis SG, Gallison L, Grines CL, Langburd AB, Bates ER, Walton JA Jr., O’Neill WW, Topol EJ: Incidence<br />
and predictors of early recurrent ischemia after successful -percutaneous transluminal coronary<br />
angioplasty for acute myocardial infarction. American Journal of Cardiology 63:263-268, 1989. [PMID<br />
2521536]<br />
68. Nicklas JM, Topol EJ, Kander N, O’Neill WW, Walton JA, Ellis S, Gorman L, Pitt B: Randomized,<br />
double-blind, placebo-controlled trial of tissue plasminogen activator in unstable angina. Journal of the<br />
American College of Cardiology 13:434-441, 1989. [PMID 2492325]<br />
69. Holland K, O’Neill WW, Bates ER, Pitt B, Topol EJ: Emergency percutaneous transluminal coronary<br />
angio-plasty during acute myocardial infarction for patients more than 70 years of age. American Journal<br />
of Cardiology 63:399-403, 1989. [PMID 2521765]<br />
70. Loscalzo J, Wharton TP, Kirshenbaum JM, Levine HJ, Flaherty JT, Topol EJ, Ramaswamy K, Kosowsky<br />
BD, Salem DN, Ganz P, Brinker JA, Gurewich V, Muller JE, and the Pro-urokinase for Myocardial<br />
Infarction Study Group: Clot-selective coronary thrombolysis with pro-urokinase. Circula-tion 79:776-<br />
782, 1989. [PMID 2494004]<br />
71. Ellis SG, O’Neill WW, Bates ER, Walton JA, Nabel EG, Topol EJ: Coronary angioplasty as primary<br />
therapy for acute myocardial infarction 6 to 48 hours after symptom onset: Report of an initial<br />
experience. Journal of the American College of Cardiology 13:1122-1126, 1989. [PMID 2522467]<br />
72. Bates ER, Topol EJ: Thrombolytic therapy for acute myocardial infarction. Chest 95:257S-264S, 1989.<br />
[PMID 2523296]<br />
73. Ellis SG, Shaw R, Gershony G, Thomas R, Roubin GS, Douglas JS, Topol EJ, Stertzer SH, Myler RK,<br />
King SB: Risk factors, time course, and treatment effect for restenosis after successful percutaneous<br />
transluminal coronary angioplasty of chronic total occlusion. American Journal of Cardiology 63:897-901,<br />
1989. [PMID 2522727]<br />
74. Ellis SG, Topol EJ: Intracoronary stents: will they fulfill their promise as an -adjunct to angioplasty?<br />
Journal of the American College of Cardiology 13:1425-1430, 1989. [PMID 2522960]<br />
75. Ellis SG, O’Neill WW, Bates EB, Walton JA, Nabel EG, Werns SW, Topol EJ: Implica-tions for patient<br />
triage from survival and left ventricular functional recovery analyses in 500 patients treated with coronary<br />
angioplasty for acute myocardial infarction. Journal of the American College of Cardiology 13:1251-1259,<br />
1989. [PMID 2522954]<br />
76. Topol EJ, Califf RM: Tissue plasminogen activator: Why the backlash? Journal of the American College<br />
of Cardiology 13:1477-1480, 1989. [PMID 2498415]<br />
77. Muller D, Ellis SG, Topol EJ: Atherectomy of the left main coronary artery with percutaneous<br />
cardiopulmonary bypass support. American Journal of Cardiology 64:114-116, 1989. [PMID 2787097]<br />
78. Bates ER, Topol EJ: Early hospital discharge in the myocardial reperfusion era. Clinical Cardiology<br />
12:65-70, 1989. [PMID 2691143]<br />
79. Kereiakes DJ, Topol EJ, Califf RM, George BS, Abbottsmith CW, Stack RS, -Candela RJ, Anderson LC<br />
and the TAMI Study Group: Favorable early and long term prognosis following coronary bypass surgery<br />
therapy for myocardial infarction: results of a multicenter trial. American Heart Journal 118:199-207,<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 5
1989. [PMID 2526573]<br />
80. Kander NH, O’Neill W, Topol EJ, Gallison L, Mileski R, Ellis SG: Long term -follow-up of patients treated<br />
with coronary angioplasty for acute myocardial infarction. American Heart Journal 118:228-233, 1989.<br />
[PMID 2526574]<br />
81. Grines CL, Topol EJ, Califf RM, Stack RS, George BS, Kereiakes D, Boswick JM, O’Neill WW and the<br />
TAMI Study Group: Prognostic implications and predictors of enhanced regional wall motion of the<br />
noninfarct zone after thrombolysis and angioplasty therapy of acute myocardial infarction. Circulation<br />
80:245-253, 1989. [PMID 2526697]<br />
82. Stump DC, Califf RM, Topol EJ, Sigmon K, Thornton D, Masek R, Anderson L, Collen D, and the TAMI<br />
Study Group: Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator.<br />
Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction.<br />
Circulation 80:1222-1230, 1989. [PMID 2509104]<br />
83. Topol EJ: Recombinant tissue plasminogen activator: implications in therapy. Seminars in Hematology<br />
and Oncology 26(Suppl 3):25-31, 1989. [PMID 2508227]<br />
84. Topol EJ, Ellis SG, Califf RM, George BS, Stump DC, Bates ER, Nabel EG, Walton JA, Candela RJ,<br />
Kline EM, Pitt B, and the Thrombolysis and Angio-plasty in Myocardial Infarction (TAMI) Study Group:<br />
Combined tissue-type plasmin-ogen activator and prostacyclin therapy for acute myocardial infarc-tion.<br />
Journal of the American College of Cardiology 14:877-884, 1989. [PMID 2528903]<br />
85. Ellis SG, Topol EJ, George BS, Kereiakes DJ, Debowey D, Sigmon KN, Pickel A, Lee KL, Califf RM:<br />
Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following<br />
successful thrombolysis with intravenous tissue plasminogen activator. Circulation 80:1159-1165, 1989.<br />
[PMID 2509102]<br />
86. Holmes DR, Topol EJ: Reperfusion momentum: lessons from the randomized -trials of immediate<br />
coronary angioplasty for acute myocardial infarction. Journal of the American College of Cardiology<br />
14:1572-1578, 1989. [PMID 2809019]<br />
87. Gacioch GM, Topol EJ: Sudden paradoxical clinical deterioration during angioplasty of the occluded<br />
right coronary artery in acute myocardial infarction. Journal of the American College of Cardiology<br />
14:1202-1209, 1989. [PMID 2808974]<br />
88. Califf RM, Topol EJ, Gersh B: From myocardial salvage to patient salvage in acute myocardial<br />
infarction: The role of reperfusion therapy. Journal of the American College of Cardiology 14:1382-1388,<br />
1989. [PMID 2681322]<br />
89. Chapekis AT, Burek K, Topol EJ: The cost:benefit ratio of acute intervention for myocardial infarction:<br />
results of a prospective, matched pair analysis. American Heart Journal 118:878-882, 1989. [PMID<br />
2510487]<br />
90. Ellis SG, Shaw RE, King SB, Myler RK, Topol EJ: Restenosis after excellent angiographic angioplasty<br />
result for chronic total coronary artery occlusion –-Implications for newer percutaneous revascularization<br />
devices. American Journal of Cardiology 64:667-668, 1989. [PMID 2528903]<br />
91. Muller DWM, Topol EJ: Acute myocardial infarction: early and late percutaneous transluminal coronary<br />
angioplasty. Current Opinion in Cardiology 4:524-530, 1989.<br />
92. Topol EJ: Acute myocardial infarction: treatment with thrombolytic therapy. -Clinical Cardiology 7:827-<br />
836, 1989. [PMID 2688884]<br />
93. Sane DC, Califf RM, Topol EJ, Stump DC, Mark DB, Greenberg CS: Bleeding during thrombolytic<br />
therapy for acute myocardial infarction: mechanisms and -management. Annals of Internal Medicine<br />
111:1010-1022, 1989. [PMID 2688504]<br />
94. Burek K, Kirscht J, Topol EJ: Exercise capacity in patients 3 days after acute, -uncomplicated<br />
myocardial infarction. Heart and Lung 18:575-580, 1989. [PMID 2684916]<br />
95. Muller DW, Topol EJ, Califf RM, Sigmon K, George BS, Kereiakes DJ, Candela RJ, Ellis SG, and the<br />
Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group: Relationship between<br />
antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 6
infarction. American Heart Journal 119:224-231, 1990. [PMID 2405608]<br />
96. Popma JJ, Topol EJ: Factors influencing restenosis after coronary angioplasty. American Journal of<br />
Medicine 88:16N-24N, 1990. [PMID 2195881]<br />
97. Kander NH, Holland KJ, Pitt B, Topol EJ: A randomized pilot trial of brief versus prolonged heparin after<br />
successful reperfusion in acute myocardial infarction. American Journal of Cardiology 65:139-142, 1990.<br />
[PMID 2404389]<br />
98. Vogel R, Shawl F, Tommaso CL, O’Neill W, Overlie P, O’Toole J, Vandormael M, Topol EJ, Tabari KK,<br />
Vogel J, Smith S, Friedmann R, White C, George B, Tierstein P: Initial report of the national registry of<br />
elective cardiopulmonary bypass supported coronary angioplasty. Journal of the American College of<br />
Cardiology 15:23-29, 1990. [PMID 2404047]<br />
99. Topol EJ, Wilson VE: The pivotal role of early and sustained infarct vessel patency in patients with acute<br />
myocardial infarction. Heart and Lung 19:584-593, 1990. [PMID 2228647]<br />
100. Muller DWM, Topol EJ: Unresolved issues: late reperfusion, lytic failure, and reocclusion. Coronary<br />
Artery Disease 1:39-49, 1990. [PMID 10148970]<br />
101. Califf RM, Topol EJ, George BS, Kereiakes DJ, Aronson LG, Martin L, Candela R, Abbottsmith CW,<br />
O’Neill WW, Stack RS and the TAMI Study Group: One-year outcome after therapy with tissue<br />
plasminogen activator: report from the Thrombolysis and Angioplasty in Acute Myocardial Infarction trial.<br />
American Heart Journal 119:777-785, 1990. [PMID 2108575]<br />
102. Kavanaugh KM, Topol EJ: Acute intervention during myocardial infarction in -patients with prior coronary<br />
bypass surgery. American Journal of Cardiology 65:924-926, 1990. [PMID 2321545]<br />
103. Topol EJ: Ultrathrombolysis. Journal of the American College of Cardiology 15:922-924, 1990. [PMID<br />
2107238]<br />
104. Muller DWM, Topol EJ: Protected coronary angioplasty: minimizing the hazards of high risk coronary<br />
interventions. Journal of Invasive Cardiology 2:103-107, 1990. [PMID 10148970]<br />
105. Sutton JM, Topol EJ: Usefulness of coronary artery angioplasty strategies in acute myocardial infarction.<br />
Canadian Journal of Cardiology 6:111-122, 1990. [PMID 2187576]<br />
106. Ellis SG, Muller DW, Topol EJ: Possible survival benefit from con-comitant beta –but not calcium –<br />
antagonist therapy during reperfusion for acute myocardial infarction. American Journal of Cardiology<br />
66:125-128, 1990. [PMID 1973588]<br />
107. Williams DO, Topol EJ, Califf RM, Roberts R, Mancini J, Joelson JM, Ellis SG: Intravenous recombinant<br />
tissue-type plasminogen activator in patients with -unstable angina pectoris. Results of a placebocontrolled,<br />
randomized trial. -Circulation 82:376-383, 1990. [PMID 2115407]<br />
108. George BS, Candela RJ, Topol EJ, Stack RS, Kereiakes DJ, Abbottsmith CW, Masek R, Pickel A, Dillon<br />
J, Harrelson L, Califf RM, and the TAMI Study Group: Brachial approach to emergency cardiac<br />
catheteriza-tion during thrombolytic thera-py for acute myocardial infarc-tion. Catheterization and Cardiovascular<br />
Diagnosis 20:221-226, 1990. [PMID 2119888]<br />
109. O’Connor CM, Califf RM, Massey EW, Mark DB, Kereiakes DJ, Candela RJ, Abbottsmith C, George B,<br />
Stack RS, Aronson L, Mantell S, Topol EJ: Stroke and acute myocardial infarction in the thrombolytic<br />
era: clinical correlates and long-term prognosis. Journal of the American College of Cardiology 16:533-<br />
540, 1990. [PMID 2117618]<br />
110. Ohman EM, Califf RM, Topol EJ, Candela RJ, Abbottsmith CW, Ellis SG, Sigmon KN, Kereiakes DJ,<br />
George BS, Stack RS and the TAMI Study Group: Conse-quences of reocclusion follow-ing successful<br />
reperfusion ther-apy in acute myocardial infarction. Circulation 82:781-791, 1990. [PMID 2394002]<br />
111. Abbottsmith CW, Topol EJ, George BS, Stack RS, Kereiakes DJ, Candela RJ, Anderson LC, Harrelson-<br />
Woodlief L, Califf RM: Fate of patients with acute myocardial infarction with patency of the infarct-related<br />
vessel achieved with successful thrombolysis versus rescue angioplasty. Journal of the American<br />
College of Cardiology 16:770-778, 1990. [PMID 1698843]<br />
112. Ellis SG, Topol EJ: Results of percutaneous transluminal coronary angioplasty of high risk angulated<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 7
stenoses. American Journal of Cardiology 66:932-937, 1990. [PMID 2220615]<br />
113. Muller DWM, Topol EJ, George BS, Kereiakes DJ, Aronson LG, Lee KL, Abbottsmith CW, Ellis SG, Califf<br />
RM, and the TAMI Study Group: Two year -outcome following angiographically documented myocardial<br />
reperfusion for acute coronary occlusion. American Journal of Cardiology 66:796-801, 1990. [PMID<br />
2220575]<br />
114. Popma JJ, Topol EJ: Accelerated, combined, and adjunctive thrombolytic strategies for acute<br />
myocardial infarction. Current Opinion in Cardiology 5:482-489, 1990.<br />
115. Muller DWM, Ellis SG, Debowey DL, Topol EJ: Quantitative angiographic -comparison of the immediate<br />
success of coronary angioplasty, coronary atherectomy and endoluminal stenting. American Journal of<br />
Cardiology 66:938-942, 1990. [PMID 2220616]<br />
116. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, Bulle TM: Coronary<br />
morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary<br />
disease: implications for patient selection. Circulation 82:1193-1202, 1990. [PMID 2401060]<br />
117. Topol EJ: Can thrombolysis be improved? Hospital Formulary 25:19-22, 1990.<br />
118. Califf RM, Harrelson-Woodlief L, Topol EJ: Left ventricular ejection fraction may not be useful as an<br />
endpoint for thrombolytic therapy comparative trials. -Circulation 82:1847-1853, 1990. [PMID 2225381]<br />
119. Wall TC, Califf RM, Harrelson-Woodlief L, Mark DM, Honan M, Abbottsmith CW, Candela R, Berrios E,<br />
Phillips HR, Topol EJ, and the TAMI study group: Usefulness of a pericardial friction rub after<br />
thrombolytic therapy during acute myocardial infarction in predicting amount of myocardial damage.<br />
American -Journal of Cardiology 66:1418-1421, 1990. [PMID 2123603]<br />
120. Bates ER, Clemmensen PM, Califf RM, Gorman LE, Aronson LG, George BS, Kereiakes DJ, Topol EJ<br />
and the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group: Precordial ST<br />
segment depression predicts a worse prognosis in inferior infarction despite reperfusion therapy. Journal<br />
of the American College of Cardiology 16:1538-1544, 1990. [PMID 2123903]<br />
121. Muller DWM, Topol EJ: Selection of patients with acute myocardial infarction for thrombolytic therapy.<br />
Annals of Internal Medicine 113:949-960, 1990. [PMID 2240919]<br />
122. Sane DC, Stump DC, Topol EJ, Sigmon KN, Clair WK, Kereiakes DJ, George BS, Stoddard MF, Bates<br />
ER, Stack RS, Califf RM, and the Thrombolysis and Angio-plasty in Myocardial Infarction Study Group:<br />
Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen<br />
activator. Increased fibrin(ogen)olysis in blacks. Circulation 83:170-175, 1991. [PMID 1898641]<br />
123. Ellis SG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, Bulle TM, Vandormael MG: Determinants of<br />
2-year outcome after coronary angioplasty in patients with multivessel disease on the basis of<br />
comprehensive preprocedural evaluation: Implications for patient selection. Circulation 83:1905-1914,<br />
1991. [PMID 2040043]<br />
124. Schatz RA, Baim DS, Leon M, Ellis SG, Goldberg S, Hirshfeld JW, Cleman MW, Cabin HS, Walker C,<br />
Stagg J, Buchbinder M, Teirstein PS, Topol EJ, Savage M, Perez J, Curry RC, Whitworth H, Sousa JE,<br />
Tio F, Almagor Y, Ponder R, Penn IM, Leonard B, Levine SL, Fish RD, Palmaz JC: Clinical experience<br />
with the Palmaz-Schatz coronary stent: initial results of a multicenter study. Circulation 83:148-161,<br />
1991. [PMID 1984878]<br />
125. Clemmenson P, Bates ER, Califf RM, Hlatky M, Aronson L, George BS, Lee KL, Kereiakes DJ, Gacioch<br />
G, Berios E, Topol EJ, and the TAMI Study Group: -Complete atrioventricular block complicating inferior<br />
wall acute myocardial infarction treated with reperfusion therapy. American Journal of Cardiology 67:225-<br />
230, 1991. [PMID 1899319]<br />
126. Topol EJ: Promises and pitfalls of new devices for coronary artery disease. -Circulation 83:689-694,<br />
1991. [PMID 1991385]<br />
127. Nabel EG, Topol EJ, Galeana A, Ellis SG, Bates ER, Werns SW, Walton JA, Muller DA, Schwaiger M,<br />
Pitt B: A randomized placebo-controlled trial of combined early intravenous captopril and recombinant<br />
tissue-type plasminogen activator therapy in acute myocardial infarction. Journal of the American<br />
College of Cardiology 17:467-473, 1991. [PMID 1825097]<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 8
128. Kereiakes DJ, Topol EJ, George BS, Stack RS, Abbottsmith CW, Ellis S, Candela RJ, Harrelson L,<br />
Martin LH, Califf RM, and the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group:<br />
Myocardial infarction with minimal coronary atherosclerosis in the era of myocardial reperfusion. Journal<br />
of the American College of Cardiology 17:304-312, 1991. [PMID 1899433]<br />
129. Popma JJ, Dick RJL, Haudenschild CC, Topol EJ, Ellis SG: Atherectomy of right coronary ostial<br />
stenoses: initial and long-term results, technical features and histologic findings. American Journal of<br />
Cardiology 67:431-433, 1991. [PMID 1994670]<br />
130. Ellis SG, Debowey D, Kline E, Bates ER, Topol EJ: Treatment of recurrent ischemia after thrombolysis<br />
and successful reperfusion for acute myocardial infarction: effect on in-hospital mortality and left<br />
ventricular function. Journal of the American -College of Cardiology 17:752-757, 1991. [PMID 1993797]<br />
131. Topol EJ: Thrombolysis: go with the flow? Chest 99:529-530, 1991. [PMID 1704825]<br />
132. Lincoff AM, Popma JJ, Vogel R, Ellis SG, Topol EJ: Percutaneous support devices for high risk or<br />
complicated coronary angioplasty. Journal of the American College of Cardiology 17:770-780, 1991.<br />
[PMID 1993799]<br />
133. Topol EJ, Ellis SG: Coronary collaterals revisited: accessory pathway to myocardial preservation during<br />
infarction. Circulation 83:1084-1086, 1991. [PMID 1999011]<br />
134. Dick RJL, Haudenschild CC, Popma JJ, Ellis SG, Muller DW, Topol EJ: Directional atherectomy for total<br />
coronary occlusions. Coronary Artery Disease 2:189-199, 1991.<br />
135. Topol EJ, Califf RM: Intravenous heparin, thrombolytics and medical marketing. Journal of<br />
Interventional Cardiology 4:1-4, 1991.<br />
136. Stewart RE, Kander N, Juni JE, Ellis SG, O’Neill WW, Schork MA, Topol EJ, Schwaiger M: Submaximal<br />
exercise Thallium-201 SPECT for assessment of interventional therapy in patients with acute myocardial<br />
infarction. American Heart Journal 121:1033-1041, 1991. [PMID 1901189]<br />
137. Muller DWM, Topol EJ, Ellis SG, Sigmon KN, Lee K, Califf RM, and the Thromboly-sis and Angioplasty in<br />
Myocardial Infarction (TAMI) Study Group: Multivessel coronary artery disease: a key predictor of shortterm<br />
prognosis following reperfusion therapy for acute myocardial infarction. American Heart -Journal<br />
121:1042-1049, 1991. [PMID 1901190]<br />
138. Sutton JM, Topol EJ: Significance of a negative exercise thallium test in the -presence of a critical<br />
residual stenosis after thrombolysis for acute myocardial infarction. Circulation 83:1278-1286, 1991.<br />
[PMID 1901529]<br />
139. Mark DB, Sigmon K, Topol EJ, Kereiakes DJ, Pryor DB, Candela RJ, Califf RM: Identification of acute<br />
myocardial infarction patients suitable for early hospital discharge after aggressive interventional therapy.<br />
Results from the Thrombolysis and Angioplasty in Acute Myocardial Infarction registry. Circulation<br />
83:1186-1193, 1991. [PMID 2013140]<br />
140. Muller DWM, Ellis SG, Topol EJ: Colchicine and antineoplastic therapy for the prevention of restenosis<br />
after percutaneous coronary interventions. Journal of the American College of Cardiology 17:126B-131B,<br />
1991. [PMID 2016470}<br />
141. Califf RM, Topol EJ, Stack RS, Ellis SG, George BS, Kereiakes DJ, Samaha JK, Worley SJ, Anderson<br />
JL, Harrelson-Woodlief L, Wall TC, Phillips HR, Abbottsmith CW, Candela RJ, Wilson B, Sasahara AA,<br />
Mantell SJ, Lee KL, for the TAMI study group: Evaluation of combination thrombolytic therapy and timing<br />
of cardiac catheterization in acute myocardial infarction. Results of Thrombo-lysis and Angioplasty in<br />
Myocardial Infarction–Phase 5 randomized trial. Circulation 83:1543-1556, 1991. [PMID 1902405]<br />
142. Ellis SG, Bates ER, Schaible T, Weisman H, Pitt B, Topol EJ: Prospects for the use of antagonists to<br />
the platelet glycoprotein IIb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis. Journal<br />
of the American College of Cardi-ology 17:89B-95B, 1991. [PMID 2016487]<br />
143. Topol EJ, Holmes DR, Rogers WJ: Coronary angiography after thrombolytic therapy for acute<br />
myocardial infarction. Annals of Internal Medicine 114:877-885, 1991. [PMID 2014950]<br />
144. Schatz RA, Goldberg S, Leon M, Baim D, Hirshfeld J, Cleman M, Ellis S, Topol EJ: Clinical experience<br />
with the Palmaz-Schatz Coronary Stent. Journal of the American College of Cardiology 17:155B-159B,<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 9
1991. [PMID 2016473]<br />
145. Topol EJ: Integration of anticoagulation, thrombolysis and coronary angioplasty for unstable angina<br />
pectoris. American Journal of Cardiology 68:136-141, 1991. [PMID 1892061]<br />
146. Califf RM, George BS, Ohman EM, Quigley PJ, Topol EJ, Kereiakes DJ, Harrelson L, Candela RJ,<br />
Flanagan C, Stack RS: The use of intraaortic balloon pumping as an adjunct to reperfusion therapy in<br />
acute myocardial infarction. American Heart Journal 121:895-901, 1991. [PMID 1900381]<br />
147. Topol EJ, Agnelli G: Strategies for administration of tissue plasminogen activator. Molecular Biology and<br />
Medicine 8:219-234, 1991. [PMID 1806764]<br />
148. Morris JA, Muller DWM, Topol EJ: Combination thrombolytic therapy: a comparison of simultaneous and<br />
sequential regimens of tissue plasminogen activator and urokinase. American Heart Journal 122:375-<br />
380, 1991. [PMID 1907086]<br />
149. Sane DC, Stump DC, Topol EJ, Sigmon K, Kereiakes DJ, George BS, Mantell SJ, Macy E, Collen D,<br />
Califf RM: Correlation between baseline plasminogen activator inhibitor levels and clinical outcome<br />
during therapy with tissue plasminogen activator for acute myocardial infarction. Thrombosis and<br />
Haemostasis 65:275-279, 1991. [PMID 1904653]<br />
150. Popma JJ, Topol EJ: Adjuncts to thrombolysis for myocardial reperfusion. -Annals of Internal Medicine<br />
115:34-44, 1991. [PMID 1675557]<br />
151. Kereiakes DJ, Califf RM, George BS, Ellis S, Samaha J, Stack RS, Martin LC, Young SY, Topol EJ, and<br />
the TAMI Study Group: A comparison of emergency and deferred coronary bypass surgery following<br />
intravenous thrombolytic therapy for acute myocardial infarction. Circulation 79:281-286, 1989. [PMID<br />
2492454]<br />
152. Kereiakes DJ, Califf RM, George BS, Ellis S, Samaha J, Stack R, Martin LH, Young S, Topol EJ, and the<br />
TAMI Study Group: Coronary bypass surgery improves global and regional left ventricular function<br />
following thrombolytic therapy for acute myocardial infarction. American Heart Journal 122:390-399,<br />
1991. [PMID 1907087]<br />
153. Dellborg M, Topol EJ, Swedberg K: Dynamic QRS complex and ST segment vectorcardiographic<br />
monitoring can identify vessel patency in patients with acute myocardial infarction treated with<br />
reperfusion therapy. American Heart Journal 122:943-948, 1991. [PMID 1927880]<br />
154. Topol EJ: Which thrombolytic agent should one choose? Progress in Cardio-vascular Disease 34:165-<br />
178, 1991. [PMID 1947122]<br />
155. Popma JJ, Califf RM, Topol EJ: Clinical trials of restenosis after coronary angioplasty. Circulation<br />
84:1426-1436, 1991. [PMID 1884465]<br />
156. Muller DWM, Topol EJ, Ellis SG, Harrelson-Woodlief LG, Sigmon KN, Kereiakes DJ, George BS, Worley<br />
SJ, Samaha JK, Phillips H III, Califf RM and the TAMI 5 Study Group: Determinants of the need for early<br />
acute intervention in patients treated conservatively following thrombolytic therapy for acute myocardial<br />
infarction. Journal of the American College of Cardiology 18:1594-1601, 1991. [PMID 1960302]<br />
157. Ellis SG, De Cesare NB, Pinkerton CA, Whitlow P, King SB III, Chazzal ZMB, Kereiakes DJ, Popma JJ,<br />
Menke KK, Topol EJ, Holmes DR: Relation of stenosis morphology and clinical presentation to the<br />
procedural results of directional coronary atherectomy. Circulation 84:644-653, 1991. [PMID 1860208]<br />
158. Muller DWM, Topol EJ: Implantable devices in the coronary artery: From metal to genes. Trends in<br />
Cardiovascular Medicine 1:225-232, 1991.<br />
159. Dick RJ, Popma JJ, Muller DW, Burek K, Topol EJ: In-hospital costs associated with new percutaneous<br />
coronary devices. American Journal of Cardiology 68:879-885, 1991. [PMID 1927947]<br />
160. Bates ER, Topol EJ: Limitations of thrombolytic therapy for acute myocardial infarction complicated by<br />
congestive heart failure and cardiogenic shock. Journal of American College of Cardiology 18:1077-<br />
1084, 1991. [PMID 1894853]<br />
161. Tenaglia AN, Califf RM, Candela RJ, Kereiakes DJ, Berrios E, Stack RS, Topol EJ: Thrombolytic<br />
therapy in patients requiring cardiopulmonary resuscitation. American Journal of Cardiology 68:1015-<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 10
1019, 1991. [PMID 1927913]<br />
162. Kirshenbaum JM, Bahr RD, Flaherty JT, Gurewich V, Levine HJ, Loscalzo J, Schumacher R, Topol EJ,<br />
Wahr D, Braunwald E and the Pro-urokinase for -Myocardial Infarction Study Group: Clot-selective<br />
coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type<br />
plasminogen -activator and recombinant tissue-type plasminogen activator. American Journal of<br />
Cardiology 68:1564-1569, 1991. [PMID 1746455]<br />
163. Muller DM, Ellis SG, Topol EJ: Experimental models of coronary artery restenosis. Journal of American<br />
College of Cardiology 19:418-432, 1992. [PMID 1732371]<br />
164. Wall TC, Califf RM, George BS, Ellis SG, Samaha J, Kereiakes DJ, Worley SJ, Sigmon K, Topol EJ for<br />
the TAMI 7 Study Group: Accelerated plasminogen -activator dose regimens for coronary thrombolysis.<br />
Journal of the American -College of Cardiology 19:482-489, 1992. [PMID 1537998]<br />
165. Ellis SG, Myler RK, King SB, Douglas JS, Topol EJ, Shaw RE, Stertzer SH, Roubin GS: Causes and<br />
correlates of death after unsupported coronary angioplasty: Implications for the use of angioplasty and<br />
advanced support techniques in high-risk settings. American Journal of Cardiology 68:1447-1451, 1991.<br />
[PMID 1746425]<br />
166. Gacioch GM, Ellis SG, Lee L, Bates ER, Kirsh M, Walton JA, Topol EJ: Cardiogenic shock complicating<br />
acute myocardial infarction: the use of coronary angioplasty and the integration of the new support<br />
devices into patient management. Journal of the American College of Cardiology 19:647-653, 1992.<br />
[PMID 1538023]<br />
167. Popma JJ, Califf RM, Ellis SG, George BS, Kereiakes DJ, Samaha JK, Worley SJ, Anderson JL, Stump<br />
D, Woodlief L, Sigmon K, Wall TC, Topol EJ: Mechanism of benefit of combination thrombolytic therapy<br />
for acute myocardial infarction: a quantitative angiographic and hematologic study. Journal of the<br />
American -College of Cardiology 20:1305-12, 1992. [PMID 1430679]<br />
168. Muller DWM, Shamir KJ, Ellis SG, Topol EJ: Peripheral vascular complications after conventional and<br />
complex percutaneous coronary interventional procedures. American Journal of Cardiology 69:63-68,<br />
1992. [PMID 1729869]<br />
169. Holmes DR, Garratt KN, Topol EJ: Coronary angioplasty versus excisional atherectomy trial: CAVEAT.<br />
International Journal of Cardiology 35:143-146, 1992. [PMID 1572733]<br />
170. Popma JJ, De Cesare NB, Ellis SG, Holmes DR, Pinkerton CA, Whitlow P, King SB III, Chazzal ZMB,<br />
Topol EJ, Garratt KN, Kereiakes DJ: Clinical, angiographic and procedural correlates of quantitative<br />
coronary dimensions after directional coronary atherectomy. Journal of the American College of<br />
Cardiology 18:1183-1189, 1991. [PMID 1918694]<br />
171. Topol EJ, Califf RM, Vandormael M, Grines CL, George BS, Sanz ML, Wall T, O’Brien M, Schwaiger M,<br />
Aguirre FV, Young S, Popma JJ, Lee KL, Ellis SG and the Thrombolysis and Angioplasty in Myocardial<br />
Infarction-6 Study Group: A randomized trial of late reperfusion therapy for acute myocardial infarction. -<br />
Circulation 85:2090-2099, 1992. [PMID 1591828]<br />
172. Muller DWM, Topol EJ: Thrombolytic therapy: Adjuvant mechanical intervention for acute myocardial<br />
infarction. American Journal of Cardiology 69:60A-70A, 1992. [PMID 1729880]<br />
173. Lincoff AM, Popma JJ, Hacker JA, Ellis SG, Topol EJ: Abrupt vessel closure -complicating coronary<br />
angioplasty: clinical, angiographic and therapeutic profile. Journal of the American College of Cardiology<br />
19:926-935, 1992. [PMID 1552113]<br />
174. Rosenschein U, Haudenschild CC, Dick RJ, Watkins JF, Ellis SG, Yakubov SJ, Topol EJ:<br />
Histopathologic correlates of coronary lesion angiographic morphology: lessons from a directional<br />
atherectomy experience. Coronary Artery Disease 3:953-961, 1992.<br />
175. Popma JJ, Topol EJ, Hinohara T, Pinkerton CA, Baim DS, King SB, Holmes DR Jr, Whitlow PL,<br />
Kereiakes DJ, Hartzler GO, Kent KM, Ellis SG, Simpson JB for the U.S. Directional Atherectomy<br />
Investigator Group: Abrupt closure after directional coronary atherectomy. Journal of the American<br />
College of Cardiology 19:1372-1379, 1992. [PMID 1593028]<br />
176. Califf RM and Topol EJ for the GUSTO Investigators: Thrombolytic therapy for myocardial infarction: a<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 11
perspective of clinical trialists. Clinical Cardiology 15:143-144, 1992. [PMID 1551260]<br />
177. Ellis SG, Van de Werf F, Ribeiro-daSilva E, Topol EJ: Present status of rescue coronary angioplasty:<br />
current polarization of opinion and randomized trials. - -Journal of the American College of Cardiology<br />
19:681-686, 1992. [PMID 1531664]<br />
178. Ver Lee PN, Muller DWM, Popma JJ, Ellis SG, Topol EJ: A comparison of clinical and quantitative<br />
angiographic outcomes of coronary stenting in elective and emergency settings: a single center<br />
experience. Coronary Artery Disease 2:945-951, 1991.<br />
179. Ellis SG, Myler RK, King SB, Douglas JS, Topol EJ, Shaw RE, Stertzer SH, Roubin GS, Murphy, MC:<br />
Causes and correlates of death after unsupported coronary angioplasty: implications for use of<br />
angioplasty and advanced support techniques in high-risk settings. American Journal of Cardiology<br />
68:1447-1451, 1991. [PMID 1746425]<br />
180. Chapman GD, Ohman EM, Topol EJ, Candela RJ, Kereiakes DJ, Samaha J, Berrios E, Pieper K, Young<br />
S, Califf RM: Minimizing the risk of inappropriately administering thrombolytic therapy (Thrombolysis and<br />
Angioplasty in Myocardial Infarction [TAMI] Study Group). American Journal of Cardiology 71:783-787,<br />
1993. [PMID 8456754]<br />
181. Ellis SG, Savage M, Fischman D, Leon M, Goldberg S, Hirshfeld JW, Baim DS, Cleman MW, Teirstein<br />
PS, Walker C, Bailey S, Topol EJ, Schatz RA: Restenosis after placement of Palmaz-Schatz stents in<br />
native coronary arteries: initial results of a multicenter experience. Circulation 86:1836-1844, 1992.<br />
[PMID 1451256]<br />
182. De Cesare NB, Popma JJ, Holmes DR Jr, Dick RJ, Whitlow PL, King SB, Pinkerton CA, Kereiakes DJ,<br />
Topol EJ, Haudenschild CC, Ellis SG: Excision beyond the “normal” arterial lumen: Clinical,<br />
angiographic and histologic correlates of ectasia after directional coronary atherectomy. American<br />
Journal of Cardiology 69:314-319, 1992. [PMID 1734641]<br />
183. Arnold AZ, Topol EJ: Assessment of reperfusion after thrombolytic therapy for myocardial infarction.<br />
American Heart Journal 124:441-447, 1992. [PMID 1636587]<br />
184. Topol EJ: The status of research in invasive cardiology. Journal of Invasive -Cardiology 4:10-17, 1992.<br />
[PMID 10149902]<br />
185. Granger CB, Califf RM, Topol EJ: Thrombolytic therapy for acute myocardial infarction. Drugs 44:293-<br />
325, 1992. [PMID 1382931]<br />
186. Topol EJ, Califf RM: Answers to complex questions cannot be derived from “simple” trials. British Heart<br />
Journal 68:348-351, 1992. [PMID 1449915]<br />
187. Wall TC, Califf RM, Ellis SG, Sigmon K, Kereiakes D, George BS, Samaha J, Sane D, Stump D, Stack<br />
RS, Topol EJ: Lack of impact of early catheterization and fibrin specificity on bleeding complications<br />
after thrombolytic therapy. Journal of the American College of Cardiology 21:597-603, 1993.<br />
188. Popma JJ, De Cesare NB, Pinkerton CA, Kereiakes DJ, Whitlow P, King SB, Topol EJ, Holmes DR,<br />
Leon MB, Ellis SB: Quantitative analysis of factors influencing late lumen loss and restenosis after<br />
directional coronary atherectomy. American Journal of Cardiology 71:552-557, 1993. [PMID 8438740]<br />
189. Topol EJ, Armstrong P, Van de Werf F, Kleiman N, Lee K, Morris D, Simmons M, Barbash G, White H,<br />
Califf RM on behalf of the GUSTO Steering Committee: Confronting the issues of patient safety and<br />
investigator conflict of interest in an international clinical trial of myocardial reperfusion. Journal of<br />
American College of Cardiology 19:1123-1128, 1992. [PMID 1564212]<br />
190. Rosenschein U, Yakubov SJ, Guberinich D, Bach DS, Sonda PL, Abrams GD, Topol EJ: Shock wave<br />
thrombus ablation, a new method for noninvasive mech-anical thrombolysis. American Journal of<br />
Cardiology 70:1358-1361, 1992. [PMID 1442591]<br />
191. Schwartz RS, Holmes DR, Topol EJ: The restenosis paradigm revisited: An -alternative proposal for<br />
cellular mechanisms. Journal of the American College of Cardiology 20:1284-1293, 1992. [PMID<br />
1401633]<br />
192. Williamson BD, Muller DWM, Topol EJ: Should older patients with acute -myocardial infarction receive<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 12
thrombolytic therapy? Drugs and Aging 2:462-468, 1992. [PMID 1493350]<br />
193. Grambow DW, Topol EJ: Effect of maximal medical therapy on refractoriness of unstable angina<br />
pectoris. American Journal of Cardiology 70:577-581, 1992. [PMID 1354937]<br />
194. Granger CB, Califf RM, Young S, Candela R, Samaha J, Worley S, Kereiakes DJ, Topol EJ: Outcome of<br />
patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic therapy. Journal<br />
of the American College of Cardiology 21:920-925, 1993. [PMID 8450161]<br />
195. Topol EJ, Califf RM: Thrombolytic therapy for elderly patients. New England Journal of Medicine<br />
327:45-46, 1992. [PMID 1598101]<br />
196. Doorey AJ, Michelson E, Topol EJ: Thrombolytic therapy of acute myocardial infarction: Keeping the<br />
unfulfilled promises. Journal of the American Medical -Association 268:3108-3114, 1992. [PMID<br />
1433742]<br />
197. Sutton JM, Topol EJ: Left ventricular function assessment and acute myocardial infarction: The role of<br />
left ventricular imaging in establishing diagnosis, prognosis and therapeutic benefit. Current Opinion in<br />
Cardiology 7:1035-1045, 1992.<br />
198. Ellis SG, Tcheng JE, Navetta FI, Muller DW, Weisman HF, Smith C, Anderson KM, Califf RM, Topol EJ.<br />
Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet<br />
glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Coronary Artery Disease 2:167-<br />
175, 1993.<br />
199. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or<br />
both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The<br />
New England Journal of Medicine 329:1615-1622, 1993. [PMID 8232430]<br />
200. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa<br />
receptor in high-risk coronary angioplasty. The New England Journal of Medicine 330:956-961, 1994.<br />
[PMID 8121459]<br />
201. Ellis SG, Mooney MR, George BS, Ribeiro da Silva EE, Talley JD, Flanagan WH, Topol EJ: Randomized<br />
trial of late elective angioplasty versus conservative management for patients with residual stenoses after<br />
thrombolytic treatment of myocardial infarction. Circulation 86:1400-1406, 1992. [PMID 1423952]<br />
202. Muller DWM, Topol EJ, Abrams GD, Gallagher KP, Ellis SG: Intramural methotrexate therapy for the<br />
prevention of neointimal thickening after balloon angioplasty. Journal of the American College of<br />
Cardiology 20:460-466, 1992. [PMID 1386089]<br />
203. Rosenschein U, Ellis SG, Haudenschild CC, Yakubov SJ, Muller DWM, Dick RJ, Topol EJ. Comparison<br />
of histopathologic coronary lesions obtained from directional atherectomy in stable angina versus acute<br />
coronary syndromes. American Journal of Cardiology 73:508-510, 1994.<br />
204. Lincoff AM, Topol EJ, Chapekis AT, George BS, Candela RJ, Muller DWM, Zimmerman CA, Ellis SG:<br />
Intracoronary stenting compared with conventional therapy for abrupt vessel closure complicating<br />
coronary angioplasty: a matched case-control study. Journal of the American College of Cardiology<br />
21:866-875, 1993. [PMID 8450155]<br />
205. Topol EJ: The restenosis “antitheory”. Mayo Clinic Proceedings 68:88-90, 1993. [PMID 8417263]<br />
206. Kalff V, Hicks RJ, Hutchins G, Topol EJ, Schwaiger M: Use of carbon-11 acetate and dynamic positron<br />
emission tomography to assess regional myocardial oxygen consumption in patients with acute<br />
myocardial infarction receiving thrombolysis or coronary angioplasty. American Journal of Cardiology<br />
71:529-535, 1993. [PMID 8438738]<br />
207. Topol EJ, Ellis SG, Cosgrove DM, Bates ER, Muller DWM, Schork N, Schork MA, Loop FD: Analysis of<br />
coronary angioplasty practice in the United States -using a private insurance database. Circulation<br />
87:1489-1497, 1993. [PMID 8141866]<br />
208. Casale PN, Whitlow PL, Franco I, Grigera F, Pashkow FJ, Topol EJ: Comparison of major complication<br />
rates with new atherectomy devices for percutaneous coronary intervention in women versus men.<br />
American Journal of Cardiology 71:1221-1223, 1993. [PMID 8480650]<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 13
209. Kleiman NS, Ohman ME, Califf RM, George B, Kereiakes D, Aquirre F, Weisman H, Schaible T, Topol<br />
EJ: Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic<br />
therapy: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study.<br />
Journal of the American College of Cardiology 22:381-389, 1993. [PMID 8335808]<br />
210. Harrison JK, Califf RM, Harrelson-Woodlief L, Kereiakes D, George BS, Stack RS, Ellis SG, Lee KL,<br />
O’Neill W, Topol EJ, and the TAMI Study Group: Systolic left ventricular function after reperfusion<br />
therapy for acute myocardial infarction: An analysis of determinants of improvement. Circulation<br />
87:1531-1541, 1993. [PMID 8491008]<br />
211. Topol EJ: Rotablator to the rescue. American Journal of Cardiology 71:858-859, 1993. [PMID 8456767]<br />
212. Topol EJ: Cardiac intervention in the elderly: State-of-the-art 1993. Cardiology in the Elderly I:51-53,<br />
1993.<br />
213. Topol EJ, Bonan R, Kakkar VV, de Bono D, Rothman M, Willerson J, Dewart D, Ganz P, Strony J, Cohen<br />
M, Raymond R, Fox I, Maraganore J, Adelman B: Use of an antithrombin, Hirulog, in place of heparin<br />
during coronary angioplasty. Circulation 87:1622-1629, 1993. [PMID 8491018]<br />
214. Lee KS, Topol EJ, Stewart WJ: Atypical presentation of papillary fibroelastoma mimicking multiple<br />
vegetations in a woman with suspected subacute bacterial endo--carditis. American Heart Journal<br />
125:1443-1445, 1993. [PMID 8480605]<br />
215. de Feyter PJ, van Suylen RJ, de Jaegere PPT, Topol EJ, Serruys PW: Interventional techniques for the<br />
treatment of lesions in saphenous venous bypass grafts. Journal of the American College of Cardiology<br />
21:1539-1549, 1993. [PMID 8496517]<br />
216. Lincoff AM, Topol EJ: Trickle down thrombolysis. Journal of the American -College of Cardiology<br />
21:1396-1398, 1993. [PMID 8473647]<br />
217. Krucoff MW, Croll MA, Pope JE, Granger CB, O’Connor Cm, Sigmon KN, Wagner BL, Ryan JA, Lee KL,<br />
Kereiakes DJ, Samaha JK, Worley SJ, Ellis SG, Wall TC, Topol EJ, Califf RM, for the TAMI 7 Study<br />
Group: Continuous 12-Lead ST segment recovery analysis: A noninvasive method for real time detection<br />
of failed myocardial reperfusion. Circulation 88:437-446, 1993. [PMID 8339407]<br />
218. Rosenschein U, Ellis SG, Yakubov SJ, Haudenschild CC, Dick RJ, Topol EJ: Histopathologic correlates<br />
of coronary lesion angiographic morphology: Lessons from a directional atherectomy experience.<br />
Coronary Artery Disease 3:953-961, 1992.<br />
219. Lincoff AM, Topol EJ: The illusion of reperfusion. Does anyone achieve optimal myocardial reperfusion?<br />
Circulation 87:1792-1805 and 88:1361-1374, 1993. [PMID 8353902]<br />
220. Flaherty JT, Pitt B, Gruber JW, Heuser RR, Rothbaum DA, George BS, Burwell LR, Kereiakes DJ,<br />
Deitchman D, Gustafson N, Brinker JA, Becker LC, Mancini GBJ, Topol EJ, Werns SW: Recombinant<br />
human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients<br />
undergoing coronary angioplasty for acute myocardial infarction. Circulation 89:1982-1991, 1994. [PMID<br />
8181121]<br />
221. Nath FC, Muller DWM, Rosenschein U, Ellis SG, Topol EJ: Heparin monitoring during coronary<br />
intervention: Activated clotting time versus activated partial thromboplastin time. Canadian Journal of<br />
Cardiology 9:797-801, 1993. [PMID 8281479]<br />
222. MacIssac A, Thomas J, Topol EJ: Toward the quiescent coronary artery plaque. Journal of the<br />
American College of Cardiology 22:1228-1241, 1993. [PMID 8104965]<br />
223. Ellis SG, Tcheng JT, Navetta FI, Muller DWM, Weisman HG, Smith C, Anderson K, Califf RM, Topol EJ:<br />
Safety and antiplatelet effect of fab murine monoclonal antibody 7E3 fab directed against platelet<br />
glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty – an initial experience.<br />
Coronary Artery -Disease 4:167-175, 1992. [PMID 8269208]<br />
224. Sane DC, Califf RM, Sigmon KN, Topol EJ, Stump DC: Effect of heparin admin-istration on<br />
fibrinogenolysis during thrombolytic therapy with tissue plasminogen activator for acute myocardial<br />
infarction. Fibrinolysis 7:103-107, 1993.<br />
225. Nath FC, Muller DWM, Ellis SG, Rosenschein U, Chapekis A, Quain L, Zimmerman C, Topol EJ:<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 14
Thrombosis of a flexible coil coronary stent: frequency, predictors and clinical outcome. Journal of the<br />
American College of Cardiology 21:622-627, 1993. [PMID 8436743]<br />
226. Topol EJ, Plow EF: Clinical trials of platelet receptor inhibitors. Thrombosis and Haemostasis 70:94-98,<br />
1993. [PMID 8236122]<br />
227. Douglas JS, Pepine CJ, Block PC, Brinker JA, Johnson WL, Klinke WP, Levin DC, Mullins CE, Nissen<br />
SE, Topol EJ, Ullyot DJ, Vetrovec GW, Vogel JHK: Recom-mendations for development and<br />
maintenance of competence in coronary interventional procedures. Journal of the American College of<br />
Cardiology 22:629-631, 1993. [PMID 8335841]<br />
228. Ohman EM, Christenson RH, Califf RM, George BS, Samaha JK, Kereiakes DJ, Worley SJ, Wall TC,<br />
Berrios E, Sigmon KN, Lee K, Topol EJ, and the TAMI 7 Study Group: Noninvasive detection of<br />
reperfusion after thrombolysis based on serum creatine kinase MB changes and clinical variables.<br />
American Heart Journal 126:819-826, 1993. [PMID 8213437]<br />
229. Lincoff AM, Califf RM, Ellis SG, Sigmon KN, Lee KL, Topol EJ for the Thrombolysis and Angioplasty in<br />
Myocardial Infarction (TAMI) Study Group: Thrombolytic therapy for women with myocardial infarction: Is<br />
there a gender gap? Journal of the American College of Cardiology 22:1780-1787, 1993. [PMID<br />
8245328]<br />
230. Topol EJ, Leya F, Pinkerton CA, Whitlow PL, Hofling B, Simonton CA, Masden RR, Serruys PW, Leon<br />
MB, Williams DO, King SB, Mark DB, Isner JM, Holmes DR, Ellis SG, Lee KL, Keeler G, Berdan LG,<br />
Hinohara T, Califf RM, on behalf of the CAVEAT Study Group: A comparison of coronary angioplasty with<br />
directional atherectomy in patients with coronary artery disease. New England Journal of Medicine<br />
329:221-227, 1993. [PMID 8316266]<br />
231. Bernardi MM, Califf RM, Kleiman N, Ellis SG, Topol EJ: Lack of usefulness of prolonged bleeding times<br />
in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody.<br />
American Journal of Cardiology 72:1121-1125, 1993. [PMID 8237799]<br />
232. DeFranco AC, Topol EJ: Invasive strategies for acute myocardial infarction in the elderly. Cardiology in<br />
the Elderly 2:274-289, 1994.<br />
233. Brown DL, Topol EJ: Stroke complicating percutaneous coronary revascularization. American Journal of<br />
Cardiology 72:1207-1209, 1993. [PMID 8237818]<br />
234 Cosgrove DM, Topol EJ: Perspectives on percutaneous coronary revascularization. Seminars in<br />
Thoracic and Cardiovascular Surgery 6:65-66, April, 1994.<br />
235. Thomas JD, Topol EJ: Wanted: Dead or alive. Assessment of myocardial viability post thrombolysis.<br />
Circulation 88:797-799, 1993. [PMID 8339439]<br />
236. The GUSTO Investigators: An international randomized trial com-paring four thrombolytic strategies for<br />
acute myocardial infarction. New England Journal of Medicine 329:673-682, 1993. [PMID 8204123]<br />
237. George BS, Voorhees WD, Roubin GS, Fearnot NE, Pinkerton CA, Raizner AE, King SB, Holmes DR,<br />
Topol EJ, Kereiakes DJ, Hartzler GO: Multicenter investigation of coronary stenting to treat acute or<br />
threatened closure after percutaneous transluminal coronary angioplasty: Clinical and angiographic<br />
outcomes. Journal of the American College of Cardiology 22:135-143, 1993. [PMID 8509533]<br />
238. Topol EJ, Califf RM: Scorecard cardiovascular medicine. Annals of Internal -Medicine 120:65-70, 1994.<br />
[PMID 8250458]<br />
239. Baim DS, Hinohara T, Holmes D, Topol EJ, Pinkerton C, King SB, Whitlow P, Kereiakes D, Farley B,<br />
Simpson JB for the U.S. Directional Coronary Atherectomy Investigator Group: Results of directional<br />
coronary atherectomy during multicenter pre-approval testing. American Journal of Cardiology 72:6E-<br />
11E, 1993. [PMID 8213572]<br />
240. Lefkovits J, Topol EJ: Future direction in thrombolysis for myocardial infarction: what are the<br />
unanswered questions? Coronary Artery Disease 5:306-316, 1994. [PMID 8044342]<br />
241. Ohman EM, Topol EJ, Califf RM, Bates ER, Ellis SG, Kereiakes D, Geroge B, Samaha JK, Kline E,<br />
Sigmon KN, Stack RS and the Thrombolysis Angioplasty in Myocardial Infarction Study Group: An<br />
analysis of the cause of early mortality after administration of thrombolytic therapy. -Coronary Artery<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 15
Disease 4:957-964,1993. [PMID 8173712]<br />
242. Topol EJ, Califf RM, Lee KL on behalf of the GUSTO Investigators: The irony of biased editors who write<br />
editorials. British Journal of Clinical Practice 47:283-284, 1993. [PMID 8015584]<br />
243. Sgarbossa EB, Topol EJ: Semantic ambiguity, the “non-”nosology and myocardial infarction. Journal of<br />
Clinical Epidemiology 47:441-446,1994. [PMID 7730869]<br />
244. Villa AE, Guzman LA, Chen W, Golomb G, Levy RJ, Topol EJ: Local delivery of dexamethasone for<br />
prevention of neointimal proliferation in a rat model of balloon arterial injury. Journal of Clinical<br />
Investigation 93:1243-1249, 1994. [PMID 8132764]<br />
245. Cowley MJ, Vandermael M, Topol EJ, Whitlow PL, Dean LS, Bulle TM, Ellis SG for the Multivessel<br />
Angioplasty Prognosis Study (MAPS) Group: Is traditionally defined complete revascularization needed<br />
for patients with multivessel disease treated by elective coronary angioplasty. Journal of the American<br />
College of Cardiology 22:1289-1297, 1993. [PMID 8227782]<br />
246. Paranandi N, Topol EJ: Contemporary clinical trials of restenosis. Journal of Invasive Cardiology 6:109-<br />
123, 1994. [PMID 10147167]<br />
247. Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ: Combination of platelet fibrinogen receptor<br />
antagonist and direct antithrombin inhibitor at low doses markedly improves thrombolysis. Circulation<br />
89:1802-1809, 1994. [PMID 8149546]<br />
248. Nissen SE, Pepine CJ, Bashore TM, Block PC, Bonchek LI, Brinker JA, Carabello B, Douglas JS, Elion<br />
JL, Hirshfeld JW, Holmes DR, Johnson WL, Klinke WP, Levin DC, Mancini GBJ, Mullins CE, Thomas JD,<br />
Topol EJ, Vogel JHK, Wondrow NA: Cardiac angiography without cine film: Erecting a "Tower of Babel"<br />
in the cardiac catheterization laboratory (Position Statement). Journal of the American College of<br />
Cardiology 24:834-837, 1994. [PMID 8077561]<br />
249. Holmes DR, Topol EJ: Dilate or debulk? Cleveland Clinic Journal of Medicine 61:124-126, 1994. [PMID<br />
8194176]<br />
250. Topol EJ: Breaking the thrombolytic gridlock: Insights from the GUSTO trial. Cleveland Clinic Journal of<br />
Medicine 60:445-447, 1993. [PMID 8287504]<br />
251. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D,<br />
Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT on behalf of the EPIC Investigators:<br />
Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of<br />
clinical restenosis: results at six months. The Lancet 343:881-886, 1994. [PMID 7908357]<br />
252. Topol EJ, Fuster V, Califf RM, Harrington RA, Kleiman NS, Kereiakes DJ, Cohen M, Chapekis A, Gold<br />
HK, Bear P, Rao AK, Debowey D, Schwartz D, Henis M, Chesebro J. Recombinant hirudin for unstable<br />
angina pectoris: A multicenter, -randomized angiographic trial. Circulation 89:1557-1566, 1994. [PMID<br />
8149521]<br />
253. Brown DL, MacIsaac AI, Topol EJ: Pulmonary hemorrhage following intracoronary stent placement.<br />
Journal of the American College of Cardiology 24:91-94, 1994. [PMID 8006287]<br />
254. Topol EJ: Validation of the early open infarct vessel hypothesis. American Journal of Cardiology 72:40G-<br />
45G, 1993. [PMID 8279360]<br />
255. Wall TC, Califf RM, Blankenship J, Talley D, Tannenbaum M, Schwaiger M, Gacioch G, Cohen M, Sanz<br />
M, Leimberger J, Topol EJ and the Thrombolysis and Angioplasty in Myocardial Infarction Research<br />
Group: Intravenous fluosol in the treatment of acute myocardial infarction: results of the Thrombolysis<br />
and Angioplasty in Myocardial Infarction 9 trial. Circulation 90:114-120, -1994. [PMID 8025985]<br />
256. Holmes DR, Topol EJ, Adelman AG, Cohen EA, Califf RM: Randomized trials of directional coronary<br />
atherectomy implications for clinical practice and future investigation. Journal of the American College of<br />
Cardiology 24:431-439, 1994. [PMID 8034880]<br />
257. Lee KL, Califf RM, Van de Werf F, Simes J, Topol EJ on behalf of the GUSTO -Investigators: Holding<br />
GUSTO up to the light. Annals of Internal Medicine 120:876-881, -1994. [PMID 8154647]<br />
258. Ellis SG, Popma JJ, Buchbinder M, Franco I, Leon MB, Kent KM, Pichard D, Satler LF, Topol EJ,<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 16
Whitlow PL: Relation of clinical presentation, stenosis morphology and operator technique to the<br />
procedural results of rotational atherectomy. Circulation 89:882-892, 1994. [PMID 8313578]<br />
259. Sullivan E, Kearney M, Isner J, Topol EJ, Losordo DW: Pathology of unstable angina: Analysis of<br />
biopsies obtained by directional coronary atherectomy. Journal of Thrombosis and Thrombolysis 1:63-71,<br />
1994. [PMID 10603514]<br />
260. Sutton JM, Ellis SG, Roubin GS, Pinkerton CA, King SB, Raizner AE, Holmes DR, Kereiakes DJ, Topol<br />
EJ for the Gianturco-Roubin Intracoronary Stent Investigator Group: Major clinical events after coronary<br />
stenting. The multicenter registry of acute and elective Gianturco-Roubin stent placement. Circulation<br />
89:1126-1137, 1994. [PMID 8124799]<br />
261. Harrington RA, Sane DC, Califf RM, Sigmon K, Abbottsmith CW, Candela RJ, Lee KL, Topol EJ, for the<br />
TAMI Study Group: Clinical importance of thrombocytopenia occurring in the hospital phase after<br />
administration of thrombolytic therapy for acute myocardial infarction. Journal of the American College of<br />
Cardiology 23:891-898, 1994. [PMID 810694]<br />
262. Faxon DP, Spiro TE, Minor S, Cote G, Douglas J, Gottlieb R, Califf R, Dorosti K, Topol E, Gordon J and<br />
the ERA Investigators: Low molecular weight heparin in the prevention of restenosis after angioplasty:<br />
The results of the Enoxaparin -Restenosis (ERA) trial. Circulation 90:908-914, 1994. [PMID 8044962]<br />
263. Lefkovits J, Topol EJ: Direct thrombin inhibitors in cardiovascular medicine. Circulation 90:1522-1536,<br />
1994. [PMID 8087958]<br />
264. Hicks RJ, Melon P, Kalff V, Wolfe E, Dick RJ, Popma JJ, Topol EJ, Schwaiger M: Metabolic imaging by<br />
positron emission tomography early after myocardial infarction as a predictor of recovery of myocardial<br />
function following reperfusion. Journal of Nuclear Cardiology 1:124-137, 1994. [PMID 9420679]<br />
265. Domanski MJ, Topol EJ: Cardiogenic shock: progress and residual questions. American Journal of<br />
Cardiology 74:724-726, 1994. [PMID 7942534]<br />
266. Jang Y, Lincoff AM, Plow EF, Topol EJ: Cell adhesion molecules in coronary artery disease. Journal of<br />
the American College of Cardiology 24:1591-1601, 1994. [PMID 7963103]<br />
267. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf<br />
RM, Topol EJ: Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antibody fab 7E3 in high risk<br />
coronary angioplasty. Circulation 90:1757-1764, 1994. [PMID 7923659]<br />
268. Savage MP, Fischman DL, Schatz RA, Tierstein P, Leon MB, Baim D, Ellis SG, Topol EJ, Hirshfeld JW,<br />
Cleman MW, Buchbinder M, Bailey S, Heuser R, Walker CG, Curry RC, Gebhardt S, Rake R, Goldberg S<br />
for the Palmaz-Schatz Stent Study Group: Long-term angiographic and clinical outcome after<br />
implantation of a -balloon expandable stent in the native coronary circulation. Journal of the American<br />
College of Cardiology 24:1207-1212, 1994. [PMID 7930240]<br />
269. Ellis SG, da Silva ER, Heyndricks G, Talley JD, Cernigliaro C, Steg G, Spaulding C, Nobuyoshi M, Erbel<br />
R, Vassanelli C, Topol EJ for the RESCUE Investigators: Randomized comparison of rescue angioplasty<br />
with conservative management of patients with early failure of thrombolysis for acute anterior myocardial<br />
infarction. Circulation 90:2280-2284, 1994. [PMID 7955184]<br />
270. Lincoff AM, Topol EJ, Ellis SG: Local drug delivery for the prevention of restenosis: Fact, fancy and the<br />
future. Circulation 90:2070-2084, 1994. [PMID 7923695]<br />
271. Grines CL, Topol EJ, O’Neill WW, George BS, Kereiakes D, Phillips HR, Leimberger JD, Woodlief LH,<br />
Califf RM: Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction.<br />
Circulation 91:298-303, 1995. [PMID 7805231]<br />
272. Kleiman NS, White, Ohman EM, Ross AM, Woodlief L, Califf RM, Holmes DR, Bates E, Pfisterer M,<br />
Vahanian A, Topol EJ: Mortality within 24 hours of thrombolysis for myocardial infarction: the importance<br />
of early reperfusion. Circulation 90:2658-2665, 1994. [PMID 7994805]<br />
273. MacIsaac AI, Ellis SG, Muller DW, Topol EJ, Whitlow PL: Comparison of three coronary stents: clinical<br />
and angiographic outcome after elective placement in 134 consecutive patients. Catheterization and<br />
Cardiovascular Diagnosis 33:199-204, 1994. [PMID 7874711]<br />
274. Braunwald E, Jones RH, Mark DB, Brown J, Brown L, Cheitlin MD, Concannon CA, Cowan MC, Edwards<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 17
C, Fuster V, Goldman L, Green LA, Grines CL, Lytle BW, McCauley KM, Mushlin AI, Rose GC, Smith EE,<br />
Swain JA, Topol EJ, Willerson JT: Diagnosing and managing unstable angina. Circulation 90:613-622,<br />
1994. [PMID 8026048]<br />
275. Mark DB, Naylor CD, Hlatky MA, Califf RM, Topol EJ, Granger CB, Knight JD, Nelson CL, Lee KL,<br />
Clapp-Channing N, Sutherland W, Pilote L, Armstrong P: Use of medical resources and quality of life after<br />
acute myocardial infarction in Canada and the United States. New England Journal of Medicine<br />
331:1130-1135, 1994. [PMID 7935638]<br />
276. Becker RC, Charlesworth A, Wilcox R, Hampton J, Skene A, Gore JM, Topol EJ: Cardiac rupture<br />
associated with thrombolytic therapy: impact of time to treatment in the LATE Study. Journal of the<br />
American College of Cardiology 25:1063-1068, 1995. [PMID 7897117]<br />
277. Omoigui N, Topol EJ: Observational versus randomized medical device testing before and after market<br />
approval - The atherectomy versus angioplasty controversy. Controlled Clinical Trials 16:143-149, 1995.<br />
[PMID 7796597]<br />
278. Steinberg JS, Hochman JS, Morgan CD, Dorian P, Theroux P, Topol EJ, Armstrong PW and the LATE<br />
Ancillary Study Investigators: The effects of thrombolytic therapy administered 6-24 hours after<br />
myocardial infarction on the signal-averaged ECG: Results of a multicenter randomized trial. Circulation<br />
90:746-752, 1994. [PMID 8044943]<br />
279. Ellis SG, Lincoff AM, George BS, Kereiakes DJ, Ohman EM, Krucoff MW, Califf RM, Topol EJ, and the<br />
Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Randomized evaluation of<br />
coronary angioplasty for early TIMI 2 flow after thrombolytic therapy for the treatment of acute myocardial<br />
infarction: a new look at an old study. Coronary Artery Disease 5:611-615, 1994. [PMID 7952423]<br />
280. Mills P, Rothman MT, Topol EJ. Surgical cover for angioplasty. British Heart Journal 72:506-508, 1994.<br />
281. Lee KL, Woodlief L, Topol EJ, Weaver WD, Betriu A, Col J, Simoons M, Aylward P, Van de Werf F, Califf<br />
RM: Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from<br />
an international trial of 41,021 patients. Circulation 91:1659-1668, 1995. [PMID 7882472]<br />
282. Boehrer JD, Kereiakes DJ, Navetta FI, Califf RM, Topol EJ for the EPIC Investigators: Effects of<br />
profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass<br />
surgery. American Journal of Cardiology 74:1166-1170, 1994. [PMID 7977081]<br />
283. Abdelmeguid AE, Whitlow PL, Sapp SK, Ellis SG, Topol EJ. Long-term outcome of transient,<br />
uncomplicated in-laboratory coronary artery closure. Circulation 91:2733-2741, 1995. [PMID 7758178]<br />
284. The GUSTO IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for<br />
acute coronary syndromes. Circulation 90:1631-37, 1994. [PMID 7923645]<br />
285. Holmes DR, Topol EJ, Califf RM, Leya F, Berberg PB, Talley JD, Kellett MA, Shani J, Gottlieb RS,<br />
Whitlow PL, Adelman AG, Pinkerton CA, Lee KL, Pieper K, Keeler GP, Ellis SG for the CAVEAT-II<br />
Investigators: A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for<br />
patients with saphenous vein bypass graft lesions. Circulation 91:1966-1974, 1995. [PMID 7895354]<br />
286. Simes RJ, Topol EJ, Holmes DR, White HD, Rutsch WR, Vahanian A, Simoons ML, Morris D, Betriu A,<br />
Califf RM, Ross AM for the GUSTO-I Investigators. The link between the angiographic substudy and<br />
mortality outcomes in a large randomized trial of myocardial reperfusion: the importance of early and<br />
complete infarct artery reperfusion. Circulation 91:1923-1928, 1995. [PMID 7895348]<br />
287. Reiner JS, Lundergan CF, van den Brand M, Boland J, Thompson MA, Machecourt J, Py A, Pilcher GS,<br />
Fink CA, Burton JR, Simoons ML, Califf RM, Topol EJ, Ross AM, for the GUSTO Angiographic<br />
Investigators. Early angiography cannot predict post-thrombotic coronary reocclusion: Observations from<br />
the GUSTO Angiographic Study. Journal of the American College of Cardiology 24:1439-1444, 1994.<br />
[PMID 7930273]<br />
288. Topol EJ. Validation of the early open infarct vessel hypothesis. American Journal of Cardiology 72:40G-<br />
45G, 1993. [PMID 8279360]<br />
289. Gersh BJ, Topol EJ. Angioplasty or thrombolysis in acute myocardial infarction: dilate or dissolve?<br />
Cleveland Clinic Journal of Medicine 62:15-19, 1995. [PMID 7859398]<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 18
290. Ellis SG, Cowley MJ, Whitlow PL, Vandormael M, Lincoff AM, DiSciascio G, Dean LS, Topol EJ for the<br />
Multivessel Angioplasty Prognosis Study (MAPS) Group: Prospective case-control comparison of<br />
percutaneous transluminal coronary revascularization in patients with multivessel disease treated in<br />
1986-87 versus 1991: Improved in-hospital and 12 month results. Journal of the American College of<br />
Cardiology 25:1137-1142, 1995. [PMID 7897127]<br />
291. Elliott JM, Berdan LG, Holmes DR, Isner JM, King SB, Keeler GP, Kearney M, Califf RM, Topol EJ for the<br />
CAVEAT Study Investigators. One-year follow-up in the Coronary Angioplasty versus Excisional<br />
Atherectomy Trial (CAVEAT-I). Circulation 91:2158-2166, 1995. [PMID 7697844]<br />
292. Villa AE, Guzman LA, Poptic E, Labhasetwar V, D’Souza S, Plow EF, Levy RJ, DiCorleto P, Topol EJ:<br />
The effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and<br />
response to vessel wall injury. Circulation Research 76:505-513, 1995. [PMID 7895327]<br />
293. Van de Werf F, Topol EJ, Lee KL, Woodlief LH, Granger CB, Armstrong PW, Barbash GI, Hampton JR,<br />
Guerci A, Simes J, Ross A, Califf RM for the GUSTO Investigators: Variations in patient management and<br />
outcome for acute myocardial infarction in the United States and other countries. Journal of the American<br />
Medical Association 273:1586-1591, 1995. [PMID 7745771]<br />
294. Karnash S, Granger C, White H, Wooflief LH, Topol EJ, Califf RM for the GUSTO Investigators: Treating<br />
menstruating women with thrombolytic therapy: Insights from the GUSTO trial. Journal of the American<br />
College of Cardiology 26:1651-56, 1995. [PMID 7594099]<br />
295. Silver MJ, Sutton JM, Hook S, Lee P, Malycky JL, Ellis SG, Topol EJ, Nicolini FA. Adjunctive selectin<br />
blockade successfully reduces infarct size beyond thrombolytics in the electrolytic canine coronary artery<br />
model. Circulation 92:492-499,1995. [PMID 7543381]<br />
296. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. New<br />
England Journal of Medicine 332:1553-1559, 1995. [PMID 7739710]<br />
297. Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M,<br />
Gottlieb R, Hanovich G, Rosenberg M, Donohue TJ, Weisman HF, Califf RM, for the EPIC Investigators:<br />
Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients<br />
undergoing percutaneous coronary intervention. Circulation 91:2882-2890, 1995. [PMID 7796496]<br />
297A. Belli G, Topol EJ. Part I: Reperfusion and antithrombotic strategies for acute MI. Contemporary<br />
Internal Medicine 7:31-38, 43-45, 1995. [PMID 10150611]<br />
298. Boehrer JD, Ellis SG, Pieper K, Holmes DR, Keeler GP, Debowey D, Chapekis AT, Leya F, Mooney MR,<br />
Gottlieb RS, Serruys PW, Califf RM, Topol EJ for the CAVEAT-I Investigators. Directional atherectomy<br />
versus balloon angioplasty for coronary ostial and non-ostial left anterior descending artery lesions:<br />
results from a randomized, multicenter trial. Journal of the American College of Cardiology 25:1380-<br />
1386, 1995. [PMID 7722137]<br />
299. Topol EJ, Califf RM, Sigmon KA, Lee KL. Thrombolytic therapy for women with acute myocardial<br />
infarction: Is there a gender gap? Cardiovascular Health and Disease in Women 1:22-27, 1995.<br />
300. Lefkovits J, Holmes DR, Califf RM, Safian RD, Pieper K, Keeler G, Topol EJ for the CAVEAT-II<br />
Investigators. Predictors and sequelae of distal embolization during saphenous vein graft intervention<br />
from the CAVEAT-II trial. Circulation 92:734-740, 1995. [PMID 7641351]<br />
301. Lincoff AM, Topol EJ, Sigmon KN, Lee KL, Ohman EM, Rosenschein U, Califf RM, Ellis SG. Significance<br />
of a coronary artery with thrombolysis in myocardial infarction grade 2 flow “patency” (outcome in the<br />
Thrombolysis and Angioplasty in Myocardial Infarction Trials). American Journal of Cardiology 75:871-<br />
876, 1995. [PMID 7732992]<br />
302. Horrigan MG, Topol EJ. Direct angioplasty in acute myocardial infarction state of the art and current<br />
controversies. Cardiology Clinics 13:321-338, 1995. [PMID 7585770]<br />
303. Topol EJ. Novel antithrombotic approaches to coronary artery disease. American Journal of Cardiology<br />
75:27B-33B, 1995. [PMID 7863968]<br />
304. Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ for the EPIC Study<br />
Investigators. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 19
percutaneous transluminal coronary angioplasty or directional atherectomy (The EPIC Trial). American<br />
Journal of Cardiology 75:559-562, 1995. [PMID 7887377]<br />
305. Gottsauner-Wolf M, Moliterno DJ, Lincoff AM, Topol EJ. Restenosis - An open file. Clinical Cardiology<br />
19:347-356, 1996. [PMID 8723592]<br />
306. Ellis SG, Miller DP, Brown KJ, Omoigui N, Howell GL, Grierson J, Kutner M, Topol EJ: The in-hospital<br />
cost of percutaneous coronary revascularization: critical determinants and implications. Circulation<br />
92:741-747, 1995. [PMID 7641352]<br />
307. DeLuca SA, Korcuska LA, Oberstar BH, Rosenthal ML, Welsh PA, Topol EJ: Are we promoting true<br />
informed consent in cardiovascular clinical trials? Journal of Cardiovascular Nursing 9:54-61, 1995.<br />
[PMID 7782813]<br />
308. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G, White H, Simoons ML,<br />
Nelson CL, Clapp-Channing N, Knight JD, Harrell FE, Simes J, Topol EJ: Cost effectiveness of<br />
thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute<br />
myocardial infarction. New England Journal of Medicine 332:1418-1424, 1995. [PMID 7723799]<br />
309. Topol EJ, Block PC, Holmes DR, Klinke WP, Brinker JA. Readiness for the scorecard era in<br />
cardiovascular medicine. American Journal of Cardiology 75:1170-1173, 1995. [PMID 7762507]<br />
310. Williams DO, Baim DS, Bates E, Bonan R, Bost JE, Cowley M, Faxon DP, Feit F, Jones R, Kellett MA,<br />
Kelsey SF, Sopko G, Stadius M, Topol EJ, and BARI Investigators: Coronary anatomic and procedural<br />
characteristics of patients randomized to coronary angioplasty in the Bypass Angioplasty<br />
Revascularization Investigation (BARI). American Journal of Cardiology 75:27C-33C, 1995. [PMID<br />
7892819]<br />
311. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI,<br />
Smith JE, Worley SJ, Miller JA, Joseph DM, Sigmon KN, Kitt MM, du Mee CP, Califf RM, Topol EJ for the<br />
IMPACT Investigators. Multicenter, randomized, double-blind placebo-controlled trial of the platelet<br />
integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention. Circulation 91:2151-2157,<br />
1995. [PMID 7697843]<br />
312. Holmes DR, Bates ER, Kleiman NS, Sadowski Z, Horgan JH, Morris DC, Califf RM, Berger PB, Topol<br />
EJ: Contemporary reperfusion therapy for cardiogenic shock: The GUSTO I Trial experience. Journal of<br />
the American College of Cardiology 26:668-674, 1995. [PMID 7642857]<br />
313. Omoigui NA, Califf RM, Pieper K, Keeler G, O'Hanesian MA, Berdan LG, Mark DB, Topol EJ for the<br />
CAVEAT Investigators: Peripheral vascular complications in the Coronary Atherectomy Versus Excisional<br />
Atherectomy Trial (CAVEAT). Journal of the American College of Cardiology 26:922-930, 1995. [PMID<br />
7560619]<br />
314. Abdelmeguid AE, Whitlow PL, Simpfendorfer C, Sapp SK, Franco I, Ellis SG, Topol EJ. Percutaneous<br />
revascularization of ostial saphenous vein graft stenoses. Journal of the American College of Cardiology<br />
26:955-960, 1995. [PMID 7560623]<br />
315. Topol EJ, Nissen S. Our preoccupation with coronary luminology: the dissociation between clinical and<br />
angiographic findings in ischemic heart disease. Circulation 92:2333-2342, 1995. [PMID 7554219]<br />
316. Christenson RH, Ohman EM, Topol EJ, O'Hanesian M, Sigmon KN, Duh S-H, Kereiakes D, Worley SJ,<br />
George BS, Pizzo CK, Wall TC, Califf RM for the TAMI Study Group. Creatine kinase MM and MB<br />
isoforms in patients receiving thrombolytic therapy and acute angiography. Clinical Chemistry 41:844-<br />
852, 1995. [PMID 7768002]<br />
317. Topol EJ. Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIb/IIIa<br />
inhibitors. American Heart Journal 130:666-672, 1995. [PMID 7668215]<br />
318. Lefkovits J, Topol EJ. Platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease. Current<br />
Opinion in Cardiology 10:420-6, 1995. [PMID 7549085]<br />
319. Barbash GI, Reiner J, White HD, Wilcox RG, Armstrong PW, Sadowski Z, Morris D, Aylward P, Woodlief<br />
LH, Topol EJ, Califf RM, Ross AM for the GUSTO-I Investigators. Evaluation of the paradoxical<br />
beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction:<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 20
Mechanism of the “smoker's paradox” from the GUSTO-I trial, with angiographic insights. Journal of the<br />
American College of Cardiology 26:1222-1229, 1995. [PMID 7594035]<br />
320. Moliterno DJ, Harrington RA, Califf RM, Rapold HJ, Topol EJ for the PARADIGM Investigators.<br />
Randomized, placebo-controlled study of Lamifiban with thrombolytic therapy for the treatment of acute<br />
myocardial infarction: rationale and design for the platelet aggregation receptor antagonist dose<br />
investigation and reperfusion gain in myocardial infarction (PARADIGM) study. Journal of Thrombosis<br />
and Thrombolysis 2:165-169, 1995. [PMID 10608020]<br />
321. Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, Ellis SG, Topol EJ: The<br />
influence of blockade at specific levels of the coagulation cascade on restenosis in rabbit atherosclerotic<br />
femoral artery injury model. Circulation 92:3041-3050, 1995. [PMID 7586275]<br />
322. Gore J, Granger C, Sloan MA, White H, Barbash G, Simoons M, Aylward P, Topol EJ, Califf RM for the<br />
GUSTO Investigators: Stroke occurrence, morbidity and mortality after thrombolytic therapy for acute<br />
myocardial infarction: Results from the GUSTO trial. Circulation 92:2811-2818, 1995. [PMID 7586246]<br />
323. Harrington RA, Lincoff AM, Califf RM, Holmes DR, Berdan LG, O'Hanesian MA, Keeler GP, Garrett K,<br />
Ohman EM, Mark DM, Jacobs AK, Topol EJ for the CAVEAT Investigators: Characteristics and<br />
consequences of myocardial infarction after percutaneous coronary intervention: insights from the<br />
Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). Journal of the American College of<br />
Cardiology 25:1693-1699, 1995. [PMID 7759725]<br />
324. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, Kottke-Marchant K, Savon SR, Selhub<br />
J, Nissen SE, Kutner M, Topol EJ, Jacobsen DW. Hyperhomocysteinemia and low pyridoxal phosphate:<br />
Common and independent reversible risk factors for coronary artery disease. Circulation 92:2825-2830,<br />
1995. [PMID 7586248]<br />
325. Pilote L, Califf RM, Sapp S, Miller DP, Mark DB, Weaver WD, Gore JM, Armstrong PW, Ohman EM,<br />
Topol EJ. Regional variability in the United States for the management of acute myocardial infarction:<br />
Insights from the GUSTO trial. New England Journal of Medicine 333:565-572, 1995. [PMID 7623907]<br />
326. Topol EJ. The stentor and the sea change. American Journal of Cardiology 76:307-308, 1995. [PMID<br />
7618630]<br />
327. Ellis SG, Omoigui N, Bittl JA, Lincoff AM, Wolfe MW, Howell G, Topol EJ: Analysis of operator-specific<br />
outcomes in interventional cardiology from a multicenter database of 4860 quality-controlled procedures.<br />
Circulation 93:431-439, 1996. [PMID 8565159]<br />
328. Guzman LA, Forudi F, Villa A, Rothlein R, Topol EJ. Role of leukocytes in neointimal formation following<br />
balloon angioplasty in the rabbit atherosclerotic model. Coronary Artery Disease 6:693-701, 1995.<br />
[PMID 8747874]<br />
329. Sgarbossa E, Pinski SL, Barbagelata A, Underwood DA, Gates KB, Topol EJ, Califf RM, Wagner GS.<br />
Electrocardiographic diagnosis of acute myocardial infarction in the presence of left bundle branch block.<br />
New England Journal of Medicine 334:481-487, 1996. [PMID 8559200]<br />
330. Topol EJ. Caveats about elective coronary stenting. New England Journal of Medicine 331:539-541,<br />
1994. [PMID 7695686]<br />
331. Van de Werf F, Califf RM, Armstrong PW, Bates ER, Ross AM, Keiman NS, Topol EJ, on behalf of the<br />
GUSTO-I Steering Committee. Progress culminating from ten years of clinical trials on thrombosis for<br />
acute myocardial infarction. European Heart Journal 16:1024-1026, 1995. [PMID 8665962]<br />
332. White H, Barbash GI, Califf RM, Simes RJ, Granger C, Weaver WD, Kleiman NS, Aylward PE, Gore JM,<br />
Vahanian A, Lee KL, Ross AM, Topol EJ for the GUSTO Investigators: Age and outcome with<br />
contemporary thrombolytic therapy: Results from the GUSTO trial. Circulation 94:1826-1833, 1996.<br />
[PMID 8873656]<br />
333. Granger CB, Hirsh J, Califf RM, Woodlief L, Bovill E, White HD, Topol EJ for the GUSTO Investigators.<br />
Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial<br />
infarction: results from the GUSTO trial. Circulation 93:870-878, 1996. [PMID 8598077]<br />
334. Omoigui NA, Miller DP, Brown KJ, Annan K, Cosgrove D, Lytle BW, Loop F, Topol EJ. Outmigration for<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 21
cardiac surgery in an era of public dissemination of clinical outcomes. Circulation 93:27-33, 1996. [PMID<br />
8616936]<br />
335. Weaver WD, White HD, Wilcox RG, Aylward PE, Morris D, Guerci A, Ohman EM, Barbash GI, Betriu A,<br />
Sadowski Z, Topol EJ, Califf RM for the GUSTO-I Investigators. Comparisons of characteristics and<br />
outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy.<br />
Journal of the American Medical Association 275:777-782, 1996. [PMID 8598594]<br />
336. Mak KH, Eisenberg MJ, Eccleston DS, Cornhill JF, Topol EJ. Reusing coronary angioplasty equipment:<br />
technical and clinical issues. American Heart Journal 131:624-630, 1996. [PMID 8604655]<br />
337. Rao AK, Sun L, Chesebro JH, Fuster V, Harrington RA, Schwartz D, Gallo P, Matos D, Topol EJ for<br />
Hirudin in Unstable Angina Trial. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin<br />
on plasma levels of Fibrinopeptide A and prothrombin fragment F1.2 in unstable angina: a multicenter<br />
trial. Circulation 94:2389-2395, 1996. [PMID 8921778]<br />
338. Pilote L, Miller DP, Califf RM, Sunil R, Weaver WD, Topol EJ. Determinants of the use of coronary<br />
angiography and revascularization after thrombolysis for acute myocardial infarction in the United States.<br />
New England Journal of Medicine 335:1198-1205, 1996. [PMID 8815943]<br />
339. Mak KH, Eisenberg MJ, Eccleston DS, Brown KJ, Ellis SG, Topol EJ. Cost-efficacy modeling of catheter<br />
reuse for percutaneous transluminal coronary angioplasty. Journal of the American College of Cardiology<br />
28:106-111, 1996. [PMID 8752801]<br />
340. Johnson TL, Topol EJ. Early, complete infarct vessel patency: arriving at a gold standard for future<br />
clinical investigation in myocardial reperfusion. Journal of Thrombosis & Thrombolysis 4:259-266, 1997.<br />
[PMID 10639267]<br />
341. Eccleston D, Topol EJ. Inhibitors of platelet glycoprotein IIb/IIIa as augmenters of thrombosis.<br />
Coronary Artery Disease 6:947-955, 1995. [PMID 8723017]<br />
342. Harrington RA, Kleiman NS, Kottke-Marchant K, Lincoff AM, Tcheng JE, Sigmon KN, Joseph D, Rios G,<br />
Greenberg C, Kitt MM, Topol EJ, Califf RM. Immediate and reversible platelet inhibition following<br />
administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.<br />
American Journal of Cardiology 76:1222-1227, 1995. [PMID 7503000]<br />
343. Muller DWM, Gordon D, Topol EJ, Levy RJ, Golomb G. Sustained release local hirulog therapy<br />
decreases early thrombosis but not neointimal thickening after arterial stenting. American Heart Journal<br />
131:211-8, 1996. [PMID 8579010]<br />
344. Abdelmeguid AE, Ellis SG, Sapp SK, Whitlow PL, Topol EJ. Defining the appropriate threshold of<br />
creatine kinase elevation after percutaneous coronary interventions. American Heart Journal 131:1097-<br />
1105, 1996. [PMID 8644587]<br />
345. Topol EJ. Potential for a new coronary thrombolytic plateau. Journal of Thrombosis and Thrombolysis<br />
3:127-134, 1996. [PMID 10602553]<br />
346. Lefkovits J, Topol, EJ. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease.<br />
European Heart Journal 17:9-18, 1996. [PMID 8665658]<br />
347. Barsness GW, Ohman EM, Califf RM, Kereiakes DJ, George BS, Topol EJ. The Thrombolysis and<br />
Angioplasty in Myocardial Infarction (TAMI) Trials: A decade of reperfusion strategies. Journal of<br />
Interventional Cardiology 9:89-115, 1996.<br />
348. Holmes DR, Simpson JB, Berdan LG, Gottlieb RS, Leya F, Keeler GP, Califf RM, Topol EJ, for the<br />
CAVEAT I Investigators. Abrupt closure: The CAVEAT I Experience. Journal of the American College of<br />
Cardiology 26:1494-1500, 1995. [PMID 7594076]<br />
349. Newby LK, Califf RM, Guerci A, Weaver WD, Col J, Horgan JH, Mark DB, Stebbins A, van de Werf F,<br />
Gore J, Topol EJ. Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated<br />
infarction from the GUSTO trial. Journal of the American College of Cardiology 27:625-32, 1996. [PMID<br />
8606274]<br />
350. Holmes DR, Isner J, O'Brien M, Califf RM, Topol EJ. Effect of subintimal resection on initial outcome and<br />
restenosis for native coronary lesions and saphenous vein graft disease treated by directional coronary<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 22
atherectomy: a report from the CAVEAT I and II investigators. Journal of American College of Cardiology<br />
28:645-51, 1996. [PMID 8772751]<br />
351. Barbagelata A, Granger CB, Topol EJ, Worley SJ, Kereiakes DJ, George BS, Ohman EM, Leimberger<br />
JD, Mark DB, Califf RM, for the TAMI Study group. Frequency, significance, and cost of recurrent<br />
ischemia after thrombolytic therapy for acute myocardial infarction. American Journal of Cardiology<br />
76:1007-1013, 1995. [PMID 7484852]<br />
352. Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, O'Hanesian MA,<br />
Wagner GS, Kleiman NS, Harrell FE, Califf RM, Topol EJ for the GUSTO-IIa Investigators. Cardiac<br />
Troponin T levels for risk stratification in acute myocardial ischemia. New England Journal of Medicine<br />
335:1333-1341, 1996. [PMID 8857016]<br />
353. Lefkovits J, Ivanhoe RJ, Califf RM, Bergelson BA, Anderson KM, Stoner GL, Weisman HF, Topol EJ for<br />
the EPIC Investigators. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric<br />
monoclonal antibody improves acute and 6 month outcomes following PTCA for acute myocardial<br />
infarction. Insights from the EPIC Trial. American Journal of Cardiology 77:1045-1051, 1996. [PMID<br />
8644655]<br />
354. Mark DB, Talley JD, Topol EJ, Bowman L, Lam LC, Anderson KM, Jollis JG, Cleman MW, Lee KL,<br />
Aversano T, Untereker WJ, Davidson-Ray L, Califf RM for the EPIC Investigators. Economic assessment<br />
of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high risk coronary<br />
angioplasty. Circulation 94:629-35, 1996. [PMID 8772681]<br />
355. Guzman LA, Labhasetwar V, Song C, Jang Y., Lincoff AM., Levy R., Topol EJ. Local intraluminal infusion<br />
of biodegradable polymeric nanoparticles: a novel approach for drug delivery after balloon angioplasty.<br />
Circulation 94:1441-1448, 1996. [PMID 8823004]<br />
356. Redlitz A., Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity: a role in clot<br />
lysis in vivo. Circulation 93:1328-1330, 1996. [PMID 8641019]<br />
357. Eisenberg MJ, Topol EJ. Pre-hospital administration of aspirin in patients with unstable angina and<br />
acute myocardial infarction. Archives of Internal Medicine 156:1506-1510, 1996. [PMID 8687258]<br />
358. Lefkovits J, Califf RM, Anderson KM, Stoner GL, Blankenship JC, Talley JD, Worley SJ, Weisman HF,<br />
Topol EJ for the EPIC Investigators. The increased risk of non Q-wave myocardial infarction following<br />
directional atherectomy is platelet-dependent. Journal of the American College of Cardiology 28:849-<br />
855, 1996. [PMID 8837559]<br />
359. Horrigan MCG, MacIsaac AI, Nicolini FA, Vince DG, Lee P. Ellis SG, Topol EJ. Reduction in myocardial<br />
infarct size by basic fibroblast growth factor following temporary coronary occlusion in a canine model.<br />
Circulation 94:1927-1933, 1996. [PMID 8873670]<br />
360. Califf RM, Lincoff AM, Tcheng JE, Topol EJ. An overview of the results of the EPIC trial. European Heart<br />
Journal 16 (Suppl L):43-49, 1995. [PMID 8869018]<br />
361. LeBreton H, Topol EJ, Plow EF. Evidence for a pivotal role of platelets in vascular reocclusion and<br />
restenosis. Cardiovascular Research 31:235-36, 1996. [PMID 8730399]<br />
362. Newby LK, Rutsch WR, Califf RM, Simoons M, Aylward P, Armstrong PW, Woodlief LH, Lee KL, Topol<br />
EJ, Van de Werf F. Time from symptom onset to treatment in the outcome of patients treated with<br />
thrombolytic therapy. Journal of the American College of Cardiology 27:1646-1655, 1996. [PMID<br />
8636549]<br />
363. Van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HMM, Serruys PW, Holmes DR, Ellis SG,<br />
Topol EJ: Marked inflammatory sequelae to implantation of biodegradable and biostable polymers in<br />
porcine coronary arteries. Circulation 94:1690-1697, 1996. [PMID 8840862]<br />
364. Lefkovits J, Topol EJ. The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic<br />
heart disease. Cleveland Clinic Journal of Medicine 63:181-189, 1996. [PMID 8665658]<br />
365. Rashid J, Eisenberg MJ, Topol EJ. Cocaine-induced aortic dissection. American Heart Journal<br />
132:1301-4, 1996. [PMID 8969594]<br />
366. Aguirre F, Topol EJ, Anderson K, Kleiman NS, Weisman HF, Califf RM. Clinical benefit within patient<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 23
subgroups receiving c7E3 Fab (Abciximab) during percutaneous coronary revascularization: subgroup<br />
analysis from the EPIC Trial. Journal of Invasive Cardiology 8(Suppl B): 21B-32B, 1996.<br />
367. Moliterno DJ, Topol EJ. Another step toward resolving the contrast controversy. Journal of the American<br />
College of Cardiology 27:1387-89, 1996. [PMID 8626948]<br />
368. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, Chandra NC,<br />
Guerci AD, Ferguson JJ, Harrington RA, Lincoff AM, Yakubov SJ, Bahr R, Wolfe CL, Yock PG, Anderson<br />
HV, Nygaard TW, Mason SJ, Effron MB, Brashears L, Gottdiener P, du Mee C, Kitt MM, Gerstenblith G.<br />
The effects of Integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina: a<br />
randomized multicenter placebo-controlled trial. Circulation 94:2083-2089, 1996. [PMID 8901655]<br />
369. Nicolini FA, Lee P, Malycky JL, Lefkovits J, Kottke-Marchant K, Plow EF, Topol EJ. Selective Inhibition of<br />
factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of<br />
coronary thrombosis. Blood Coagulation and Fibrinolysis 7:39-48, 1996. [PMID 8845461]<br />
370. Califf RM, White HD, Van de Werf F, Sadowski Z, Armstrong PW, Vahanian A, Simoons ML, Simes J, Lee<br />
KL, and Topol EJ, for the GUSTO-I Investigators. One-year results from the global utilization of<br />
streptokinase and t-PA for occluded coronary arteries (GUSTO-I) Trial. Circulation 94:1233-1238, 1996.<br />
[PMID 8822974]<br />
371. Rosenschein U, Topol EJ. Uncoupling clinical outcomes and coronary angiography: a review and<br />
perspective of recent trials in coronary artery disease. American Heart Journal 132:910-920, 1996.<br />
[PMID 883190]<br />
372. Moliterno DJ, Elliott JM, Topol EJ. Randomized trials of myocardial revascularization. Current Problems<br />
in Cardiology XX:121-192, 1995. [PMID 7600846]<br />
373. Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, Califf RM, Topol EJ, and the<br />
GUSTO-I Investigators. The influence of diabetes mellitus on clinical outcome in the thrombolytic era of<br />
acute myocardial infarction. Journal of the American College of Cardiology 30:171-79, 1997. [PMID<br />
9207639]<br />
374. Vogel RA, and Topol EJ. Practice guidelines and physician scorecards: grading the graders. Cleveland<br />
Clinic Journal of Medicine 63:124-128, 1996. [PMID 8819697]<br />
375. Peterson ED, Hathaway WR, Zabel KM, Pieper KS, Granger CG, Wagner GS, Topol EJ, Bates ER,<br />
Simoons ML, Califf RM. The prognostic significance of precordial ST depression in inferior myocardial<br />
infarction in the thrombolytic era: results in 16,521 patients. Journal of the American College of<br />
Cardiology 28:305-312, 1996. [PMID 8800102]<br />
376. Holmes DR, Jr., Califf RM, Topol EJ. Lessons we have learned from the GUSTO trial. Global Utilization<br />
of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries. Journal of the American<br />
College of Cardiology 25(Suppl 7):10S-17S, 1995. [PMID 7775708]<br />
377. Abdelmeguid AE, Topol EJ. The myth of the myocardial "infarctlet" during percutaneous coronary<br />
revascularization procedures. Circulation 94:3369-3375, 1996. [PMID 8989153]<br />
378. Brener SJ, Leya FS, Apperson-Hansen C, Cowley MJ, Califf RM, Topol EJ. A comparison of debulking<br />
versus dilatation of bifurcation coronary lesions: lessons from the CAVEAT-I trial. American Journal of<br />
Cardiology 78:1039-1041, 1996. [PMID 8916485]<br />
379. Almony GT, Lefkovits J, Topol EJ. Antiplatelet and anticoagulant use after myocardial infarction. Clinical<br />
Cardiology 19:357-365, 1996. [PMID 8723593]<br />
380. Topol EJ. Early myocardial reperfusion: an assessment of current strategies in acute myocardial<br />
infarction. European Heart Journal 17(E) 42-48, 1996. [PMID 11824003]<br />
381. Lefkovits J, Malycky JL, Rao JS, Hart CE, Plow EF, Topol EJ, Nicolini FA. Selective inhibition of Factor<br />
Xa is more efficient than Factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis<br />
in the canine model. Journal of American College of Cardiology 28:1858-65, 1996. [PMID 8962577]<br />
382. Pepine CJ, Holmes DR, Brinker JA, Block PC, Mark DB, Mullins CE, Nissen SE, Topol EJ, Williams DO,<br />
Goldberg S, Serruys PW, and the Cardiac Catheterization Committee. Expert Consensus Document:<br />
Coronary Artery Stents. Journal of the American College of Cardiology 28:782-94, 1996. [PMID<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 24
8772772]<br />
383. Metz BK, and Topol EJ. Heparin as an adjuvant to thrombolytic therapy in acute myocardial infarction.<br />
Biomedicine and Pharmacotherapy 50:243-253, 1996. [PMID 8952863]<br />
384. Langer A, Goodman SG, Topol EJ, Charlesworth A, Skene AM, Wilcox RG, Armstrong PW, for the LATE<br />
Study Investigators. Late Assessment of Thrombolytic Efficacy (LATE) study: Prognosis in patients with<br />
non-Q wave myocardial infarction. Journal of the American College of Cardiology 27:1327-32, 1996.<br />
[PMID 8626939]<br />
385. Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley D, Anderson HV, Ellis SG, Cohen M,<br />
Sprigg D, Miller M, Kereiakes D, Yakubov S, Kitt MM, Sigmon KN, Califf RM, Krucoff MW, Topol EJ, for<br />
the IMPACT-AMI Investigators. Combined accelerated tissue-plasminogen activator and platelet<br />
glycoprotein IIb/IIIa integrin receptor blockade with integrelin in acute myocardial infarction: results of a<br />
randomized, placebo-controlled, dose-ranging trial. Circulation 95:846-854, 1997. [PMID 9054741]<br />
386. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of<br />
creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 94:1528-1536, 1996.<br />
[PMID 8840840]<br />
387. Brener SJ, Ellis SG, Apperson-Hansen C, Leon MB, Topol EJ. Comparison of stenting and balloon<br />
angioplasty for narrowings in aorto-coronary saphenous vein conduits in place for more than 5 years.<br />
American Journal of Cardiology 79:13-18, 1997. [PMID 9024728]<br />
388. Mak KH, Eisenberg MJ, Plante S, Strauss BH, Arheart KL, Topol EJ. Absence of increased in-hospital<br />
complications with reused balloon catheters. American Journal of Cardiology 78:717-719, 1996. [PMID<br />
8831419]<br />
389. Labinaz M, Sketch Jr. MH, Stebbins AL, DeFranco AC, Holmes DR, Kleiman NAS, Betriu A, Rutsch WR,<br />
Vahanian A, Topol EJ, Califf RM, for the GUSTO-I Investigators. Thrombolytic therapy for patients with<br />
prior percutaneous transluminal coronary angioplasty and evolving myocardial infarction. American<br />
Journal of Cardiology 78:1338-1344, 1996. [PMID 8970403]<br />
390. Barbagelata NA, Granger CB, Oqueli E, Suarez LD, Borruel M, Pieper KS, Topol EJ, Califf RM. TIMI<br />
Grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis. American Heart<br />
Journal 133:273-82, 1997. [PMID 9060794]<br />
391. GUSTO IIb Investigators. A comparison of recombinant hirudin versus heparin for the treatment of acute<br />
coronary syndromes. New England Journal of Medicine 335:775-82, 1996. [PMID 8778585]<br />
392. Lincoff AM, Tcheng JE, Califf RM, Bass T, Popma JJ, Teirstein PS, Kleiman NS, Hattel L, Anderson HV,<br />
Ferguson JJ, Cabot CF, Weisman HF, Anderson KM, Berdan LG, Musco MH, Topol EJ for the PROLOG<br />
Investigators: Standard versus low dose weight-adjusted heparin in patients treated with the platelet GP<br />
IIb/IIIa receptor antibody fragment c7E3 (Abciximab) Fab during percutaneous coronary<br />
revascularization. American Journal of Cardiology 79:286-291, 1997. [PMID 9036746]<br />
393. Simpfendorfer C, Kottke-Marchant K, Lowrie M, Miller DP, Cove CS, DeFranco AC, Ellis SG, Moliterno<br />
DJ, Raymond RE, Sutton JM, Topol EJ. First chronic platelet glycoprotein IIb/IIIa integrin blockade: a<br />
randomized placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary<br />
interventions. Circulation 96:76-81, 1997. [PMID 9236420]<br />
394. Berger PB, Holmes DR, Stebbins AL, Bates ER, Califf RM, Topol EJ. for the GUSTO-I Investigators.<br />
Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients<br />
with cardiogenic shock: results from the GUSTO-I Trial. Circulation 96:122-127, 1997. [PMID<br />
9236426]<br />
395. Holmes DR, Califf RM, Van de Werf F, Berger PB, Bates ER, Simoons ML, White HD, and Topol EJ, for<br />
the GUSTO-I Investigators. Difference in countries use of resources and clinical outcome in patients with<br />
cardiogenic shock after myocardial infarction: results from the GUSTO trial. Lancet 349:75-78, 1997.<br />
[PMID 8996417]<br />
396. LeBreton H, Plow EF, Topol EJ. The role of platelets in restenosis following percutaneous coronary<br />
revascularization. Journal of the American College of Cardiology 28:1643-1651, 1996. [PMID 8962547]<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 25
397. Challapalli R, Lefkovits J, Topol EJ. Clinical trials of recombinant hirudin in acute coronary syndromes.<br />
Coronary Artery Disease 7:429-437, 1996. [PMID 8889358]<br />
398. Lefkovits J, Topol EJ. Pharmacological approaches for the prevention of restenosis after percutaneous<br />
coronary intervention. Progress in Cardiovascular Diseases 40:141-158, 1997. [PMID 9327830]<br />
399. Belli G, Ellis SG, Topol EJ. Stenting for ischemic heart disease. Progress in Cardiovascular Diseases<br />
40:159-182, 1997. [PMID 9327831]<br />
400. Hannan EL, Racz M, Ryan TJ, McCallister BD, Johnson LW, Arani DT, Guerci AD, Sosa J, Topol EJ.<br />
Coronary angioplasty volume - outcome relationships for hospitals and operators in New York state:<br />
1991-1994. Journal of the American Medical Association 277:892-898, 1997. [PMID 9062327]<br />
401. Tardiff BE, Califf RM, Morris D, Bates E, Woodlief LH, Lee KL, Rutsch W, Topol EJ for the GUSTO<br />
Investigators. Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on<br />
survival after thrombolysis. Journal of the American College of Cardiology 29:240-249, 1997. [PMID<br />
9014973]<br />
402. Berkowitz SD, Granger CB, Pieper KS, Lee KL, Gore JM, Simoons M, Armstrong PW, Topol EJ, Califf<br />
RM for the GUSTO-I Investigators. Incidence and predictors of bleeding following contemporary<br />
thrombolytic therapy for myocardial infarction. Circulation 95:2508-2516, 1997. [PMID 9184581}<br />
403. Migrino RQ, Young JB, Ellis SG, White HD, Lundergan CF, Miller DP, Granger CB, Ross AM, Califf RM,<br />
Topol EJ, for the GUSTO-I Angiographic Investigators. End-systolic volume index at 90-180 minutes<br />
into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality.<br />
Circulation 96:116-121, 1997. [PMID 9236420]<br />
404. Lincoff AM, Furst JG, Tuch RJ, Ellis SG, and Topol EJ. Sustained local delivery of dexamethasone by a<br />
novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. Journal of the<br />
American College of Cardiology 29:808-816, 1997. [PMID 9091528]<br />
405. Mak KH, Challapalli R, Eisenberg MJ, Anderson KM, Califf RM, Topol EJ for the EPIC Investigators.<br />
Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous<br />
revascularization of aortocoronary saphenous vein grafts. American Journal of Cardiology 80:985-988,<br />
1997. [PMID 9352964]<br />
406. Aylward PE, Wilcox RG, Horgan JH, White HD, Granger CB, Califf RM, Topol EJ, for the GUSTO-I<br />
Investigators. Increased arterial blood pressure, mortality, and stroke with contemporary thrombolytic<br />
therapy for acute myocardial infarction. Annals of Internal Medicine 125:891-900, 1996. [PMID<br />
8967669]<br />
407. Pietila K, Hermens WT, Harmoinen A, Baardman T, Pasternack A, Topol EJ, Simoons ML. Comparison<br />
of peak serum C-reactive protein and hydroxybutyrate dehydrogenase levels in patients with acute<br />
myocardial infarction treated with alteplase and streptokinase. American Journal of Cardiology 80:1075-<br />
1077, 1997. [PMID 9352981]<br />
408. Eisenberg MJ, Califf RM, Cohen EA, Adelman AG, Keeler G, Mark DB, Topol EJ. Use of evidencebased<br />
medical therapy in patients undergoing percutaneous coronary revascularization: a comparison of<br />
practice patterns in the United States, Europe, and Canada. American Journal of Cardiology 79:867-872,<br />
1997. [PMID 9104896]<br />
409. Woodfield SL, Lundergan CF, Reiner JS, Thompson MA, Rohrbech SC, Deychak Y, Smith JO, Burton JR,<br />
McCarthy WF, Califf RM, White HD, Weaver WD, Topol EJ, Ross AM. Gender and acute myocardial<br />
infarction: is there a different response to thrombolysis? Journal of the American College of Cardiology<br />
29:35-42, 1997. [PMID 8996292]<br />
410. O'Brien JE, Peterson ED, Keeler GP, Berdan LG, Ohman EM, Faxon DP, Jacobs AK, Topol EJ, Califf<br />
RM. Relation between estrogen replacement therapy and restenosis after percutaneous coronary<br />
interventions. Journal of the American College of Cardiology 28:1111-1118, 1996. [PMID 8890803]<br />
411. Christenson RH, Ohman EM, Topol EJ, Peck S, Newby LK, Duh S-H, Kereiakes DJ, Worley SJ,<br />
Alosozana GL, Wall TC, Califf RM, for the TAMI-7 Study Group. Assessment of coronary reperfusion<br />
after thrombolysis with a model containing myoglobin, creatine linase-MB, and clinical variables.<br />
Circulation 96:1776-1782, 1997. [PMID 9323061]<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 26
412. Woodfield SL, Lundergan CF, Reiner JS, Greenhouse S, Thompson MA, Rohrbech SC, Deychak Y,<br />
Simoons ML, Califf RM, Topol EJ, Ross AM for the GUSTO-I Angiographic Investigators. Angiographic<br />
findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial<br />
infarction: the GUSTO-I experience. Journal of the American College of Cardiology 28:1661-1669, 1996.<br />
[PMID 8962549]<br />
413. Mak K-H, Topol EJ. Clinical trials to prevent restenosis after percutaneous coronary revascularization.<br />
Annals of the New York Academy of <strong>Science</strong>s 811:255-288, 1997. [PMID 9186603]<br />
414. Topol EJ. Journal of Thrombosis and Thrombolysis 5:S125-S131, 1998.<br />
415. Topol EJ. Reperfusion for acute myocardial infarction: 1997 and beyond. Cleveland Clinic Journal of<br />
Medicine 64:9-12, 1997. [PMID 9014377]<br />
416. Topol EJ. Treatment of acute myocardial infarction: in which patients should primary PTCA be preferred<br />
to thrombolysis? Cardiologia 41:843-847, 1996. [PMID 8940780]<br />
417. Moen EK, Miller DP, Asher CR, Weaver WD, White HD, Califf RM, Topol EJ. Long-term follow-up of<br />
gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I<br />
Trial. Journal of Women's Health 6:285-293, 1997. [PMID 9201663]<br />
418. Topol EJ. Eric Jeffrey Topol: a conversation with the editor. American Journal of Cardiology 78:72-81,<br />
1996.<br />
419. Granger CB, Becker R, Tracy RP, Califf RM, Topol EJ, Pieper KS, Ross AM, Roth S, Lambrew C, Bovill<br />
EG, for the GUSTO Hemostasis Substudy Group. Thrombin generation, inhibition, and clinical outcomes<br />
in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from<br />
the GUSTO trial. Journal of the American College of Cardiology 31:497-505, 1998. [PMID 9502626]<br />
420. Ward SR, Sutton JM, Pieper K, Schwaiger M, Califf RM, Topol EJ, for the TAMI-5 Investigators. Effects<br />
of thrombolytic regimen, early catheterization, and predischarge angiographic variables on six week left<br />
ventricular function: results from the TAMI 5 MUGA Substudy. American Journal of Cardiology 79:539-<br />
544, 1997. [PMID 9068505]<br />
421. Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, Harrington RA, Topol EJ, for<br />
the EPIC Investigators. Evidence for prevention of death and myocardial infarction with platelet<br />
membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable<br />
angina undergoing percutaneous coronary revascularization. Journal of the American College of<br />
Cardiology 30:149-56, 1997. [PMID 9207636]<br />
422. The GUSTO II Angioplasty Substudy Investigators. A clinical trial comparing primary coronary<br />
angioplasty with tissue plasminogen activator and recombinant hirudin with heparin for acute myocardial<br />
infarction. New England Journal of Medicine 336:1621-28, 1997. [PMID 9173270]<br />
423. Brener SJ, Loop FD, Lytle BW, Cosgrove DM, Ellis SG, Topol EJ. Repeat myocardial revascularization:<br />
a profile of candidates for angioplasty or surgery. Journal of Thoracic and Cardiovascular Surgery<br />
114:153-161, 1997. [PMID 9270630]<br />
424. Gottsauner-Wolf M, Jang Y, Lincoff AM, Cohen JL, Labhasetwar V, Poptic EJ, Forudi F, Guzman LA,<br />
DiCorleto PE, Levy RJ, Topol EJ, Ellis SG. Influence of local delivery of the protein tyrosine kinase<br />
receptor inhibitor tyrphostin-47 on smooth muscle cell proliferation in the rat carotid balloon injury model.<br />
American Heart Journal 133:329-34, 1997. [PMID 9060802]<br />
425. Gottsauner-Wolf M, Jang Y, Penn MS, Kaplan A, Ellis SG, Chisolm GM, Topol EJ, Lincoff AM.<br />
Quantitative evaluation of local drug delivery using the Infusasleeve catheter. Catheterization and<br />
Cardiovascular Diagnosis 42:102-108, 1997. [PMID 9286553]<br />
426. EPILOG Investigators. Effect of the platelet glycoprotein IIb/IIIa receptor inhibitor abciximab with lower<br />
heparin dosages on ischemic complications of percutaneous coronary revascularization. New England<br />
Journal of Medicine 336:1689-96, 1997. [PMID 9182212]<br />
427. Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Wang AL, Anderson KM, and Califf RM on<br />
behalf of the EPIC Investigators. Long term protection from myocardial ischemic events after brief<br />
integrin blockade with percutaneous coronary intervention. Journal of the American Medical Association<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 27
278:479-484, 1997. [PMID 9256222]<br />
428. Forrester JS, Topol EJ, Abele JE, Holmes DR Jr, Skorton DJ. Task Force 5. Assessment, approval, and<br />
regulation of new technology. Journal of the American College of Cardiology 29:1171-1179, 1997. [PMID<br />
9137210]<br />
429. Crenshaw BS, Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf RM, for the GUSTO-I trial<br />
Investigators. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO experience.<br />
Journal of the American College of Cardiology 30:406-13, 1997. [PMID 9247512]<br />
430. Topol EJ. Targeted approaches to thrombus inhibition: an end to the shotgun approach. Clinical<br />
Cardiology 20: 122-126, 1997.<br />
431. Levine GN, Jacobs AK, Keeler GP, Berdan LG, Leya F, Topol EJ, Califf RM, for the CAVEAT-I<br />
Investigators. The impact of diabetes mellitus on percutaneous revascularization: results of CAVEAT-I.<br />
American Journal of Cardiology 79:748-755, 1997. [PMID 9070553]<br />
432. Califf RM, Woodlief L, Lee KL, Harrell FE, White H, Guerci A, Barbash G, Simes RJ, Weaver WD,<br />
Simoons ML, Topol EJ for the GUSTO-I Investigators: Selection of thrombolytic therapy for individual<br />
patients: development of a clinical model. American Heart Journal 133:630-639, 1997. [PMID 9200390]<br />
433. Zabel KM, Granger CB, Becker RC, Bovill EG, Hirsh J, Aylward PE, Topol EJ, Califf RM for the GUSTO-I<br />
Investigators. The use of a bedside activated partial thromboplastin time (aPTT) monitor to adjust level of<br />
anticoagulation following thrombolysis in a large, multinational trial of acute myocardial infarction.<br />
American Heart Journal 136:868-76, 1998. [PMID 9812083]<br />
434. Califf RM, Abdelmeguid A, Kuntz R, Popma JJ, Tardiff BE, Crenshaw B, Bauman RP, Davidson CJ,<br />
Cohen EA, Kleiman NS, Mahaffey KW, Topol EJ, Pepine CJ, Lipicky R, Granger CB, Harrington RA,<br />
Zuckerman B, Chaitman, Bittl JA, Ohman EM. Myonecrosis after revascularization procedures. Journal<br />
of the American College of Cardiology 31:241-51, 1998. [PMID 999462562]<br />
435. Anderson, RD, Ohman EM, Holmes DR, Col J, Stebbins A, Bates ER, Stomel RJ, Granger CB, Topol EJ,<br />
and Califf RM, for the GUSTO-I Investigators. Use of intraaortic balloon counterpulsation in patients<br />
presenting with cardiogenic shock: observations from the GUSTO-I study. Journal of the American<br />
College of Cardiology 30:708-15, 1997. [PMID 9283530]<br />
436. Brieger DB, Topol EJ. Local drug delivery systems and prevention of restenosis. Cardiovascular<br />
Research 35:405-413, 1997. [PMID 9415284]<br />
437. Ellis SG, Brener S, DeLuca S, Tuzcu EM, Raymond R, Whitlow PL, and Topol EJ. Late myocardial<br />
ischemic events after saphenous vein graft intervention - importance of initially "nonsignificant" vein graft<br />
lesion. American Journal of Cardiology 79:1460-1464, 1997. [PMID 9185633]<br />
438. Brieger DB, Topol EJ. Hirudin in acute coronary syndromes: when cents override good sense. Journal<br />
of Thrombosis and Thrombolysis 4:325-328, 1997. [PMID 10639635]<br />
439. Topol EJ, Califf RM, Van de Werf F, Simoons M, Hampton J, Lee KL, White H, Simes J, Armstrong PW<br />
for the VIGOUR Group. Perspectives on large scale cardiovascular clinical trials for the new millennium.<br />
Circulation 95:1072-1082, 1997. [PMID 9054772]<br />
440. O'Connor CM, Hathaway WR, Bates ER, Leimberger J, Sigmon KN, Kereiakes DJ, George BS, Samaha<br />
JK, Abbottsmith CW, Candela RJ, Topol EJ, Califf RM. Clinical characteristics and long-term outcome of<br />
patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial<br />
infarction: Development of a predictive model. American Heart Journal 133:663-73, 1997. [PMID<br />
9200394]<br />
441. Omoigui NA, Silver MJ, Rybicki LA, Rosenthal M, Berdan LG, Pieper K, Califf RM, and Topol EJ for the<br />
CAVEAT Investigators. Influence of a randomized clinical trial on practice by participating investigators:<br />
lessons from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). Journal of the<br />
American College of Cardiology 31:265-72, 1998. [PMID 9462565]<br />
442. The GUSTO-III Investigators. An international, multicenter, randomized comparison of reteplase with<br />
alteplase for acute myocardial infarction. New England Journal of Medicine 337: 1118-23, 1997. [PMID<br />
9340503]<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 28
443. Mahaffey KW, Granger CB, Toth C, White HD, Stebbins AL, Barbash GI, Vahanian A, Topol EJ, Califf<br />
RM, for the GUSTO-I Investigators. Diabetic retinopathy should not be a contraindication to thrombolytic<br />
therapy for acute myocardial infarction: quantification of risk in 6011 diabetic patients in the GUSTO-I<br />
trial. Journal of the American College of Cardiology 30:1606-10, 1997. [PMID 9385883]<br />
444. Khan MM, Ellis SG, Aguirre FV, Weisman HF, Wilderman N, Califf RM, Topol EJ, Kleiman NS. Does<br />
intracoronary thrombus influence the outcome of high risk percutaneous transluminal angioplasty?<br />
Clinical and angiographic outcomes in a large multicenter trial. Journal of the American College of<br />
Cardiology 31:31-36, 1998. [PMID 9426014]<br />
445. Brieger DB, Mak K-H, White HD, Kleiman NS, Miller DP, Vahanian A, Ross AM, Califf RM, Topol EJ, for<br />
the GUSTO-I Investigators. Benefit of early sustained reperfusion in patients with prior myocardial<br />
infarction. (The GUSTO-I Trial). American Journal of Cardiology 81:282-287, 1998. [PMID 9468068]<br />
446. Kleiman NS, Lincoff AM, Kereiakes DJ, Miller DP, Aguirre FV, Anderson K, Weisman HF, Califf RM, Topol<br />
EJ. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a<br />
multicenter trial. Circulation 97:1912-1920, 1998. [PMID 9609084]<br />
447. Moliterno DJ, Topol EJ. Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic<br />
therapy for acute myocardial infarction. Thrombosis and Haemostasis 78:214-219, 1997. [PMID<br />
9198156]<br />
448. The IMPACT II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on<br />
complications of percutaneous coronary intervention. Lancet 349:1422-1428, 1997. [PMID 9164315]<br />
449. Pfisterer M, Cox JL, Granger CB, Brener S, Naylor CD, Califf RM, Armstrong PW, Van de Werf F,<br />
Stebbins AL, Lee KL, Topol EJ, for the GUSTO Investigators. Atenolol use and clinical outcomes after<br />
thrombolysis for acute myocardial infarction: The GUSTO-I Experience. Journal of the American College<br />
of Cardiology 32:634-40, 1998. [PMID 9741504]<br />
450. The BARI Investigators. The Bypass Angioplasty Revascularization Investigation (BARI): Influence of<br />
diabetes on 5 year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients<br />
with multivessel disease. Circulation 96:1761-1769, 1997. [PMID 9323059]<br />
451. Holmes DR, Topol EJ. Cardiogenic shock: Does it matter where and how a patient is treated?<br />
European Heart Journal 18:1839-1840, 1997. [PMID 9447304]<br />
452. Narins CR, Holmes DR, Topol EJ. A call for provisional stenting: The balloon is back! Circulation<br />
97:1298-1305, 1998. [PMID 9570201]<br />
453. Topol EJ. Towards a new frontier in myocardial reperfusion therapy. Circulation 97:211-218, 1998.<br />
[PMID 9445175]<br />
454. Gebel JM, Sila CA, Sloan MA, Granger CB, Mahaffey KW, Weisenberger J, Green CL, White HD, Gore<br />
JM, Weaver WD, Califf RM, Topol EJ, for the GUSTO-I Investigators. Thrombolysis-related intracranial<br />
hemorrhage: An analysis of 244 cases from the GUSTO-I trial. Stroke 29:563-569, 1998. [PMID<br />
9506593]<br />
455. Mak K-H, Tan ATH, Chan C, Koh T-H, Topol EJ. The clinical impact of glycoprotein IIb/IIIa receptor<br />
blockade in cardiovascular medicine. Japanese Circulation Journal 62:233-243, 1998. [PMID 9583455]<br />
456. Mahaffey KW, Granger CB, Sloan MA, Thompson TD, Gore JM, Weaver WD, White HD, Simoons ML,<br />
Barbash GI, Topol EJ, Califf RM, for the GUSTO-I Investigators. Risk factors for in-hospital<br />
nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results<br />
from GUSTO-I. Circulation 97:757-764, 1998. [PMID 9498539]<br />
457. Ghaffari S, Kereiakes DJ, Lincoff AM, Kelly TA, Timmis GC, Kleiman NS, Ferguson JJ, Miller DP, Califf<br />
RM, and Topol EJ for the EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade with<br />
abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy.<br />
American Journal of Cardiology 82:7-12, 1998. [PMID 9671000]<br />
458. Christenson RH, Duh S-H, Newby LK, Ohman EM, Califf RM, Granger CB, Pecl S, Pieper KS, Armstrong<br />
PW, Katus HA, Topol EJ for the GUSTO II-a Investigators. Cardiac troponin T and cardiac troponin I:<br />
relative values in short-term risk stratification of patients with acute coronary syndromes. Clinical<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 29
Chemistry 97:494-501, 1998. [PMID 9510853]<br />
459. Brieger DB, Mak K-H, Kottke-Marchant K, Topol EJ. Heparin induced thrombocytopenia. Journal of the<br />
American College of Cardiology 31:1449-1459, 1998. [PMID 9626819]<br />
460. Benzaquen BS, Eisenberg MJ, Challapalli R, Nguyen T, Brown KJ, Topol EJ. Correlates in in-hospital<br />
cost among patients undergoing abdominal aortic aneurysm repair. American Heart Journal 136:696-<br />
702, 1998. [PMID 9778074]<br />
461. Guetta V, Topol EJ. Pacifying the infarct vessel. Circulation 96:713-15, 1997. [PMID 9264471]<br />
462. Topol EJ. Validation for coronary stenting: A permanent implant for interventional cardiology. European<br />
Heart Journal 18:1525-1526, 1997. [PMID 9347260]<br />
463. Steinhubl S, Topol EJ. Stenting for acute myocardial infarction. Lancet 350:532-33, 1997. [PMID<br />
9284772]<br />
464. Kereiakes DJ, Lincoff AM, Miller DP, Tcheng JE, Weisman HF, Anderson KM, Cabot K, Califf RM, Topol<br />
EJ, for the EPILOG Trial Investigators. Abciximab therapy and unplanned coronary stent deployment:<br />
Favorable effects on stent utilization, clinical outcomes and bleeding complications. Circulation 97:857-<br />
864, 1998. [PMID 9521334]<br />
465. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition and<br />
prevention. Circulation 97:916-931, 1998. [PMID 9521341]<br />
466. Sgarbossa EB, Pinski SL, Topol EJ, Califf RM, Barbagelata A, Goodman SG, Gates KB, Granger CB,<br />
Miller D, Underwood DA, Wagner GS, for the GUSTO-I Investigators. Acute myocardial infarction and<br />
bundle branch block at hospital admission: Clinical characteristics and outcomes in the thrombolytic era.<br />
Journal of the American College of Cardiology 31:105-110, 1998. [PMID 9426026]<br />
467. Serebruany VL, Gurbel PA, Shustov AR, Dalesandro M, Gumbs CI, Grabletz LB, Bahr RD, Ohman EM,<br />
Topol EJ. Depressed platelet status in a patient with hemorrhagic stroke following thrombolysis for acute<br />
myocardial infarction. Stroke 29:235-238, 1998. [PMID 9445356]<br />
468. Gibler WB, Wilcox RG, Bode C, Castaigne AD, Delooz H, Elich D, Fox KAA, Kereiakes DJ, Rupprecht H,<br />
Topol EJ. Prospective use of glycoprotein IIb/IIIa receptor blockers in the emergency department<br />
setting. Annals of Emergency Medicine 32:712-722, 1998. [PMID 9919443]<br />
469. Blankenship JC, Hellkamp AS, Aguirre FV, Demko SL, Topol EJ Califf RM, for the EPIC Investigators.<br />
Vascular access site complications after percutaneous coronary intervention with abciximab in the<br />
evaluation of c7E3 for the prevention of ischemic complications (EPIC) trial. American Journal of<br />
Cardiology 81:36-40, 1998. [PMID 9462603]<br />
470. Thel MC, Califf RM, Tcheng JE, Sigmon K, Topol EJ, and Ellis SG for the EPIC Investigators. Clinical<br />
risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC<br />
Trial. American Heart Journal 137:264-73, 1999. [PMID 9924160]<br />
471. Savonitto S, Ardissino D, Granger CB, Morando G, Prando M, Mafrici A, Thompson T, Vahanian A,<br />
Ohman EM, Califf RM, Van de Werf F, Topol EJ. Prognostic value of the admission electrocardiogram in<br />
acute coronary syndromes: results from the GUSTO-IIb trial. Journal of the American Medical<br />
Association 281:707-713, 1999. [PMID 10052440]<br />
472. Kereiakes DJ, Kleiman NS, Ferguson JJ, Masud AZ, Fitzgerald G, Broderick TM, Abbottsmith CW,<br />
Anderson LC, Anders RJ, Dreiling RJ, Hantsbarger GL, Bryzinski B, Topol EJ, for the ORBIT<br />
Investigators. Pharmacodynamic efficacy, clinical safety and outcomes following prolonged platelet<br />
glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter placebo controlled<br />
randomized trial. Circulation 98:1268-1278, 1998. [PMID 9751674]<br />
473. Narins CR, Topol EJ. Attention shifts to the white clot. Lancet 350 (Suppl 3):2, 1997. [PMID 9465178]<br />
474. Gurbel PA, Serebruany VL, Shustov AR, Bahr RD, Carpo C, Ohman EM, and Topol EJ for the GUSTO III<br />
Investigators. Effects of reteplase and alteplase on platelet aggregation and major receptor expression<br />
during the first 24 hours of acute myocardial infarction treatment. The GUSTO III platelet study. Journal<br />
of the American College of Cardiology 31:1466-73, 1998. [PMID 9626821]<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 30
475. The PARAGON Investigators. An international, randomized, controlled trial of lamifiban, a platelet<br />
glycoprotein IIb/IIIa inhibitor, heparin, or both in unstable angina. Circulation 97:2386-2395, 1998. [PMID<br />
9641689]<br />
476. The PURSUIT (Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin<br />
Therapy) Trial Investigators. Inhibition of the platelet glycoprotein IIb/IIIa with eptifibatide in patients with<br />
acute coronary syndromes without persistent ST-segment elevation. New England Journal of Medicine<br />
339:436-443, 1998. [PMID 9705684]<br />
477. Goodman SG, Langer A, Wildermann N, Barbagelata A, Sgarbossa EB, Wagner GS, Granger CB, Califf<br />
RM, Topol EJ, Ross AM, Armstrong PW, for the GUSTO-I Angiographic Investigators. Non-Q vs. Qwave<br />
myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the<br />
GUSTO-I Angiographic Substudy. Circulation 97:444-450, 1998. [PMID 9490238]<br />
478. Metz BK, White HD, Granger CB, Simes RJ, Armstrong PW, Hirsh J, Fuster V, MacAulay CM, Califf RM,<br />
Topol EJ, for the GUSTO IIb Investigators. A randomized comparison of direct thrombin inhibition versus<br />
heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO IIb<br />
trial. Journal of the American College of Cardiology 31:1493-1498, 1998. [PMID 9626825]<br />
479. Mahaffey KW, Granger CB, Sloan MA, Green CL, Gore JM, Weaver WD, White HD, Simoons ML,<br />
Barbash GI, Topol EJ, Califf RM and the GUSTO-I Investigators. Neurosurgical evacuation of<br />
intracranial hemorrhage following thrombolytic for acute myocardial infarction is associated with improved<br />
outcome: results from the GUSTO-I trial. American Heart Journal 138:493-9, 1999. [PMID 10467200]<br />
480. Alexander KP, Peterson ED, Granger CB, Casas AC, Van de Werf F, Armstrong PW, Guerci A, Topol EJ,<br />
Califf RM, for the GUSTO IIb Investigators. Potential impact of evidence-based medicine in acute<br />
coronary syndromes: insights from GUSTO IIb. Journal of the American College of Cardiology 32:2023-<br />
2030, 1998. [PMID 9857888]<br />
481. Tardiff BE, Califf RM, Tcheng JE, Lincoff AM, Sigmon KN, Harrington RA, Mahaffey KW, Ohman EM,<br />
Blankenship J, Kitt MM, Topol EJ for the IMPACT-II Investigators. Clinical outcomes after detection of<br />
elevated cardiac enzymes in patients undergoing percutaneous intervention. Journal of the American<br />
College of Cardiology 33:88-96, 1999. [PMID 9935014]<br />
482. Harrington RA, Califf RM, Holmes DR, Pieper KS, Lincoff AM, Berdan LG, Thompson TD, and Topol EJ,<br />
for the CAVEAT-I Investigators. Is unstable angina the same? Insights from the Coronary Angioplasty<br />
Versus Excisional Atherectomy Trial (CAVEAT-I). American Heart Journal 137:227-33, 1999. [PMID<br />
9924155]<br />
483. Hochrein J, Sun F, Pieper KS, Lee KL, Gates KB, Armstrong PW, Topol EJ, Califf RM, Granger CB,<br />
Wagner GS. Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic<br />
therapy for acute myocardial infarction: a GUSTO-I substudy. American Journal of Cardiology 81:1078-<br />
1084, 1998. [PMID 9605045]<br />
484. Newby LK, Christenson RH, Ohman EM, Armstrong PW, Peck SL, Lee KL, Hamm CW, Katus HA,<br />
Cianciolo C, Granger CB, Topol EJ, Califf RM, for the GUSTO-IIa Investigators. The value of serial<br />
troponin T measurements for early and late risk stratification in patients with acute coronary syndromes.<br />
Circulation 98:1853-1859, 1998. [PMID 9799204]<br />
485. Topol EJ. Patient stratification and its predictive value for cardiac events. European Heart Journal<br />
19(Suppl K): K5-K7, 1998. [PMID 9790282]<br />
486. Sloan MA, Sila CA, Mahaffey KW, Granger CB, Green CL, Longstreth WT, Koudstaal P, White HD, Gore<br />
JM, Simoons ML, Weaver WD, Topol EJ. Mortality prediction for patients with intracranial hemorrhage<br />
after thrombolysis for acute myocardial infarction. Circulation 98:1376-82, 1998. [PMID 9760291]<br />
487. Kleiman NS, Granger CB, White HD, Armstrong P, Ardissino D, Van de Werf F, Zoldeyhi P, Thompson TD,<br />
Califf RM, and Topol EJ for the GUSTO-IIb Investigators. Death and reinfarction within the first 24 hours<br />
after presentation with an acute coronary syndrome: Experience from GUSTO-IIb. American Heart<br />
Journal 137:12-23, 1999. [PMID 9878932]<br />
488. Simons GR, Sgarbossa E, Wagner G, Califf RM, Topol EJ, Natale A. Atrioventricular and intraventricular<br />
conduction disorders in acute myocardial infarction: A reappraisal in the thrombolytic era. PACE 21:2651-<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 31
2663, 1998. [PMID 9894656]<br />
489. Serebruany VL, Gurbel PA, Shustov AR, Ohman EM, Topol EJ. Heterogeneity of platelet aggregation<br />
and major surface receptor expression in patients presenting with acute myocardial infarction. American<br />
Heart Journal 136:398-405, 1998. [PMID 9736129]<br />
490. Berkowitz SD, Sane DC, Sigmon KN, Shavender JH, Harrington RA, Tcheng JE, Topol EJ, Califf RM, for<br />
the EPIC study group. Occurrence and clinical significance of thrombocytopenia in a population<br />
undergoing high-risk percutaneous coronary revascularization. Journal of the American College of<br />
Cardiology 32:311-319, 1998. [PMID 9708455]<br />
491. Berger PB, Ellis SG, Holmes DR Jr, Granger CB, Criger DA, Betriu A, Topol EJ, and Califf RM for the<br />
GUSTO-I Investigators. Relationship between delay in performing direct coronary angioplasty and early<br />
clinical outcome in patients with acute myocardial infarction: results from the Global Use of Strategies to<br />
Open Occluded Arteries in Acute Coronary Syndromes (GUSTO-IIb) Trial. Circulation 100:14-20, 1999.<br />
[PMID 10393675]<br />
492. Ross AM, Coyne K, Moreyra E, Reiner JS, Greenhouse SW, Walker P, Simoons ML, Draoui Y, Califf RM,<br />
Topol EJ, van de Werf F, Lundergan CF, for the GUSTO-I Angiographic Investigators. The extended<br />
mortality benefit of early post infarction reperfusion. Circulation 97:1549-1556, 1998. [PMID 9593559]<br />
493. Ellis SG, Brown KJ, Ellert R, Howell GL, Miller DP, Flowers NM, Ott PA, Keyes T, Loop FD, Topol EJ.<br />
Cost of cardiac care in the three years after coronary catheterization in a contained care system - critical<br />
determinants and implications. Journal of the American College of Cardiology 31:1306-13, 1998. [PMID<br />
9581725]<br />
494. Topol EJ and Serruys PW. Frontiers in interventional cardiology. Circulation 98:1802-1820, 1998.<br />
[PMID 9788837]<br />
495. Eisenberg MJ, Taylor JM, Cove CJ, Brown KJ, Ellis SG, Topol EJ. Comparison of percutaneous<br />
coronary revascularization costs among HMO and non-HMO cardiologists practicing in the same<br />
institution. Journal of Cardiovascular Diagnosis and Procedures 16:109-119, 1999.<br />
496. Brener SJ, Barr LA, Burchenal JEB, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ,<br />
Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ, on behalf of the RAPPORT Investigators. A<br />
randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for<br />
acute myocardial infarction. Circulation 98:734-741, 1998. [PMID 9727542]<br />
497. Alexander JH, Granger CB, Sadowski Z, Aylward PE, White HD, Thompson TD, Califf RM, Topol EJ, for<br />
the GUSTO-I and GUSTO-IIb Investigators. Prophylactic lidocaine in acute myocardial infarction:<br />
incidence and outcomes from two international acute myocardial infarction trials. American Heart Journal<br />
137:799-805, 1999. [PMID 10220627]<br />
498. Gurbel PA, Serebruany VL, Shustov AR, Dalesandro M, Gumbs CI, Grablutz LB, Bahr RD, Ohman EM,<br />
Topol EJ. Increased baseline levels of platelet P-selectin, and platelet-endothelial cell adhesion<br />
molecule-1 in patients with acute myocardial infarction as predictors of unsuccessful thrombolysis.<br />
Coronary Artery Disease 9:451-456, 1998. [PMID 9822864]<br />
499. Armstrong PW, Fu Y, Chang W-C, Topol EJ, Granger CB, Lee KL, Califf RM for the GUSTO II<br />
Investigators. Acute coronary syndromes in the GUSTO IIb trial: Prognostic insights and impact of<br />
recurrent ischemia. Circulation 98:1860-1868, 1998. [PMID 9799205]<br />
500. Mandak JS, Blankenship JC, Gardner LH, Berkowitz SD, Aguirre FV, Sigmon KN, Timmis GC, Gilchrist<br />
IC, McIvor M, Resar J, Weiner BH, George BS, Talley JD, Lincoff AM, Tcheng JE, Califf RM, and Topol<br />
EJ for the IMPACT II Investigators. Modifiable risk factors for vascular access site complications in the<br />
IMPACT II trial of angioplasty with versus without eptifibatide. Journal of the American College of<br />
Cardiology 31:1518-24, 1998. [PMID 9626829]<br />
501. Bhatt DL, Lincoff AM, Kereiakes DJ, Tcheng JE, Godfrey N, Califf RM, Topol EJ. Reduction in the need<br />
for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary<br />
intervention. American Journal of Cardiology 82:1105-1106, 1998. [PMID 9817488]<br />
502. EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to<br />
assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 352:87-92,<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 32
1998. [PMID 9672272]<br />
503. Kong DF, Califf RM, Miller DP, Moliterno DJ, Harrington RA, Tcheng JE, Lincoff AM, Hasselblad V, Topol<br />
EJ. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in<br />
ischemic heart disease. Circulation 98:2829-2835, 1998. [PMID 9860783]<br />
504. Steinhubl SR, Lauer MS, Mukherjee DP, Moliterno DJ, Lincoff AM, Ellis SG, Topol EJ. The duration of<br />
pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave<br />
myocardial infarction. Journal of the American College of Cardiology 32:1366-70, 1998. [PMID<br />
9809949]<br />
505. Tung CY, Granger CB, Sloan MA, Topol EJ, Knight JD, Weaver WD, Mahaffey KW, White H, Clapp-<br />
Channing N, Simoons ML, Gore JM, Califf RM, Mark DB, for the GUSTO-I Investigators. The effects of<br />
stroke on medical resource use and costs in acute myocardial infarction. Circulation 99:370-376, 1999.<br />
[PMID 9918523]<br />
506. Gebel JM, Sila CA, Sloan MA, Mahaffey KW, Granger CB, Weisenberger JP, Green CL, Topol EJ.<br />
Comparison of the ABC/2 estimation technique to computer-assisted volumetric analysis of<br />
intraparenchymal and subdural hematomas complicating the GUSTO-I trial. Stroke 29:1799-1801, 1998.<br />
[PMID 9731597]<br />
507. Rabbani R, Topol EJ. Strategies to achieve coronary arterial plaque stabilization. Cardiovascular<br />
Research 41:402-417, 1999. [PMID 10341840]<br />
508. Hasdai D, Holmes DR, Topol EJ, Berger PB, Criger DA, Hochman JS, Bates ER, Vahanian A, Armstrong<br />
PW, Wilcox R, Ohman EM, Califf RM. Frequency and clinical outcome of cardiogenic shock during acute<br />
myocardial infarction among patients receiving reteplase or alteplase: results from GUSTO III. European<br />
Heart Journal 20:128-135, 1999. [PMID 10099909]<br />
509. Betriu A, Califf RM, Stebbins AL, Guerci A, Topol EJ. Recurrent ischemia after thrombolysis: importance<br />
of associated clinical findings. Journal of the American College of Cardiology 31:94-102, 1998. [PMID<br />
9426024]<br />
510. Berger PB, Tuttle RH, Holmes DR, Topol EJ, Aylward PE, Horgan JH, and Califf RM for the GUSTO I<br />
Investigators. One year survival among patients with acute myocardial infarction complicated by<br />
cardiogenic shock, and its relationship to early revascularization: Results from the GUSTO-I trial.<br />
Circulation 99:873-878, 1999. [PMID 10027808]<br />
511. Simoons ML, van den Brand M, Lincoff M, Harrington R, van der Wieken R, Vanhanian A, Rutsch W,<br />
Califf RM, Topol EJ. Minimal myocardial damage during coronary intervention is associated with<br />
impaired outcome. European Heart Journal 20:1112-1119, 1999. [PMID 10413641]<br />
512. Topol EJ. Current and emerging antithrombotic therapies for acute coronary syndromes. The Journal of<br />
Invasive Cardiology 10(Suppl D): 2D-7D, 1998. [PMID 10762992]<br />
513. Topol EJ. The future of antithrombotic and anti-platelet therapy for ischemic heart disease. American<br />
Heart Journal 136(4) Part 2:S66-S68, 1998. [PMID 9778089]<br />
514. Puma JA, Sketch MH, Thompson TD, Pieper KS, Simes RJ, Morris DC, Topol EJ, Califf RM. Support for<br />
the open-artery hypothesis in survivors of acute myocardial infarction: an analysis of 11,228 patients<br />
treated with thrombolytic therapy. American Journal of Cardiology 83:482-487, 1999. [PMID 10073847]<br />
515. Ellis SG, Lincoff AM, Miller D, Tcheng JE, Kleiman NS, Kereiakes D, Califf RM, Topol EJ, for the EPIC<br />
and EPILOG Investigators. Reduction in complications of angioplasty with abciximab occurs largely<br />
independently of baseline lesion morphology. Journal of the American College of Cardiology 32:1619-23,<br />
1998. [PMID 9822087]<br />
516. Schwartz RS, Topol EJ, Holmes Jr. DR. Editorial: Artery size, neointima, and remodeling: time for some<br />
standards. Journal of the American College of Cardiology 32:2087-94, 1998. [PMID 9857898]<br />
517. Ellis SG, Miller D, Keyes T, Brown K, Ellert R, Howell G, Lincoff AM, Topol EJ. Comparing physicianspecific<br />
two year patient outcomes after coronary angiography: methodologic issues and results. Journal<br />
of the American College of Cardiology 33:1278-85, 1999. [PMID 10193728]<br />
518. Narins CR, Miller DP, Califf RM, Topol EJ. The relationship between periprocedural myocardial infarction<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 33
and clinical restenosis following percutaneous coronary revascularization: Insights from the EPIC Trial.<br />
Journal of the American College of Cardiology 33:647-53, 1999. [PMID 10080464]<br />
519. Topol EJ. The drafter and the draftee. Lancet 352:897-98, 1998. [PMID 9743001]<br />
520. Topol EJ. What role for catheter laboratories in unstable angina? Lancet 352:500-501, 1998. [PMID<br />
9716048]<br />
521. Marso SP and Topol EJ. The paradoxical benefit of sulfonylurea agents in diabetics undergoing<br />
coronary revascularization. European Heart Journal 19:1601-1603, 1998. [PMID 9857909]<br />
522. Gibler WB, Wilcox RG, Bode C, Castaigne AD, Delooz H, Elich D, Fox KAA, Kereiakes DJ, Rupprecht H,<br />
Topol EJ. Prospective use of GP IIb/IIIa receptor blockers in the emergency department setting.<br />
European Journal of Emergency Medicine 5(4):391-402, 1998. [PMID 9919443]<br />
523. Mak K-H, Kottke-Marchant K, Brooks LM, Topol EJ. In vitro efficacy of platelet glycoprotein IIb/IIIa<br />
antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia.<br />
Thrombosis and Haemostasis 80:989-93, 1998. [PMID 9869172]<br />
524. Anderson RD, Ohman EM, Holmes DR Jr, Harrington RA, Wildermann NM, Phillips HR, Topol EJ, Califf<br />
RM. The prognostic value of congestive heart failure history in patients undergoing percutaneous<br />
interventions. Journal of the American College of Cardiology 32:936-941, 1998. [PMID 9768714]<br />
525. The PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor<br />
lamifiban: Results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion<br />
Gain in Myocardial Infarction (PARADIGM) Trial. Journal of the American College of Cardiology 32:2003-<br />
10, 1998. [PMID 9857885]<br />
526. Newby KH, Thompson T, Stebbins A, Topol EJ, Califf RM, Natale A, for the GUSTO Investigators.<br />
Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes.<br />
Circulation 98:2567-73, 1998. [PMID 9843464]<br />
527. Patel VB, Topol EJ. The pathogenesis and spectrum of acute coronary syndromes: From plaque<br />
formation to thrombosis. The Cleveland Clinic Journal of Medicine 66:561-571, 1999. [PMID 10535182]<br />
528. Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C,<br />
Cabot CF, Anderson KM, Weisman HF, Topol EJ, for the EPILOG Investigators. Sustained suppression<br />
of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one<br />
year outcome in the EPILOG Trial. Circulation 99:1951-1958, 1999. [PMID 10208997]<br />
529. Mahaffey KW, Harrington RA, Simoons ML, Granger CB, Graffagnino C, Alberts MJ, Laskowitz DT, Miller<br />
JM, Sloan MA, Berdan LG, MacAulay CM, Lincoff AM, Deckers J, Topol EJ, Califf RM for the PURSUIT<br />
Investigators. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet<br />
glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial.<br />
Circulation 99:2371-2377, 1999. [PMID 10318656]<br />
530. Gilchrist IC, Gardner LH, Muhlestein JB, Arnold AM, Lincoff AM, Califf RM, Tcheng JE, Topol EJ. The<br />
effect of institutional volume and academic status on outcomes from coronary interventional procedures:<br />
IMPACT II Experience. American Heart Journal 138:976-82, 1999. [PMID 10539832]<br />
531. Steinhubl SR, Topol EJ. Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary<br />
stenting. Journal of Thrombosis and Thrombolysis 7:227-231, 1999. [PMID 10373712]<br />
532. Topol EJ. Coronary-artery stents--gauging, gorging, and gouging. New England Journal of Medicine<br />
339:1702-1704, 1998. [PMID 9834311]<br />
533. Thel MC, Califf RM, Tardiff BE, Gardner LH, Sigmon KN, Lincoff AM, Topol EJ, Kitt M, Blankenship JC,<br />
Tcheng JE, for the IMPACT-II Investigators. Timing of risk and factors for clinical ischemic events after<br />
percutaneous coronary intervention: insights from IMPACT-II. American Journal of Cardiology 85:427-<br />
434, 2000. [PMID 10728945]<br />
534. Steinhubl SR, Tan WA, Foody JM, Topol EJ, for the EPISTENT Investigators. The incidence and clinical<br />
course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. Journal of<br />
the American Medical Association 281:806-810, 1999. [PMID 10071001]<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 34
535. Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers JW, Simoons ML, Guerci A,<br />
Hochman JS, Wilcox RG, Kitt MM, Califf RM, Topol EJ, Armstrong PW, on behalf of the PURSUIT<br />
Investigators. Prior aspirin use predicts worse outcomes in patients with non-ST elevation acute<br />
coronary syndromes: Insights from PURSUIT. American Journal of Cardiology 83:1147-1151, 1999.<br />
[PMID 10215274]<br />
536. McClure MW, Berkowitz SD, Sparapani R, Tuttle R, Kleiman NS, Berdan LG, Lincoff AM, Deckers J, Diaz<br />
R, Karsch KR, Gretler D, Kitt M, Simoons M, Topol EJ, Califf RM, Harrington RA, for the PURSUIT<br />
Investigators. The clinical significance of thrombocytopenia during a non-ST elevation acute coronary<br />
syndrome: The PURSUIT Experience. Circulation 99:2892-2900, 1999. [PMID 10359733]<br />
537. Kong DF, Topol EJ, Bittl JA, White HD, Theroux P, Hasselblad V, Califf RM. Clinical outcomes of<br />
bivalirudin for ischemic heart disease. Circulation 100:2049-2053, 1999. [PMID 10562259]<br />
538. Mark DB, Harrington RA, Lincoff AM, Califf RM, Nelson CL, Tsiatis AA, Buell H, Mahaffey KW, Davidson-<br />
Ray L, Topol EJ. Cost effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients<br />
with non-ST elevation acute coronary syndromes. Circulation 101:366-371, 2000. [PMID 10653826]<br />
539. Topol EJ, Byzova T, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 353:227-231, 1999 [PMID 9923894]<br />
540. Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery<br />
disease. Journal of the American College of Cardiology 35:1103-1115, 2000. [PMID 10758948]<br />
541. Steinhubl SR, Kottke-Marchant K, Moliterno DJ, Rosenthal ML, Godfrey NK, Coller BS, Topol EJ, Lincoff<br />
AM. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic<br />
and nondiabetic patients undergoing percutaneous coronary intervention. Circulation 100:1977-1982,<br />
1999. [PMID 10556224]<br />
542. Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, Talley D, Sapp S, Booth J, Cabot CF,<br />
Anderson KM, Califf RM, on behalf of the EPISTENT Investigators. Outcomes at 1 year and economic<br />
implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results<br />
from a multicenter randomized trial. The Lancet 354:2019-2024, 1999. [PMID 10636365]<br />
543. Marso SP, Ellis SG, Tuzcu EM, Whitlow PL, Franco I, Raymond RE, Topol EJ. The importance of<br />
proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics.<br />
Journal of the American College of Cardiology 33:1269-77, 1999. [PMID 10193727]<br />
544. Holmes DR, White HD, Pieper KS, Ellis SG, Califf RM, Topol EJ. Effect of age on outcome with primary<br />
angioplasty versus thrombolysis. Journal of the American College of Cardiology 33:412-19, 1999.<br />
[PMID 9973021]<br />
545. Miller JM, Smalling R, Ohman EM, Bode C, Betriu A, Kleiman NS, Schildcrout JS, Bastos E, Topol EJ,<br />
Califf RM for the GUSTO III Investigators. Effectiveness of early angioplasty and abciximab for failed<br />
thrombolysis (Reteplase or Alteplase) during acute myocardial infarction: Results from the GUSTO III<br />
Trial. American Journal of Cardiology 84:779-784, 1999. [PMID 10513773]<br />
546. Califf RM, Stump D, Topol EJ, Mark DB. The impact of cost-effectiveness study of GUSTO-I on decision<br />
making with regard to fibrinolytic therapy. American Heart Journal 137:S90-S93, 1999. [PMID<br />
10220606]<br />
547. Gassler J and Topol EJ. Reperfusion revisited. Clinical Cardiology 22:IV20-29, 1999. [PMID 10492850]<br />
548. Lincoff AM, Califf RM, Moliterno DJ, Tcheng JE, Ellis SG, Ducas J, Kramer JH, Talley JD, Caramori PO,<br />
Kleiman NS, Cohen EA, Burton JR, Kelly TA, Booth JE, Sapp SK, Ivanc TB, Cabot CF, Topol EJ, for the<br />
EPISTENT Investigators. Complementary clinical benefits of coronary artery stenting and blockade of<br />
platelet glycoprotein IIb/IIIa receptors. New England Journal of Medicine 341:319-27, 1999. [PMID<br />
10423466]<br />
549. Hasdai D, Lerman A, Rihal CS, Garratt KN, Betriu A, White HD, Topol EJ, Granger CB, Ellis SG, Califf<br />
RM, Holmes DR. Smoking status and outcome following primary coronary angioplasty for acute<br />
myocardial infarction. American Heart Journal 137:612-620, 1999. [PMID 10097222]<br />
550. Sane DC, Damaraju LV, Topol EJ, Cabot CF, Mascelli MA, Harrington RA, Simoons ML, Califf RM.<br />
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. Journal of<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 35
the American College of Cardiology 36:75-83, 2000. [PMID 10898416]<br />
551. Califf RM, Pieper KS, Lee KL, Van de Werf F, Simes RJ, Armstrong PW, and Topol EJ, for the GUSTO-I<br />
Investigators. Prediction of 1 year survival after thrombolysis for acute myocardial infarction in the<br />
GUSTO-I trial. Circulation 101:2231-2238, 2000. [PMID 10811588]<br />
552. Bruce CJ, Kuntz RE, Popma JJ, Pieper KS, Topol EJ, Holmes Jr. DR. Application of a continuous<br />
regression model of restenosis to saphenous vein grafts after successful PTCA or DCA. Journal of the<br />
American College of Cardiology 35:619-623, 2000. [PMID 10716463]<br />
553. Hochman JS, Tamis JE, Thompson TD, Weaver WD, Van de Werf F, Aylward P, Topol EJ, Califf RM, for<br />
the GUSTO IIb Investigators. Sex, clinical presentation, and outcomes in patients with acute coronary<br />
syndromes: The GUSTO IIb experience. New England Journal of Medicine 341:226-32, 1999. [PMID<br />
10413734]<br />
554. Crenshaw BS, Granger CB, Birnbaum Y, Pieper KS, Morris DC, Kleiman NS, Vahanian A, Califf RM, and<br />
Topol EJ, for the GUSTO-I Trial Investigators. Risk factors, angiographic patterns, and outcomes in<br />
patients with ventricular septal defect complicating acute myocardial infarction. Circulation 101:27-32,<br />
2000. [PMID 10618300]<br />
555. Asher CR, Topol EJ, Moliterno DJ. Coronary artery disease in Black Americans. Journal of the<br />
American College of Cardiology 138:1073-81, 1999. [PMID 10577437]<br />
556. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang W-C, Lee KL, Akkerhuis KM, Harrington RA,<br />
Deckers JW, Armstrong PW, Lincoff AM, Califf RM, Topol EJ, Simoons ML, for the PURSUIT<br />
Investigators. Predictors of outcome in patients with acute coronary syndromes without persistent STsegment<br />
elevation: Results from an international trial of 9,461 patients. Circulation 101:2557-2567, 2000.<br />
[PMID 10840005]<br />
557. Cohen MG, Granger CB, Ohman EM, Stebbins AL, Grinfeld LR, Cagide AM, Elizari MV, Betriu A, Kong<br />
DF, Topol EJ, Califf RM. Outcome of Hispanic patients treated with thrombolytic therapy for acute<br />
myocardial infarction: results from the GUSTO-I and -III trials. Journal of the American College of<br />
Cardiology 34:1729-37, 1999. [PMID 10577563]<br />
558. Ohman EM, Armstrong PW, White HD, Granger CB, Wilcox RG, Weaver WD, Gibler WB, Stebbins AL,<br />
Cianciolo C, Califf RM, Topol EJ. Risk stratification with a point-of-care cardiac troponin T test in acute<br />
myocardial infarction: a GUSTO III substudy. American Journal of Cardiology 84:1281-1286, 1999.<br />
[PMID 10614791]<br />
559. Brener SJ, Topol EJ. Logic and logistics: conundrum in reperfusion therapy. Heart 82:402-403, 1999.<br />
[PMID 10490544]<br />
560. Boersman E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa<br />
receptor inhibition in non-ST-elevation acute coronary syndromes: Early benefit during medical treatment<br />
only, with additional protection during percutaneous coronary intervention. Circulation 100:2045-2048,<br />
1999. [PMID 10562258]<br />
561. Akkerhuis KM, Deckers JW, Boersma E, Harrington RA, Stepinska J, Mahaffey KW, Wilcox RG, Lincoff<br />
AM, Keltai M, Topol EJ, Califf RM, Simoons ML, for the PURSUIT Investigators. Geographic variability in<br />
outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary<br />
syndromes: Results from PURSUIT. European Heart Journal 21:371-381, 2000. [PMID 10666351]<br />
562. Horrigan MCG, Malycky JL, Ellis SG, Topol EJ, Nicolini FA. Reduction in myocardial infarct size by basic<br />
fibroblast growth factor following coronary occlusion in a canine model. International Journal of<br />
Cardiology 68(1): S85-S91, 1999. [PMID 10328616]<br />
563. Marso SP, Lincoff AM, Ellis SG, Bhatt DL, Tanguay J-F, Kleiman NS, Hammoud T, Booth JE, Sapp SK,<br />
Topol EJ, for the EPISTENT Investigators. Optimizing the percutaneous interventional outcomes for<br />
patients with diabetes mellitus: Results of the EPISTENT diabetic substudy. Circulation 100:2477-2484,<br />
1999. [PMID 10604884]<br />
564. Hasdai D, Holmes DR Jr, Califf RM, Thompson TD, Hochman JS, Pfisterer M, Topol EJ, for the GUSTO-I<br />
Investigators. Cardiogenic shock complicating acute myocardial infarction: Predictors of death.<br />
American Heart Journal 138:21-31,1999. [PMID 10385759]<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 36
565. Holmes DR, Berger PB, Hochman JS, Granger CB, Thompson TD, Califf RM, Vahanian A, Bates ER,<br />
Topol EJ. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment<br />
elevation: A report from the GUSTO IIb study. Circulation 100:2067-2073, 1999. [PMID 10562262]<br />
566. Newby LK, Eisenstein EL, Califf RM, Thompson TD, Hasselblad V, Nelson CL, Peterson ED, Armstrong<br />
PW, Van de Werf F, White HD, Topol EJ, Mark DB. Early discharge after acute myocardial infarction:<br />
clinical determinants and cost effectiveness. The New England Journal of Medicine 342:749-755, 2000.<br />
[PMID 10717009]<br />
567. Ellis SG, Guetta V, Miller D, Whitlow PL, Topol EJ. Relation between lesion characteristics and the risk<br />
with percutaneous intervention in the stent and glycoprotein IIb/IIIa era: An analysis of results from<br />
10,907 lesions and proposal for new classification scheme. Circulation 100:1971-1976, 1999. [PMID<br />
10556223]<br />
568. Topol EJ, Yadav J. Recognition of the importance of embolization in atherosclerotic vascular disease.<br />
Circulation 101:570-580, 2000. [PMID 10662756]<br />
569. Mak K-H, Topol EJ. Emerging concepts in the management of acute myocardial infarction in patients<br />
with diabetes mellitus. Journal of the American College of Cardiology 35:563-568, 2000. [PMID<br />
10716456]<br />
570. Lauer MS, Blackstone EH, Young JB, Topol EJ. Cause of death in clinical research. Journal of the<br />
American College of Cardiology 34:618-620, 1999. [PMID 10483939]<br />
571. Hasdai D, Holmes Jr DR, Criger DA, Topol EJ, Califf RM, Harrington RA for the Platelet Glycoprotein<br />
IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators.<br />
Age and outcome after acute coronary syndromes without persistent ST-segment elevation. American<br />
Heart Journal 139:858-866, 2000. [PMID 10783220]<br />
572. Hasdai D, Califf RM, Thompson TD, Hochman JS, Ohman EM, Pfisterer M, Bates ER, Vahanian A,<br />
Armstrong PW, Criger DA, Topol EJ, Holmes Jr. DR. Predictors of cardiogenic shock after thrombolytic<br />
therapy for acute myocardial infarction. Journal of the American College of Cardiology 35:136-143,<br />
2000. [PMID 10636271]<br />
573. Brener SJ, Barr LA, Burchenal JEB, Wolski KE, Effron MB, Topol EJ, for the RAPPORT Investigators.<br />
Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with<br />
primary angioplasty. American Journal of Cardiology 84:728-730, 1999. [PMID 10498145]<br />
574. Christenson RH, Vollmer RT, Ohman EM, Peck S, Thompson T, Duh S-H, Ellis SG, Newby LK, Topol EJ,<br />
Califf RM, for the TAMI Study Group. Relation of temporal creatine kinase-MB release and clinical<br />
outcome after thrombolytic therapy for acute myocardial infarction. American Journal of Cardiology<br />
85:543-547, 2000. [PMID 11078264]<br />
575. The SPEED Group (Strategies for the Patency Enhancement in the Emergency Department).<br />
Randomized trial of abciximab with and without low-dose reteplase for acute myocardial infarction.<br />
Circulation 101:2788-2794, 2000. [PMID 10859283]<br />
576. Wong C-K, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, Ohman EM, for the GUSTO-III<br />
Investigators. New atrial fibrillation after acute myocardial infarction independently predicts mortality: the<br />
GUSTO-III experience. American Heart Journal 140:878-885, 2000. [PMID 11099991]<br />
577. Bhatt DL, Lincoff AM, Califf RM, Simoons ML, Tcheng JE, Brener SJ, Wolski KE, Topol EJ. The benefit<br />
of abciximab in percutaneous coronary revascularization is not device-specific. American Journal of<br />
Cardiology 85:1060-1064, 2000. [PMID 10781752]<br />
578. Topol EJ. New platelet glycoprotein IIb/IIIa inhibitor trials in percutaneous coronary intervention. The<br />
Journal of Invasive Cardiology Vol. 11(Suppl C):3C-6C, 1999. [PMID 10745614]<br />
579. Marso SP, Ellis SG, Gurm HS, Lytle BW, Topol EJ. Proteinuria is a key determinant of mortality in<br />
diabetic patients following isolated coronary artery bypass grafting. American Heart Journal 139:939-<br />
944, 2000. [PMID 10827372]<br />
580. Topol EJ, Easton JD, Amarenco P, Califf RM, Harrington R, Graffagnino C, Davis S, Diener HC,<br />
Ferguson J, Fitzgerald D, Shuaib A, Koudstaal PJ, Theroux P, Van de Werf F, Willerson JT, Chan R,<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 37
Samuels R, Ilson B, Granett J. Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid<br />
vascular occlusion (BRAVO) trial. American Heart Journal 139:927-933, 2000. [PMID 10827369]<br />
581. Gebel JM, Brott TG, Sila CA, Tomsick TA, Jauch E, Salisbury S, Khoury J, Miller R, Pancioli A, Duldner<br />
JE, Topol EJ, Broderick JP. Decreased perihematomal edema in thrombolysis-related intracerebral<br />
hemorrhage as compared to spontaneous intracerebral hemorrhage. Stroke 31(3):596-600, 2000.<br />
[PMID 10700491]<br />
582. Marso SP, Mak K-H, Topol EJ. Diabetes mellitus: biological determinants of atherosclerosis and<br />
restenosis. Seminars in Interventional Cardiology 4:129-143, 1999. [PMID 10545619]<br />
583. Kleiman NS, Tracy RP, Talley JD, Sigmon K, Joseph D, Topol EJ, Califf RM, Kitt M, Ohman EM.<br />
Inhibition of platelet aggregation with glycoprotein IIb/IIIa antagonist does not prevent thrombin<br />
generation in patients undergoing thrombolysis for acute myocardial infarction. Thrombosis and<br />
Thrombolysis 9:5-12, 2000. [PMID 10590183]<br />
584. Kleiman NS, Lincoff AM, Flaker GC, Pieper KS, Wilcox RG, Berdan LG, Lorenz TJ, Simoons ML,<br />
Boersma E, Topol EJ, Califf RM, and Harrington RA for the PURSUIT Investigators. Early percutaneous<br />
coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute<br />
coronary syndromes. Circulation 101:751-757, 2000. [PMID 10683348]<br />
585. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics<br />
following percutaneous coronary intervention. Journal of the American College of Cardiology 35:922-<br />
928, 2000. [PMID 10732889]<br />
586. Labinaz M, DeFranco AC, Sketch Jr. MH, Ellis SG, Abramowitz BM, Stebbins AL, Pieper KS, Holmes Jr.<br />
DR, Califf RM, Topol EJ, for the GUSTO-I Investigators. Outcome of acute ST-segment elevation<br />
myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy.<br />
American Heart Journal 141:469-477, 2001. [PMID 11231447]<br />
587. The SYMPHONY Investigators. A randomized comparison of sibrafiban, an oral platelet glycoprotein<br />
IIb/IIIa receptor antagonist, with aspirin for acute coronary syndromes. The Lancet 355:337-345, 2000.<br />
[PMID 1066552]<br />
588. McGuire DK, Emanuelsson H, Granger CB, Ohman EM, Moliterno DJ, White HD, Ardissino D, Box JW,<br />
Califf RM, Topol EJ, for the GUSTO-IIb Investigators. Influence of diabetes mellitus on clinical outcomes<br />
across the spectrum of acute coronary syndromes: findings from the GUSTO-IIb study. European Heart<br />
Journal 21:1750-1758, 2000. [PMID 11052839]<br />
589. Alexander JH, Sparapani RA, Mahaffey KW, Deckers JW, Newby LK, Ohman EM, Corbalan R, Simoons<br />
ML, Topol EJ, Califf RM, Harrington RA, on behalf of the PURSUIT Investigators. Even minor elevations<br />
of creatine-kinase-MB are associated with higher mortality in patients with acute coronary syndromes<br />
without ST-segment elevation. Journal of the American Medical Association 283:347-353, 2000. [PMID<br />
10647797]<br />
590. Roe MT, Harrington RA, Prosper DM, Pieper KS, Bhatt DL, Lincoff AM, Simoons ML, Akkerhuis M,<br />
Ohman EM, Kitt MM, Vahanian A, Ruzyllo W, Karsch K, Califf RM, Topol EJ, for the PURSUIT<br />
Investigators. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who<br />
did not have significant coronary artery disease. Circulation 102:1101-1106, 2000. [PMID 10973837]<br />
591. Brieger DB, Mak K-H, Granger CB, Miller DP, Califf RM, Topol EJ, for the GUSTO-I Investigators. A<br />
hierarchy of risk based on history and location of prior myocardial infarction in the thrombolytic era.<br />
American Heart Journal 140:29-33, 2000. [PMID 10874260]<br />
592. Braunwald E, Califf RM, Cannon CP, Fox KAA, Fuster V, Gibler WB, Harrington RA, King III, SB, Kleiman<br />
NS, Theroux P, Topol EJ, Van de Werf F, White HD, Wallentin L, Willerson JT. Redefining current<br />
treatment algorithms in the management of unstable angina. American Journal of Medicine 108:41-53,<br />
2000. [PMID 11059440]<br />
593. Cura FA, Bhatt DL, Lincoff AM, Kapadia SR, L'Allier PL, Ziada KM, Wolski KE, Moliterno DJ, Brener SJ,<br />
Ellis SG, Topol EJ. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa<br />
inhibition in complex atherosclerotic lesions. Circulation 102:28-34, 2000. [PMID 10880411]<br />
594. Kereiakes DJ, Berkowitz SD, Achenbach R, Simoons ML, Vanhanian A, Lincoff AM, Tcheng JE, Anderson<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 38
K, Califf RM, Topol EJ. Clinical correlates and clinical course of thrombocytopenia during percutaneous<br />
coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. American Heart<br />
Journal 140:74-80, 2000. [PMID 10874266]<br />
595. Menon V, Hochman JS, Stebbins A, Pfisterer M, Col J, Anderson RD, Holmes DR, Bates ER, Topol EJ,<br />
Califf RM, Ohman ME, for the GUSTO Investigators. Lack of progress in cardiogenic shock: Lessons<br />
from the GUSTO Trials. European Heart Journal 21:1928-1936, 2000. [PMID 11071798]<br />
596. Batchelor WB, Granger CB, Kleiman NS, Phillips HR, Ellis SG, Betriu A, Criger DA, Stebbins AL, Topol<br />
EJ, Califf RM for the GUSTO IIb Investigators. A comparison of ionic versus nonionic contrast medium<br />
during primary PTCA for acute MI: Results from GUSTO IIb. American Journal of Cardiology 85:692-<br />
697, 2000. [PMID 12000041]]<br />
597. Harrington RA, Armstrong PW, Graffagnino C, Van de Werf F, Kereiakes DJ, Sigmon KN, Card T, Joseph<br />
DM, Samuels R, Granett J, Califf RM, Topol EJ for the Anti-PLAtelet Useful Dose (APLAUD) Study<br />
Investigators. Dose-finding, safety, and tolerability of an oral platelet glycoprotein IIb/IIIa inhibitor,<br />
lotrafiban, in patients with coronary or cerebral atherosclerotic disease. Circulation 102:728-735, 2000.<br />
[PMID 10942739]<br />
598. Bhatt DL, Hirsch AT, Ringleb PA, Hacke W, Topol EJ, on behalf of the CAPRIE Investigators. Reduction<br />
in the need for hospitalization for recurrent ischemic events with clopidogrel instead of aspirin. American<br />
Heart Journal 140:67-73, 2000. [PMID 10874265]<br />
599. Hasdai D, Harrington RA, Hochman JS, Califf RM, Battler A, Box JW, Simoons ML, Deckers J, Topol EJ,<br />
Holmes DR Jr. Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating<br />
acute coronary syndromes without persistent ST-segment elevation. Journal of the American College of<br />
Cardiology 36:685-92, 2000. [PMID 10987585]<br />
600. Brener SJ, Ellis SG, Sapp SK, Betriu A, Granger CB, Burchenal JEB, Moliterno DJ, Califf RM, Topol EJ,<br />
for the GUSTO IIb and RAPPORT Investigators. Predictors of death and reinfarction at 30 days after<br />
primary angioplasty: The GUSTO IIb and RAPPORT Trials. American Heart Journal 139: 476-81, 2000.<br />
[PMID 10689260]<br />
601. Hasdai D, Holmes DR Jr, Criger DA, Topol EJ, Califf RM, Harrington RA, for the Platelet Glycoprotein<br />
IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators.<br />
Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent<br />
ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. American Heart<br />
Journal 139: 454-60, 2000. [PMID 10689260]<br />
602. Cho L, Marso SP, Bhatt DL, Topol EJ. Optimizing percutaneous coronary revascularization in diabetic<br />
women: Analysis from the EPISTENT Trial. Journal of Women's Health and Gender-Based Medicine<br />
9:741-46, 2000. [PMID 11025866]<br />
603. Chang W-C, Fu Y, Ohman EM, Gupta M, Morris A, Roth SN, Granger CB, Califf, RM, Topol EJ, Mark DB,<br />
Armstrong PW, for the North American GUSTO-I and GUSTO-III Investigators. Temporal evolution in the<br />
management of acute ST elevation myocardial infarction: The 7 year GUSTO experience from Canada<br />
and the U.S. Canadian Journal of Cardiology 16(10):1231-1239, 2000. [PMID 11064297]<br />
604. Hasdai D, Granger CB, Srivatsa SS, Criger DA, Ellis SG, Califf RM, Topol EJ, Holmes, Jr., DR. Diabetes<br />
mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: Lessons from<br />
the GUSTO IIb angioplasty substudy. Journal of the American College of Cardiology 35:1502-1512,<br />
2000. [PMID 10807453]<br />
605. Sgarbossa EB, Meyer PM, Pinski SL, Pavlovic-Surjancev B, Barbagelata A, Goodman SG, Lum AS,<br />
Underwood DA, Gates KB, Califf RM, Topol EJ, Wagner GS. Negative T waves shortly after STelevation<br />
acute MI: A marker for improved survival? American Heart Journal 140:385-94, 2000. [PMID<br />
10966535]<br />
606. Topol EJ, Ohman EM, Armstrong PW, Wilcox R, Skene AM, Aylward P, Simes J, Dalby A, Betriu A, Bode<br />
C, White HD, Hochman JS, Emanuelson H, Vahanian A, Sapp S, Stebbins A, Moliterno DJ, Califf RM, on<br />
behalf of the GUSTO-III Investigators. Survival outcomes 1 year after reperfusion therapy with either<br />
alteplase or reteplase for acute myocardial infarction: results from the GUSTO III Trial. Circulation<br />
102:1761-1765, 2000. [PMID 11023929]<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 39
607. Topol EJ. Inflammation and embolization in ischemic heart disease. The Journal of Invasive Cardiology<br />
Supplement 12(Suppl B): 2B-7B, 2000. [PMID 10731293]<br />
608. Marso SP, Bhatt DL, Roe MT, Houghtaling Pl, Labinaz M, Kleiman NS, Dyke C, Simoons ML, Califf RM,<br />
Harrington RA, Topol EJ for the PURSUIT Investigators. Enhanced efficacy of eptifibatide administration<br />
to patients with an acute coronary syndromes requiring in-hospital coronary artery bypass grafting.<br />
Circulation 102:2952-2958, 2000. [PMID 11113045]<br />
609. Bhatt DL, Topol EJ. Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart<br />
disease. Medical Clinics of North America Vol. 84(1): 163-179, 2000. [PMID 10685133]<br />
610. Bhatt DL, Topol EJ. Percutaneous coronary intervention for patients with prior bypass surgery: Therapy<br />
in evolution. The American Journal of Medicine 108:176-177, 2000. [PMID 11126314]<br />
611. Topol EJ. Acute myocardial infarction--thrombolysis. Heart 83:122-126, 2000. [PMID 10618353]<br />
612. Brener SJ, Topol EJ. Troponin, embolization and restoration of microvascular integrity. European Heart<br />
Journal 21:1117-1119, 2000. [PMID 10924291]<br />
613. Topol EJ. Cardiology in the 21st century. European Heart Journal 2 (Suppl E): E18-E27, 2000.<br />
614. Lincoff AM, LeNarz LA, Despotis GJ, Smith PK, Booth JE, Raymond RE, Sapp SK, Cabot CF, Tcheng JE,<br />
Califf RM, Effron MB, Topol EJ, for the EPILOG and EPISTENT Investigators. Abciximab and bleeding<br />
complications during coronary surgery: Results from the EPILOG and EPISTENT Trials. Annals of<br />
Thoracic Surgery 70:516-26, 2000. [PMID 10969673]<br />
615. Hasdai D, Topol EJ, Califf RM, Berger PB, Holmes Jr. DR. Cardiogenic shock complicating acute<br />
coronary syndromes: Current perspectives. The Lancet 356:749-56, 2000. [PMID 11085707]<br />
616. Cura FA, Kapadia SR, L'Allier PL, Schneider JP, Kreindel MS, Silver MJ, Yadav JS, Tuzcu EM,<br />
Simpfendorfer CC, Raymond RR, Franco I, Whitlow PL, Topol EJ, Ellis SG. Safety of femoral closure<br />
devices after percutaneous coronary interventions in the era of glycoprotein IIb/IIIa platelet blockade.<br />
American Journal of Cardiology 86:780-782, 2000. [PMID 11018201]<br />
617. Lincoff AM, Topol EJ. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary<br />
revascularization: What more needs to be proven? European Heart Journal 21:863-867, 2000. [PMID<br />
10806004]<br />
618. Peterson JG, Topol EJ, Sapp SK, Young JB, Lincoff AM, Lauer MS. Evaluation of combining aspirin and<br />
angiotensin converting enzyme inhibitors in patients with coronary artery disease. American Journal of<br />
Medicine 109:371-377, 2000. [PMID 11020393]<br />
619. BARI Investigators. Seven year outcome in the Bypass Angioplasty Revascularization Investigation<br />
(BARI) by treatment and diabetic status. Journal of the American College of Cardiology 35:1122-29,<br />
2000. [PMID 10758950]<br />
620. Cho L, Topol EJ, Balog C, Foody JM, Booth JE, Cabot C, Kleiman NS, Tcheng JE, Califf RM, Lincoff AM.<br />
Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender. Journal of the<br />
American College of Cardiology 36:381-86, 2000. [PMID 10933346]<br />
621. Moliterno DJ, Topol EJ. A direct comparison of tirofiban and abciximab during percutaneous coronary<br />
revascularization and stent placement: Rationale and design of the TARGET Study. The TARGET<br />
International Steering Committee. American Heart Journal 140:722-26, 2000. [PMID 11054616]<br />
622. Reginelli JP, Topol EJ. Glycoprotein IIb/IIIa inhibitors: Current indications and future prospects.<br />
American Journal of Medicine 109:252-254, 2000. [PMID 10974193]<br />
623. Bhatt DL, Topol EJ. The current role of platelet glycoprotein IIb/IIIa inhibitors in the management of<br />
acute coronary syndromes. Journal of the American Medical Association 284:1549-1558, 2000. [PMID<br />
11000650]<br />
624. Topol EJ. Managing acute coronary syndromes: The New paradigms. American Heart Journal<br />
138:S561-562, 1999. [PMID 10577462]<br />
625. Pilote L, Miller DP, Califf RM, Topol EJ for the GUSTO-I Investigators. Recurrent ischemia after<br />
thrombolysis for acute myocardial infarction. American Heart Journal 141:559-65, 2001. [PMID<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 40
11275920]<br />
626. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa<br />
antagonists: A meta-analysis of the Phase III multicenter randomized trials. Circulation 103:201-206,<br />
2001. [PMID 11208677]<br />
627. Chew DP, Bhatt DL, Robbins MA, Mukherjee D, Roffi M, Schneider JP, Topol EJ, Ellis SG. Effect of<br />
clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with Creactive<br />
protein. American Journal of Cardiology 88:672-674, 2001. [PMID 11564394]<br />
628. Bhatt DL, Chew DP, Hirsh AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin<br />
in patients with prior coronary artery bypass surgery. Circulation 103:363-368, 2001. [PMID 11157686]<br />
629. Lincoff AM, Harrington RA, Califf RM, Hochman JS, Guerci AD, Ohman EM, Pepine CJ, Kopecky SL,<br />
Kleiman NS, Pacchiana CM, Berdan LG, Kitt MM, Simoons ML, Topol EJ, for the PURSUIT Trial<br />
Investigators. Management of patients with acute coronary syndromes in the United States by platelet<br />
glycoprotein IIb/IIIa inhibition. Insights from the Platelet Glycoprotein IIb/IIIa in Unstable Angina:<br />
Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial. Circulation 102:1093-1100, 2000.<br />
[PMID 10973836]<br />
630. Chew DP, Bhatt DL, Lincoff AM, Moliterno DJ, Brener SJ, Wolski KE, Topol EJ. Defining the optimal ACT<br />
during percutaneous coronary intervention: Aggregate results from six randomized controlled trials.<br />
Circulation 103:961-966, 2001. [PMID 11181470]<br />
631. Mukherjee D, Reginelli JP, Moliterno DJ, Yadav JS, Schneider JP, Raymond R, Whitlow PL, Franco I,<br />
Topol EJ, Ellis SG. Unexpected mortality reduction with abciximab for in-stent restenosis. Journal of<br />
Invasive Cardiology 12:540-544, 2000. [PMID 11060563]<br />
632. Fu Y, Chang W-C, Mark D, Califf RM, Mackenzie B, Granger CB, Topol EJ, Hlatky M, Armstrong PW, for<br />
the GUSTO IIb Investigators. Canadian-American differences in the management of acute coronary<br />
syndromes in GUSTO IIb: 1 year follow-up of patients with versus those without ST segment elevation.<br />
Circulation 102:1375-1381, 2000. [PMID 10993855]<br />
633. Lauer MA, Peterson JG, Granger CB, Bhatt DL, Houghtaling PL, Sapp SK, Harrington RA, Topol EJ,<br />
Lincoff AM. Attenuation of rebound ischemia following discontinuation of heparin therapy by glycoprotein<br />
IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: Observations from the<br />
PURSUIT Trial. Circulation 104:2772-2777, 2001. [PMID 11733393]<br />
634. Barbash GI, Birnbaum Y, Bogaerts K, Lesaffre E, Houbracken K, Munsters K, Hudson M, Granger CB,<br />
Pieper K, Califf RM, Topol EJ, Van de Werf F. Treatment of reinfarction after thrombolytic therapy for<br />
acute myocardial infarction: An analysis of outcomes and treatment choices in the GUSTO I and ASSENT<br />
2 Studies. Circulation 103:954-960, 2001. [PMID 11181469]<br />
635. Lincoff AM, Mark DB, Tcheng JE, Califf RM, Bala MV, Anderson KM, Davidson-Ray L, Knight JD, Cabot<br />
CF, Topol EJ for the EPILOG Investigators. Economic assessment of platelet glycoprotein IIb/IIIa<br />
receptor blockade with abciximab with low-dose heparin during percutaneous coronary revascularization:<br />
Results from the EPILOG randomized trial. Circulation 102:2923-2929, 2000. [PMID 11113041]<br />
636. Herrmann HC, Moliterno DJ, Ohman EM, Stebbins AL, Bode C, Betriu A, Forycki F, Miklin JS, Bachinsky<br />
WB, Lincoff AM, Califf RM, Topol EJ. Facilitation of early percutaneous coronary intervention after<br />
reteplase with or without abciximab in acute myocardial infarction: Results from the SPEED (GUSTO-4<br />
Pilot) Trial. Journal of the American College of Cardiology 36:1489-96, 2000. [PMID 11079647]<br />
637. Cohen MG, Pacchiana CM, Corbalan R, Perez JEI, Ponte CI, Oropeza ES, Diaz R, Paolasso E, Izasa D,<br />
Rodas MA, Urrutia CE, Harrington RA, Topol EJ, Califf RM. Variation in patient management and<br />
outcomes for acute coronary syndromes in Latin America and North America: results from PURSUIT.<br />
American Heart Journal 141:391-401, 2001. [PMID 11231436]<br />
638. Anderson KM, Califf RM, Stone GW, Neuman F-J, Montalescot G, Miller DP, Ferguson III JJ, Willerson<br />
JT, Weisman HF, Topol EJ. Long-term mortality benefit with abciximab in patients undergoing<br />
percutaneous coronary intervention. Journal of the American College of Cardiology 37:2059-65, 2001.<br />
[PMID 11419888]<br />
639. Greenbaum AB, Harrington RA, Hudson MP, MacAulay CM, Wilcox RG, Simoons ML, Berdan LG, Guerci<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 41
A, Cokkinos DV, Kitt MM, Lincoff AM, Topol EJ, Califf RM, Ohman EM, for the PURSUIT Investigators.<br />
Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers<br />
early after admission for acute coronary syndromes. Journal of the American College of Cardiology<br />
37:492-498, 2001. [PMID 11216968]<br />
640. Topol EJ. The future of antiplatelet therapy: Optimizing management in acute coronary syndrome<br />
patients. Clinical Cardiology 23(Suppl VI): V23-28, 2000. [PMID 11129683]<br />
641. Bahit MC, Topol EJ, Califf RM, Armstrong PW, Criger DA, Hasselblad V, Betriu A, Hirsh J, Ardissino D,<br />
Granger CB. Reactivation of ischemic events in acute coronary syndromes: Results from GUSTO-IIb.<br />
Journal of the American College of Cardiology 37:1001-1007, 2001. [PMID 11263599]<br />
642. Yamada DM, Topol EJ. Importance of microembolization and inflammation in atherosclerotic heart<br />
disease. American Heart Journal Supplement Vol 140(6):S90-102, 2000. [PMID 11100003]<br />
643. Bhatt DL, Kapadia SR, Yadav JS, Topol EJ. Update on clinical trials of antiplatelet therapy for<br />
cerebrovascular diseases. Cerebrovascular Diseases 10 (Suppl 5): 34-40, 2000. [PMID 11096181]<br />
644. Kaul P, Fu Y, Chang W-C, Harrington RA, Wagner GS, Goodman SG, Granger CB, Moliterno DJ, Van de<br />
Werf F, Califf RM, Topol EJ, Armstrong PW, for the PARAGON and GUSTO-IIb Investigators. Prognostic<br />
value of ST-segment depression in acute coronary syndromes: Insights from PARAGON-A applied to<br />
GUSTO-IIb. Journal of the American College of Cardiology 38:64-71, 2001. [PMID 11451297]<br />
645. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Yakubov SJ, Cohen EA,<br />
Bertrand M, Neumann F-J, Stone GW, DiBattiste PM, Demopoulos L, for the TARGET Investigators.<br />
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of<br />
ischemic events with percutaneous coronary intervention. New England Journal of Medicine 344:1888-<br />
1894, 2001. [PMID 11419425]<br />
646. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary<br />
angioplasty for unstable or post-infarction angina: The final report of the bivalirudin angioplasty study.<br />
American Heart Journal 142:952-59, 2001. [PMID 11718438]<br />
647. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and<br />
prevalence of aspirin resistance in patients with cardiovascular disease. American Journal of Cardiology<br />
88:230-35, 2001. [PMID 11472699]<br />
648. Patel V, Robbins M, Topol EJ. Inflammation and coronary artery disease. The Cleveland Clinic Journal<br />
of Medicine 68:521-524, 2001. [PMID 11405613]<br />
649. Cho L, Bhatt DL, Wolski K, Lincoff AM, Topol EJ, Moliterno DJ. Effect of smoking status and abciximab<br />
use on the outcome after percutaneous coronary revascularization. American Heart Journal 141:599-<br />
602, 2001. [PMID 11275926]<br />
650. The 2nd SYMPHONY Investigators. Randomized trial of aspirin, sibrafiban, or both to prevent ischemic<br />
events after acute coronary syndromes. Circulation 103:1727-1733, 2001. [PMID 11282902]<br />
651. Newby LK, Ohman EM, Christenson RH, Moliterno DJ, Harrington RA, White HD, Armstrong PW, Van de<br />
Werf F, Pfisterer M, Hasselblad V, Califf RM, Topol EJ, for the PARAGON-B Steering Committee. Benefit<br />
of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin-t positive status:<br />
the PARAGON-B Troponin-T Substudy. Circulation 103:2891-96, 2001. [PMID 11413076]<br />
652. Steinhubl SR, Ellis SG, Wolski K, Lincoff AM, Topol EJ, for the EPISTENT Investigators. Ticlopidine<br />
pretreatment prior to coronary stenting is associated with a sustained decrease in adverse cardiac<br />
events. Circulation 103:1403-1409, 2001. [PMID 11245644]<br />
653. Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, Frederick B, Topol EJ.<br />
Abciximab suppresses the rise in levels of circulation inflammatory markers following percutaneous<br />
coronary revascularization. Circulation 104:163-167, 2001. [PMID 11440969]<br />
654. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, Harrington RA, Califf RM,<br />
Ohman EM, Kleiman NS, Keltai M, Wilcox RG, Vahanian A, Armstrong PW, Lauer MS. Effect of lipidlowering<br />
therapy on early mortality after acute coronary syndromes: an observational study. The Lancet<br />
357:1063-68, 2001. [PMID 11297956]<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 42
655. Peterson JG, Topol EJ, Roe MT, Sapp SK, Lincoff AM, Deckers JW, Blackstone EH, Harrington RA,<br />
Califf RM, Lauer MS, on behalf of the PURSUIT Investigators. Prognostic importance of concomitant<br />
heparin with eptifibatide in acute coronary syndromes. American Journal of Cardiology 87:532-536,<br />
2001. [PMID 11230834]<br />
656. Wang K, Zhou Z, Zhou X, Tarakji K, Topol EJ, Lincoff AM. Prevention of intimal hyperplasia with<br />
recombinant soluble P-selectin glycoprotein ligand-Ig (rPSGL-Ig) in the porcine coronary artery balloon<br />
injury model. Journal of the American College of Cardiology 38:577-82, 2001. [PMID 11499755]<br />
657. Cura FA, L'Allier PL, Kapadia SR, Houghtaling PL, Dipaola LM, Ellis SG, Topol EJ, Brener SJ, on behalf<br />
of the GUSTO IIb and RAPPORT Investigators. Predictors and prognosis of suboptimal coronary blood<br />
flow after primary angioplasty in patients with acute myocardial infarction. American Journal of<br />
Cardiology 88:124-128, 2001. [PMID 11448407]<br />
658. The GUSTO IV-ACS Investigators. Glycoprotein IIb/IIIa receptor blocker abciximab does not improve<br />
outcome in patients with acute coronary syndromes without early coronary revascularization. The Lancet<br />
357:1915-24, 2001. [PMID 11425411]<br />
659. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy<br />
or combination low dose fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO 5<br />
Trial. The Lancet 357:1905-14, 2001. [PMID 11425410]<br />
660. Chew DP, Roffi M, Topol EJ. Statistical significance versus clinical relevance: Intravenous glycoprotein<br />
IIb/IIIa inhibition in non-ST elevation acute coronary syndromes. Progress in Cardiovascular Medicine<br />
44:195-206, 2001. [PMID 11727277]<br />
661. Bhatt DL, Topol EJ. Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart<br />
disease. Cardiology Clinics 19:253-265, 2001.<br />
662. Topol EJ. Introduction: The role of bivalirudin in percutaneous coronary intervention. Journal of<br />
Interventional Cardiology Vol 12(Suppl F): 1F, 2000. [PMID 11156726]<br />
663. Chew DP, Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS, Topol EJ, Ellis SG. The<br />
incremental prognostic value of an elevated baseline C-reactive protein among established markers of<br />
risk in percutaneous coronary intervention. Circulation 104:992-997, 2001. [PMID 11524391]<br />
664. Ronner E, Boersma E, Akkerhuis KM, Harrington RA, Lincoff AM, Deckers JW, Armstrong PW, Karsch K,<br />
Kleiman NS, Vahanian A, Topol EJ, Califf RM, Simoons ML. Patients with acute coronary syndromes<br />
without persistent ST-elevation undergoing percutaneous coronary intervention benefit most of early<br />
intervention with protection by a glycoprotein IIb/IIIa receptor blocker. European Heart Journal 23:239-<br />
246, 2002. [PMID 11792139]<br />
665. Mukherjee D, Nissen S, Topol EJ. Risk of cardiovascular events associated with selective COX-2<br />
inhibitors. Journal of the American Medical Association 286:954-59, 2001. [PMID 11509060]<br />
666. Bhatt DL, Bertrand ME, Berger PB, L'Allier PP, Moussa I, Moses JW, Dangas G, Taniuchi M, Lasala JM,<br />
Holmes DR, Ellis SG, Topol EJ. Meta-analysis of randomized and registry comparisons of ticlopidine<br />
with clopidogrel after stenting. Journal of the American College of Cardiology 39:9-14, 2002. [PMID<br />
11755280]<br />
667. Penn MS, Topol EJ. Tissue factor, the emerging link between inflammation, thrombosis and vascular<br />
remodeling. Circulation Research 89:1-2, 2001. [PMID 11440969]<br />
668. Al-Khatib SM, Pieper KS, Lee KL, Mahaffey KW, Hochman JS, Pepine CJ, Kopecky SL, Akkerhuis M,<br />
Stepinska J, Simoons ML, Topol EJ, Califf RM, Harrington RA. Atrial fibrillation and mortality among<br />
patients with acute coronary syndromes without ST-segment elevation: Results from the PURSUIT Trial.<br />
American Journal of Cardiology 88:76-79, 2001. [PMID 11423065]<br />
669. Akkerhuis KM, Deckers JW, Lincoff AM, Tcheng JE, Boersma E, Anderson K, Balog C, Califf RM, Topol<br />
EJ, Simoons ML. Risk of stroke associated with abciximab among patients undergoing percutaneous<br />
coronary intervention. Journal of the American Medical Association 286:78-82, 2001. [PMID 11434830]<br />
670. Lundergan CF, Ross AM, McCarthy WF, Reiner JS, Coyne KS, Califf RM, Ross AM, Boyle D, van de<br />
Brand M, Fink C, Topol EJ, Simoons ML, Van de Werf F. Predictors of left ventricular following acute<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 43
myocardial infarction; effects of time to treatment, patency and body mass index: The GUSTO-I<br />
Angiographic Experience. American Heart Journal 142:43-50, 2001. [PMID 11431655]<br />
671. Park S-H, Marso SP, Zhou Z, Forudi F, Topol EJ, Lincoff AM. Neointimal hyperplasia following arterial<br />
injury is increased in a rat model of non-insulin-dependent diabetes mellitus. Circulation 104:815-819,<br />
2001. [PMID 11502708]<br />
672. Hudson MP, Granger CB, Topol EJ, Pieper KS, Armstrong PW, Barbash GI, Guerci AD, Vahanian A,<br />
Califf RM, Ohman EM. Early reinfarction after fibrinolysis: Experience from GUSTO-I and GUSTO-III.<br />
Circulation 104:1229-1235, 2001. [PMID 11551872]<br />
673. Zhang R, Brennan M-L, Fu X, Aviles RJ, Pearce G, Penn MS, Topol EJ, Sprecher DL, Hazen SL.<br />
Association between myeloperoxidase levels and risk of coronary artery disease. Journal of the<br />
American Medical Association 286:2136-2142, 2001. [PMID 11694155]<br />
674. Bhatt DL, Topol EJ. PCI or CABG for multivessel disease? No clear winner in an unfair fight. Current<br />
Controlled Trials in Cardiovascular Medicine 2:260-262, 2001. [PMID 11806809]<br />
675. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Robbins MA, Moliterno DJ, Heeschen C, Hamm<br />
CW, Califf RM, Harrington RA, White HD, Kleinman NS, Theroux P, Topol EJ. Platelet glycoprotein<br />
IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment elevation acute coronary<br />
syndromes. Circulation 104:2767-2771, 2001. [PMID 11733392]<br />
676. Bhatt DL, Kapadia SR, Bajzer CT, Chew DP, Ziada KM, Mukherjee D, Roffi M, Topol EJ, Yadav JS. Dual<br />
antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting. Journal of Invasive<br />
Cardiology 13:767-771, 2001. [PMID 11731685]<br />
677. Ellis SG, Brener SJ, Lincoff AM, Moliterno DJ, Whitlow PL, Schneider JP, Topol EJ. Beta-blockers before<br />
percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme rise.<br />
Circulation 104:2685-2688, 2001. [PMID 11723019]<br />
678. Topol EJ, McCarthy J, Gabriel S, Moliterno DJ, Rogers WJ, Newby LK, Freedom M, Metivier J, Cannata<br />
R, O'Donnell CJ, Kottke-Marchant K, Murugesan G, Plow EF, Stenina O, Daley GQ, for the GeneQuest<br />
Investigators. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be<br />
associated with familial premature myocardial infarction. Circulation 104:2641-2644, 2001 [PMID<br />
11723011]<br />
679. Chew DP, Bhatt DL, Topol EJ. Oral glycoprotein IIb/IIIa inhibitors: Why don't they work? American<br />
Journal of Cardiovascular Drugs 1:421-428, 2001. [PMID 14728001]<br />
680. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de Werf F, de Torbal A, Pieper K,<br />
Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ, Simoons ML. Platelet<br />
glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. A meta-analysis of all major randomized<br />
clinical trials. Lancet 359:189-98, 2002. [PMID 11812552]<br />
681. Zhou Z, Lauer MA, Wang K, Forudi F, Zhou X-R, Song X-Y, Kapadia SR, Nakada MT, Topol EJ, Lincoff<br />
AM. Effects of ani-tumor necrosis factor (TNF)-alpha polyclonal antibody on restenosis following balloon<br />
angioplasty in a rabbit atherosclerotic model. Atherosclerosis 161:153-59, 2002. [PMID 11882327]<br />
682. Gibler WB, Armstrong PW, Ohman EM, Weaver WD, Stebbins AL, Gore JM, Newby LK, Califf RM, Topol<br />
EJ, for the GUSTO Investigators. Persistence of delays in treatment for patients with acute MI: The<br />
GUSTO-I and GUSTO-III experience. Annals of Emergency Medicine 39(2): 123-130, 2002. [PMID<br />
11823765]<br />
683. Roe MT, Granger CB, Puma JA, Hellkamp AS, Hochman JS, Ohman EM, White HD, Van de Werf F,<br />
Armstrong PW, Ellis SG, Califf RM, Topol EJ. Comparison of benefits and complications of hirudin<br />
versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary<br />
intervention. American Journal of Cardiology 88:1403-6, 2001. [PMID 11741559]<br />
684. Brener SJ, Topol EJ. Epicardial versus microcirculatory dissociation. European Heart Journal 23:274-<br />
76, 2002. [PMID 11812062]<br />
685. Labinaz M, Kilaru R, Pieper K, Marso SP, Kitt MM, Simoons ML, Califf RM, Topol EJ, Armstrong PW,<br />
Harrington RA, for the PURSUIT Investigators. Outcomes of patients with acute coronary syndromes<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 44
and prior coronary artery bypass grafting: Results from the PURSUIT Trial. Circulation 105:322-327,<br />
2002. [PMID 11804987]<br />
686. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ, Heeschen C, Hamm CW, Robbins<br />
MA, Kleiman NS, Theroux P, White HD, Topol EJ. Platelet glycoprotein IIb/IIIa inhibition in acute<br />
coronary syndromes: Gradient of benefit related to revascularization strategy. European Heart Journal<br />
23:1441-1448, 2002.<br />
687. Casserly I, Topol EJ. Glycoprotein IIb/IIIa antagonists--From bench to practice. Cellular and Molecular<br />
Life <strong>Science</strong>s Journal 59: 478-500, 2002. [PMID 11964126]<br />
688. Mukherjee D, Topol EJ. Pharmacogenomics in cardiovascular disease. Progress in Cardiovascular<br />
Disease 44:479-98, 2002 [PMID 12077721]<br />
689. Brener SJ, Zeymer U, Adgey AJ, Vrobel TR, Ellis SG, Neuhaus K-L, Juran N, Ivanc TB, Ohman EM,<br />
Strony J, Kitt M, Topol EJ. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial<br />
infarction: The Integrilin and Low-Dose Thrombolytics in Acute Myocardial Infarction - INTRO AMI Trial.<br />
Journal of the American College of Cardiology 39:377-86, 2002. [PMID 11823073]<br />
690. Lewis D, Wang Q, Topol EJ. Ischaemic heart disease. Encyclopedia of Life <strong>Science</strong>s Website:<br />
www.els.net, 2001.<br />
691. Gibler WB, Topol EJ, Holroyd B, Armstrong PW. Cardiology and emergency medicine: United we stand,<br />
divided we fall. Annals of Emergency Medicine 39(2): 164-167, 2002. [PMID 11823771]<br />
692. Mahaffey KW, Harrington RA, Akkerhius M, Kleiman NS, Berdan LG, Crenshaw BS, Tardiff BE, Granger<br />
CB, DeJong I, Bhapkar M, Widimsky P, Corbalon R, Lee KL, Deckers JW, Simoons ML, Topol EJ, Califf<br />
RM, for the PURSUIT Investigators. Clinical events committee adjudication of myocardial infarction<br />
endpoints in a multicenter, international clinical trial: Review of the PURSUIT Study. Current Controlled<br />
Trials in Cardiovascular Medicine 2:187-94, 2001. [PMID 11806793]<br />
693. Chan AW, Chew DP, Bhatt DL, Moliterno DJ, Topol EJ, Ellis SG. Long-term mortality benefit with the<br />
combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction: A 7<br />
year prospective analysis. American Journal of Cardiology 89:132-136, 2002. [PMID 11792330]<br />
694. Quinn MJ, Topol EJ. Common variations in platelet glycoproteins: pharmacogenomic implications.<br />
Pharmacogenomics 2:341-352, 2001 [PMID 11722284]<br />
695. Mukherjee D, Nissen SE, Topol EJ. COX-2 inhibitors and cardiovascular risk: we defend our data and<br />
suggest caution. Cleveland Clinic Journal of Medicine 68:963-64, 2001.<br />
696. Anderson RD, White HD, Ohman EM, Wagner GS, Krucoff MW, Armstrong PW, Weaver WD, Gibler WB,<br />
Califf RM, Topol EJ. Predicting outcome after thrombolysis in acute myocardial infarction according to<br />
ST Segment resolution at 90 minutes: A substudy of the GUSTO-III Trial. American Heart Journal<br />
144:81-8, 2002. [PMID 12094192]<br />
697. Lauer MA, Karweit JA, Cascade EF, Lin ND, Topol EJ. Practice patterns and outcomes of percutaneous<br />
coronary interventions in the United States: 1995-1997. American Journal of Cardiology 89: 924-29,<br />
2002. [PMID 11950429]<br />
698. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, Ellis SG. Early and sustained survival<br />
benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation<br />
105:691-96, 2002. [PMID 11839623]<br />
699. Moliterno DJ, Topol EJ. TARGET (do Tirofiban And Reopro Give Similar Efficacy outcomes Trial) hit or<br />
miss? European Heart Journal 11:835-37, 2002. [PMID 12042001]<br />
700. Moliterno DJ, Yakubov SJ, DiBattiste PM, Herrmann HC, Stone GW, Macaya C, Neumann F-J, Ardissino<br />
D, Bassand J-P, Borzi L, Yeung AC, Harris KA, Demopoulos LA, Topol EJ. Outcomes at 6 months for<br />
the direct comparison of Tirofiban and Abciximab during percutaneous coronary Revascularization with<br />
Stent Placement: The TARGET Study. The Lancet 360:355-360, 2002. [PMID 12241774]<br />
701. Ellis SG, Lincoff AM, Whitlow PL, Raymond RE, Franco I, Schneider JP, Topol EJ. Evidence that<br />
angiotensin converting enzyme inhibitor diminishes coronary revascularization after stenting. American<br />
Journal of Cardiology 89: 937-40, 2002. [PMID 11950431]<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 45
702. HERO-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients<br />
receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 Trial. The Lancet 358:1855-63,<br />
2001. [PMID 11741625]<br />
703. Penn MS, Francis GS, Ellis SG, Young JB, McCarthy P, Topol EJ. Autologous cell transplantation for the<br />
treatment of damaged myocardium. Progress in Cardiovascular Disease 45:21-32, 2002. [PMID<br />
12138412]<br />
704. Mahaffey KW, Roe MT, Dyke CK, Newby LK, Kleiman NS, Connolly P, Berdan LG, Sparapani R, Lee KL,<br />
Armstrong PW, Topol EJ, Califf RM, Harrington RA, for the PARAGON-B Investigators. Misreporting of<br />
myocardial infarction end points: Results of adjudication by a central clinical events committee in the<br />
PARAGON-B trial. American Heart Journal 143:242-48, 2002. [PMID 11835026]<br />
705. Mahaffey KW, Harrington RA, Akkerhius M, Kleiman NS, Berdan LG, Crenshaw BS, Tardiff BE, Granger<br />
CB, DeJong I, Bhapkar M, Widimsky P, Corbalon R, Lee KL, Deckers JW, Simoons ML, Topol EJ, Califf<br />
RM, for the PURSUIT Investigators. Systemic adjudication of myocardial infarction endpoints in an<br />
international clinical trial. Current Controlled Trials in Cardiovascular Medicine 2:180-86, 2001.<br />
706. Roffi M, Cattaneo F, Topol EJ. Thyrotoxicosis and the cardiovascular system. The Cleveland Clinic<br />
Journal of Medicine 70:57-63, 2003. [PMID 12549727]<br />
707. Cantor WJ, Newby LK, Christenson RH, Tuttle RH, Hasselblad V, Armstrong PW, Moliterno DJ, Califf RM,<br />
Topol EJ, Ohman EM, for the SYMPHONY and 2nd SYMPHONY Cardiac Markers Substudy<br />
Investigators. Prognostic significance of elevated troponin-I after percutaneous coronary intervention.<br />
Journal of the American College of Cardiology 39:1738-44, 2002. [PMID 12039485]<br />
708. Topol EJ, Lincoff AM, Kereiakes DJ, Kleiman NS, Cohen EA, Ferguson JJ, Tcheng JE, Califf RM, for the<br />
EPIC, EPILOG and EPISTENT Investigators. Multi-year follow-up of abciximab therapy in three<br />
randomized, placebo-controlled trials of percutaneous coronary revascularization. American Journal of<br />
Medicine 113:1-6, 2002. [PMID 12106616]<br />
709. Lincoff AM, Kleiman NS, Kottke-Marchant K, Maierson ES, Maresh K, Wolski KE, Topol EJ. Bivalirudin<br />
with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous<br />
coronary revascularization. American Heart Journal 143:847-53, 2002. [PMID 12040347]<br />
710. Savonitto S, Granger CB, Ardissino D, Gardner L, Cavallini C, Galvani M, Ottani F, White HD, Armstrong<br />
PW, Ohman EM, Pieper KS, Califf RM, Topol EJ, on behalf of the GUSTO-IIb Investigators. The<br />
prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary<br />
syndromes. Journal of the American College of Cardiology 39:22-29, 2002. [PMID 11755282]<br />
711. Estess JM, Topol EJ. Fibrinolytic therapy for elderly patients with myocardial infarction. Heart 87:308-<br />
311, 2002. [PMID 11906993]<br />
712. The PARAGON-B Investigators. Randomized, placebo-controlled trial of titrated intravenous lamifiban for<br />
acute coronary syndromes. Circulation 105:316-321, 2002. [PMID 11804986]<br />
713. Jeremias A, Bhatt DL, Chew DP, Ziada KM, Albirini A, Brener SJ, Lincoff AM, Topol EJ, Ellis SG. Safety<br />
of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency.<br />
American Journal of Cardiology 89:1209-1211, 2002. [PMID 12008179]<br />
714. Stone GW, Moliterno DJ, Bertrand M, Neumann F-J, Herrmann HC, Powers ER, Grines CL, Moses JW,<br />
Cohen DJ, Cohen EA, Cohen M, DiBattiste PM, Topol EJ. Impact of clinical syndrome acuity on the<br />
different response to two glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: The<br />
TARGET Trial. Circulation 105:2347-54, 2002. [PMID 12021219]<br />
715. Gurm HS, Brennan DM, Booth J, Tcheng JE, Lincoff AM, Topol EJ. The obesity paradox, the impact of<br />
body mass index on outcome after percutaneous coronary intervention. American Journal of Cardiology<br />
90:42-45, 2002. [PMID 12088778]<br />
716. Ellis SG, Schneider JP, Topol EJ. Comparison of long-term survival following non-Q-wave creatine<br />
kinase elevation after percutaneous coronary intervention in patients discharged on a beta blocker versus<br />
those not so treated. American Journal of Cardiology 89:751-753, 2002. [PMID 11897218]<br />
717. Wang K, Zhou X, Zhou Z, Tarakji K, Qin JX, Sitges M, Shiota T, Forudi F, Schaub RG, Kumar A, Penn<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 46
MS, Topol EJ, Lincoff AM. Recombinant soluble P-selectin glycoprotein ligand-Ig (rPSGL-Ig) attenuates<br />
infarct size and myeloperoxidase activity in a canine model of ischemia-reperfusion. Thrombosis and<br />
Haemostasis 88:149-54, 2002. [PMID 12152656]<br />
718. Al-Khatib SM, Granger CB, Huang Y, Lee KL, Califf RM, Simoons ML, White HD, Armstrong PW, Van de<br />
Werf F, Topol EJ, Ohman M, Moliterno D, Harrington R.. Sustained ventricular arrhythmias among<br />
patients with acute coronary syndromes with no ST-segment elevation: Incidence, predictors, and<br />
outcomes. Circulation 106:309-12, 2002. [PMID 12119245]<br />
719. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors: Recognition of a two-edged sword?<br />
Circulation 106:379-85, 2002. [PMID 12119257]<br />
720. Bhatt DL, Topol EJ. The need to test the arterial inflammation hypothesis. Circulation 106:136-40, 2002.<br />
[PMID 12093783]<br />
721. Mazur W, Kaluza GL, Sapp S, Balog C, Topol EJ, Mark DB, Ellis SG, Kereiakes D, Lincoff AM, Kleiman<br />
NS. Glycoprotein IIb/IIIa inhibition with abciximab and postprocedural risk assessment: Lessons from<br />
EPISTENT and implication for ad hoc use of GP IIb/IIIa antagonists. American Heart Journal 143: 594-<br />
601, 2002. [PMID 11923795]<br />
722. Mukherjee D, Mahaffey KW, Moliterno DJ, Harrington RA, Yadav JS, Pieper KS, Gallup D, Dyke C, Roe<br />
MT, Berdan L, Lauer MS, Manttari M, White HD, Califf RM, Topol EJ. The promise of combined lowmolecular-weight<br />
heparin and platelet glycoprotein IIb/IIIa inhibition--Results from PARAGON-B.<br />
American Heart Journal 144:995-1002, 2002. [PMID 12486423]<br />
723. Ronner E, Boersma E, Laarman G-J, Somsen GA, Harrington RA, Deckers JW, Topol EJ, Califf RM,<br />
Simoons ML. Early angioplasty in acute coronary syndromes without persistent ST-elevation improves<br />
outcome, but increases need for 6 month repeat revascularization. An analysis of the PURSUIT-trial.<br />
Journal of the American College of Cardiology 39:1924-29, 2002. [PMID 12084589]<br />
724. Califf RM, Pieper KS, Lee KL, Van de Werf F, Simes RJ, Armstrong PW, Topol EJ. Prediction of 1-year<br />
survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and<br />
TPA for occluded coronary arteries trial. Circulation 101:2231-2238, 2000. [PMID 10811588]<br />
725. Brener SJ, Midei MG, Nukta D, Kereiakes DJ, Rizik DG, Murphy D, Brennan D, Moliterno DJ, Topol EJ.<br />
A randomized multicenter trial comparing a new, low-pressure versus a conventional coronary stent:<br />
primary results from the CONSERVE trial. Journal of Invasive Cardiology 15:128-132, 2003. [PMID<br />
12612386]<br />
726. Wong C-K, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, Ohman EM, for the GUSTO III<br />
Investigators. Management and outcome of patients with atrial fibrillation during acute myocardial<br />
infarction: The GUSTO-III Experience. Heart Journal 88:357-62, 2002. [PMID 12231591]<br />
727. Roffi M, Moliterno DJ, Meier B, Powers ER, Grines CL, DiBattiste PM, Herrmann HC, Bertrand M, Harris<br />
KA, Demopoulos LA, Topol EJ, for the TARGET Investigators. The impact of different platelet<br />
glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary<br />
intervention: TARGET 1-year follow-up. Circulation 105:2730-36, 2002. [PMID 12057986]<br />
728. Yoon J, Wu C-J, Homme J, Tuch RJ, Wolff RG, Topol EJ, Lincoff AM. Local delivery of nitric oxide from<br />
an eluting stent to inhibit neointimal thickening in the porcine coronary artery injury model. Yonsei<br />
Medical Journal 43:242-51, 2002. [PMID 11971219]<br />
729. Blankenship JC, Balog C, Sapp SK, Godfrey N, Califf RM, Lincoff AM, Tcheng JE, Topol EJ. Reduction<br />
in vascular access site bleeding in sequential abciximab coronary intervention trials. Catheterization and<br />
Cardiovascular Interventions 57:476-83, 2002. [PMID 12455081]<br />
730. Chan AW, Quinn MJ, Bhatt DL, Chew DP, Moliterno DJ, Topol EJ, Ellis SG. Mortality benefit of betablockade<br />
after successful percutaneous coronary intervention. Journal of the American College of<br />
Cardiology 40:669-75, 2002. [PMID 12204496]<br />
731. Al-Khatib SM, Stebbins AL, Califf RM, Lee KL, Granger CB, White HD, Armstrong PW, Topol EJ, Ohman<br />
M. Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction:<br />
results from the GUSTO-III trial. American Heart Journal 145:515-21, 2003. [PMID 12660676]<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 47
732. Brener SJ, Ellis SG, Schneider J, Topol EJ. Frequency and long-term impact of myonecrosis after<br />
coronary stenting. European Heart Journal 11:869-76, 2002. [PMID 12042008]<br />
733. Dauterman K, Topol EJ. Optimal treatment and current situation in reperfusion after thrombolysis for<br />
acute myocardial infarction. Annals of Medicine 34:514-522, 2002.<br />
734. Tamberella MR, Bhatt DL, Chew DP, Kereiakes DJ, Topol EJ, Steinhubl SR, on behalf of the GOLD<br />
Investigators. Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major<br />
bleeding (from the GOLD study). American Journal of Cardiology 89:1429-1431, 2002. [PMID 12062743]<br />
735. Mukherjee D, Topol EJ. The role of low-molecular weight heparin in cardiovascular disease. Progress in<br />
Cardiovascular Diseases 45:139-156, 2002. [PMID 12411975]<br />
736. Mehta RH, Criger DA, Granger CB, Califf RM, Topol EJ, Bates ER. Patient outcomes after fibrinolytic<br />
therapy for acute myocardial infarction at hospitals with or without coronary revascularization capability.<br />
Journal of the American College of Cardiology 40:1034-40, 2002. [PMID 12354424]<br />
737. Jeremias A, Albirini A, Ziada KM, Chew DP, Brener SJ, Topol EJ, Ellis SG. Prognostic significance of<br />
creatine kinase-MB elevation after percutaneous coronary intervention in patients with chronic renal<br />
dysfunction. American Heart Journal 143:1040-45, 2002. [PMID 12075261]<br />
738. Aviles RJ, Askari AT, Jia G, Ohman EM, Mahaffey KW, Newby LK, Berger PB, Califf RM, Lindahl B,<br />
Wallentin L, Topol EJ, Lauer MS. Troponin T levels in patients with acute coronary syndromes, with or<br />
without renal dysfunction. New England Journal of Medicine 346:2047-52, 2002. [PMID 12087140]<br />
739. Roffi M, Mukherjee D, Chew DP, Bhatt DL, Cho L, Robbins MA, Ziada KM, Brennan DM, Ellis SG, Topol<br />
EJ. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive<br />
treatment for percutaneous interventions of aortocoronary bypass grafts: A pooled analysis of five<br />
randomized clinical trials. Circulation 106:3063-67, 2002. [PMID 12473552]<br />
740. Kottke-Marchant K, Bahit MC, Granger CB, Zoldhelyi P, Ardissino D, Zaramo C, Griffin JH, Pothoff RF,<br />
Van de Werf F, Califf RM, Topol EJ. Effect of hirudin versus heparin on hemostatic activity in patients<br />
with acute coronary syndromes: the GUSTO-IIb Hemostasis Substudy. European Heart Journal 15:1202-<br />
12, 2002. [PMID 12127922]<br />
741. Robbins M, Topol EJ. Inflammation as the principal pathway to acute coronary syndromes. The<br />
Cleveland Clinic Journal of Medicine 69(Suppl 2):SII130-42, 2002. [PMID 12086253]<br />
742. Mukherjee D, Gurm H, Tang WHW, Roffi M, Wolski K, Moliterno DJ, Guetta V, Ardissino D, Bode C, Steg<br />
G, Lincoff AM, Topol EJ. Outcome of acute myocardial infarction in patients with prior coronary artery<br />
bypass surgery treated with combination reduced fibrinolytic therapy and abciximab. American Journal of<br />
Cardiology 90:1198-1203, 2002. [PMID 12450598]<br />
743. Islam MA, Blankenship JC, Balog CA, Iliadis EA, Lincoff AM, Tcheng JE, Califf RM, Topol EJ, for the<br />
EPISTENT Investigators. Effect of abciximab on angiographic complications during percutaneous<br />
coronary intervention with stents in the EPISTENT Trial. American Journal of Cardiology 90:916-21,<br />
2002. [PMID 12398954]<br />
744. Zhou Z, Penn MS, Forudi F, Zhou X, Tarakji K, Topol EJ, Lincoff AM, Wang K. Administration of a<br />
recombinant P-selectin glycoprotein ligand Fc fusion protein suppresses inflammation and neointimal<br />
formation in a Zucker diabetic rat model. Atherosclerosis, Thrombosis and Vascular Biology 22:1598-<br />
1603, 2002. [PMID 12377736]<br />
745. Cho L, Bhatt DL, Marso SP, Brennan D, Holmes DR Jr., Califf RM, Topol EJ. An invasive strategy is<br />
associated with decreased mortality in patients with unstable angina and non-ST-elevation myocardial<br />
infarction: GUSTO IIB Trial. American Journal of Medicine 114:106-111, 2003. [PMID 12586229]<br />
746. Ellis SG, Chew D, Chan A, Whitlow PL, Schneider JP, Topol EJ. Death following creatine kinase-MB<br />
elevation after coronary intervention. Identification of an early risk period; importance of creatine kinase-<br />
MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy.<br />
Circulation 106:1205-1210, 2002. [PMID 12208794]<br />
747. Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, Creager MA, Easton JD, Gavin III JR,<br />
Greenland P, Hankey G, Hanrath P, Hirsch AT, Meyer J, Pearson TA, Smith SC, Sullivan F, Weber MA.<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 48
Critical issues in peripheral arterial disease detection and management: A call to action. Archives of<br />
Internal Medicine 163:884-892, 2003. [PMID 12719196]<br />
748. Topol EJ. Economics and quality of care for patients with acute coronary syndromes: The impending<br />
crisis. Clinical Cardiology 25:I9-I15, 2002. [PMID 12428814]<br />
749. Kereiakes DJ, Lincoff AM, Anderson KM, Achenbach R, Patel K, Barnathan E, Califf RM, Topol EJ, on<br />
behalf of the EPIC, EPILOG, and EPISTENT Investigators. Abciximab survival advantage following<br />
percutaneous coronary intervention is predicted by clinical risk profile. American Journal of Cardiology<br />
90:628-630, 2002. [PMID 12231090]<br />
750. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus<br />
aspirin in patients with diabetes mellitus. American Journal of Cardiology 90:625-628, 2002. [PMID<br />
12231089]<br />
751. Cura FA, Kapadia SR, L'Allier PL, Ziada KM, Mukherjee D, Wolski KE, Yadav JS, Brener SJ, Whitlow PL,<br />
Topol EJ, Ellis SG. Effect of uncoated stenting-vs-balloon angioplasty alone of long coronary (>20mm)vs-shorter<br />
narrowings on 1-year event-free survival. American Journal of Cardiology 91:587-90, 2003.<br />
[PMID 12615267]<br />
752. Ottervanger JP, Armstrong PW, Barnathan ES, Boersma E, Cooper JS, Ohman EM, James S, Topol EJ,<br />
Wallentin L, Simoons ML, for the GUSTO IV ACS Investigators. Long-term results after the IIb/IIIa<br />
inhibitor abciximab in unstable angina: 1-year survival in the GUSTO IV ACS Trial. Circulation 107:437-<br />
442, 2003.<br />
753. Mukherjee D, Topol EJ. COX-2: Where are we in 2003? Arthritis Research & Therapy, 5:8-11, 2003.<br />
[PMID 12716442]<br />
754. Agah R, Topol EJ. Genetic testing for coronary heart disease: the approaching frontier. Expert Review<br />
of Molecular Diagnostics 2:448-60, 2002. [PMID 12271816]<br />
755. Casserly IP, Topol EJ. The primacy of clinical effectiveness for cost-effectiveness analysis. Heart<br />
89:249-50, 2003. [PMID 12591818]<br />
756. Steinhubl SR, Berger PB, Mann JT, Fry ETA, DeLargo A, Wilmer C, Topol EJ, for the CREDO<br />
Investigators. Early and sustained dual oral antiplatelet therapy for percutaneous coronary intervention:<br />
results of the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial. Journal of the<br />
American Medical Association 288:2411-20, 2002. [PMID 12435254]<br />
757. Topol EJ. Aspirin with bypass surgery---from taboo to new standard of care. New England Journal of<br />
Medicine 347:1359-1360, 2002. [PMID 12397195]<br />
758. Brener SJ, Lytle BW, Schneider JP, Ellis SG, Topol EJ. Association between CK-MB elevation after<br />
percutaneous or surgical revascularization and three-year mortality. Journal of the American College of<br />
Cardiology 40:1961-67, 2002. [PMID 12475456]<br />
759. Lincoff AM, Califf RM, van de Werf F, Willerson JT, White HD, Armstrong PW, Guetta V, Gibler WB,<br />
Hochman JS, Bode C, Vahanian A, Steg PG, Ardissino D, Savonitto S, Bar F, Sadowsky Z, Betriu A,<br />
Booth JE, Wolski K, Waller M, Topol EJ, for the GUSTO V Investigators. Mortality at 1 year with<br />
combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy versus<br />
conventional fibrinolytic therapy for acute myocardial infarction: the GUSTO V Randomized Trial. Journal<br />
of the American Medical Association 288:2130-2135, 2002. [PMID 12413372]<br />
760. Kaul P, Newby LK, Fu Y, Hasselblad V, Mahaffey KW, Christenson RH, Harrington RA, Ohman EM, Topol<br />
EJ, Califf RM, Van de Werf F, Armstrong PW, for the PARAGON-B Investigators. Troponin T and<br />
quantitative ST-segment depression offer complimentary prognostic information in the risk stratification of<br />
acute coronary syndrome patients. Journal of the American College of Cardiology 41:371-80, 2003.<br />
[PMID 12575962]<br />
761. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the<br />
natural history of aspirin resistance among stable patients with cardiovascular disease. Journal of the<br />
American College of Cardiology 41:961-65, 2003. [PMID 12651041]<br />
762. Cho L, Bhatt DL, Brennan D, Wilcox RG, Topol EJ. Relation of insurance status to performance of<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 49
coronary angiography in patients with unstable angina pectoris or acute myocardial infarction. American<br />
Journal of Cardiology 91:721-23, 2003. [PMID 12633807]<br />
763. Newby LK, Harrington RA, Bhapkar MV, Hochman JS, Granger CB, Davis CG, Topol EJ, Simes RJ,<br />
Califf RM, Van de Werf F, Moliterno DJ, for the PARAGON A Investigators. An automated strategy for<br />
bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary<br />
syndromes: Implications for clinical trials and clinical practice. Journal of Thrombosis and Thrombolysis<br />
14:33-42, 2002. [PMID 12652148]<br />
764. Lee MS, Wali AU, Menon V, Berkowitz SD, Thompson TD, Califf RM, Topol EJ, Granger CB, Hochman<br />
JS. The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin<br />
time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary<br />
syndromes: a review of GUSTO-IIb. Journal of Thrombosis and Thrombolysis 14:91-101, 2002. [PMID<br />
12714828]<br />
765. Brener SJ, Ellis SG, Schneider J, Apperson-Hansen C, Topol EJ. Abciximab-facilitated percutaneous<br />
coronary intervention and long-term survival - a prospective single-center registry. European Heart<br />
Journal 24:630-38, 2003. [PMID 12657221]<br />
766. Yen MH, Topol EJ. Atheromatous showers, periprocedural myocardial infarction, and fatality. American<br />
Heart Journal 145:933-35, 2003. [PMID 12796744]<br />
767. Topol EJ, Kereiakes DJ. Regionalization of care for ischemic heart disease: A call for specialized<br />
centers. Circulation 107:1463-66, 2003. [PMID 12654599]<br />
768. James S, Armstrong P, Barnathan E, Califf R, Lindahl B, Siegbahn A, Simoons M, Topol EJ, Wenge P,<br />
Wallentin L, and the GUSTO-IV ACS Investigators. Troponin and C-reactive protein have different<br />
relations to subsequent mortality and myocardial infarction after unstable coronary syndrome--a GUSTO-<br />
IV Substudy. Journal of the American College of Cardiology 41:916-24, 2003. [PMID 12651034]<br />
769. O'Shea JC, Wilcox RG. Skene AM, Stebbins AL, Granger CB, Armstrong PW, Bode C, Ardisssino D,<br />
Emanuelsson H, Aylward PE, White HD, Sadowski Z, Topol EJ, Califf RM, Ohman EM. Comparison of<br />
outcomes of patients with myocardial infarction when living alone versus those not living alone. American<br />
Journal of Cardiology 90:1374-77, 2002. [PMID 12480048]<br />
770. Wang K, Zhou X, Zhou Z, Tarakji K, Carneiro M, Penn MS, Murray D, Klein A, Humphries RG, Turner J,<br />
Thomas JD, Topol EJ, Lincoff AM. Blockade of platelet P2Y12 receptor by AR-C69931MX sustains<br />
coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis<br />
model. Arteriosclerosis, Thrombosis and Vascular Biology 23:357-362, 2003. [PMID 12588784]<br />
771. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nature Reviews Drug<br />
Discovery, 2:15-28, 2003. [PMID 12509756]<br />
772. Askari AT, Brennan M-L, Zhou X, Drinko J, Morehead A, Thomas JD, Topol EJ, Hazen SL, Penn MS.<br />
Myeloperoxidase and plasminogen activator inhibitor-1 play a central role in ventricular remodeling after<br />
myocardial infarction. Journal of Experimental Medicine 197:615-624, 2003. [PMID 12615902]<br />
773. Mukherjee D, Topol EJ. Pharmaceutical advertising versus research spending: Are profits more<br />
important than patients? American Heart Journal 146:563-64, 2003. [PMID 14564305]<br />
774. Hasdai D, Topol EJ, Kilaru R, Battler A, Harrington RA, Vahanian A, Ohman EM, Granger CB, Van de<br />
Werf F, Simoons ML, O'Connor CM, Holmes Jr DR. Frequency, patient characteristics and outcomes of<br />
mild to moderate heart failure complicating ST-segment elevation acute myocardial infarction: Lessons<br />
from 4 International Fibrinolytic Therapy Trials. American Heart Journal 145:73-79, 2003. [PMID<br />
12514657]<br />
775. Stenina OI, Krukovets I, Forudi F, Wang K, Penn M, Topol EJ, Plow EF. The increased expression of<br />
thrombospondin-1 in the vessel wall of a diabetic Zucker rat. Circulation 107:3209-3215, 2003. [PMID<br />
12810612]<br />
776. You S-A, Archacki SR, Angheloiu G, Kinter M, Moravec CS, Topol EJ, Wang Q. Proteomic approach to<br />
coronary atherosclerosis indicates ferritin light chain as a significant marker: Evidence to support the iron<br />
hypothesis in atherosclerotic disease. Physiological Genomics 13:25-30, 2003. [PMID 12644631]<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 50
777. Zhou Z, Wang K, Penn MS, Marso SP, Lauer MA, Forudi F, Zhou X, Qu W, Lu Y, Stern DM, Schmidt AM,<br />
Lincoff AM, Topol EJ. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial<br />
injury in diabetic rats. Circulation 107:2238-43, 2003. [PMID 12719284]<br />
778. McCarthy JJ, Lehner T, Moliterno DJ, Newby LK, Rogers WJ, Topol EJ, for the GeneQuest Investigators.<br />
Association of genetic variants in the HDL receptor, SR-B1, with abnormal lipids in women with coronary<br />
artery disease. Journal of Medical Genetics 40:453-458, 2003 [PMID 12807968]<br />
779. Chan AW, Bhatt DL, Chew DP, Reginelli J, Schneider JP, Topol EJ, Ellis SG. Relation of inflammation<br />
and benefit of statins following percutaneous coronary interventions. Circulation 107:1750-56, 2003.<br />
[PMID 12665489]<br />
780. Rao S, Li X, Guo Z, Moser KL, Topol EJ, Wang Q. An analysis-of-variance (ANOVA) approach for sibpair<br />
linkage analysis of complex ordinal human diseases. Chinese Journal of Biomedical Engineering<br />
11:104-112, 2002.<br />
781. Breeman A, Mercado N, Lenzen M, van den Brand MMJ, Harrington RA, Califf RM, Topol EJ, Simoons<br />
ML, Boersma E, for the PURSUIT Investigators. Characteristics, treatment and outcome of patients with<br />
non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: Observations from<br />
PURSUIT. Cardiology 98:195-201, 2002. [PMID 12566649]<br />
782. Lincoff AM, Bittl JA, Kleiman NS, Sarembock IJ, Jackman JD, Mehta S, Kereiakes DJ, Harrington RA,<br />
Maierson EF, Chew DP, Topol EJ, for the REPLACE-1 Investigators. Bivalirudin and provisional<br />
glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during<br />
percutaneous coronary intervention: the randomized evaluation of PCI linking angiomax to reduced<br />
clinical events (REPLACE) - 2 Trial. Journal of the American Medical Association 289:853-63, 2003.<br />
[PMID 12588269]<br />
783. Topol EJ. A guide to therapeutic decision-making in patients with non-ST-segment elevation acute<br />
coronary syndromes. Journal of the American College of Cardiology 41:123S-129S, 2003. [PMID<br />
12644350]<br />
784. Gurm HS, Bhatt DL, Gupta R, Ellis SG, Topol EJ, Lauer MS. Impact of preprocedural white blood cell<br />
count on long-term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG,<br />
and EPISTENT trials. Heart 89:1200-4, 2003. [PMID 12975419]<br />
785. Wang K, Kessler PD, Zhou Z, Penn MS, Forudi F, Zhou X, Tarakji K, Kibbe M, Kovesdi I, Brough DE,<br />
Topol EJ, Lincoff AM. Local adenoviral-mediated inducible nitric oxide synthase (iNOS) gene transfer<br />
inhibits neointimal formation in the porcine coronary stented model. Molecular Therapy 7:597-603, 2003.<br />
[PMID 12718902]<br />
786. Newby LK, Bhapkar MV, White HD, Topol EJ, Dougherty FC, Harrington RA, Smith MC, Asarch LF, Califf<br />
RM, for the SYMPHONY and 2nd SYMPHONY Investigators. Predictors of 90 day outcome in patients<br />
stabilized after acute coronary syndromes. European Heart Journal 24:172-182, 2003.<br />
787. Ross MJ, Herrmann HC, Moliterno DJ, Blankenship JC, DiBattiste PM, Ellis SG, Frey MJ, Gazzal Z,<br />
Martin JL, White J, Topol EJ. Angiographic variables predict increased risk for adverse ischemic events<br />
following coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET Trial. Journal of<br />
the American College of Cardiology 42:981-88, 2003. [PMID 13678916]<br />
788. Cho L, Chew DP, Moliterno DJ, Roffi M, Ellis SG, Franco I, Bajzer C, Bhatt DL, Dorosti K, Simpfendorfer<br />
C, Tuzcu M, Yadav JS, Brener S, Raymond R, Whitlow P, Topol EJ, Lincoff AM. Safe and efficacious use<br />
of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor<br />
inhibition. American Journal of Cardiology 91:742-43, 2003. [PMID 12633814]<br />
789. Casserly IP, Topol EJ, Jia G, Lange RA, Hamm C, Meier B, DiBattiste PM, Lakkis N, Chew DP, Stone<br />
GW, Cohen DJ, Moliterno DJ. Effect of abciximab and tirofiban on activated clotting time during<br />
percutaneous intervention and its relation to clinical outcomes. American Journal of Cardiology 92:125-<br />
29, 2003. [PMID 12860211]<br />
790. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, Barnathan ES, Califf RM, Topol<br />
EJ, Simoons ML., Wallentin L. N-terminal pro brain natriuretic peptide and other risk-markers for the<br />
separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 51
artery disease--a GUSTO IV Substudy. Circulation 108:275-281, 2003. [PMID 12847065]<br />
791. Migrino RQ, Topol EJ. A matter of life and death? The Heart Protection Study and protection of clinical<br />
trial participants. Controlled Clinical Trials 24:501-5, 2003. [PMID 14500049]<br />
792. Topol EJ. Current status and future prospects for acute myocardial infarction. Circulation 108:III 6-13,<br />
2003. [PMID 14605014]<br />
793. Lauer MS, Topol EJ. Clinical trials: Multiple endpoints, and multiple lessons. Journal of the American<br />
Medical Association 289:2575-77, 2003. [PMID 12759328]<br />
794. Stenina OI, Desai S, Kight K, Janigro D, Topol EJ, Plow EF. Thrombospondin-4 and its variants:<br />
Expression and differential effects on endothelial cells. Circulation 108:1514-19, 2003. [PMID<br />
12952849]<br />
795. Khadour FH, Fu Y, Chang WC, Ma X, Mark D, Granger CB, Topol EJ, Califf RM, Armstrong PW. Impact<br />
of on-site cardiac interventional facilities on management and outcome of patients with acute coronary<br />
syndromes. Canadian Journal of Cardiology 19:257-63, 2003. [PMID 12677281]<br />
796. Quinn MJ, Byzova TV, Qin J, Topol EJ, Plow EF. Integrin alpha IIb beta-3 and its antagonism.<br />
Arteriosclerosis, Thrombosis and Vascular Biology 23:945-952, 2003. [PMID 12637342]<br />
797. Aronow HD, Novaro GM, Lauer MS, Brennan DM, Lincoff AM, Topol EJ, Kereiakes DJ, Nissen SE. Inhospital<br />
initiation of lipid-lowering therapy following coronary intervention is the strongest predictor of<br />
long-term utilization: A propensity analysis. Archives of Internal Medicine 163:2576-82, 2003. [PMID<br />
14638557]<br />
798. Brennan M-L, Penn MS, Van Lente F, Nambi V, Shishehbor MO, Aviles RJ, Goormastic M, Pepoy ML,<br />
McErlean ES, Topol EJ, Nissen SE, Hazen SL. Prognostic value of myeloperoxidase in patients with<br />
chest pain. New England Journal of Medicine 349:1595-604, 2003. [PMID 14573731]<br />
799. Gurm HS, Bhatt DL, Gupta R, Ellis SG, Topol EJ, Lauer MS. Preprocedural white blood cell count and<br />
death after percutaneous coronary intervention. American Heart Journal 146:692-98, 2003. [PMID<br />
14564325]<br />
800. Chan AW, Moliterno DJ, Berger PB, Stone GW, DiBattiste PM, Yakubov SL, Wolski K, Bhatt DL, Topol<br />
EJ, for the TARGET Investigators. Triple antiplatelet therapy during percutaneous coronary intervention<br />
is associated with improved outcomes including 1-year survival. Results from the do Tirofiban and<br />
ReoPro Give similar Efficacy outcome Trial (TARGET). Journal of the American College of Cardiology<br />
42:1188-95, 2003. [PMID 14522478]<br />
801. Newby LK, Hasselblad V, Armstrong PW, Van de Werf F, Mark DB, White HD, Topol EJ, Califf RM.<br />
Time-based risk assessment after myocardial infarction. Implications for timing of discharge and<br />
applications to medical decision making. European Heart Journal 24:182-89, 2003. [PMID 12573275]<br />
802. Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, Topol EJ, for the CREDO<br />
Investigators. Lack of adverse clopidogrel--atorvastatin clinical interaction from secondary analysis of a<br />
randomized, placebo-controlled clopidogrel trial. Circulation 108:921-924, 2003. [PMID 12925453]<br />
803. Savonitto S, Armstrong PW, Ardissino D, Lincoff AM, Jia G, Booth J, Sila CA, Terrosu P, White HD, Califf<br />
RM, Topol EJ, for the GUSTO V Investigators. Risk of intracranial hemorrhage with combined fibrinolytic<br />
and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction: dichotomous response as a<br />
function of age in the GUSTO V trial. European Heart Journal 24:1807-1814, 2003. [PMID 14563339]<br />
804. Yen MH, Bhatt DL, Chew DP, Harrington RA, Newby LK, Ardissino D, Van de Werf F, White JA, Moliterno<br />
DJ, Topol EJ, for the PARAGON A Investigators. Association between admission white blood cell count<br />
and 1 year mortality in patients with acute coronary syndromes. American Journal of Medicine 115:318-<br />
21, 2003. [PMID 12967697]<br />
805. Tolleson TR, Newby LK, Harrington RA, Bhapkar MV, Berger P, Moliterno DJ, White HD, Ohman EM,<br />
Verheugt FWA, Van de Werf F, Topol EJ, Califf RM, for the SYMPHONY and 2nd SYMPHONY<br />
Investigators. Frequency of stent thrombosis after acute coronary syndromes. American Journal of<br />
Cardiology 92:330-333, 2003. [PMID 12888148]<br />
806. Topol EJ, Easton D, Harrington RA, Amarenco P, Califf RM, Graffagnino C, Davis S, Diener H-C,<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 52
Ferguson J, Fitzgerald D, Granett J, Shuaib A, Koudstaal PJ, Theroux P, Van de Werf F, Sigmon K,<br />
Willerson JT, on behalf of the BRAVO Investigators. Randomized, double-blind, placebo-controlled,<br />
international trial of oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation<br />
108:399-406, 2003. [PMID 12874182]<br />
807. Chiu JH, Topol EJ, Whitlow PL, Hsu AP, Tuzcu EM, Franco I, Moliterno DJ. Peripheral vascular disease<br />
and 1-year mortality following percutaneous coronary revascularization. American Journal of Cardiology<br />
92:582-83, 2003. [PMID 12943879]<br />
808. Exaire JE, Dauerman HL, Topol EJ, Blankenship JC, Wolski K, Raymond RE, Cohen EA, Moliterno DJ,<br />
for the TARGET Investigators. Triple antiplatelet therapy does not increase femoral access bleeding with<br />
vascular closure devices. American Heart Journal 147:31-34, 2004. [PMID 14691415]<br />
809. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention<br />
of cardiovascular disease: A meta-analysis of randomized trials. The Lancet 361:2017-23, 2003. [PMID<br />
12814711]<br />
810. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, Rovner A, Ellis SG, Thomas JT,<br />
DiCorleto PE, Topol EJ, Penn MS. Effect of stromal cell-derived factor-1 mediates stem cell homing and<br />
tissue regeneration in ischemic cardiomyopathy. The Lancet 362:697-703, 2003. [PMID 12957092]<br />
811. Shishehbor MH, Bhatt DL, Topol EJ. Using C-reactive protein to assess cardiovascular disease risk.<br />
Cleveland Clinic Journal of Medicine 70:634-640, 2003. [PMID 12882386]<br />
812. Topol EJ, Neumann F-J, Montalescott G. A preferred reperfusion strategy for acute myocardial<br />
infarction. Journal of the American College of Cardiology 42:1886-89, 2003. [PMID 14662246]<br />
813. Bhatt DL, Chew DP, Lincoff AM, Simoons ML, Harrington RA, Ommen SR, Jia G, Topol EJ.<br />
Revascularization attenuates the increased mortality associated with an elevated white blood cell count<br />
in acute coronary syndromes. American Journal of Cardiology 92:136-40, 2003. [PMID 12860213]<br />
814. Ellis K, Tcheng JE, Sapp S, Topol EJ, Lincoff AM. Mortality benefit of beta blockade in patients with<br />
acute coronary syndromes undergoing coronary intervention. Pooled results from the EPIC, EPILOG,<br />
EPISTENT, CAPTURE and RAPPORT trials. Journal of Interventional Cardiology 16:299-305, 2003.<br />
[PMID 14562669]<br />
815. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ.<br />
Prevalence of conventional risk factors in patients with coronary heart disease. Journal of the American<br />
Medical Association 290:898-904, 2003. [PMID 12928466]<br />
816. Brener SJ, Lytle BW, Casserly I, Schneider JP, Topol EJ, Lauer MS. A propensity analysis of long-term<br />
survival after surgical or percutaneous revascularization in high-risk patients with multivessel coronary<br />
artery disease. Circulation 109:2290-95, 2004. [PMID 15117846]<br />
817. Archacki SR, Angheloiu G, Tan FL, DiPaola N, Shen G-Q, Moravec C, Ellis S, Topol EJ, Wang Q.<br />
Identification of new genes associated with coronary artery disease by expression profiling.<br />
Physiological Genomics 15:65-74, 2003 [PMID 12902549]<br />
818. L'Allier PL, Aronow HD, Cura FA, Bhatt DL, Albirini A, Schneider JP, Topol EJ, Ellis SG. Clopidogrel is<br />
associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting.<br />
Canadian Journal of Cardiology 19:1041-46, 2003. [PMID 12915931]<br />
819. Quinn MJ, Aronow HD, Califf RM, Bhatt DL, Sapp Shelly, Kleiman NS, Harrington RA, Kong DF, Kandzari<br />
DE, Topol EJ. Aspirin dose and six-month outcome after an acute coronary syndrome. Journal of the<br />
American College of Cardiology 43:972-78, 2004. [PMID 15028352]<br />
820. Mukherjee D, Hsu A, Moliterno DJ, Lincoff AM, Goormastic M, Topol EJ. Percutaneous coronary<br />
intervention in young adults: Risk factors for premature atherosclerosis and determinants of adverse<br />
outcomes after revascularization. American Journal of Cardiology 92:1465-67, 2003. [PMID 14675589]<br />
821. McCarthy JJ, Meyer J, Moliterno DJ, Newby LK, Rogers WJ, Topol EJ, for the GeneQuest Investigators.<br />
Evidence for substantial effect modification by gender in a large-scale genetic association study of the<br />
metabolic syndrome. Human Genetics 114:87-98, 2003 [PMID 14557872]<br />
822. Brener SJ, Bhatt DL, Moliterno DJ, Schneider JP, Ellis SG, Topol EJ. Revisiting optimal anticoagulation<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 53
with unfractionated heparin during coronary stent implantation. American Journal of Cardiology 92:1468-<br />
71, 2003. [PMID 14675590]<br />
823. Khot UN, Jia G, Moliterno DJ, Lincoff AM, Khot MB, Harrington RA, Topol EJ. Prognostic importance of<br />
physical examination for heart failure in non-ST-elevation acute coronary syndromes: The enduring value<br />
of Killip classification. Journal of the American Medical Association 290:2174-2181, 2003. [PMID<br />
14570953]<br />
824. Kong DF, Hasselblad V, Harrington RA, White HD, Tcheng JE, Kandzari DE, Topol EJ, Califf RM. Metaanalysis<br />
of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions.<br />
American Journal of Cardiology 92:651-55, 2003. [PMID 12972100]<br />
825. Gurm H, Lincoff AM, Lee D, Tang WHW, Jia G, Booth JE, Califf RM, Ohman EM, Van de Werf F,<br />
Armstrong PW, Guetta V, Wilcox R, Topol EJ. Outcome of acute ST-segment elevation myocardial<br />
infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet<br />
glycoprotein IIb/IIIa inhibition: Lessons from the GUSTO V trial. Journal of the American College of<br />
Cardiology 43:542-48, 2004. [PMID 14975461]<br />
826. Topol EJ, Lauer MS. The rudimentary phase of personalized medicine: Risk scores. Lancet 362:1776-<br />
77, 2003. [PMID 14654312]<br />
827. Roffi M, Topol EJ. Percutaneous coronary intervention in diabetic patients with non-ST-segment<br />
elevation acute coronary syndromes. European Heart Journal 25:190-98, 2004. [PMID 14972418]<br />
828. Brener SJ, Topol EJ. Adjunctive therapy for percutaneous revascularization in acute myocardial<br />
infarction. Current Pharmaceutical Design 10:399-405, 2004. [PMID 14965201]<br />
829. Bittl JA, Chew DP, Topol EJ, Kong DF, Califf RM: Meta-analysis of randomized trials of percutaneous<br />
transluminal coronary angioplasty versus atherectomy, atherotomy or laser angioplasty. Journal of the<br />
American College of Cardiology 43:936-942, 2004. [PMID 15028347]<br />
830. Chiu JH, Bhatt DL, Ziada KM, Whitlow PL, Lincoff AM, Chew DP, Ellis SG, Topol EJ. Impact of female<br />
sex on outcomes following percutaneous coronary intervention: A decade of progress. American Heart<br />
Journal 148:998-1002, 2004. [PMID 15632884]<br />
831. Lee DS, Bhatt DL, Moliterno DJ, Peacock WF, Ellis SG, Topol EJ. The combination of enoxaparin,<br />
glycoprotein IIb/IIIa inhibitors and an early invasive approach in patients with acute coronary syndromes.<br />
Journal of Invasive Cardiology 16:46-51, 2004. [PMID 14760188]<br />
832. Kandzari DE, Granger CB, Simoons M, White HD, Simes J, Mahaffey KW, Gore J, Weaver WD,<br />
Longstreth WT, Stebbins A, Lee KL, Califf RM, Topol EJ, for the GUSTO-I Investigators. Risk factors for<br />
intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy: A case-control study from<br />
the GUSTO-I trial. Journal of the American College of Cardiology 93:458-61, 2004. [PMID 14969623]<br />
833. Wang Q, Rao S, Shen G-Q, Li L, Moliterno D, Newby LK, Rogers WJ, Cannata R, Zirzow E, Elston RC,<br />
Topol EJ. Premature myocardial infarction novel susceptibility locus on chromosome 1p34-36 identified<br />
by genome-wide linkage analysis. American Journal of Human Genetics, 74:262-271, 2004 [PMID<br />
14732905]<br />
834. Wang L, Fan C, Topol SE, Topol EJ, Wang Q. Mutation of MEF2A in an inherited disorder with features<br />
of coronary artery disease. <strong>Science</strong> 302:1578-81, 2003. [PMID 14645853]<br />
835. Kramer JM, Newby LK, Chang W-C, Simes J, Van de Werf F, Granger CB, Lee KL, White HD, Bhapkar<br />
MV, Piegas LS, Topol EJ, Califf RM, Armstrong PW, for the SYMPHONY and 2nd SYMPHONY<br />
Investigators. International variation in the use of evidence-based medicines for acute coronary<br />
syndromes: Insights from the SYMPHONY studies. European Heart Journal 24:2133-41, 2003. [PMID<br />
14643274]<br />
836. Askari, A.T., Unzek, S., Goldman, C.K., Kiedrowski, M., Forudi, F., Ellis, S.G., Thomas, J.D., Topol, E.J.,<br />
DiCorleto, P.E., Penn, M.S. Cellular, but not direct adenoviral delivery of VEGF results in improved LV<br />
function and neovascularization in dilated ischemic cardiomyopathy. Journal of the American College of<br />
Cardiology 43:1908-1914, 2004. [PMID 15145120]<br />
837. Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, Ohman EM. Significance of atrial<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 54
fibrillation during acute myocardial infarction, and its current management insights from the GUSTO-3<br />
Trial. Cardiac Electrophysiology Review 7:201-207, 2003. [PMID 14739713]<br />
838. Roe MT, Mahaffey KW, Kilaru R, Alexander JH, Harrington RA, Tardiff BE, Granger CB, Ohman EM,<br />
Moliterno DJ, Lincoff AM, Armstrong PW, Akkerhuis M, Simoons ML, Van de Werf F, Califf RM, Topol EJ.<br />
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in<br />
patients with acute coronary syndromes. European Heart Journal 4:313-21, 2004. [PMID 14984920]<br />
839. McCarthy JJ, Parker A, Moliterno DJ, Salem R, Wang Q, Plow EF, Rao S, She G-Q, Rogers WJ, Newby<br />
LK, Cannata R, Glatt K, Topol EJ, for the GENEQUEST Investigators. Large-scale association analysis<br />
for identification of genes underlying premature coronary heart disease: Cumulative perspective from<br />
analysis of 111 candidate genes. Journal of Medical Genetics 41:334-41, 2004. [PMID 15121769]<br />
840. Kaul P, Fu Y, Newby LK, Califf RM, Topol EJ, Aylward P, Granger CB, Van de Werf F, Mark DB,<br />
Armstrong PW, for the VIGOUR Group. International differences in the evolution of early discharge after<br />
acute myocardial infarction. Lancet 363:511-17, 2004. [PMID 14975612]<br />
841. Rao S, Li L, Li X, Moser KL, Guo Z, Shen G, Zhang T, Cannata R, Zirzow E, Topol EJ, Wang Q. Genetic<br />
linkage analysis of longitudinal hypertension phenotypes using three summary measures. BMC Genetics<br />
4:S24, 2003. [PMID 14975092]<br />
842. Guo Z, Rao S, Moser KL, Zhang T, Gong B, Shen G, Li L, Cannata R, Zirzow E, Topol EJ, Wang Q.<br />
Multivariate sib-pair linkage analysis of longitudinal phenotypes by three stepwise analysis approaches.<br />
BMC Genetics 4:S68, 2003. [PMID 14975136]<br />
843. Agah R, Ellis S, Chase S, Henderson M, Mlady L, Li J, Tubbs R, Marchant K, Warshawsky I, Rouse C,<br />
Hughes K, Welch P, Topol EJ. Creation of a genetic databank for cardiovascular association studies:<br />
Genebank at the Cleveland Clinic Heart Center (GATC). American Heart Journal 150:500-506, 2005.<br />
[PMID 16169331]<br />
844. Li X, Rao S, Zhang T, Guo Z, Moser KL, Topol EJ. An ensemble method for gene discovery based on<br />
DNA microarray data. <strong>Science</strong> in China 47:396-405, 2004. [PMID 15623151]<br />
845. Wessel J, Topol EJ, Ji M, Meyer J, McCarthy JJ. Replication of the association between the<br />
thrombospondin-4 A387P polymorphism and myocardial infarction: Importance of effect modification by<br />
waist to hip ratio. American Heart Journal 147:905-909, 2004. [PMID 15131549]<br />
846. Narizhneva NV, Byers-Ward VJ, Quinn MJ, Zidar FJ, Plow EF, Topol EJ, Byzova TV. Molecular and<br />
functional differences induced in thrombospondin-1 by the single nucleotide polymorphism associated<br />
with the risk of premature, familial myocardial infarction. Journal of Biological Chemistry 279:21651-57,<br />
2004 [PMID 15007078]<br />
847. Casserly IP, Topol EJ. Convergence of atherosclerosis and Alzheimer's disease: inflammation,<br />
cholesterol, and unfolded proteins. Lancet 363:1139-1146, 2004. [PMID 15064035]<br />
848. Maroo A, Topol EJ. The early history and development of thrombolysis in acute myocardial infarction.<br />
Journal of Thrombosis and Haemostasis 2:1867-70, 2004. [PMID 15550011]<br />
849. Freedman ML, Reich DE, Penney KL, McDonald G, Mignault AA, Patterson N, Gabriel SB, Topol EJ,<br />
Smoller JW, Pato CN, Petryshen T, Kolonel L, Lander ES, Sklar P, Henderson B, Hirschhorn JN, Altshuler<br />
D. Assessing the impact of population stratification on genetic association studies. Nature Genetics<br />
36:388-93, 2004. [PMID 15052270]<br />
850. Ellis SG, Bajzer CT, Bhatt DL, Brener SJ, Whitlow PL, Lincoff AM, Moliterno DJ, Raymond RE, Tuzcu EM,<br />
Franco I, Dushman-Ellis S, Lander KJ, Schneider JP, Topol EJ. Real world bare metal stenting -<br />
identification of patients at low or very low risk of 9-month coronary revascularization. Catheterization<br />
and Cardiovascular Interventions 63:135-140, 2004. [PMID 15390245]<br />
851. Lincoff AM, Bittl JA, Kleiman NS, Sarembock IJ, Jackman D, Mehta S, Tannenbaum MA, Niederman AL,<br />
Bachinsky WB, Tift-Mann III J, Parker G, Kereiakes DJ, Harrington RA, Feit F, Maierson ES, Chew DP,<br />
Topol EJ, for the REPLACE-1 Investigators. Comparison of bivalirudin versus heparin during<br />
percutaneous coronary intervention: the Randomized Evaluation of PCI Linking Angiomax to reduced<br />
Clinical Events (REPLACE-1) Trial. American Journal of Cardiology 93:1092-96, 2004. [PMID<br />
15110198]<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 55
852. Labinaz M, Mathias J, Pieper K, Granger CB, Lincoff AM, Moliterno DJ, Van de Werf F, Simes J, White<br />
HD, Simoons ML, Califf RM, Topol EJ, Armstrong PW, Harrington RA. Outcomes of patients with acute<br />
coronary syndromes and prior percutaneous coronary intervention: A pooled analysis of 3 randomized<br />
clinical trials. European Heart Journal 26:128-136, 2005. [PMID 15618068]<br />
853. Ringleb PA, Bhatt DL, Hirsch AT, Topol EJ, Hacke W. Benefit of clopidogrel over aspirin is amplified in<br />
patients with a history of ischemic events. Stroke 35:528-32, 2004 [PMID 14739421]<br />
854. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, Thorsteinsdottir U,<br />
Thorgeirsson G, Sveinbjornsdottir S, Valdimarsson EM, Gudmundsdottir O, Thorhallsdottir M,<br />
Andresdottir M, Frigge ML, Samani NJ, Topol EJ, Kong A, Gudnason V, Hakonarson H, Gulcher JR,<br />
Stefansson K. The gene encoding 5-lipoxygenase activating protein (FLAP) confers risk of myocardial<br />
infarction and stroke. Nature Genetics 36:233-39, 2004 [PMID 14770184]<br />
855. Merlini PA, Rossi M, Menozzi A, Buratti S, Brennann FD, Moliterno DJ, Topol EJ, Ardissino D.<br />
Thrombocytopenia caused by abciximab versus tirofiban, and its association with clinical outcome.<br />
Circulation 109:2203-06, 2004. [PMID 15117843]<br />
856. Stenina OI, Byzova TV, Adams JC, McCarthy JJ, Topol EJ, Plow EF. Coronary artery disease and the<br />
thrombospondin single nucleotide polymorphisms. International Journal of Biochemistry and Cell Biology<br />
36:1013-1030, 2004. [PMID 15094117]<br />
857. McGuire DK, Newby LK, Bhapkar MV, Moliterno DJ, Hochman JS, Klein WW, Weaver WD, Pfisterer M,<br />
Corbalan R, Dellborg M, Granger CB, Van de Werf F, Topol EJ, Califf RM, for the SYMPHONY and 2nd<br />
SYMPHONY Investigators. Association of diabetes mellitus and glycemic control strategies with clinical<br />
outcomes after acute coronary syndromes. American Heart Journal 147:246-52, 2004. [PMID 14760321]<br />
858. Brener SJ, Moliterno DJ, Lincoff AM, Steinhubl SR, Wolski KE, Topol EJ. The relationship between<br />
activated clotting time and ischemic or hemorrhagic complications. Analysis of four recent randomized<br />
clinical trials of percutaneous coronary intervention. Circulation 110:994-98, 2004. [PMID 15302778]<br />
859. Topol EJ. Invisible showers. Catheterization & Cardiovascular Interventions 63:42-43, 2004.<br />
[PMID15343565]<br />
860. Topol EJ. Intensive statin therapy--a sea change in cardiovascular prevention. New England Journal of<br />
Medicine 350:1562-64, 2004. [PMID 15007111]<br />
861. Quinn MJ, Bhatt DL, Zidar F, Vivekananthan D, Chew DP, Ellis SG, Plow E, Topol EJ. Effect of<br />
clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous<br />
coronary intervention. American Journal of Cardiology 93:679-84, 2004. [PMID 15019868]<br />
862. Bhatt DL, Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and highrisk<br />
primary prevention: Rationale and design of the CHARISMA trial. American Heart Journal 148:263-<br />
68, 2004. [PMID 15308995]<br />
863. Gurm HS, Lincoff AM, Aronow HD, Askari AT, Brennan DM, Booth J, Lincoff AM, Topol EJ. The double<br />
jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions.<br />
American Journal of Cardiology 94:30-34, 2004. [PMID 15219504]<br />
864. Kaul P, Armstrong PW, Chang W-C, Granger CB, Lee K, Peterson ED, Califf RM, Topol EJ, Mark DB.<br />
Long-term mortality of patients with acute myocardial infarction: A comparison of United States and<br />
Canadian patients enrolled in GUSTO-I. Circulation 110:1754-60, 2004. [PMID 15381645]<br />
865. Ellis SG, Armstrong P, Betriu A, Brodie B, Herrmann H, Montalescot G, Neumann F-J, Smith JJ, Topol<br />
EJ, on behalf of the FINESSE Investigators. Facilitated percutaneous coronary intervention versus<br />
primary PCI: The FINESSE (Facilitated INtervention with Enhanced reperfusion Speed to Stop Events)<br />
Trial: Design and rationale. American Heart Journal 147:E16, 2004. [PMID 15077099]<br />
866. Saw J, Topol EJ, Steinhubl SR, Brennan D, Berger PB, Moliterno DJ, for the CREDO Investigators.<br />
Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary<br />
intervention or coronary artery bypass versus that after the second or repeat intervention. American<br />
Journal of Cardiology 94:623-25, 2004. [PMID 15342293]<br />
867. Cohen DJ, Lincoff AM, Lavelle TA, Chen H-L, Bakhai A, Berezin RH, Topol EJ, on behalf of the<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 56
REPLACE-2 Investigators. Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIa<br />
inhibition vs. heparin with routine glycoprotein IIb/IIIa inhibition for percutaneous coronary intervention:<br />
Results from the REPLACE-2 Trial. Journal of the American College of Cardiology 44:1792-1800, 2004.<br />
[PMID 15519009]<br />
868. Asher CR, Moliterno DJ, Bhapkar MV, McGuire DK, Rao SV, Holmes DR, Newby LK, Bates ER, Topol<br />
EJ, for the SYMPHONY and 2nd SYMPHONY Investigators. Association of race with complications and<br />
prognosis following acute coronary syndromes. American Journal of Cardiology 94:792-94, 2004.<br />
[PMID 15374792]<br />
869. Cura FA, Roffi M, Pasca N, Wolski KE, Lincoff AM, Topol EJ, Lauer MS, for the GUSTO V Investigators.<br />
ST-segment resolution 60 minutes after the combination treatment of abciximab with reteplase or<br />
reteplase alone for acute myocardial infarction. American Journal of Cardiology 94:859-863, 2004.<br />
[PMID 15464665]<br />
870. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D,<br />
Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, de Feyter P,<br />
Vahanian A, and Topol EJ, for the REPLACE-2 Investigators. Long-term efficacy of bivalirudin and<br />
provisional glycoprotein IIb/IIIa blockade versus heparin and planned glycoprotein IIb/IIIa blockade during<br />
percutaneous coronary revascularization. REPLACE-2 Randomized Trial. Journal of the American<br />
Medical Association 292:696-703, 2004. [PMID 15304466]<br />
871. Vivekananthan DP, Bhatt DL, Chew DP, Chan AW, Moliterno DJ, Ellis SG, Topol EJ. Effect of clopidogrel<br />
pretreatment prior to percutaneous coronary intervention markedly attenuates periprocedural rise in Creactive<br />
protein. American Journal of Cardiology 94:358-60, 2004. [PMID 15276105]<br />
872. Saw J, Lincoff AM, Desmet W, Betriu A, Rutsch W, Wilcox RG, Kleiman NS, Wolski K, Topol EJ, for the<br />
REPLACE-2 Investigators. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin<br />
with provisional GPIIb/IIIa blockade compared to heparin with routine GPIIb/IIIa blockade. A REPLACE-2<br />
substudy. Journal of the American College of Cardiology 44:1194-99, 2004. [PMID 15364319]<br />
873. Rajagopal V, Gurm HS, Bhatt DL, Lincoff AM, Tcheng JE, Kereiakes DJ, Kleiman NS, Jia G, Topol EJ.<br />
Elevated WBC count after percutaneous coronary intervention correlates with an increased risk of longterm<br />
mortality. American Journal of Cardiology 94:190-92, 2004. [PMID 15246898]<br />
874. Stenina OI, Krukovets I, Marinic T, Topol EJ, Plow EF. Polymorphisms A387P in thrombospondin-4 and<br />
N700S in thrombospondin-1 perturb calcium binding sites. FASEB Journal 19:1893-95, 2005. [PMID<br />
16148025]<br />
875. Narizhneva NV, Podrez EA, Byers-Ward VJ, Topol EJ, Byzova TV. Thrombospondin-1 upregulates cell<br />
adhesion molecules and monocytes binding to endothelium via integrin associated protein. FASEB<br />
Journal 19:1158-60, 2005 [PMID 15833768]<br />
876. McCarthy JJ, Meyer J, Moliterno DJ, Newby K, Rogers WJ, Topol EJ, for the GeneQuest Investigators.<br />
LRPAP1 identified as a possible gene for the metabolic syndrome through a candidate gene scan.<br />
Genome Research, in press, 2006.<br />
877. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, Lindblad L, Pieper K, Topol<br />
EJ, Stamler JS, Califf RM. Relationship of blood transfusion and clinical outcomes in patients with acute<br />
coronary syndromes. Journal of the American Medical Association 292:1555-1562, 2004 [PMID<br />
15467057]<br />
878. Li L, Jiang W, Li X, Moser KL, Du L, Topol EJ, Wang Q, Rao S. A robust hybrid between genetic<br />
algorithm and support vector machine for extracting an optimal feature gene subset(s). Genomics 85:16-<br />
23, 2005 [PMID 15607418]<br />
879. Topol EJ, Falk GW. A coxib a day won't keep the doctor away. The Lancet 364:639-640, 2004 [PMID<br />
15325809]<br />
880. Penn MS, Zhang M, Deglurkar I, Topol EJ. Role of stem cell homing in myocardial regeneration.<br />
International Journal of Cardiology 95:S23-25, 2004 [PMID 15336840]<br />
881. Bhagavatula MRK, Fan C, Shen G-Q, Cassano J, Plow EF, Topol EJ, Wang Q. Transcription factor<br />
MEF2A mutations in patients with coronary artery disease. Human Molecular Genetics 13:3181-88, 2004<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 57
[PMID 15496429]<br />
882. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet<br />
responsiveness to clopidogrel among 544 individuals. Journal of the American College of Cardiology<br />
45:246-51, 2005 [PMID 15653023]<br />
883. Jefferson BK, Foster JH, McCarthy JJ, Ginsburg G, Parker A, Kottke-Marchant K, Topol EJ. Aspirin<br />
resistance and a single gene. American Journal of Cardiology 95:805-808, 2005 [PMID 15757620]<br />
884. Topol EJ. Failing the public health--rofecoxib, Merck, and the FDA. New England Journal of Medicine<br />
351:1707-1709, 2004 [PMID 15470193]<br />
885. Gurm HS, Topol EJ. The electrocardiogram in acute coronary syndromes--new tricks from an old dog.<br />
Heart 7:851-53, 2005 [PMID 15958340]<br />
886. Gurm HS, Rajagopal V, Fathi R, Vivekanathan D, Yadav JS, Bhatt DL, Ellis G, Lincoff AM, Topol EJ.<br />
Effectiveness and safety of bivalirudin during percutaneous coronary intervention - experience from a<br />
single registry. American Journal of Cardiology 95:716-21, 2005 [PMID 15757596]<br />
887. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol<br />
EJ., for the CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in<br />
patients with coronary disease and normal blood pressure. The CAMELOT Study: A randomized<br />
controlled trial. Journal of the American Medical Association 292:2217-2226, 2004 [PMID 15536108]<br />
888. Chan AW, Yadav JS, Bhatt DL, Bajzer CT, Roffi M, Cho L, Agah R, Topol EJ, Comparison of the safety<br />
and efficacy of distal emboli protection versus platelet glycoprotein IIb/IIIa inhibition during carotid<br />
stenting. American Journal of Cardiology 95:791-95, 2005 [PMID 15757616]<br />
889. Nallamothu BK, Bates ER, Hochman JS, Granger CB, Guetta V, Wilcox RG, White HD, Armstrong PW,<br />
Savonitto S, Jia G, Lincoff AM, Topol EJ, for the GUSTO-V Investigators. Prognostic implication of<br />
activated partial thromboplastin time (aPTT) after reteplase or half-dose reteplase plus abciximab:<br />
Results from the GUSTO-V Trial. European Heart Journal 26:1506-1512, 2005 [PMID 15800019]<br />
890. Jefferson BK, Topol EJ. Molecular mechanisms of myocardial infarction. Current Problems in<br />
Cardiology 30:333-374, 2005 [PMID 15973291]<br />
891. Karha J, Topol EJ. The sad story of vioxx and what we should learn from it. Cleveland Clinic Journal of<br />
Medicine 71:933-939, 2004 [PMID 15641522]<br />
892. Guo Z, Zhang T, Li X, Xu J, Wang Q, Yu H, Zhu J, Wang H, Topol EJ, Wang Q, Rao S. Towards precise<br />
classification of cancers based on robust gene functional expression profiles. BMC Bioinformatics 6:58,<br />
2005 [PMID 15774002]<br />
893. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Oshrine BR, Baggish JS, Bhatt DL, Topol EJ. The<br />
risk of bleeding complications after different doses of aspirin: A post-hoc analysis of 192,036 patients<br />
enrolled in 31 randomized controlled trials. American Journal of Cardiology 95:1218-22, 2005 [PMID<br />
15877994]<br />
894. Topol EJ. Arthritis medicines and cardiovascular events--"House of Coxibs". Journal of the American<br />
Medical Association 293:366-368, 2005 [PMID 15623849]<br />
895. Topol EJ. Cholesterol, racial variation, and targeted cardiovascular medicine. Nature Medicine, 11:122-<br />
23, 2005 [PMID 15692593]<br />
896. Wang K, Tarakji K, Zhou Z, Zhang M, Forudi F, Zhou X, Koki AT, Smith ME, Keller BT, Topol EJ, Lincoff<br />
AM, Penn MS. Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant<br />
protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model.<br />
Journal of Cardiovascular Pharmacology 45:61-67, 2005 [PMID 15613981]<br />
897. Bhatt DL, Topol EJ. Does creatinine kinase-MB elevation after percutaneous coronary intervention<br />
predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes.<br />
Circulation 112:906-15; discussion 923, 2005 [PMID 160877811]<br />
898. Beinart SC, Kolm PG, Veledar E, Zhang Z, Mahoney EM, Bouin O, Gabriel S, Jackson J, Chen R, Caro J,<br />
Steinhubl S, Topol EJ, Weintraub WS. Short and long-term cost effectiveness of early and sustained<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 58
dual oral antiplatelet therapy with clopidogrel following percutaneous coronary intervention: Results from<br />
CREDO. Journal of the American College of Cardiology 46:761-69, 2005<br />
899. Chew DP, Lincoff AM, Gurm H, Wolski K, Cohen DJ, Henry T, Berger P, Feit F, Topol EJ, for the<br />
REPLACE-2 Trial. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal<br />
impairment undergoing percutaneous coronary intervention: A sub-analysis of the REPLACE-2 trial.<br />
American Journal of Cardiology 95:581-585, 2005 [PMID 15721095]<br />
900. Rebeiz AG, Johanson P, Green CL, Crater SW, Roe MT, Langer A, Giugliano RP, Lincoff AM, Newby LK,<br />
Harrington RA, Topol EJ, Califf RM, Wagner GS, Krucoff MW. ST-segment resolution with combined<br />
fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone: Pooled data from four<br />
clinical trials. American Journal of Cardiology 95:611-614, 2005 [PMID 15721101]<br />
901. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann F-J, Van de Werf F, Topol<br />
EJ. Long-term mortality benefits from adjunctive abciximab to mechanical revascularization for STsegment<br />
elevation myocardial infarction: a meta-regression analysis of randomized trials. Journal of the<br />
American Medical Association 293:1759-65, 2005 [PMID 15827315]<br />
902. Mukherjee D, Topol EJ, Moliterno DJ, Brennan D, Ziada K, Steinhubl SR, for the CREDO Investigators.<br />
Extra-cardiac vascular disease and effectiveness of sustained clopidogrel therapy. Heart 92:49-51, 2006<br />
[PMID 15845611]<br />
903. Hakonarson H, Thorvaldsson S, Helgadottir A, Gudbjartsson D, Zink F, Andresdottir M, Arnar DO,<br />
Andersen K, Sigurdsson A, Thorgeirsson G, Jonsson A, Agnarsson U, Bjornsdottir H, Gottskalksson G,<br />
Einarsson A, Gudmundsdottir H, Gudmundsson K, Thjodleifsson B, Adalsteinsdottir AE, Gudmundsson K,<br />
Sverrisdottir A, Gudbjartsson H, Kristjansson K, Hardarson T, Kristinsson A, Ando G, Topol EJ, Gulcher<br />
J, Kong A, Gurney M, Thorgeirsson G, Stefansson K. Effect of a 5-lipoxygenase activating protein<br />
inhibitor on biomarkers associated with risk of myocardial infarction. Journal of the American Medical<br />
Association 293:2245-2256, 2005 [PMID 15886380]<br />
904. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: An emerging clinical entity. European<br />
Heart Journal 27:647-54, 2006 [PMID 16364973]<br />
905. Salpeter SR, Gregor P, Ormiston TM, Whitlock R, Raina R, Thebane L, Topol EJ. Meta-Analysis:<br />
Cardiovascular events associated with nonsteroidal anti-inflammatory drugs. American Journal of<br />
Medicine 119:552-559, 2006 [PMID 16828623]<br />
906. Meine TJ, Al-Khatib SM, Alexander JH, Granger CB, White HD, Kilaru R, Williams K, Ohman EM, Topol<br />
EJ, Califf RM. Incidence, predictors, and outcomes of high-degree atriovantricular block complicating<br />
acute myocardial infarction treated with thrombolytic therapy. American Heart Journal 149:670-74, 2005<br />
[PMID 159990751]<br />
907. Vasilyev N, Williams T, Brennan M-L, Unzek S, Zhou X, Heinecke JW, Spitz DR, Topol EJ, Hazen SL,<br />
Penn MS. Myeloperoxidase-generated oxidants modulate left ventricular remodeling, but not infarct size<br />
following myocardial infarction. Circulation 112:2812-20, 2005 [PMID 16267254]<br />
908. Topol EJ, Blumenthal D. Physicians and the investment industry. Journal of the American Medical<br />
Association 293:2654-57, 2005 [PMID 15928288]<br />
909. Savonitto S, Cohen MG, Politi A, Hudson MP, Granger CB, Kong DF, Huang Y, Pieper KS, Mauri F,<br />
Wagner GS, Califf RM, Topol EJ. The extent of ST-segment depression on the admission<br />
electrocardiogram is a powerful predictor of mortality in the non-ST elevation acute coronary syndromes.<br />
European Heart Journal 26:2106-2113, 2005 [PMID 15987706]<br />
910. Berger PB, Best PJ, Topol EJ, White J, DiBattiste PM, Chan AW, Kristensen SD, Herrmann HC,<br />
Moliterno DJ. The relation of renal function to ischemic and bleeding outcomes with 2 different<br />
glycoprotein IIb/IIIa inhibitors: The do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET)<br />
trial. American Heart Journal 149:869-75, 2005 [PMID 15894970]<br />
911. Wang K, Zhou X, Zhou Z, Fan L, Zhang M, Lincoff AM, Plow E, Topol EJ, Penn MS. Platelet, not<br />
endothelial P-selectin, is required for neointimal formation after vascular injury. Arteriosclerosis,<br />
Thrombosis, and Vascular Biology 25:1584-89, 2005 [PMID 15947246]<br />
912. Mehta RH, Califf RM, Garg J, Pieper KS, Alexander JH, Moliterno DJ, Van de Werf F, Ohman EM, White<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 59
HD, Topol EJ, Granger CB. Association of height with clinical outcomes in patients with acute<br />
myocardial infarction receiving reperfusion therapy. American Journal of Cardiology 95:1371-75, 2005<br />
[PMID 15904648]<br />
913. Mahaffey KW, Roe MT, Kilaru R, French JK, Alexander JH, Berdan LG, Van De Werf F, Simoons ML,<br />
Weaver WD, White HD, Lincoff AM, Kleiman NS, Topol EJ, Harrington RA. Characterization of<br />
myocardial infarction as an endpoint in two large trials of acute coronary syndromes. American Journal of<br />
Cardiology 95:1404-08, 2005 [PMID 15950560]<br />
914. Gurm HS, Sarembock IJ, Kereiakes DJ, Young JJ, Harrington RA, Kleiman N, Feit F, Wolski K, Bittl JA,<br />
Wilcox R, Topol EJ, Lincoff AM: REPLACE-2 Investigators. Use of bivalirudin during percutaneous<br />
coronary intervention in patients with diabetes mellitus: An analysis from the Randomized Evaluation in<br />
Percutaneous coronary intervention Linking Angiomax to reduced Clinical Events (REPLACE)-2 Trial.<br />
Journal of the American College of Cardiology 45:1932-38, 2005 [PMID 15963389]<br />
915. Eikelboom J, Feldman M, Mehta SR, Michelson AD, Oates JA, Topol EJ. Aspirin resistance and its<br />
imlications fin clinical practice. MedGenMed 11:73-76, 2005 [PMID 1636999302]<br />
916. Topol EJ. Nesiritide--Not verified. New England Journal of Medicine 353:113-6, 2005 [PMID 16014879]<br />
917. Topol EJ. The genomic basis of myocardial infarction. Journal of the American College of Cardiology<br />
46:1456-65, 2005 [PMID 16226168]<br />
918. Pluskota E, Stenina OI, Krukovets I, Szpak D, Topol EJ, Plow EF. The mechanisms and impact of TSP-4<br />
polymorphisms on neutrophil function. Blood 106:3970-3978, 2005 [PMID 16099885]<br />
919. Brener SJ, Lincoff AM, Bates ER, Jia G, Armstrong PW, Guetta V, Hichman JS, Savonito S, Wilcox RW,<br />
White HD, Topol EJ. The relationship between baseline risk and mortality in ST-elevation acute<br />
myocardial infarction treated with pharmacological reperfusion. Insights from the GUSTO V trial.<br />
American Heart Journal 150:89-93, 2005 [PMID 16084153]<br />
920. Chen MS, Bhatt DL, Chew DP, Moliterno DJ, Ellis SG, Topol EJ. Outcomes in African Americans and<br />
Whites after percutaneous coronary intervention. American Journal of Medicine 118:1019-25, 2005<br />
[PMID 16164889]<br />
921. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen E, Creager MA, Easton<br />
JD, Flather M, Haffner SM, Hamm CW, Hankey GJ, Johnson SC, Mak K-H, Mas J-L, Montalescot G,<br />
Pearson TA, Steg PG, Steinhubl SR, Weber M, Booth J, Topol EJ, on behalf of the CHARISMA<br />
Investigators. A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High<br />
Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.<br />
American Heart Journal 150:401.e7, 2005 [PMID 16169314]<br />
922. Galla JM, Mahaffey KW, Sapp SK, Alexander JH, Roe MT, Ohman EM, Granger CB, Armstrong PW,<br />
Harrington RA, White HD, Simoons ML, Newby LK, Califf RM, Topol EJ. Elevated creatine-kinase-MB<br />
with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: Results<br />
from four large clinical trials. American Heart Journal 151:16-24, 2006 [PMID 16368286]<br />
923. Mukherjee D, Topol EJ, Bertrand ME, Dalby-Kristensen S, Herrmann HC, Neumann F-J, Yakubov SJ,<br />
Bassand J-P, McClure RR, Stone GW, Ardissino D, Moliterno DJ, for the TARGET Investigators. Mortality<br />
at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary<br />
revascularization. European Heart Journal 23:2524-28, 2005 [PMID 16107485]<br />
924. Helgadottir A, Manolescu A, Helgason A, Thorleifsson G, Thorsteinsdottir U, Gudbjartsson D,<br />
Gretarsdottir S, Magnusson KP, Gudmundsson G, Hicks A, Jonsson T, Grant SFA, Sainz J, O’Brien SJ,<br />
Sveinbjornsdottir S, Valdimarsson EM, Mattiasson SE, Levey AI, Thorgeirsson G, Abramson JL, Reilly M,<br />
Vaccarino V, Wolfe M, Gudnason V, Quyyumi AA, Topol EJ, Rader D, Gulcher J, Hakonarsson H, Kong<br />
A, Steffansson K. A variant of the gene encoding Leukotriene A4 Hydrolase confers ethnic specific risk of<br />
myocardial infarction. Nature Genetics 38:68-74, 2006 [PMID 16282974]<br />
925. Shishehbor MH, Topol EJ, Mukherjee D, Hu T, Cohen DJ, Stone GW, McClure R, Roffi M, Moliterno DJ<br />
for the TARGET Investigators. Outcome of multivessel coronary intervention in the contemporary<br />
percutaneous revascularization era. American Journal of Cardiology 97:1585-90, 2006 [PMID 16728219]<br />
926. Stenina OI, Topol EJ, Plow EF. Thrombospondins, their polymorphisms, and cardiovascular disease.<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 60
Atherosclerosis, Thrombosis and Vascular Biology 27:1886-94, 2007 [PMID 17569884]<br />
927. Shiffman D, Ellis SG, Rowland CM, Malloy MJ, Luke MM, Iakoubova OA, Pullinger CR, Cassano J,<br />
Aouizerat BE, Fenwick RG, Reitz RE, Catanese JJ, Leong DU, Zellner C, Sninsky JJ, Topol EJ, Devlin<br />
JJ, Kane JP. Identification of four gene variants associated with myocardial infarction. American Journal<br />
of Human Genetics 77:596-605, 2005 [PMID 16175505]<br />
928. Topol EJ. Genetics of heart attack. Heart 92:855-61, 2006 [PMID 16698843]<br />
929. Sinnaeve PR, Simes J, Yusuf S, Pieper K, Mehta S, Eikelboom J, Bittl JA, Serruys P, Topol EJ, Granger<br />
CB. Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early<br />
percutaneous coronary intervention. European Heart Journal 26:2396-403, 2005 [PMID 16214829]<br />
930. Kao J, Lincoff AM, Topol EJ, Madrid A, Price M, Sawhney N, Teirstein PS. Direct thrombin inhibition<br />
appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions.<br />
Catheterization and Cardiovascular Intervention 68:352-6, 2006 [PMID 16892428]<br />
931. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular<br />
events in patients with Type II Diabetes Mellitus. Journal of the American Medical Association 294:2581-<br />
86, 2005 [PMID 16239637]<br />
932. Brener SJ, Lytle BW, Casserly IP, Ellis SG, Topol EJ, Lauer MS. Predictors of revascularization method<br />
and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in<br />
patients with multivessel coronary disease and previous coronary bypass surgery. European Heart<br />
Journal 27:413-418, 2006 [PMID 16272211]<br />
933. Karha J, Topol EJ. Primary percutaneous coronary intervention versus fibrinolytic therapy for acute STelevation<br />
myocardial infarction in the elderly. American Journal of Geriatric Cardiology 15:19-21, 2006<br />
[PMID 16415642]<br />
934. Bushnell CD, Griffin J, Newby LK, Goldstein LB, Mahaffey KW, Graffagnino CA, Harrington RA, White<br />
HD, Simes RJ, Califf RM, Topol EJ, Easton JD. Statin use and sex-specific stroke outcomes in patients<br />
with vascular disease. Stroke 37:1427-31, 2006 [PMID 16645137]<br />
935. Schoenhagen P, Stillman A, Garcia M, Halliburton S, Tuzcu EM, Nissen S, Modic M, Lytle B, Topol EJ,<br />
White RD. Coronary imaging with multi-detector row computed tomography: A call for an evidencebased,<br />
multi-disciplinary approach. American Heart Journal 151:945-48, 2006 [PMID 16644309]<br />
936. Robertson JO, Lincoff AM, Wollski K, Topol EJ. Planned versus provisional use of glycoprotein IIb/IIIa<br />
inhibitors in smokers undergoing percutaneous coronary intervention. American Journal of Cardiology<br />
97:1679-84, 2006 [PMID 16765113]<br />
937. Dorsey K, Slymen D, Topol EJ, McCarthy JJ. Association between chromosome 12q23-24 positional<br />
candidate gene, SR-BI, and abdominal obesity. Journal of Medical Genetics, in press, 2006.<br />
938. Martin JL, Jia G, Martin SS, Shapiro TA, Herrmann HC, DiBattiste PM, Topol EJ, Moliterno DJ. The<br />
relationship of obesity to ischemic outcomes following coronary stent placement in contemporary<br />
practice. Catheterization & Cardiovascular Interventions 67:563-70, 2006 [PMID 16532491]<br />
939. Wang K, Zhou Z, Zhang M, Fan L, Forudi F, Zhou X, Lincoff AM, Topol EJ, Penn MS. Peroxisome<br />
proliferator-activated receptor �down-regulates receptor for advanced glycation end products and inhibits<br />
smooth muscle cell proliferation in a diabetic and non-diabetic rat carotid artery injury model. Journal of<br />
Pharmacological Experimental Therapy 317:37-43, 2006 [PMID 16368901]<br />
940. Ebrahimi R, Lincoff AM, Bittl JA, Chew D, Wolski K, Wadhani N, Toggart EJ, Topol EJ. Bivalirudin versus<br />
heparin in percutaneous coronary intervention: A pooled analysis. Journal of Cardiovascular<br />
Pharmacology and Therapeutics 10:209-16, 2005 [PMID 16382257]<br />
941. Chew DP, Bhatt DL, Lincoff AM, Wolski K, Topol EJ. Clinical endpoint definitions following percutaneous<br />
coronary intervention and their relationship to late mortality: An assessment by attributable risk. Heart<br />
92:945-50, 2006 [PMID 16387822]<br />
942. Mak K-H, Ma S, Heng D, Tan C-E, Tai E-S, Cutter J, Topol EJ, Chew S-K. Impact of gender, metabolic<br />
syndrome, and diabetes mellitus on cardiovascular events. American J Cardiology, 100:227-233, 2007<br />
[PMID 17631075]<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 61
943. Mehta RH, Marks D, Califf RM, Sohn S, Pieper KS, Van de Werf F, Peterson ED, Ohman EM, White HD,<br />
Topol EJ, Granger CB. Differences in the clinical features and outcomes in African Americans and<br />
whites with myocardial infarction. American Journal of Medicine 119:70.e1-70.e8, 2006 [PMID 16431189]<br />
944. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann F-J, Bonizzoni E, Topol EJ,<br />
Chiariello M. Relationship between patient's risk profile and benefits in mortality from adjunctive<br />
abciximab to mechanical revascularization for ST-segment elevation myocardial infarction; a metaregression<br />
analysis of randomized trials. Journal of the Ameican College of Cardiology 47:685-86, 2006<br />
[PMID 16458158]<br />
945. Steinhubl SR, Berger PB, Brennan DM, Topol EJ, for the CREDO Investigators. Optimal timing of<br />
pretreatment with 300 mg of clopidogrel prior to percutaneous coronary intervention: An analysis from<br />
the CREDO Trial. Journal of the American College of Cardiology 47:939-43, 2006 [PMID 16516075]<br />
946. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA,<br />
Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL,<br />
Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J,<br />
Topol EJ. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.<br />
New England Journal of Medicine 354: 1706-17, 2006 [PMID 16531616]<br />
947. Hewson MG, Fox JEB, Copeland HL, Mascha E, Arrigaine S, Topol EJ. Integrative medicine:<br />
implementation and evaluation of a professional development program using experiential learning and<br />
conceptual change teaching approaches. Patient Education and Counseling 62:5-12 2006 [PMID<br />
16766243]<br />
948. Kelly RV, Hsu A, Topol EJ, Steinhubl SR. The influence of body mass index on anti-platelet therapy<br />
following percutaneous coronary intervention. Journal of Invasive Cardiology 18: 115-119, 2006 [PMID<br />
16598110]<br />
949. Smith J, Topol EJ, Identification of atherosclerosis modifying genes: pathogenic insights and therapeutic<br />
potential. Expert Reviews in Cardiovascular Medicine 4:703-709, 2006 [PMID 17081092]<br />
950. Shiffman D, Rowland CM, Louie JZ, Luke MM, Bare LA, Bolonick JI, Young BA, Catanese JJ, Stiggins<br />
CF, Pullinger CR, Topol EJ, Malloy MJ, Kane, JP, Ellis SG, Devlin JJ. Gene variants of VAMP8 and<br />
HNRPUL1 are associated with early-onset myocardial infarction. Arteriosclerosis Thrombosis and<br />
Vascular Biology 26: 16143-18, 2006 [PMID 16690874]<br />
951. Chacko M, Lincoff AM, Wolski, HE, Cohen DJ, Bittl JA, Lansky AJ, Tscuchiya Y, Betriu A, Yen MH, Chew<br />
DP, Cho L, Topol EJ. Ischemic and bleeding outcomes in women treated with bivalirudin during<br />
percutaneous coronary intervention: a subgroup analysis of the randomized evaluation in PCI linking<br />
angiomax to redcued clinical events (REPLACE-2) trial. American Heart Journal 151:1032.e1-1032.e7,<br />
2006 [PMID 16644331]<br />
952. Anwaruddin S, Askari A, Topol EJ, Redefining risk in acute coronary syndromes using molecular<br />
medicine. Journal of the American College of Cardiology, 49:279-289, 2007 [PMID 17239708]<br />
953. Topol EJ, Smith J, Plow EF, Wang QK. Genetic susceptibility to myocardial infarction and coronary artery<br />
disease. Human Molecular Genetics, 15: Spec No 2:R117-23, 2006 [PMID 16987874]<br />
954. Shishebor MH, Topol EJ, Mukhurjee D, Hu T, Cohen D, Stone GW, McCLure R, Roffi M, Moliterno DJ.<br />
Outcome of multivessel coronary intervention in the contemporary percutaenous revascularization era.<br />
American Journal of Cardiology 97:1585-1590, 2006 [PMID 16728219]<br />
955. Blankenship JC, Haldis T, Feit F, Hu T, Kleiman NS, Topol EJ, Lincoff AM, Angiographic adverse events,<br />
creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention<br />
(a REPLACE-2 substudy). American Journal of Cardiology 97:1591-1596, 2006 [PMID 16728220]<br />
956. Saw J, Bhatt DL, Moliterno DJ, Brener SJ, Steinhubl SR, Lincoff AM, Tcheng JE, Harrington RA, Simoons<br />
M, Hu T, Sheikh MA, Kereiakes DJ, Topol EJ. The influence of peripheral arterial disease on outcomes: A<br />
pooled analysis of mortality in 8 large randomized percutaneous intervention trials. Journal of the<br />
American College of Cardiology 48:1567-72, 2006 [PMID 17045889]<br />
957. Exaire JE, Butman SM, Ebrahimi R, Kleiman NS, Harrington RA, Schweiger MJ, Bittl JA, Wolski K, Topol<br />
EJ, Lincoff AM, for the REPLACE-2 Investigators. Provisional glycoprotein IIb/IIIa blockade in a<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 62
andomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during<br />
percutaneous coronary intervention: Predictors and outcome in the Randomized Evaluation in<br />
Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.<br />
American Heart Journal 152:157-63, 2006 [PMID 16824849]<br />
958. Rajagopal V, Lincoff AM, Cohen DJ, Gurm HS, Hu T, Desmet WJ, Kleiman NS, Bittl JA, Feit F, Topol EJ.<br />
Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during<br />
percutaneous coronary intervention: An analysis from the Randomized Evaluation in PCI Linking<br />
Angiomax to Reduce Clinical Events (REPLACE-2) trial. American Heart Journal 152:149-54, 2006<br />
[PMID 16824845]<br />
959. Goodman SG, Fu Y, Langer A, Barr A, Tan M, Wagner GS, Barbagetala A, Sgarbossa EB, Birnbaum Y,<br />
Granger CB, Califf RM, Van de Werf F, Topol EJ, Armstrong PW, for the GUSTO IIb Investigators. The<br />
prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes:<br />
The GUSTO IIb ECG Core Laboratory Experience. American Heart Journal 152:277-84, 2006 [PMID<br />
16875908]<br />
960. Nadeau JH, Topol EJ. The genetics of health. Nature Genetics 38:1095-1098, 2006 [PMID 17006459]<br />
961. Shishehbor MH, Zhang R, Medina H, Brennan M-L, Brennan DM, Ellis SG, Topol EJ, Hazen SL.<br />
Systemic elevations of free radical oxidation products of arachidonic acid in plasma are associated with<br />
angiographic evidence of coronary artery disease. Free Radical Biology & Medicine 41(11):1678-1683,<br />
2006 [PMID 17145556]<br />
962. Tang WH, Steinhubl SR, Van Lente F, Brennan D, McErlean E, Maroo A, Francis GS, Topol EJ. Risk<br />
stratification for patients undergoing elective percutaneous coronary intervention using N-terminal pro-Btype<br />
natriuretic peptide: A Clopidogrel for the Reduction of Events During Observation (CREDO) Sub-<br />
Study. American Heart Journal 153:36-41, 2007 [PMID 17174634]<br />
963. Mehta RH, Califf RM, Garg J, White HD, Van de Werf F, Armstrong PW, Pieper KS, Topol EJ, Granger<br />
CB. The impact of anthropomorphic indices on clinical outcomes in patienst with acute ST-elevation<br />
myocardial infarction. European Heart Journal, 28:415-24, 2006 [PMID 17040928]<br />
964. Luo AK, Jefferson BK, Garcia MJ, Ginsburg GS, Topol EJ. Challenges in the phenotypic<br />
characterization of patients in genetic studies of coronary artery disease. Journal of Medical Genetics,<br />
44:161-5, 2007 [PMID 1715893]<br />
965. Salpeter SR, Grego P, Ormiston TM, Whitlock R, Raina P, Thabane L, Topol EJ, Meta-analysis:<br />
cardiovascular events associated with non-steroidal anti-inflammatory drugs. American Journal of<br />
Medicine 119:552.559, 2006 [PMID 16828623]<br />
966. Topol EJ. Stents and sensibility. Catheterization and Cardiovascular Interventions, 69:616-7, 2007<br />
[PMID 17323364]<br />
967. Topol EJ and Frazer KA, The resquencing imperative. Nature Genetics, 39:439-440, 2007 [PMID<br />
17392801]<br />
968. Shishebor MH, Lauer MS, Singh IM, CHew DP, Karha J, Brener SJ, Moliterno DJ, Ellis SG, Topol EJ,<br />
Bhatt, DB. In unstable angina or non-ST-segment acute coronary syndrome, should patients with<br />
multivessel coronary artery disease undergo multivessel or culprit-only stenting? J Am Coll Cardiology<br />
49:849-54, 2007 [PMID 17320742]<br />
969. Luke MM, Kane JP, Liu DM, Rowland CM, Shiffman D, Cassano J, Catanese JJ, Pullinger CR, Leong<br />
DU, Arellano AR, Tong CH, Movsesyan I, Naya-Vigne J, Noordhof C, Feric NT, Malloy MJ, Topol EJ<br />
Koschinsky ML, Devlin JJ, Ellis SG. Polymorphism in the Protease-like Domain of Apolipoprotein(a) is<br />
Associated with Severe Coronary Artery Disease. Art Throm Vasc Biol 27:2030-6, 2007 [PMID 17569884]<br />
970. Mahaffey KW, Roe MT, Kilaru R, Alexander JH, Can de Werf F, Califf RM, Simmons ML, Topol, EJ,<br />
Harrington, RA. Creatine-kinase-MB elevation after coronary artery bypass grafting surgery in patients<br />
with non-ST segment elevation acute coronary syndromes predict worse outcomes" results from four<br />
large clinical trials. European Heart Journal 28:425-32, 2007 [PMID 17267458]<br />
971. Ellis SG, Penn MS, Bolwell B, Garcia M, Chacko M, Wang T, Brezina KJ, McConnell G, Topol EJ.<br />
Granulocyte colony stimulating factor in patients with large acute myocardial infarction" results of a pilot<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 63
dose-escalation randomized trial. American Heart Journal 152:e9-e14, 2006 [PMID 17161051]<br />
972. Reynolds, H. Farkouh ME, Lincoff, AM, Hsu A, Farkouh M, Swahn E, Sadowski ZP, White,J,Topol EJ,<br />
Hochman J. Impact of female sex on death and bleeding after fibrinolytic treatment of Female sex<br />
independently predicted death and bleeding after fibrinolytic treatment of MI in GUSTO-V, Archives Intern<br />
Med, 167(19):2054-60, 2007 [PMID 17954798]<br />
973. Topol EJ, Murray, SS, Frazer KA. The genomics gold rush. Journal of the American Medical Association<br />
298: 218-221, 2007 [PMID 177622604]<br />
974. Saw J, Brennan DM, Steinhubl SR, Bhatt DL, Mak KH, Fox KA, Topol EJ. Lack of Evidence of a<br />
clopidogrel – statin interaction in the CHARISMA Trial. J Am College of Cardiology 50:291-5, 2007 [PMID<br />
17659194]<br />
975. Inrig JK, Gillespie BS,.Patel U, Briley LP, She L Easton JD, Topol EJ, Szczech LA. Risk of<br />
cardiovascular outcomes among subjects with atherosclerotic cardiovascular disease and greater than<br />
normal estimated glomerular filtration rate. J Am Society of Nephrology, 2(6):1215-22, 2007<br />
[PMID17942781]<br />
976. Karp I,Topol EJ Pilote L. Population attributable fraction: its implications for genetic epidemiology and<br />
illness prevention. American Heart Journal, 154:607-609, 2007 [PMID 17892977]<br />
977. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Horkko S, Barnard J, Topol EJ, Hazen SL. Protein<br />
carbamylation links inflammation, smoking, uremia and atherogenesis. Nature Medicine 13(10):1176-84,<br />
2007 [PMID 17828273]<br />
978. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Crager MA,<br />
Easton JD, Hamm CW, Hankey GJ, Johnston SJ, Mak KH, Mas JL, Montelescot G, Pearson TA, Steg<br />
PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ, Fox KAA. Patients with prior myocardial<br />
infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiology<br />
19:1982-8 2007 [PMID 171498584]<br />
979. Wang TH, Bhatt DL, Fox KAA, Steinhubl SR, Brennan DM, Hacke W, Mak KH, Pearson TA, Boden<br />
WE,Steg PG,Flather MD, Montalescot G, Topol EJ. .An analysis of mortality rates with dual antiplatelet<br />
therapy in the primary prevention population of the CHARISMA Trial, European Heart Journal,<br />
28(18):2200-7, 2007 [PMID 1763448]<br />
980. Feit F, Voeltz MD, Attubato MJ, Lincoff AM, Chew DP, Bittl JA, Topol EJ, Manoukian SV. Predictors and<br />
impact of major hemorrhage on mortality following percutaneous coronary intervention from the<br />
REPLACE-2 trial. Am J Cardiology 100(9):1364-9, 2007 [PMID 17950791]<br />
981. Bhatt DL, Chew DP, Grines C, Mukherjee D, Leesar M, Gilchrist IC, Corbelli JC, Blankenship JC, Eres A,<br />
Steinhubl S, Tan WA, Resar JR, AlMahameed A, Abdel-Latif A, Tang WH, Brennan D, McErlean E, Hazen<br />
SL, Topol EJ. Peroxisome proliferator-activated receptor γ agonists for the Prevention of Adverse events<br />
following percutaneous coronary Revascularization--results of the PPAR Study. American Heart Journal.<br />
154:137-43, 2007 [PMID 17584566]<br />
982. Brener SJ, Steinhubl SR, Berger PB, Brennan DM, Topol EJ, Prolonged dual antiplatelet thearpy after<br />
percutaneous coronary intervention reduces ischemic events without affecting the need for repeat<br />
revascularization. J Invasive Cardiology 19:287-290, 2007 [PMID 17620671]<br />
983. Shen GQ, Li L, Girelli D,. Seidelmann SB, Rao S, Fan C, Park JE, Xi Q,Li, J ,Hu J, Olivieri O, Marchant<br />
K, Barnard J,Corrocher R, Elston R, Cassano J, Henderson S, Hazen SL, Plow EF, Topol EJ, Wang QK.<br />
An LRP8 variant Is associated with familial and premature coronary artery disease and myocardial<br />
infarction, American Journal of Human Genetics, 81(4):780-91, 2007 [PMID 17847002]<br />
984. Damani SB, Topol EJ, Future use of genomics in coronary artery disease. J Am College of Cardiology<br />
50:1933-40, 2007 [PMID 17996556]<br />
985. Singh M, White J, Hasdai D, Hodgson PK, Berger PB, Topol EJ, Califf RM, Holmes DR. Long-term<br />
outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated<br />
by shock. J American College of Cardiology 50(18): 1752-8, 2007 [PMID 17964038]<br />
986. Hart RG, Bhatt DL, Hacke W, Fox KAA, Hu T, Topol EJ. Clopidogrel and aspirin versus aspirin alone for<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 64
the prevention of vascular events in patients with atrial fibrillation: Subgroup analysis of the randomized<br />
CHARISMA trial. Cerebrovascular Diseases, 25(4): 344-7, 2008 [PMID:18303254]<br />
987. Inrig JK, Patel UD, Briley LP, She L, Gillespie BS, Easton JD, Topol EJ, Szczech LA. Mortality, kidney<br />
disease and cardiac procedures following acute coronary syndrome Nephrology Dialysis and<br />
Transplantation. 23(3): 934-40, 2007 [PMID 17984102]<br />
988. Bhattacharyya T, Nicholls, SJ, Topol EJ, Zhang R, Yang X, Allayee H, Schmitt D, Fu X, Shao M, Brennan<br />
DM, Ellis SG, Brennan ML, Lusis AJ, Hazen SL. Relationship of paraoxonase (PON1) gene<br />
polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. Journal of<br />
the American Medical Association. 299(11):1265-76, 2008 [PMID 18349088]<br />
989. Jozic J, Orford J, Steinhubl S, Berger P, Hsu A, Topol EJ. Timing and correlates of very early major<br />
adverse clinical events following percutaneous coronary intervention. The Journal of Invasive Cardiology.<br />
20:113-8, 2008 [PMID 18316826]<br />
990. Elias DJ, Topol EJ. A big step forward for individualized medicine: enlightened dosing of warfarin.<br />
European Journal of Human Genetics. 16(5):532-4, 2008 [PMID 18301451]<br />
991. Seidelmann SB, Li L, Shen GQ, Topol EJ, Wang QK. Identification of a novel locus for triglyceride on<br />
chromosome 1p31-32 in families with premature CAD and MI. J Lipid Res. 49(5):1034-1038 2008. [PMID<br />
18245017]<br />
992. Murray SS, Topol EJ. Gaining insights in coronary disease genomics. J Am Coll Cardiol, 52(5):385-386,<br />
2008. [PMID 18652947]<br />
993. Abdullah KG, Li, L, Shen GQ, Topol EJ, Wang QK. Four SNPs on chromosome 9p21 confer risk to<br />
premature, familial CAD and MI in an american caucasian population (GeneQuest). Annals of Human<br />
Genetics. 72(5):654-657, 2008. [PMID: 18505420]<br />
994. Berger JS, Bhatt DL, Cannon CP, Chen Z, Jiang L, Jones JB, Mehta SR, Sabatine MS, Steinhubl SR,<br />
Topol EJ, Berger PB. The relative efficacy and safety of clopidogrel in women and men: A sex-specific<br />
collaborative meta-analysis. Lancet (in review, 2009).<br />
995. Rahim N, Harismendy O, Topol EJ, Frazer KA. Genetic determinants of phonotypic diversity in humans.<br />
Genome Biology. 9(4):215, 2008. [PMID: 18439327]<br />
996. Musunuru K, Kral BG, Blumenthal RS, Fuster V, Campbell CY, Gluckman TJ, Lange RA, Topol EJ,<br />
Willerson JT, Desai MY, Davidson MH, Mora S. The use of high sensitivity C-reactive protein in clinical<br />
practice. Nature Clinical Practice Cardiovascular Medicine. 5:621-635, 2008. [PMID 18711404]<br />
997 Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, Califf RM, Topol EJ; CREDO<br />
Investigators. The efficacy and safety of short-and long-term antiplatelet therapy in patients with mild or<br />
moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During<br />
Observation (CREDO) trial. American Heart Journal. 155(4): 687-93, 2008 [PMID: 18371477]<br />
998. Sabatine MD, Hamdalla HN, Mehta SR, Fox KA, Topol EJ, Steinhubl SR, Cannon CP. Efficacy and<br />
safety of clopidogrel pretreatment before percutaneous coronary intervention with and without<br />
glycoprotein IIb/IIIa inhibitor use. American Heart Journal. 155: 910-7, 2008 [PMID 18440341]<br />
999. Topol EJ. Genome scanning and cardiovascular disease. Heart. 94: 1361-3, 2008 [PMID 18669546]<br />
1000. Eikelboom JW, Hankey GJ, Thorn J, Bhatt DL, Gabriel Steg P, Montalescot G, Claiborne Johnston S,<br />
Steinhubl SR, Mak K-H, Donald Easton J, Hamm C, Hu T, AA Fox K, Topol EJ; on behalf of the<br />
CHARISMA investigators. Incomplete inhibition of thromboxane biosynthesis by ASA: determinants and<br />
effect on cardiovascular risk. Circulation. 118:1705-1712, 2008 [PMID 18838564]<br />
1001. Aronow HD, Califf RM, Harrington RA, Vallee M,Graffagnino ,Shuaib C,Fitzgerald DJ , Easton JD , Van<br />
de Werf F, Diener H-C, Ferguson J, MD, Koudstaal PJ , Amarenco P, Theroux P, Davis S, Topol EJ.<br />
Relation between aspirin dose, all-cause mortality and bleeding in patients with recent cerebrovascular<br />
or coronary ischemic events from the BRAVO trial. American J Cardiology. 102: 1285-90, 2008 [PMID<br />
18993142]<br />
1002. Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, Andersen HR, Betriu A,<br />
Savonitto S, Adamus J, Peruga JZ, Kosmider M, Katz O, Neunteufl T, Jorgova J, Dorobantu M, Grinfeld<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 65
L, Armstrong P, Brodie BR, Herrmann HC, Montalescot G, Neumann FJ, Effron MB, Barnathan ES,<br />
Topol EJ; FINESSE Investigators Facilitated PCI in patients with ST-elevation myocardial infarction.<br />
New England Journal of Medicine. 358: 2205-17, 2008 [PMID 18499565]<br />
1003. Musunuru K, Kral BG, Blumenthal RS, Fuster V, Campbell CY, Gluckman TJ, Lange RA, Topol EJ,<br />
Willeron JT, Desai MY, Davidson MH, Mora S. The use of high-sensitivity assays for C-reactive protein<br />
in clinical practice. Nat Clin Pract Cardiovasc Med. 5(10):621-635, 2008 [PMID 18711404]<br />
1004. Torkamani A, Topol EJ, Schork, NJ. Pathway analysis of seven common diseases assessed by<br />
genome-wide association. Genomics. 92: 265-72, 2008 [PMID 18722519]<br />
1005. Robertson JO, Li W, Silverstein RL, Topol EJ, Smith JD. Deficiency of LRP8 in mice is associated with<br />
altered platelet function and prolonged time for in vivo thrombosis. Thrombosis Research. 123: 644-<br />
652, 2009 [PMID 18706682]<br />
1006. Mak K-H, Bhatt DL, Mingyuan S, Hankey GJ, Easton JD, Fox KAA, Topol EJ. Ethnic variation in<br />
adverse cardiovascular outcomes and bleeding complications in the CHARISMA study. American Heart<br />
Journal. 157(4):658-665, 2009 [PMID 19332192]<br />
1007. Aronow HD, Steinhubl SR, Brennan DM, Berger PB, Topol EJ. Bleeding Risk Associated With One<br />
Year of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Insights From the<br />
CREDO Trial. American Heart Journal. 157:369-74, 2009 [PMID 19185647]<br />
1008. Elias DJ, Topol EJ. Warfarin Pharmacogenomics: a Big Step Forward for Individualized Medicine:<br />
Enlightened Dosing of Warfarin. European Journal of Human Genetics. 16: 532-4, 2008 [PMID<br />
18301451]<br />
1009. Van de Werf FJ, Topol EJ, Sobel BE. The impact of fibrinolytic therapy for ST-segment-elevation acute<br />
myocardial infarction through 2008. Thrombosis and Haemostasis. 7: 14-20, 2009 [PMID 19090814]<br />
1010. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA; for the CHARISMA Investigators. Patients with<br />
peripheral arterial disease in the CHARISMA trial. Eur Heart J. 30:192-201, 2009 [PMID 19136484]<br />
1011. Mak KH, Bhatt DL, Shao M, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Montalescot G, Steg<br />
PG, Steinhubl SR, Fox KA, Topol EJ. The influence of body mass index on mortality and bleeding<br />
among patients with or at high-risk of atherothrombotic disease. Eur Heart J. 30(7):857-865, 2009<br />
[PMID 19233855]<br />
1012. Steinhubl SR, Bhatt DL, Brennan DM, Montalescot G, Hankey GJ, Eikelboom JW, Berger PB, Topol<br />
EJ; CHARISMA Investigators. Aspirin to prevent cardiovascular disease: the association of aspirin dose<br />
and clopidogrel with thrombosis and bleeding. Ann Intern Med. 150(6):379-386, 2009 [PMID 19293071]<br />
1013. Frazer KA, Murray SS, Schork NJ, Topol EJ. Human genetic variation and its contribution to complex<br />
traits. Nat Rev Genet. 10(4):241-251, 2009 [PMID 1923820]<br />
1014. Harismendy O, Ng PC, Strausberg RL, Wang X, Stockwell TB, Beeson KY, Schork NJ, Murray SS,<br />
Topol EJ, Levy S, Frazer K. Evaluation of next generation sequencing platforms for population targeted<br />
sequencing strategies. Genome Biology 10(3):R32, 2009 [PMID 19327155]<br />
1015. Topol, EJ. Past the wall in cardiovascular R&D. Nat Rev Drug Discov. 8(4)259, 2009 [PMID 19348004]<br />
1016. Price MJ, Berger PB, Angiolillo DJ, Teirstein PS, Tanguay JF, Kandzari DE, Cannon CP, Topol EJ.<br />
Evaluation of individualized clopidogrel therapy after drug eluting stent implantation in patients with high<br />
residual platelet reactivity: design and rationale of the GRAVITAS trial. American Heart Journal<br />
157(5):818-824, 2009 [PMID 19376306]<br />
1017. Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak KH, Fox KA, Montalescot G, Weber MA,<br />
Haffner SM, Dimas AP, Steg PG, Topol EJ; CHARISMA Investigators. Clinical outcomes of patients<br />
with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc<br />
analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and<br />
avoidance [CHARISMA] trial). American Journal of Cardiology 103(10):1359-1363, 2009 [PMID<br />
19427428]<br />
1019. Damani SB, Topol EJ. Molecular genetics of atrial fibrillation. Genome Medicine 1(5):54, 2009. [PMID<br />
19490585]<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 66
1020. Chen J, Bhatt DL, Dunn ES, Shi C, Caro JJ, Mahoney EM, Gabriel S, Jackson JD, Topol EJ, Cohen<br />
DJ. Cost-Effectiveness of Clopidogrel plus Aspirin versus Aspirin Alone for Secondary Prevention of<br />
Cardiovascular Events: Results from the CHARISMA Trial. Value Health 12(6):872-879, 2009. [PMID<br />
19490556]<br />
1021. Schork NJ, Murray SS, Frazer KA, Topol EJ. Common vs. rare allele hypotheses for complex disease.<br />
Curr Opin Genet Dev 19(3):212-219, 2009. [PMID 19481926]<br />
1022. Shishehbor MH, Madhwal S, Rajagopal V, Hsu A, Kelly P, Gurm HS, Kapadia SR, Lauer MS, Topol EJ.<br />
Impact of blood transfusion on short- and long-term mortality in patients with ST-segment elevation<br />
myocardial infarction. JACC Cardiovasc Interv 2(1):46-53, 2009. [PMID 19463397]<br />
1023. Collet JP, Montalescot G, Steg PG, Steinhubl SR, Fox KA, Hu TF, Johnston SC, Hamm CW, Bhatt DL,<br />
Topol EJ. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the<br />
CHARISMA trial. Arch Cardiovasc Dis 102(6-7):485-96, 2009. [PMID 19664568]<br />
1024. Joyner AH, Roddey JC, Bloss, CS, Bakken TE, Rimol LM, Melle I, Agartz I, Djurovic S, Topol EJ,<br />
Schork NJ, Andreassen OA, Dale AM. A common MECP2 haplotype associates withreduced cortical<br />
surface area in humans in two independent populations. Proceedings of the National Academy of<br />
<strong>Science</strong>s 106(36):15483-15488, 2009. [PMID 19717458]<br />
1025. Berger JS, Elliott L, Gallup D, Roe M, Granger CB, Armstrong PW, Simes RJ, White HD, Van de Werf F,<br />
Topol EJ, Hochman JS, Newby LK, Harrington RA, Califf RM, Becker RC, Douglas PS. Sex<br />
Differences in Mortality Following Acute Coronary Syndromes. Journal of the American Medical<br />
Association 302:874-882, 2009. [PMID 19706861]<br />
1026. Berger JS, Bhatt DL, Cannon CP, Chen Z, Jiang L, Jones JB, Mehta SR, Sabatine MS, Steinhubl SR,<br />
Topol EJ, Berger PB. The Relative Efficacy and Safety of Clopidogrel in Women and Men: A Sex-<br />
Specific Collaborative Meta-Analysis. Journal of the American College of Cardiology 54(21):1935-1945,<br />
2009. [PMID 19909874]<br />
1027. Valgimigli M, Biondi-Zoccai G, Tebaldi M, van 't Hof AW, Campo G, Hamm C, Ten Berg J, Bolognese L,<br />
Saia F, Danzi GB, Briguori C, Okmen E, King SB, Moliterno DJ, Topol EJ. Tirofiban as adjunctive<br />
therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of<br />
randomized trials. European Heart Journal 2009 Sep 14 (Epub ahead of print) [PMID: 19755402]<br />
1028. Topol, EJ. How Genomic Medicine Will Affect the Future of Healthcare. Futurescan 2010: American<br />
College of Healthcare Executives (In press, Jan 2010)<br />
1029. Berger JS, Bhatt DL, Steinhubl SR, Shao M, Steg PG, Montalescot G, Hacke W, Fox KA, Lincoff AM,<br />
Topol EJ, Berger PB, for the CHARISMA Investigators. Smoking, Clopidogrel, and Mortality in Patients<br />
with Established Cardiovascular Disease. Circulation 120(23):2337-2344, 2009. [PMID 19933933]<br />
1030. Schork NJ, Topol EJ. Genotype-Based Risk and Pharmacogenetic sampling in clinical trials. Journal of<br />
Biopharmaceutical Statistics 20(2):315-333, 2010. [PMID 20309761]<br />
1031. Tewhey R, Nakano M, Wang X, Pabón-Peña C, Novak B, Giuffre A, Lin E, Happe S, Roberts DN,<br />
LeProust EM, Topol EJ, Harismendy O, Frazer KA. Enrichment of sequencing targets from the human<br />
genome by solution hybridization. Genome Biology 10(10):R116, 2009. [PMID 19835619]<br />
1032. Ellis SG, Tendera M, de Belder MA, can Boven AJ, Widimsky P, Anderson HR, Betriu A, Savonitto S,<br />
Adamus J, Peruga JZ, Hamankiewicz M, Pluta W, Oldroyd K, Ecollan P, Janssens L, Armstrong P,<br />
Brodie BR, Hermann HC, Montalescot G, Neumann FJ, Effron MB, Barnathan ES, Topol EJ; FINESSE<br />
Investigators. 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE<br />
(Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. Journal of the<br />
American College of Cardiology, Cardiovascular Interventions 2(10):909-916, 2009. [PMID 19850248]<br />
1033. Hermann HC, Lu J, Brodie BR, Armstrong PW, Montalescot G, Betriu A, Neuman FJ, Effron MB,<br />
Barnathan ES, Topol EJ, Ellis SG; FINESSE Investigators. Benefit of facilitated percutaneous coronary<br />
intervention in high-risk ST-segment elevation myocardial infarction patients presenting to<br />
nonpercutaneous coronary intervention hospitals. Journal of the American College of Cardiology,<br />
Cardiovascular Interventions 2(10):917-924, 2009. [PMID 19850249]<br />
1034. Tewhey R, Warner JB, Nakano M, Libby B, Medkova M, David PH, Kotsopoulos SK, Samuels ML,<br />
Hutchison JB, Larson JW, Topol EJ, Weiner MP, Harismendy O, Olson J, Link DR, Frazer KA.<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 67
Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nature Biotechnology<br />
27(11):1025-1031, 2009. [PMID 19881494]<br />
1035. Dosh K, Berger PB, Marso S, van Lente F, Brennan DM, Charnigo R, Topol EJ, Steinhubl S.<br />
Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events<br />
after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events<br />
during observation trial. Circ. Cardiovasc. Interv. 2(6):503-512, 2009. [PMID 20031767]<br />
1036. Yang R, Li L, Seidelmann SB, Shen GQ, Sharma S, Rao S, Abdullah KG, Mackinlay KG, Elston RC,<br />
Chen Q, Topol EJ, Wang QK. A genome-wide linkage scan identifies multiple QTLs for HDL cholesterol<br />
levels in families with premature CAD and MI. Journal of Lipid Research 51(6):1446-1451, 2010. [PMID<br />
20075193]<br />
1037. Montalescot G, Ellis SG, de Belder MA, Janssens L, Katz O, Pluta W, Ecollan P, Tendera M, van Boven<br />
AJ, Widimsky P, Andersen HR, Betriu A, Armstrong P, Brodie BR, Hermann HC, Neumann FJ, Effron<br />
MB, Lu J, Barnathan ES, Topol EJ, FINESSE Investigators. Enoxaparin in primary and facilitated<br />
percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial<br />
(Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events). Journal of the American<br />
College of Cardiology, Cardiovascular Interventions 3(2):203-212, 2010. [PMID 20170878]<br />
1038. Schork NJ, Topol EJ. Genotype-based risk and pharmacogenetic sampling in clinical trials. Journal of<br />
Biopharmaceutical Statistics 20(2):315-33, 2010. [PMID 20309761]<br />
1039. Ellinor PT, Lunetta KL, Glazer NL, Pfeufer A, Alonso A, Chung MK, Sinner MF, de Bakker PW, Mueller<br />
M, Lubitz SA, Fox E, Darbar D, Smith NL, Smith JD, Schnabel RB, Soliman EZ, Rice KM, Van Wagoner<br />
DR, Beckmann B-M, van Noord C, Wang K, Ehret GB, Rotter JI, Hazen S, Steinbeck G, Smith AV,<br />
Launer LJ, Harris TB, Makino S, Nelis M, Milan DJ, Perz S, Esko T, Köttgen A, Moebus S, Newton-<br />
Cheh C, Li M, Möhlenkamp S, Wang TJ, Kao WHL, Vasan RS, Nöthen M, MacRae CA, Stricker BHCh,<br />
Hofman A, Uitterlinden AG, Levy D, Boerwinkle E, Metspalu A, Topol EJ, Chakravarti A, Gudnason V,<br />
Psaty BM, Roden DM, Meitinger T, Wichmann H-E, Witteman JCM, Barnard J, Arking DE, Benjamin EJ,<br />
Heckbert SR, Kääb S. Common Variants in KCNN3 are Associated with Lone Atrial Fibrillation. Nature<br />
Genetics 42(3):240-244, 2010. [PMID 20173747]<br />
1040. Bansal V, Harismendy O, Tewhey R, Murray SS, Schork NJ, Topol EJ, Frazer KA. Accurate detection<br />
and genotyping of SNPs utilizing population sequencing data. Genome Research 20(4):537-545, 2010.<br />
[PMID 20150320]<br />
1041. Damani S, Topol EJ. The Case for Routine Genotyping in Dual Antiplatelet Therapy. Journal of the<br />
American College of Cardiology 56(2):109-111, 2010. [PMID 20471193]<br />
1042. Topol, EJ. Transforming Medicine via Digital Innovation. <strong>Science</strong> <strong>Translational</strong> Medicine 2(16):16cm4,<br />
2010. [PMID 20371472]<br />
1043. Topol EJ. “Health Policy: The consumer movement in health care” Pharos Alpha Omega Alpha Honor<br />
Med Soc. 73(2):34-5, Spring 2010. [PMID 20455379]<br />
1044. Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KA, Shao M, Brennan DM, Hacke W, Montalescot G,<br />
Steinhubl SR, Topol EJ; CHARISMA Investigators. Bleeding complications with dual antiplatelet<br />
therapy among patients with stable vascular disease or risk factors for vascular disease: results from<br />
the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and<br />
Avoidance (CHARISMA) trial. Circulation 121(23):2575-2583, 2010. [PMID 20516378]<br />
1045. Hankey GJ, Hacke W, Easton JD, Johnston SC, Mas JL, Brennan DM, Bhatt DL, Fox KA, Topol EJ;<br />
CHARISMA Trial Investigators. Effect of clopidogrel on the rate and functional severity of stroke among<br />
high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk<br />
and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial. Stroke 41(8):1679-1683,<br />
2010. [PMID 20595658]<br />
1046. Topol EJ. Pharmacy benefit managers, pharmacies, and pharmacogenomic testing: prescription for<br />
progress? <strong>Science</strong> <strong>Translational</strong> Medicine 2(44):44cm22, 2010. [PMID 20702854]<br />
1047. Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, Hamm CW, Montalescot G,<br />
Steg PG, Pearson TA, Cohen E, Gaudin C, Job B, Murphy JH, Bhatt DL; for The CRESCENDO<br />
Investigators. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised,<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 68
multicentre, placebo-controlled trial. The Lancet 376(9740):517-523, 2010. [PMID 20709233]<br />
1048. Bloss CS, Ornowski L, Silver E, Cargill M, Vanier V, Schork NJ, Topol EJ. Consumer perceptions of<br />
direct-to-consumer personalized genomic risk assessments. Genetics in Medicine 12(9):556-566, 2010.<br />
[PMID 20717041]<br />
1049. Damani SB, Topol EJ. Emerging clinical applications in cardiovascular pharmacogenomics. Wiley<br />
Interdisciplinary Reviews-Systems Biology Medicine 2010 Aug 20, ePub ahead of print. [PMID<br />
20730785]<br />
1050. Smith EN, Chen W, Kahonen M, Kettunen J, Lehtimaki T, Peltonen L, Raitakari OT, Salem RM, Schork<br />
NJ, Shaw M, Srinivasan SR, Topol EJ, Viikari JS, Berenson GS, Murray SS. PLoS Genetics 6(9):pii:<br />
e1001094, 2010. [PMID 20838585]<br />
1051. Topol EJ, Damani SB. The KIF6 Collapse. Journal of the American College of Cardiology 56(19):1564-<br />
1566, 2010. [PMID 20888161]<br />
1052. Rosenberg S, Elashoff MR, Beineke P, Daniels SE, Wingrove JA, Tingley WG, Sager PT, Sehnert AJ,<br />
Yau M, Kraus WE, Newby LK, Schwartz RS, Voros S, Ellis SG, Tahirkheli N, Waksman R, McPherson<br />
J, Lansky A, Winn ME, Schork NJ, Topol EJ; PREDICT (Personalized Risk Evaluation and Diagnosis in<br />
the Coronary Tree) Investigators. Multicenter validation of the diagnostic accuracy of a blood-based<br />
gene expression test for assesing coronary artery disease in nondiabetic patients. Annals of Internal<br />
Medicine 153(7):425-434, 2010. [PMID 20921541]<br />
1053. Tackett AH, Bailey AL, Foody JM, Miller JM, Apperson-Hansen C, Ohman EM, Hochman JS, Karnash<br />
SL, Califf RM, Topol EJ, Moliterno DJ. Hormone replacement therapy among postmenopausal women<br />
presenting with acute myocardial infarction: Insights from the GUSTO-III trial. American Heart Journal<br />
160(4):678-684, 2010. [PMID 20934562]<br />
1054. Barker CM, Murray SS, Teirstein PS, Kandzari DE, Topol EJ, Price MJ. Pilot study of the antiplatelet<br />
effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in<br />
patients with high on-treatment reactivity. Journal of the American College of Cardiology,<br />
Cardiovascular Interventions 33(10):1001-1007, 2010. [PMID 20965456]<br />
1055. Bhatia G, Bansal V, Harismendy O, Schork NJ, Topol EJ, Frazer K, Bafna V. A covering method for<br />
detecting genetic associations between rare variants and common phenotypes. PLoS Comput Biol.<br />
6(10):e1000954, 2010. [PMID 20976246]<br />
1056. Harismendy O, Bansal V, Bhatia G, Nakano M, Scott M, Wang X, Dib C, Turlotte E, Sipe JC, Murray<br />
SS, Deleuze JF, Bafna V, Topol EJ, Frazer KA. Population sequencing of two endocannabinoid<br />
metabolic genes identifies rare and common regulatory variants associated with extreme obesity and<br />
metabolite level. Genome Biology 11(11):R118, 2010. [PMID 21118518]<br />
1057. Hankey GJ, Johnston SC, Easton JD, Hacke W, Mas JL, Brennan D, Mak KH, Bhatt DL, Fox KA, Topol<br />
EJ; CHARISMA trial investigators. Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic<br />
stroke: a substudy of the CHARISMA trial. Int J Stroke 6(1):3-9, 2011. [PMID 21205234]<br />
1058. Mehta RH, O'Shea JC, Stebbins AL, Granger CB, Armstrong PW, White HD, Topol EJ, Califf RM,<br />
Ohman EM. Association of Mortality With Years of Education in Patients With ST-Segment Elevation<br />
Myocardial Infarction Treated With Fibrinolysis. Journal of the American College of Cardiology<br />
57(2):138-146, 2011. [PMID 21211684]<br />
1059. Topol EJ, Schork NJ. Catapulting clopidogrel pharmacogenomics forward. Nature Medicine 17(1):40-<br />
41, 2011. [PMID 21217678]<br />
1060. Bansal V, Tewhey R, Topol EJ, Schork NJ. The next phase in human genetics. Nature Biotechnology<br />
29(1):38-39, 2011. [PMID 21221098]<br />
1061. Bloss CS, Schork NJ, Topol EJ. Effect of Direct-to-Consumer Genomewide Profiling to Assess<br />
Disease Risk. New England Journal of Medicine 364(6):524-534, 2011. [PMID 21226570]<br />
1062. Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, Heintzman N, Ren B, Fu X-D, Topol EJ,<br />
Rosenfeld MG, Frazer KA. 9p21 DNAvariants associated with coronary artery disease impair interferonc<br />
signalling response. Nature 470(7333):264-268, 2011. [PMID 21307941]<br />
1063. Tewhey R, Bansal V, Torkamani A, Topol EJ, Schork NJ. The importance of phase information for<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 69
human genomics. Nature Reviews Genetics 12(3):215-223, 2011. [PMID 21301473]<br />
1064. Topol EJ, Schork NJ, Smith JM. Digital Medicine and the <strong>Scripps</strong> <strong>Translational</strong> <strong>Science</strong> <strong>Institute</strong>.<br />
Clinical and <strong>Translational</strong> <strong>Science</strong> 4(1):8-9, 2011. [PMID 21348949]<br />
1065. Weber M, Bhatt DL, Brennan DM, Hankey GJ, Steinhubl SR, Johnston SC, Montalescot G, Mak KH,<br />
Easton DJ, Topol EJ, Hamm CW; for the CHARISMA Investigators. High-sensitivity C-reactive protein<br />
and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the<br />
CHARISMA trial. Heart 97(8):626-631, 2011. [PMID 21393433]<br />
1066. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt<br />
KN, Bertrand OF, Stillablower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV,<br />
Cannon CP, Schork NJ, Topol EJ; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based<br />
on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.<br />
Journal of the American Medical Association 305(11):1097-1105, 2011. [PMID 21406646]<br />
1067. Elashoff MR, Wingrove JA, Beineke P, Daniels SE, Tingley WG, Rosenberg S, Voros S, Kraus WE,<br />
Ginsburg GS, Schwartz RS, Ellis SG, Tahirkheli N, Waksman R, McPherson J, Lansky AJ, Topol EJ.<br />
Development of a blood-based gene expression algorithm for assessment of obstructive coronary<br />
artery disease in non-diabetic patients. BMC Med Genomics 4(1):26, 2011. [PMID 21443790]<br />
1068. Chen J, Shi C, Mahoney EM, Dunn ES, Rinfret S, Caro JJ, O'Brien J, El-Hadi W, Bhatt DL, Topol EJ,<br />
Cohen DJ. Economic Evaluation of Clopidogrel Plus Aspirin for Secondary Prevention of<br />
Cardiovascular Events in Canada for Patients With Established Cardiovascular Disease: Results From<br />
the CHARISMA Trial. Can J Cardiol 27(2):222-231, 2011. [PMID 21459271]<br />
1069. Damani SB, Topol EJ. Emerging genomic applications in coronary artery disease. Journal of the<br />
American College of Cardiology, Cardiovascular Interventions 4(5):473-482, 2011. [PMID 21596318]<br />
Profiles<br />
1. Emma Wilkinson. From Mechanics to Genetics in Cardiology. European Heart Journal 30.2291-93, 2009.<br />
2. Daniel S. Levine. Lost in Translation. The Journal of Life <strong>Science</strong>s, Fall 2009.<br />
3. Elaine Musgrave, Ph.D. Exciting Interventions in Individualized Medicine – An Interview with Eric J. Topol,<br />
MD of the <strong>Scripps</strong> <strong>Translational</strong> <strong>Science</strong> <strong>Institute</strong>. Clinical and <strong>Translational</strong> <strong>Science</strong>, 2(6):392-393, 2009.<br />
[PMID 20443929]<br />
4. Price Waterhouse Coopers’ Health Research <strong>Institute</strong>, Healthcare unwired: New business models<br />
delivering care anywhere, September 2010.<br />
Consumer/Public Editorials/Op-Eds<br />
1. Topol EJ. “Good riddance to a bad drug.” New York Times, A27, October 2, 2004.<br />
2. Topol EJ. “How not to do a clinical trial.” Forbes Magazine, October 4, 2004.<br />
3. Topol EJ. “COX-2 Inhibitors: Safety Trials Needed.” Wall Street Journal, July 30, 2002.<br />
4. Topol EJ. “Shotgun medicine.” Los Angeles Times, A21, March 28, 2007.<br />
5. Topol EJ. “What You Can Learn From a Gene Scan.” Wall Street Journal, A10, December 22, 2007.<br />
6. Topol EJ. “The Case for Putting Genomic Medicine to Work” San Diego Union Tribune, August 16, 2010.<br />
7. Topol EJ. “Drugstore Geneticist” Project Syndicate, Sweden August 2010.<br />
Consumer Books<br />
1. Topol EJ, Digitizing Man, Basic Books/Perseus, New York, 2011.<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 70
Collaborative Group "Silent" Authored Papers<br />
1. Participants in the National Heart, Lung, and Blood <strong>Institute</strong> Conference on the Evaluation of Emerging<br />
Coronary Revascularization Technologies: Evaluation of emerging technologies for coronary<br />
revascularization. Circulation 85:357-361, 1992.<br />
2. Protocol for the bypass angioplasty revascularization investigation: The BARI –Protocol. Circulation<br />
84:V1-V27, 1991.<br />
3. Tommaso CL, Vogel JHK, Vogel RA for the National Registry of Elective Supported Angioplasty: Coronary<br />
angioplasty in high-risk patients with left main coronary stenosis. Catheterization and Cardiovascular<br />
Diagnosis 25:169-173, 1992.<br />
4. The LATE Steering Committee: Late assessment of thrombolytic efficacy with alteplase 6-24 hours after<br />
onset of acute myocardial infarction. The Lancet 342:759-766, 1993.<br />
5. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group: Indications for fibrinolytic therapy in suspected<br />
acute myocardial infarction: collaborative overview of mortality and major morbidity results from all<br />
randomized trials of more than 1,000 patients. The Lancet 343:311-322, 1994.<br />
6. The GUSTO Angiographic Investigators: The comparative effects of tissue plas-minogen activator,<br />
streptokinase, or both on coronary artery patency, ventricular function, and survival after acute<br />
myocardial infarction. New England Journal of Medicine 329:1615-1622, 1993.<br />
7. The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for<br />
acute myocardial infarction. New England Journal of Medicine 329:673-682, 1993.<br />
8. National Heart Attack Alert Program Coordinating Committee 60 Minutes to Treatment Working Group:<br />
Rapid identification and treatment of acute myocardial infarction in the emergency department. Annals of<br />
Emergency Medicine 23(2): 311-329, 1994.<br />
9. Cardiac Catheterization Committee. Bethesda Conference 17: Adult Cardiology Training Task Force III:<br />
Training in Cardiac Catheterization. Journal of the -American College of Cardiology 22(2): 629-31, 1993.<br />
10. The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa<br />
receptor in high-risk coronary angioplasty. New England Journal of Medicine 330:956-961, 1994.<br />
11. Michels KB, Yusuf S: Does PTCA in acute myocardial infarction affect mortality and reinfarction rates?<br />
Circulation 91:476-485, 1995.<br />
12. The GUSTO IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for<br />
acute coronary syndromes. Circulation 90:1631-1637, 1994.<br />
13. The BARI Investigators. The Bypass Angioplasty Revascularization Investigation (BARI): Comparison of<br />
coronary bypass surgery with angioplasty in patients with multivessel disease. The New England Journal<br />
of Medicine 335:217-225, 1996.<br />
14. The Global Utilization of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A<br />
comparison of recombinant hirudin versus heparin for the treatment of acute coronary syndromes. New<br />
England Journal of Medicine 335:775-782, 1996.<br />
15. The IMPACT II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on<br />
complications of percutaneous coronary intervention. The Lancet 349:1422-1428, 1997.<br />
16. The GUSTO II Angioplasty Substudy Investigators. A clinical trial comparing primary coronary<br />
angioplasty with tissue plasminogen activator for acute myocardial infarction. New England Journal of<br />
Medicine 336:1621-28, 1997.<br />
17. CAPRIE Investigators. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of<br />
ischemic events (CAPRIE). The Lancet 348:1329-1339, 1996.<br />
18. EPILOG Investigators. Effect of the platelet glycoprotein IIb/IIIa receptor inhibitor abciximab with lower<br />
heparin dosages on ischemic complications of percutaneous coronary revascularization. New England<br />
Journal of Medicine 336:1689-96, 1997.<br />
19. The Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Five-<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 71
year clinical and functional outcome comparing bypass surgery and angioplasty in patients with<br />
multivessel coronary disease. Journal of the American Medical Association 277:715-721, 1997.<br />
20 The GUSTO-III Investigators. An international, multicenter, randomized comparison of reteplase with<br />
alteplase for acute myocardial infarction. New England Journal of Medicine 337:1118-23, 1997.<br />
21. The BARI Investigators. The Bypass Angioplasty Revascularization Investigation (BARI): Influence of<br />
diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients<br />
with multivessel disease. Circulation 96:1761-1769, 1997.<br />
22. The PARAGON Investigators. An international, randomized, controlled trial of lamifiban, a platelet<br />
glycoprotein IIb/IIIa inhibitor, heparin, or both in unstable angina. Circulation 97:2386-2395, 1998.<br />
23. The PURSUIT (Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin<br />
Therapy) Trial Investigators. Inhibition of the platelet glycoprotein IIb/IIIa with eptifibatide in patients with<br />
acute coronary syndromes without persistent ST-segment elevation. New England Journal of Medicine<br />
339:436-443, 1998.<br />
24. EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to<br />
assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. The Lancet 352:87-<br />
92, 1998.<br />
25. The PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor<br />
lamifiban: Results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion<br />
Gain in Myocardial Infarction (PARADIGM) Trial. Journal of the American College of Cardiology 32:2003-<br />
10, 1998.<br />
26. BARI Investigators. Seven year outcome in the Bypass Angioplasty Revascularization Investigation<br />
(BARI) by treatment and diabetic status. Journal of the American College of Cardiology 35:1122-29,<br />
2000.<br />
27. ASSENT-2 (Assessment of the Safety and Efficacy of a New Thrombolytic) Investigators. Single-bolus<br />
tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 doubleblind<br />
randomized trial. The Lancet 354:716-722, 1999.<br />
28. The SYMPHONY Investigators. A randomized comparison of sibrafiban, an oral platelet glycoprotein<br />
IIb/IIIa receptor antagonist, with aspirin for acute coronary syndromes. The Lancet 355:337-345, 2000.<br />
29. The SPEED Group (Strategies for the Patency Enhancement in the Emergency Department).<br />
Randomized trial of abciximab with and without low-dose reteplase for acute myocardial infarction.<br />
Circulation 101:2788-2794, 2000.<br />
30. The 2nd SYMPHONY Investigators. Aspirin, sibrafiban, or both to prevent ischemic events after acute<br />
coronary syndromes: A randomized, double-blind, multicenter trial. Circulation 103:1727-1733, 2001.<br />
31. The PARAGON-B Investigators. Randomized, placebo-controlled trial of titrated intravenous lamifiban for<br />
acute coronary syndromes. Circulation 105:316-321, 2002.<br />
32. The GUSTO IV-ACS Investigators. Glycoprotein IIb/IIIa receptor blocker abciximab does not improve<br />
outcome in patients with acute coronary syndromes without early coronary revascularization. The Lancet<br />
357: 1915-24, 2001.<br />
33. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy<br />
or combination low dose fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO 5<br />
Trial. The Lancet 357:1905-1914, 2001.<br />
34. HERO-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients<br />
receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 Trial. The Lancet 358:1855-63,<br />
2001.<br />
35. The Direct Thrombin Inhibitor Trialists' Group. Direct thrombin inhibitors in acute coronary syndromes:<br />
principal results of a meta-analysis based on individual patients' data. The Lancet 359:294-302, 2002.<br />
36. PCAT Collaborators. Primary coronary angioplasty compared with intravenous thrombolytic therapy for<br />
acute myocardial infarction: Six-month follow-up and analysis of individual patient data from randomized<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 72
trials. American Heart Journal 145:47-57, 2003.<br />
37. Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Brown T, Eckert SL, Butson M,<br />
Sadovnick AD, Quaid KA, Chen C, Cook-Deegan R, Farrer LA; REVEAL Study Group. Disclosure of<br />
APOE genotype for risk of Alzheimer's disease. New England Journal of Medicine. 16;361(3):245-54,<br />
2009. [PMID 19605829]<br />
Books<br />
1. Topol EJ ed., Acute Coronary Intervention, Alan R. Liss, Inc., New York, New York, 1988.<br />
2. Topol EJ ed., Textbook of Interventional Cardiology, W.B. Saunders, Philadelphia, PA, 1990.<br />
3. Topol EJ ed., Textbook of Interventional Cardiology, 2nd Edition, W.B. Saunders, Philadelphia, PA, 1994.<br />
4. Topol EJ, Serruys PW eds., Current Review of Interventional Cardiology, Current Medicine, Philadelphia,<br />
PA, 1994.<br />
5. Fuster V, Ross R, Topol EJ eds., Atherosclerosis and Coronary Artery Disease, Lippincott-Raven Press,<br />
Philadelphia, PA, 1996.<br />
6. Popma JJ, Leon M, Topol EJ ed., Atlas of Interventional Cardiology, W.B. Saunders, Philadelphia, PA,<br />
1994.<br />
7. Khan MG, Bartlett JG, Chopra S, Topol EJ eds., Medical Diagnosis and Therapy, Lea & Febiger,<br />
Malvern, PA, 1994.<br />
8. Topol EJ, Serruys PW ed., Current Review of Interventional Cardiology, 2nd Edition, Current Medicine,<br />
Philadelphia, PA, 1995.<br />
9. Khan MG, Topol EJ, Saksena S, Goodwin JF eds. Heart Disease Diagnosis and Therapy, Williams &<br />
Wilkins, Baltimore, MD, 1996.<br />
10. LaFont A, Topol EJ eds. Arterial Remodeling: A Critical Factor in Restenosis, Kluwer, Norwell, MA, 1997.<br />
11. Verstraete M, Fuster V, Topol EJ ed. Cardiovascular Thrombosis - Thrombocardiology, 2nd Edition,<br />
Lippincott-Raven, Philadelphia, PA, 1998.<br />
12. Topol EJ ed., Textbook of Cardiovascular Medicine, Lippincott-Raven, Philadelphia, PA, 1998.<br />
13. Topol EJ ed., Acute Coronary Syndromes, Marcel Dekker, New York, NY, 1998.<br />
14. Topol EJ ed., Comprehensive Cardiovascular Medicine, Lippincott-Raven, Philadelphia, PA, 1998.<br />
15. Topol EJ ed., Textbook of Interventional Cardiology, 3rd Edition, W.B. Saunders, Philadelphia, PA, 1999.<br />
16. Lincoff AM, Topol EJ eds., Platelet IIb/IIIa Inhibitors in Cardiology, Humana Press Inc., Totowa, NJ, 1999.<br />
17. Marso SP, Griffin BP, Topol EJ. Manual of Cardiovascular Medicine, Lippincott Williams & Wilkins,<br />
Philadelphia, PA, 2000.<br />
18. Topol EJ ed., The Cleveland Clinic Heart Book, Hyperion, New York, NY, 2000.<br />
19. Topol EJ ed., Acute Coronary Syndromes, 2nd Edition, Marcel Dekker, New York, NY, 2001.<br />
20. Lanzer P, Topol EJ eds., PanVascular Medicine, Springer Verlag, Heidelberg, Germany, 2002.<br />
21. Topol EJ ed., Textbook of Cardiovascular Medicine, 2nd Edition, Lippincott-Williams & Wilkins,<br />
Philadelphia, PA, 2002.<br />
22. Topol EJ ed., Textbook of Interventional Cardiology, 4th Edition, Harcourt/Elsevier, Philadelphia, PA,<br />
2003.<br />
23. Roffi M, Meier B, Topol EJ eds., The Essentials of Cardiology, Handheldmed (HHM), 2003.<br />
24. Cho L, Griffin BP, Topol EJ. The Cardiology Intensive Board Review Question Book. Lippincott Williams<br />
& Wilkins, Philadelphia, PA, 2003.<br />
25. Topol EJ ed., Atlas of Atherothrombosis, <strong>Science</strong> Press Ltd, London, England, 2004.<br />
26. Aviles RJ, Messerli AW, Askari A, Penn MS, Topol EJ eds., Introductory Guide to Cardiac<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 73
Catheterization, Lippincott-Williams & Wilkins, Philadelphia, PA, 2004.<br />
27. Griffin BP, Topol EJ, Hook M, McRae AT, III, Messerli A. Manual of Cardiovascular Medicine, 2nd Edition,<br />
Lippincott Williams & Wilkins, Philadelphia, PA, 2004.<br />
28. Fuster V, Nabel E, Topol EJ eds., Atherothrombosis and Coronary Artery Disease, 2nd Edition,<br />
Lippincott-Williams & Wilkins, Philadelphia, PA, 2005.<br />
29. Topol EJ ed., Acute Coronary Syndromes, 3rd Edition, Marcel Dekker, New York, NY, 2005.<br />
30. Topol EJ ed., Textbook of Cardiovascular Medicine, 3rd Edition, Lippincott-Williams & Wilkins,<br />
Philadelphia, PA, 2007.<br />
31. Topol EJ ed., Textbook of Interventional Cardiology, 5th Edition, Harcourt/Elsevier, Philadelphia, PA,<br />
2008.<br />
32. Topol EJ, Teirstein PS eds., Textbook of Interventional Cardiology, 6th Edition, Harcourt/Elsevier,<br />
Philadelphia, PA, 2010.<br />
Book Chapters<br />
1. Topol EJ, Fortuin NJ: Cardiac tumors and carcinoid heart disease. In: Fortuin NJ ed. Current Therapy in<br />
Cardiovascular Disease, B.C. Decker, Inc., Toronto, 354-358, 1984.<br />
2. Topol EJ, Califf RM: The role of tissue plasminogen activator in acute myocardial infarction. In: Califf RM,<br />
Wagner GS eds. Acute Coronary Care 1987, Martinus Nijhoff Publishing, Hingham, MA, 73-87, 1986.<br />
3. Topol EJ: Cardiac tumors and carcinoid heart disease. In: Fortuin NJ ed. Current Therapy in<br />
Cardiovascular Disease - 2, B.C. Decker, Inc., Toronto, 311-314, 1986.<br />
4. Topol EJ, O'Neill WW: Myocardial infarction: thrombolysis and angioplasty. In: Sobel B, Collen D,<br />
Grossbard EB eds. Tissue Plasminogen Activators in Thrombolytic Therapy, Marcel Dekker, Inc., New<br />
York, 87-114, 1987.<br />
5. Pitt B, O'Neill WW, Topol EJ: Percutaneous transluminal coronary angioplasty after acute myocardial<br />
infarction. In: Roberts R ed. Current Perspective in Coronary Care, Excerpta Medica, Princeton, NJ, 17-<br />
20, 1987.<br />
6. Collen D, Topol EJ: Tissue Plasminogen Activator. In: Topol EJ ed. Acute Coronary Intervention, Alan R.<br />
Liss, Inc., New York, New York, 35-48, 1987.<br />
7. Topol EJ: Thrombolysis and angioplasty in myocardial infarction (TAMI). In: Topol EJ ed. Acute<br />
Coronary Intervention, Alan R. Liss, Inc., New York, New York, 153-174, 1987.<br />
8. Topol EJ: Direct or sequential PTCA. In: Topol EJ ed. Acute Coronary Intervention, Alan R. Liss, Inc.,<br />
New York, New York, 79-94, 1987.<br />
9. Topol EJ: Lessons from the TAMI Study. In: Califf RM, Mark D, Wagner GS eds. Acute Coronary Care in<br />
the Thrombolytic Era, Yearbook Publishers, New York, 316-330, 1988.<br />
10. Topol EJ: Mechanical reperfusion in acute myocardial infarction. In: Gotsman MS ed. Reperfusion in<br />
Acute Myocardial Infarction, 659-669, 1988.<br />
11. Califf RM, Mark DM, Topol EJ: Current and future randomized trials of acute coronary intervention. In:<br />
Califf RM, Mark D, Wagner GS eds. Acute Coronary Care in the Thrombolytic Era, Yearbook Publishers,<br />
New York, 347-363, 1988.<br />
12. Topol EJ: Mechanical interventions: acute coronary balloon angioplasty. In: Anderson J ed. Critical Care<br />
Cardiology, Progress in Critical Care Medicine, Vol 3, Karger, Basel, Switzerland, 63-89, 1988.<br />
13. Topol EJ: Early hospital discharge in the era of myocardial reperfusion. In: Califf RM, Mark D, Wagner<br />
GS eds. Acute Coronary Care in the Thrombolytic Era, Yearbook Publishers, New York, 657-669, 1988.<br />
14. Topol EJ: Thrombolytic intervention. In: Topol EJ ed. Textbook of Interventional Cardiology, W.B.<br />
Saunders, Philadelphia, PA, 76-120, 1989.<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 74
15. Meyer J, Erbel R, Pop T, Topol EJ: Angioplasty and surgical revascularization after thrombolysis. In:<br />
Julian D, Kubler W, Norris RM, Swan HJC, Collen D, Verstraete M eds. Thrombolysis in Cardiovascular<br />
Disease, Marcel Dekker, Inc., New York, New York, 179-201, 1989.<br />
16. Topol EJ: Mechanical interventions for Acute Myocardial Infarction. In: Topol EJ ed. Textbook of<br />
Interventional Cardiology, W.B. Saunders, Philadelphia, PA, 269-299, 1989.<br />
17. Muller D, Topol EJ: Reperfusion in acute myocardial infarction. In: Parmley WW, Chatterjee K eds.<br />
Cardiology, J.P. Lippincott, Philadelphia, PA, Chapter 11, 1-19, 1990.<br />
18. Sutton J, Topol EJ: Thrombolysis and angioplasty for acute ischemic syndromes. In: Serruys PW ed.<br />
Coronary Angioplasty: A Controlled Model for Ischemia, Martinus Nijhoff, Norwell, MA, 351-370, 1989.<br />
19. Topol EJ: How Should Intravenous Thrombolytic Agents for Acute Myocardial Infarction Be Selected? In:<br />
Cheitlin MD ed. Dilemmas in Clinical Cardiology, FA Davis, New York, 57-76, 1990.<br />
20. Muller D, Topol EJ: Should thrombolytic therapy be used in suspected cases of myocardial infarction by<br />
appropriately trained paramedics? In: Gitnick G ed. -Debates in Medicine, Yearbook Publishers, New<br />
York, 56-77, 1990.<br />
21. Topol EJ: Interventions in acute myocardial infarction. In: Meier B ed. Interventional Cardiology, Hans<br />
Huber Publishers, Bern, Switzerland, 185-210, 1990.<br />
22. Topol EJ: Selection of thrombolytic agents for clinical use. In: Haber E and Braunwald E eds.<br />
Thrombolysis: Basic Contributions and Clinical Progress, C.V. Mosby Yearbook, St. Louis, Missouri, 301-<br />
314, 1991.<br />
23. Popma JJ, Topol EJ: The role of coronary angioplasty in acute myocardial infarction. In: Anderson JL ed.<br />
Modern Management of Acute Myocardial Infarction in the Community Hospital, Marcel Dekker, Inc., New<br />
York, New York, 303-330, 1991.<br />
24. Popma JJ, Ellis SG, Topol EJ: Angiographic results following directional coronary atherectomy. In:<br />
Holmes D ed. Atherectomy, Blackwell Scientific Publications, Cambridge, Massachusetts, 81-105, 1992.<br />
25. Muller DWM, Topol EJ: Trial design in restenosis: problems and solutions. In: Schwartz RS ed.<br />
Restenosis, Blackwell Scientific Publications, Cambridge, Massachusetts, 138-168, 1993.<br />
26. Grines CL, O’Neill WW, Topol EJ: The emerging role of combination thrombolytic therapy in acute<br />
myocardial infarction. In: Bates E ed. Adjunctive Therapy for Acute Myocardial Infarction, Marcel Dekker,<br />
Inc., New York, New York, 271-282, 1992.<br />
27. Topol EJ: Foreword. In: Serruys PW, Strauss B, King S eds. Restenosis in the Coronary Arteries<br />
Following Intervention with New Mechanical Devices, Kluwer Academic Publishers, Norwell,<br />
Massachusetts, 131:V-VII, 1992.<br />
28. Bates ER, Topol EJ: Thrombolytic mortality trials. In Bates E ed. Adjunctive Therapy for Acute Myocardial<br />
Infarction, Marcel Dekker, Inc., New York, New York, 63-89, 1992.<br />
29. Muller DW, Topol EJ: Reperfusion in acute myocardial infarction. In: Chatterjee K, Cheitlin MD, Karliner<br />
J, Parmley WW, Rapaport E, Scheinman M eds. Cardiology. An Illustrated Text/Reference. Lippincott,<br />
Philadelphia, PA, 69(2):163-178, 1991.<br />
30. Muller DW, Topol EJ: New Devices for Coronary Revascularization. In: Topol EJ ed. Textbook of<br />
Interventional Cardiology – Update 1. W B Saunders, Philadelphia, PA, 1-14, 1991.<br />
31. Muller DW, Topol EJ: Reperfusion therapy for acute myocardial infarction. In: Topol EJ ed. Textbook of<br />
Interventional Cardiology – Update 4. W B Saunders, Philadelphia, 59-74, 1992.<br />
32. Lincoff AM, Topol EJ: Abrupt Vessel Closure. In: Topol EJ ed. Textbook of -Interventional Cardiology –<br />
Update 5. W B. Saunders, Philadelphia, PA, 75-92, 1992.<br />
33. Sutton JM, Topol EJ: Coronary angioplasty strategies for the treatment of acute myocardial infarction. In:<br />
Faxon D ed. Practical Angioplasty, Raven Press, New York, New York, 135-152, 1993.<br />
34. Abdelmequid A, Topol EJ: Thrombolytic Therapy In Acute Myocardial Infarction. In: Agnelli G ed. Year<br />
Book on Thrombolytic Therapy, Excerpta Medica, Amsterdam, The Netherlands, 57-99, 1993.<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 75
35. Topol EJ, Califf RM, Sigmon KM, Lee KL: Thrombolytic Therapy for Women With Acute Myocardial<br />
Infarction: Is There a Gender Gap? In: Wenger, Speroff & Packard ed. Cardiovascular Health and<br />
Diseases in Women, LeJacq Communications Inc., Greenwich, Connecticut, 109-112, 1993.<br />
36. Brown DL, Topol EJ: The Late Assessment of Thrombolytic Efficacy (LATE) Trial: Impact and<br />
Implications. In: Becker RC ed. The Modern Era of Coronary Thrombolysis, Kluwer Academic Publishers,<br />
Norwell, Massachusetts, 121-134, 1993.<br />
37. Muller D, Topol EJ: Overview of Coronary Atherectomy. In: Topol EJ ed. Textbook of Interventional<br />
Cardiology, 2nd Edition, W.B. Saunders, Philadelphia, PA, 678-684, 1994.<br />
38. Topol EJ: Quality of Care in Interventional Cardiology. In: Topol EJ ed. Textbook of Interventional<br />
Cardiology, 2nd Edition, W.B. Saunders, Philadelphia, PA, 1354-1366, 1994.<br />
39. Topol EJ: Thrombolytic Intervention. In: Topol EJ ed. Textbook of Interventional Cardiology, 2nd Edition,<br />
W.B. Saunders, Philadelphia, PA, 68-111, 1994.<br />
40. Sutton JM, Topol EJ: Principles of Thrombolytic Therapy: Impact on Mortality and Left Ventricular<br />
Function in Acute Myocardial Infarction. In: Woosley R ed. Cardiovascular Pharmacology and<br />
Therapeutics, Churchill Livingstone, Inc., New York, New York, 481-498, 1994.<br />
41. Stone G, Grines CL, Topol EJ: Percutaneous Transluminal Coronary Angioplasty. In: Topol EJ ed.<br />
Current Review of Interventional Cardiology, W.B. Saunders Co., Philadelphia, Pennsylvania, 7.1-7.24,<br />
1994.<br />
42. Lincoff AM, Topol EJ: Abrupt Vessel Closure. In: Topol EJ ed. Textbook of Interventional Cardiology, 2nd<br />
Edition, W.B. Saunders, Philadelphia, PA, 207-230, 1994.<br />
43. Khan MG, Topol EJ: Acute Myocardial Infarction. In : Khan MG ed. Medical Diagnosis and Therapy, Lea<br />
& Febiger, Malvern, Pennsylvania, 65-88, 1994.<br />
44. Levy RJ, Golomb G, Trachy J, Labhasetwar V, Muller D, Topol EJ: Strategies for treating arterial<br />
restenosis using polymeric controlled release implants. In: Gebelein CG ed. Biotechnology and Bioactive<br />
Polymers, Lionfire, Inc., Edgewater, Florida, 259-268, 1994.<br />
45. Topol EJ: Mechanical Interventions for Acute Myocardial Infarction. In: Topol EJ ed. Textbook of<br />
Interventional Cardiology, 2nd Edition, W.B. Saunders, Philadelphia, PA, 292-317, 1994.<br />
46. DeFranco A, Topol EJ: Angiography and Angioplasty. In: Julian D, Braunwald E eds. Management of<br />
Acute Myocardial Infarction, W.B. Saunders, Philadelphia, PA, 107-146, 1994.<br />
47. Topol EJ: Thrombolytic Therapy in Acute Myocardial Infarction. In: Agnelli G ed. Yearbook on<br />
Thrombolytic Therapy, Excerpta Medica, Amsterdam, The Netherlands, 57-104, 1994.<br />
48. Califf RM, Topol EJ: The paradigm of acute reperfusion and the GUSTO trial. In: Califf RM, Mark D,<br />
Wagner GS eds. Acute Coronary Care in the Thrombolytic Era, Mosby-Year Book, Inc. St. Louis, MO, 69-<br />
83, 1995.<br />
49. DeFranco A, Sutton JM, Topol EJ: Role of Coronary Angiography after Acute Myocardial Infarction. In:<br />
Califf, Mark D & Wagner GS ed. Acute Coronary Care in the Thrombolytic Era, 2nd Edition, Mosby-Year<br />
Book, St. Louis, MO, 391-406, 1995.<br />
50. Pietrolungo JF, Topol EJ: Thrombolytic Therapy in Acute Myocardial Infarction. In: Comerota AJ ed.<br />
Thrombolytic Therapy, 2nd Edition, Lippincott-Raven, Philadelphia, PA, 349-398, 1995.<br />
51. Topol EJ: Intravascular Ultrasound; Cost/Benefits in the Treatment with Percutaneous Transluminal<br />
Coronary Angioplasty; Revascularization using New Devices; Clinical Aspects of Restenosis after<br />
Coronary Angioplasty; Some Considerations regarding Thrombolytic Therapy; Invasive Approach for the<br />
Treatment of Acute Myocardial Infarction. In: Pajaron A, Jose S, de Prada JA ed. Ischemic Heart Disease,<br />
NCR, S.A., Barcelona, Spain 43-195, 1995.<br />
52. Stone G, Grines CL, Topol EJ: Update on Percutaneous Transluminal Coronary Angioplasty. In: Topol<br />
EJ, Serruys PW, eds. Current Review of Interventional Cardiology, 2nd Edition, Current Medicine,<br />
Philadelphia, Pennsylvania, 1-57, 1995.<br />
53. Lefkovits J, Topol EJ: Direct Thrombin Inhibitors in Acute Coronary Syndromes and Coronary<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 76
Angioplasty. In: Topol EJ, Serruys PW, eds. Current Review of Interventional Cardiology, 2nd Edition,<br />
Current Medicine, Philadelphia, Pennsylvania, 71-88, 1995.<br />
54. Boehrer JD, Topol EJ: Platelet IIb/IIIa Blockade for Prevention of Abrupt Closure and Restenosis. In:<br />
Topol EJ, Serruys PW, eds. Current Review of Interventional Cardiology, 2nd Edition, Current Medicine,<br />
Philadelphia, Pennsylvania, 89-101, 1995.<br />
55. Moliterno DJ, Topol EJ. Restenosis following coronary intervention. In: Topol EJ, ed. Textbook of<br />
Interventional Cardiology -Update 17. W.B. Saunders, Philadelphia, Pennsylvania. 1995.<br />
56. Lincoff AM, Topol EJ: Thrombolytic Therapy. In: Fuster V, Ross R, Topol EJ eds. Atherosclerosis and<br />
Coronary Artery Disease, Lippincott-Raven Press, New York, New York, 955-977, 1996.<br />
57. Topol EJ. Introduction: Atherectomy. In: Sigwart U, Bertrand M, Serruys PW, eds. Handbook of<br />
Cardiovascular Interventions, Churchill Livingstone, New York, New York, 721-722, 1996.<br />
58. Moliterno D, Topol EJ: Clinical Evaluation of Restenosis. In: Fuster V, Ross R, Topol EJ eds.<br />
Atherosclerosis and Coronary Artery Disease, Lippincott-Raven Press, New York, New York, 1505-1526,<br />
1996.<br />
59. Elliott J, Topol EJ: Lessons from CAVEAT I and II Trials. In: Bertrand M, Serruys P, Sigwart U eds. The<br />
Handbook of Cardiovascular Interventions, Churchill Livingstone, -London, England 729-738, 1996.<br />
60. DeFranco A, Topol EJ: Elective Coronary Intervention. In: Bertrand M, Serruys P, Sigwart U eds. The<br />
Handbook of Cardiovascular Interventions, Churchill Livingstone, London, England 413-430, 1996.<br />
61. Moliterno D, Topol EJ: Thrombolytic Therapy in Acute Myocardial Infarction. In: Messerli FH ed.<br />
Cardiovascular Drug Therapy, 2nd Edition. W.B. Saunders Co., Philadelphia, Pennsylvania, 1430-1442,<br />
1996.<br />
62. Horrigan M, Topol EJ: Angioplasty strategies in acute myocardial infarction. In: Smith TW ed.<br />
Cardiovascular Therapeutics, W.B. Saunders, Philadelphia, PA, 600-620, 1996.<br />
63. Pietrolungo J, Topol EJ: Thrombolytics and New Antiplatelet Agents. In: Ellis SG, Holmes DA eds.<br />
Strategic Approaches in Coronary Intervention, Williams & Wilkins, Baltimore, Maryland, 668-697, 1996.<br />
64. Horrigan M, Topol EJ: Coronary Stents: Definition of Unsatisfactory Results not Treated by Stenting. In:<br />
Sigwart U ed. Endoluminal Stenting, W.B. Saunders Ltd., London, England, 252-262, 1996.<br />
65. Boehrer J, Topol EJ: Aorto-ostial Stenosis. In: Ellis SG, Holmes DA eds. Strategic -Approaches in<br />
Coronary Intervention, Williams & Wilkins, Baltimore, Maryland, 309-320, 1996.<br />
66. Khan MG, Topol EJ: Acute Myocardial Infarction. In: Khan MG ed. Heart Disease Diagnosis and<br />
Therapy, Williams and Wilkins, Baltimore, MD, 1-59, 1996.<br />
67. Moliterno DJ, Topol EJ: Percutaneous versus surgical coronary revascularization: A summary of the<br />
RITA, CABRI, GABI, EAST, and BARI Trials. In: Topol EJ ed. Textbook of Interventional Cardiology –<br />
Update 23. W B Saunders, Philadelphia, PA. 335-344, 1996<br />
68. Mak K-H, Topol EJ: Platelet glycoprotein IIb/IIIa inhibitors for acute coronary syndromes and<br />
percutaneous coronary intervention. In: Topol EJ ed. Textbook of Interventional Cardiology – Update 24.<br />
W B Saunders, Philadelphia, PA. 345-362, 1996<br />
69. DeFranco A, Topol EJ: Functional Testing in Patients with Previous Coronary Interventions. In: Marwick<br />
TH ed. Cardiac Stress Testing and Imaging, Churchill Livingston, New York, NY, 323-354, 1996.<br />
69A. Erickson BR, Topol EJ. Local Drug Delivery for Prevention of Restenosis. In Verstraete M ed. Vessels,<br />
Excerpta Medica, Amsterdam, the Netherlands, 2(2): 22-32, 1996.<br />
70. Topol EJ: Foreword. In Marwick TH ed. Cardiac Stress Testing and Imaging, Churchill Livingston, New<br />
York, NY, XI-XII, 1996.<br />
71. Topol EJ: Discussions throughout. In: Safian RD and Freed M ed. Tough Calls in Interventional<br />
Cardiology, Physician's Press, Birmingham, MI, 1996.<br />
72. Rogers WJ, Topol EJ. The role of angiography. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and<br />
Coronary Artery Disease. Philadelphia: Lippincott-Raven, Volume 2.:1125-1142, 1996.<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 77
73. Mousa SA, Topol EJ: Recent Advances in the Development of Platelet GPIIb/IIIa Receptor Antagonists.<br />
In Holmes D ed. Current Review of Interventional Cardiology, Current Medicine, Philadelphia, PA, 113-<br />
130, 1997.<br />
74. Erickson BR, Topol EJ: Direct Thrombin Inhibitors in Arterial Thrombosis. In Hirsh J. and Weitz J ed. New<br />
Therapeutic Agents in Thrombosis and Thrombolysis, Marcel Dekker, New York, NY. 169-189, 1997.<br />
75. Eccleston D, Topol EJ: Clinical Trials of Restenosis. In: Feuerstein, GZ, ed. Coronary Restenosis from<br />
Genestics to Therapeutics, Marcel Dekker Publishers, Inc., New York, NY, 333-381, 1997.<br />
76. Topol EJ, Mark D: Chronic Coronary Artery Disease. In: Talley JD, ed. Cost Effective Diagnosis and<br />
Treatment of Coronary Artery Disease, Williams & Wilkins Medical Publishers, Inc., Baltimore, Maryland,<br />
168-177, 1997.<br />
77. Lincoff AM, Topol EJ: Interventional Catheterization Techniques (Balloon Angioplasty, Valvuloplasty, and<br />
Related Procedures). In: Braunwald E ed. Heart Disease, 5th Edition, W.B. Saunders, Philadelphia, PA,<br />
1366-1391, 1997.<br />
78. Topol EJ: Foreword. In: Thompson P, ed. Coronary Care Manual, Churchill Livingston, London, England,<br />
XII-XIV, 1997.<br />
79. Topol EJ: Foreword. In Becker RC ed. Textbook of Coronary Thrombosis and Thrombolysis, Kluwer<br />
Academic Publishers, Norwell, Massachusetts, XV, 1997.<br />
80. Topol EJ: Clinical Cardiology: The History. In: Topol EJ, ed. Comprehensive Cardiovascular Medicine,<br />
Lippincott-Raven, Philadelphia, PA, 315-321, 1998.<br />
81. Brener S, Topol EJ: Thrombolysis for AMI: Third Generation (r-PA, n-PA, TNK, STAR, bat-PA). In Topol<br />
EJ ed. Acute Coronary Syndromes, Marcel Dekker, New York, NY, 167-192, 1998.<br />
82. Lefkovits J, Topol EJ: Advances in Anti-Platelet Therapy for Acute Cardiovascular Disease. In Topol EJ<br />
ed. Acute Coronary Syndromes, Marcel Dekker, New York, NY, 327-360, 1998.<br />
83. Migrino R, Topol EJ: Review of the GUSTO Trials (I, II and III). In Topol EJ ed. Acute Coronary<br />
Syndromes, Marcel Dekker, New York, NY, 461-500, 1998.<br />
84. Steinhhubl S, Topol EJ: Stenting for Acute Coronary Syndromes. In Topol EJ ed. Acute Coronary<br />
Syndromes, Marcel Dekker, New York, NY, 529-554, 1998.<br />
85. Kapadia SR, Topol EJ: Cardiac Trauma. In: Topol EJ ed. Comprehensive Cardiovascular Medicine,<br />
Lippincott-Raven, Philadelphia, PA,1097-1110, 1998.<br />
86. Topol EJ: Thrombolytic Therapy in Acute Myocardial Infarction. In: Agnelli G ed. Yearbook on<br />
Thrombolytic Therapy, Excerpta Medica, Amsterdam, The Netherlands, 83-120, 1998.<br />
87. Moliterno D, Topol EJ: Restenosis: Epidemiology and Treatment. In Topol EJ ed. Comprehensive<br />
Cardiovascular Medicine, Lippincott-Raven, Philadelphia, PA, 2397-2432, 1998.<br />
88. Topol EJ, Califf RM: Quality Assessment and Outcome-Effectiveness. In Topol EJ ed. Comprehensive<br />
Cardiovascular Medicine, Lippincott-Raven, Philadelphia, PA, 1259-1274, 1998.<br />
89. Topol EJ, Van de Werf F: Acute Myocardial Infarction: Early Management. In Topol EJ ed.<br />
Comprehensive Cardiovascular Medicine, Lippincott-Raven, Philadelphia, PA, 425-466, 1998.<br />
90. Moliterno D, Topol EJ: Restenosis: Epidemiology and Treatment. In Topol EJ ed. Textbook of<br />
Cardiovascular Medicine, Lippincott-Raven, Philadelphia, PA, 2065-2100, 1998.<br />
91. Topol EJ, Van de Werf F: Acute Myocardial Infarction: Early Management. In: Topol EJ, ed. Textbook of<br />
Cardiovascular Medicine, Lippincott-Raven, Philadelphia, PA, 395-435, 1998.<br />
92. Topol EJ, Califf RM: Quality of Care in Cardiovascular Medicine. In: Topol EJ, ed. Textbook of<br />
Cardiovascular Medicine, Lippincott-Raven, Philadelphia, PA, 1119-1133, 1998.<br />
93. Mayer E, Robinson K, Topol EJ. Homocysteine and Coronary Artery Disease. In: Freeman GL ed.<br />
Developments in Cardiology, W.B. Saunders, Philadelphia, PA, 1998.<br />
94. Topol EJ: Clinical Cardiology: The History. In: Topol EJ, ed. Textbook of Cardiovascular Medicine,<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 78
Lippincott-Raven, Philadelphia, PA, 285-291, 1998.<br />
95. Lefkovits J, Topol EJ. Platelet Glycoprotein IIb/IIIa. In: Topol EJ ed. Textbook of Cardiovascular Medicine<br />
Update Series, Lippincott Williams & Wilkins, Philadelphia, PA, Volume 1, No. 6, 1998.<br />
96. Van de Werf, F, Topol EJ. Acute phase treatment of myocardial infarction: selecting patients for<br />
thrombolysis. In: Verstraete M, Fuster V, Topol EJ ed. Cardiovascular Thrombosis - Thrombocardiology,<br />
2nd Edition, Lippincott-Raven, Philadelphia, PA, 471-484, 1998.<br />
97. Narins CR, Topol EJ. Angiogenesis and transmyocardial revascularization. In: Topol EJ ed. Textbook of<br />
Cardiovascular Medicine Update Series, Lippincott Williams & Wilkins, Philadelphia, PA, Volume 1, No. 3,<br />
1998.<br />
98. Lincoff AM, Topol EJ: Abrupt Vessel Closure. In: Topol EJ ed. Textbook of Interventional Cardiology, 3rd<br />
Edition, W.B. Saunders, Philadelphia, PA, 163-187, 1999.<br />
99. Topol EJ: Catheter-Based Reperfusion for Acute Myocardial Infarction. In: Topol EJ ed. Textbook of<br />
Interventional Cardiology, 3rd Edition, W.B. Saunders, Philadelphia, PA, 265-279, 1999.<br />
100. Narins CR, Topol EJ: Percutaneous Myocardial Revascularization and Angiogenesis. In: Topol EJ ed.<br />
Textbook of Interventional Cardiology, 3rd Edition, W.B. Saunders, Philadelphia, PA, 664-683, 1999.<br />
101. Topol EJ: Quality of Care in Interventional Cardiology. In: Topol EJ ed. Textbook of Interventional<br />
Cardiology, 3rd Edition, W.B. Saunders, Philadelphia, PA, 910-920, 1999.<br />
102. Thamilarasan M, Topol EJ. Thrombolysis: GUSTO-I. In: Nash IS and Fuster V ed. Efficacy of Myocardial<br />
Infarction Therapy in 1998, Marcel Dekker, Inc., New York, NY. 31-52, 1999.<br />
103. Brener S, Topol EJ. Primary Angioplasty. In: Cannon CP ed. The Management of Acute Coronary<br />
Syndromes, Humana Press, Inc., Totowa, NJ, 267-292, 1999.<br />
104. Lefkovits J, Topol EJ: Role of Platelet-Inhibitor Agents in Coronary Artery Disease. In: Topol EJ ed.<br />
Textbook of Interventional Cardiology, 3rd Edition, W.B. Saunders, Philadelphia, PA, 3-24, 1999.<br />
105. Narins CR, Topol EJ: Approach to Restenotic Lesions. In: Topol EJ ed. Textbook of Interventional<br />
Cardiology, 3rd Edition, W.B. Saunders, Philadelphia, PA, 417-432, 1999.<br />
106. Topol EJ: Thrombolytic Intervention. In: Topol EJ ed. Textbook of Interventional Cardiology, 3rd Edition,<br />
W.B. Saunders, Philadelphia, PA, 78-109, 1999.<br />
107. Topol EJ. Platelet glycoprotein IIb/IIIa inhibition in the management of acute coronary syndromes. In: E.<br />
Braunwald ed. Harrison's Online Textbook, McGraw Hill, February 10, 1999.<br />
108. Barsness GW, Ohman EM, Califf RM, Kereiakes DJ, George BS, Topol EJ.. The Thrombolysis and<br />
Angioplasty in Myocardial Infarction (TAMI) trials: A decade of reperfusion strategies. In: Timmis GC, ed.<br />
Thrombolytic Therapy. Armonk, NY, Futura Publishing Co., Inc., 195-229, 1999.<br />
109. Lincoff AM, Topol EJ. Overview of the glycoprotein IIb/IIIa inhibitor in interventional trials. In: Lincoff AM,<br />
Topol EJ, eds. Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. Totowa, NJ, Humana<br />
Press, 169-197, 1999.<br />
110. Roffi M, Topol EJ. Anticoagulant therapy in unstable angina In: Topol EJ ed. Textbook of Cardiovascular<br />
Medicine Update Series, Lippincott Williams & Wilkins, Philadelphia, PA, Vol 3(2):1-11, 2000.<br />
111. Steinhubl SR, Topol EJ. The role of oral platelet GP IIb/IIIa antagonists in the setting of percutaneous<br />
coronary intervention. In: Ellis SG and Holmes D eds. Strategic Approaches in Coronary Intervention, 2nd<br />
edition, Lippincott, Williams & Wilkins, Philadelphia, PA, 564-574, 2000.<br />
112. Lewis D, Topol EJ, Wang Q.; Ischemic Heart Disease. Nature Encyclopedia of Life <strong>Science</strong>s 10:508-515,<br />
2000. London: Nature Publishing Group. http://www.els.net/ [doi:10.1038/ngp.els.0002113]<br />
113. Topol EJ: Perspectives on Restenosis: 1997 and Beyond. In Schwartz RS ed. Restenosis 2001.<br />
114. Narins CR and Topol EJ. Angiographic versus clinical restenosis. In: Holmes DR and Serruys PW.<br />
Current Review of Interventional Cardiology, 4th Edition, Current Medicine, Philadelphia, PA, 2001.<br />
115. Rubin DN, Topol EJ. Reducing hospital length of stay for cardiovascular disease states: cost-effective<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 79
evaluation and treatment. In: Becker RC, Alpert JS eds. Cardiovascular Medicine: Practice, and<br />
Management Chapman & Hall, New York, NY, 485-500, 2001.<br />
116. Chiu AC, Topol EJ. Comparative evaluation of t-PA versus streptokinase: the GUSTO-I Trial. In:<br />
Bachmann F ed. Fibrinolytics and Antifibrinolytics, Springer-Verlag, Heidelberg, Germany, 261-286, 2001.<br />
117. L'Allier P, Topol EJ, Ellis SG. Catheter-based interventions for treatment of acute coronary syndromes.<br />
In: DeBono D and Sobel B eds. Challenges in Acute Coronary Syndromes, Blackwell <strong>Science</strong>, Malden,<br />
MA, 269-296, 2001.<br />
118. Bhatt D, Topol EJ. Embolization in acute coronary syndromes. In: Topol EJ ed. Acute Coronary<br />
Syndromes, 2nd edition, Marcel Dekker, New York, NY, 79-110, 2001.<br />
119. Robbins M, Topol EJ. Inflammation as the principal pathway to acute coronary syndromes. In: Topol EJ<br />
ed. Acute Coronary Syndromes, 2nd edition, Marcel Dekker, New York, NY, 1-31, 2001.<br />
120. Brener S, Topol EJ. Third generation thrombolytic agents. In: Topol EJ ed. Acute Coronary Syndromes,<br />
2nd edition, Marcel Dekker, New York, NY, 243-270, 2001.<br />
121. Steinhubl S, Topol EJ. Primary angioplasty and stenting in acute MI. In: Topol EJ ed. Acute Coronary<br />
Syndromes, 2nd edition, Marcel Dekker, New York, NY, 373-390, 2001.<br />
122. Topol EJ: Thrombolytic Therapy in Acute Myocardial Infarction. In: Agnelli G ed. Yearbook 2000 on<br />
Thrombolytic Therapy, Excerpta Medica, Amsterdam, The Netherlands, 2001.<br />
123. Lefkovits J, Topol EJ. Intravenous antiplatelet therapy for acute coronary syndromes. In: Topol EJ ed.<br />
Acute Coronary Syndromes, 2nd edition, Marcel Dekker, New York, NY, 419-452, 2001.<br />
124. Patel V, Topol EJ. Lessons from the GUSTO 1-4 trials. In: Topol EJ ed. Acute Coronary Syndromes, 2nd<br />
edition, Marcel Dekker, New York, NY, 725-764, 2001.<br />
125. Topol EJ. Foreword. In: Thompson PD, ed. Exercise and Sports Cardiology, McGraw-Hill, Medical Pub.<br />
Division, New York, NY, 2001.<br />
126. Bhatt DL, Topol EJ. Acute coronary syndromes. In: Topol EJ ed. Textbook of Cardiovascular Medicine<br />
Update Series, Lippincott Williams & Wilkins, Philadelphia, PA, Vol 4(2): 1-14, 2001.<br />
127. Topol EJ. Foreword. In: Rimmerman CM, Jain AK eds. Interactive Electrocardiography, CD-ROM and<br />
workbook, Lippincott Williams & Wilkins, Philadelphia, PA, 2001.<br />
128. Topol EJ. Preface. In: Boland J and Muller D eds. Cardiology and Cardiac Catheterization: the essential<br />
guide, Harwood Academic Publishers, Singapore, 2001.<br />
129. Agah R, Plow E, Topol EJ. GPIIb/IIIa antagonists. In: Michelson A ed. Platelets, Academic Press, New<br />
York, NY, 769-785, 2002.<br />
130. Tolleson TR, Topol EJ, Harrington RA. Adjunctive therapies in percutaneous coronary interventions<br />
(PCI). In: Serruys PW, Colombo A, Leon MB, Kutryk M eds. Coronary Lesions: A Pragmatic Approach,<br />
Martin Dunitz, London, England, 291-318, 2002.<br />
131. Aronow HD, Topol EJ. Antiplatelet therapy in cardiology. In: Gresele P, Page CP, Vermylen J, and Fuster<br />
V eds. Platelets in Thrombotic and non-Thrombotic Disorders, Cambridge University Press, Cambridge,<br />
UK, 2002.<br />
132. Topol EJ. History of cardiovascular medicine. In: Topol EJ ed. Textbook of Cardiovascular Medicine, 2nd<br />
edition, Lippincott Williams & Wilkins, Philadelphia, PA, 265-272, 2002.<br />
133. Topol EJ, Van de Werf F. Acute myocardial infarction: Early diagnosis and management. In: Topol EJ ed.<br />
Textbook of Cardiovascular Medicine, 2nd edition, Lippincott Williams & Wilkins, Philadelphia, PA, 385-<br />
419, 2002.<br />
134. Kapadia SR, Topol EJ. Cardiac trauma. In: Topol EJ ed. Textbook of Cardiovascular Medicine, 2nd<br />
edition, Lippincott Williams & Wilkins, Philadelphia, PA, 901-915, 2002.<br />
135. Topol EJ, Califf RM. Medical Errors and Quality of Care in Cardiovascular Medicine. In: Topol EJ, ed.<br />
Textbook of Cardiovascular Medicine, 2nd edition, Lippincott Williams & Wilkins, Philadelphia, PA, 1005-<br />
1028, 2002.<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 80
136. Bhatt DL, Topol EJ. Post-myocardial Infarction Management. In: Topol EJ ed. Textbook of<br />
Cardiovascular Medicine, 2nd edition, Lippincott Williams & Wilkins, Philadelphia, PA, 463-482, 2002.<br />
137. Moliterno DJ, Topol EJ. Restenosis: epidemiology and treatment. In: Topol EJ ed. Textbook of<br />
Cardiovascular Medicine, 2nd edition, Lippincott Williams & Wilkins, Philadelphia, PA, 1715-1750, 2002.<br />
138. Califf RM, Topol EJ. Considerations in the design and conduct of clinical studies and the interpretation of<br />
quantitative evidence. In: Topol EJ, ed. Textbook of Cardiovascular Medicine, 2nd edition, Lippincott<br />
Williams & Wilkins, Philadelphia, PA, CD-ROM only, 2002.<br />
139. Lincoff AM, Topol EJ. Overview of the glycoprotein IIb/IIIa interventional trials. In: Lincoff AM, ed. Platelet<br />
glycoprotein IIb/IIIa inhibitors in cardiovascular disease. 2nd Edition, Humana Press, Totowa, NJ, 167-<br />
199, 2003.<br />
140. Chan AW, Topol EJ. Enhanced understanding of statins: Mechanisms and indications. In: Topol EJ ed.<br />
Textbook of Cardiovascular Medicine Update Series, Lippincott Williams & Wilkins, Philadelphia, PA, Vol<br />
5(5):1-16, 2002.<br />
141. Lefkovits J, Topol EJ. Role of platelet-inhibitor agents in coronary artery disease. In: Topol EJ ed.<br />
Textbook of Interventional Cardiology, 4th Edition, Harcourt/Elsevier, Philadelphia, PA, 3-32, 2003.<br />
142. Topol EJ. Thrombolytic intervention. In: Topol EJ ed. Textbook of Interventional Cardiology, 4th Edition,<br />
Harcourt/Elsevier, Philadelphia, PA, 91-118, 2003.<br />
143. Bhatt DL, Topol EJ. Periprocedural myocardial infarction and emboli protection. In: Topol EJ ed.<br />
Textbook of Interventional Cardiology, 4th Edition, Harcourt/Elsevier, Philadelphia, PA, 251-266, 2003.<br />
144. Brener S, Topol EJ. Catheter-based reperfusion for acute myocardial infarction. In: Topol EJ ed.<br />
Textbook of Interventional Cardiology, 4th Edition, Harcourt/Elsevier, Philadelphia, PA, 285-301, 2003.<br />
145. Narins CR, Topol EJ. In-stent restenosis. In: Topol EJ ed. Textbook of Interventional Cardiology, 4th<br />
Edition, Harcourt/Elsevier, Philadelphia, PA, 455-473, 2003.<br />
146. Chew DP, Topol EJ. Stents: indications and limitations. In: Topol EJ ed. Textbook of Interventional<br />
Cardiology, 4th Edition, Harcourt/Elsevier, Philadelphia, PA, 631-647, 2003.<br />
147. Topol EJ. Quality of care in interventional cardiology. In: Topol EJ ed. Textbook of Interventional<br />
Cardiology, 4th Edition, Harcourt/Elsevier, Philadelphia, PA, 1021-1031, 2003.<br />
148. Aronow HD, Topol EJ. Detection of vulnerable plaque. In: Topol EJ ed. Textbook of Interventional<br />
Cardiology, 4th Edition, Harcourt/Elsevier, Philadelphia, PA, 1063-1087, 2003.<br />
149. Brener SJ and Topol EJ. Primary Angioplasty. In: Cannon C ed. Management of Coronary Syndromes,<br />
2nd Edition, The Humana Press, Inc., Totowa, NJ, 281-313, 2003.<br />
150. Aronow HD and Topol EJ. Identifying the vulnerable plaque and the vulnerable patient. In: Theroux P ed.<br />
Acute Coronary Syndromes: A companion to Braunwald's Heart Disease. Harcourt Health <strong>Science</strong>s, WB<br />
Saunders, Philadelphia, PA, 661-676, 2003.<br />
151. Sachar R, Topol EJ. Future perspectives in the management of ACS. In: Bhatt DL, Flather M, eds.<br />
Handbook of Acute Coronary Syndromes, Remedica Publishing, London, UK, 275-302, 2004.<br />
152. Topol EJ. Foreword. In: Savage RM and Aronson S eds. Comprehensive Textbook of Intraoperative<br />
Transesophageal Echocardiography, Lippincott Williams & Wilkins, Philadelphia, PA, 2005.<br />
153. Agah R, Topol EJ. Genetic basis of acute coronary syndromes. In: Topol EJ ed. Acute Coronary<br />
Syndromes, 3rd Edition. Marcel Dekker, New York, NY, 33-57, 2005.<br />
154. Bhatt D, Topol EJ. Embolization as a pathological mechanism. In: Topol EJ ed. Acute Coronary<br />
Syndromes, 3rd Edition. Marcel Dekker, New York, NY, 77-101, 2005.<br />
155. Gurm H, Topol EJ. Intravenous glycoprotein IIb/IIIa receptor inhibitor agents for acute coronary<br />
syndromes. In: Topol EJ ed. Acute Coronary Syndromes, 3rd Edition. Marcel Dekker, New York, NY,<br />
369-395, 2005.<br />
156. Mak K-H, Topol EJ. Diabetes in ACS. In: Topol EJ ed. Acute Coronary Syndromes, 3rd Edition. Marcel<br />
Dekker, New York, NY, 549-581, 2005.<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 81
157. Yen M, Topol EJ. The microcirculation in MI. In: Topol EJ ed. Acute Coronary Syndromes, 3rd Edition.<br />
Marcel Dekker, New York, NY, 615-633, 2005.<br />
158. McWilliams MJ, Topol EJ. Percutaneous coronary intervention in the elderly. In: Gerstenblith G ed.<br />
Cardiovascular Disease in the Elderly. Humana Press, Totowa, NJ, 159-177, 2005.<br />
159. Gurm H, Topol EJ. Definitions of acute coronary syndromes In: Fuster V, Nabel E, Topol EJ eds.<br />
Atherothrombosis and Coronary Artery Disease, 2nd Edition, Lippincott-Williams & Wilkins, Philadelphia,<br />
PA, 791-803, 2005.<br />
160. Sachar R, Topol EJ. Local gene and cell delivery devices. In: Duckers E, Nabel E, Serruys P eds.<br />
Essentials of Restenosis for the Interventional Cardiologist. Humana Press, Totowa, NJ, Chapter 27, 421-<br />
444, 2007.<br />
161. Saw J, Topol EJ. Antiplatelet therapy. In: Cho L, Schneck M eds. Cerebrovascular Disease - A Cardiac<br />
Perspective, Blackwell/Futura, Blackwood, NJ, in press, 2006.<br />
162. Vivekananthan DP, Bhatt D, Topol EJ. Glycoprotein IIb/IIIa in percutaneous coronary intervention. In:<br />
Ellis S ed. Strategic Approaches in Coronary Intervention, 3rd edition, Lippincott-Williams & Wilkins,<br />
Philadelphia, PA, in press, 2006.<br />
163. Fathi RB, Bhatt D, Topol EJ. Clopidogrel and other platelet ADP inhibitors. In: Kristensen SD, DeCaterina<br />
R, Moliterno DJ eds. Therapeutic Strategies in Thrombosis, Clinical Publishing Co., Oxford, England, in<br />
press, 2006.<br />
164. Jefferson BK, Topol EJ. Genetics in cardiovascular medicine. In: Griffin B, Rimmerman C, Topol EJ eds.<br />
Cleveland Clinic Board Review, Lippincott, Williams & Wilkins, Philadelphia, PA, in press, 2006.<br />
165. Topol EJ. Foreword. In: Schoenhagen P. ed. Atlas and Manual of Cardiovascular Multidetector<br />
Computed Tomography. Taylor & Francis, New York, in press, 2006.<br />
166. Agah R, Plow E, Topol EJ. GPIIb/IIIa antagonists. In: Michelson A ed. Platelets, 2nd Edition, Academic<br />
Press, Burlington, MA, 1145-1163, 2007.<br />
167. Topol EJ. History of cardiovascular medicine. In: Topol EJ ed. Textbook of Cardiovascular Medicine, 3rd<br />
edition, Lippincott Williams & Wilkins, Philadelphia, PA, 186-192, 2007.<br />
168. Topol EJ, Van de Werf F. Acute myocardial infarction: Early diagnosis and management. In: Topol EJ ed.<br />
Textbook of Cardiovascular Medicine, 3rd edition, Lippincott Williams & Wilkins, Philadelphia, PA, 280-<br />
302, 2007.<br />
169. Kapadia SR, Topol EJ. Cardiac trauma. In: Topol EJ ed. Textbook of Cardiovascular Medicine, 3rd<br />
edition, Lippincott Williams & Wilkins, Philadelphia, PA, 698-709, 2007.<br />
170. Califf RM, Topol EJ. Considerations in the design, conduct, and interpretation of quantitative clinical<br />
evidence. In: Topol EJ ed. Textbook of Cardiovascular Medicine, 3rd edition, Lippincott Williams &<br />
Wilkins, Philadelphia, PA, DVD chapter, 2007.<br />
171. Jefferson B, Kotte-Marchant K, Topol EJ. Platelet genomics. In: Bhatt D ed. Platelets in Cardiovascular<br />
Disease, Imperial College Press, London, UK, in press, 2007.<br />
172. Hubbard CA, Topol EJ. Genomics of myocardial infarction. In: Willard HF and Ginsburg GS eds.<br />
Handbook of Genomic Medicine, Elsevier, New York, NY, in press, 2007.<br />
173. Anwaruddin S, Topol EJ. Inflammation status. In. Topol EJ ed. Textbook of Interventional Cardiology, 5th<br />
edition, Harcourt/Elsevier, Philadelphia, PA, in press, 2007.<br />
174. Chacko M, Topol EJ. Thrombolytic intervention. In. Topol EJ ed. Textbook of Interventional Cardiology,<br />
5th edition, Harcourt/Elsevier, Philadelphia, PA, in press, 2007.<br />
175. Schork NJ, Malo N. Topol EJ Study Design and Statistical Methods in Pharmacogenomics Research:<br />
From Candidate Genes to Genome Wide Screens. Pharmacogenetics and Personalized Medicine, in<br />
press 2007. <br />
176. Damani SB, Topol EJ. The Genomics of Cardiovascular Disease. Genomic and Personalized Medicine,<br />
2nd ed, Chapter 50, Academic Press Elsevier Inc, Philadelphia, PA, in press, 2011.<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 82
Letters to the Editor<br />
1. Traill TA, Topol EJ, Fortin NJ: Hypertensive hypertrophic cardiomyopathy. New England Journal of<br />
Medicine 312:1456, 1985.<br />
2. Topol EJ, Califf RM, George BS, Kereiakes DJ, Candela RJ, Abbottsmith CW, Pitt B, Stack RS:<br />
Thrombolysis and angioplasty in acute myocardial infarction. New England Journal of Medicine 318:578,<br />
1988.<br />
3. Topol EJ: Shortening the hospital stay for myocardial infarction. New England Journal of Medicine<br />
319:1021, 1988.<br />
4. Topol EJ, Gacioch GM: Discordance in results of right coronary intervention. Circulation, 84:955, 1991.<br />
5. Califf RM, Woodlief, LH, Topol EJ: Point of view: Use of left ventricular function as prognostic factor.<br />
Circulation, 83:1452-1453, 1991.<br />
6. Ohman EM, Stack RS, Topol EJ, Califf RM: Consequences of reocclusion after successful reperfusion<br />
therapy in acute myocardial infarction. Circulation, 83:1454, 1991.<br />
7. Sane DC, Stump DC, Topol EJ, Sigmon KN, Clair WK, Kereiakes DJ, George BS, Stoddard MF, Bates<br />
ER, Stack RS, Califf RM: Profile of racial differences in thrombolytic effects of streptokinase. Circulation<br />
84:2206, 1991.<br />
8. Topol EJ: Thrombolytic therapy in acute MI: Safe during menses? Journal of Critical Illness 7:14, 1992<br />
9. Califf RM, Popma J, Topol EJ: Small trials and new therapies. Circulation 85:1636-1637, 1992.<br />
10. Topol EJ, Califf RM: Thrombolytic therapy for elderly patients. New England Journal of Medicine 327:45-<br />
47, 1992.<br />
11. Topol EJ, Ellis SG: Coronary angioplasty practice in the United States. Circulation 89:508, 1994.<br />
12. Topol EJ, Ellis SG, Califf RM. Coronary atherectomy versus angioplasty. New England Journal of<br />
Medicine 329:1892,1993.<br />
13. Topol EJ, Califf RM, Van de Werf F. Thrombolytic therapy for acute myocardial infarction: GUSTO<br />
criticized. New England Journal of Medicine 330:505-506, 1994.<br />
14. Omoigui N, Topol EJ. On-site facilities and utilization of coronary angiography after myocardial infarction.<br />
New England Journal of Medicine 330:289, 1994.<br />
15. Lee KL, Califf RM, Topol EJ. The last word on GUSTO, for now. Annals of Internal Medicine 120:970,<br />
1994.<br />
16. Topol EJ, Califf RM, Lee KL. Update on GUSTO data. New England Journal of Medicine 331:277-278,<br />
1994.<br />
17. Lee KL, Topol EJ, Califf RM. More on the GUSTO trial. Annals of Internal Medicine 121:819-820, 1994.<br />
18. Topol EJ. Coronary-stent placement compared with balloon angioplasty. New England Journal of<br />
Medicine 332:538, 1995.<br />
19. Abdelmeguid A., Topol EJ. Creatine kinase elevation with percutaneous coronary revascularization.<br />
Circulation, 93:397-398, 1996.<br />
20. Pilote L, Topol EJ. Regional variation across the United States for the management of acute myocardial<br />
infarction. The New England Journal of Medicine 334(3):194-195, 1996.<br />
21. Topol EJ, Nissen S. Our preoccupation with coronary luminology: the dissociation between clinical and<br />
angiographic findings in ischemic heart disease. Circulation 94:1142, 1996.<br />
22. Silver MJ, Topol EJ, Young JB. Amiodarone in congestive heart failure. The New England Journal of<br />
Medicine, 333:1639-41, 1995.<br />
23. Migrino RQ, Moliterno DJ, Topol EJ. Preinfarction angina. The New England Journal of Medicine 335:59-<br />
61, 1996.<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 83
24. Mak K-H, Topol EJ. Cost efficacy modeling of catheter reuse. Journal of the American College of<br />
Cardiology, 28:1640-1641, 1996.<br />
25. Langer A, Topol EJ, Wilcox RG, Armstrong PW. Non-Q wave infarction after thrombolytic therapy.<br />
Journal of the American College of Cardiology, 28:1638-1639, 1996.<br />
26. Abdelmeguid A, Topol EJ. Creatine kinase elevation with percutaneous coronary revascularization.<br />
Circulation 95:1665-66, 1997.<br />
27. van der Giessen WJ, van Beusekom HMM, Serruys PW, Lincoff AM, Ellis SG, Topol EJ, Schwartz RS,<br />
Holmes DR. Inflammatory response to coronary artery stenting. Circulation 96:2091-2093, 1997.<br />
28. Pilote L, Califf RM, Topol EJ. Use of coronary angiography and revascularization after acute MI. New<br />
England Journal of Medicine 336:1024-1025, 1997.<br />
29. Ohman EM, Califf, RM, Topol EJ. Cardiac troponins in acute coronary syndromes. New England Journal<br />
of Medicine 336:1257-1259, 1997.<br />
30. Topol EJ, Califf RM, Van de Werf F. Heparin versus hirudin for acute coronary syndromes. New England<br />
Journal of Medicine 336:730-731, 1997.<br />
31. Gent M. for the CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in<br />
patients at risk of ischemic events (CAPRIE), Lancet 349:806, 1997.<br />
32. Ohman, EM, Califf, RM, Topol EJ. Trials in myocardial infarction. (IMPACT-AMI) Circulation 96:3814-<br />
3815, 1997.<br />
33. Simes RJ, Kleiman NS, Califf RM, Topol EJ. Early mortality differences in GUSTO I: no evidence against<br />
the early hazard phenomenon. Circulation 96:3780-3781, 1997.<br />
34. Ellis SG, Topol EJ, Betriu A, Califf RM. GUSTO IIb: Direct PTCA response. New England Journal of<br />
Medicine 337:1168-1170, 1997.<br />
35. Lincoff AM, Topol EJ, Califf RM. Platelet glycoprotein IIb/IIIa receptor blockade after coronary<br />
angioplasty. New England Journal of Medicine 337:1243-1245, 1997.<br />
36. Topol EJ, Califf RM, Wilcox R. Thrombolytic therapy for myocardial infarction. New England Journal of<br />
Medicine 338:545-547, 1998.<br />
37. Narins CR, Topol EJ, Holmes Jr., DR. A call for provisional stenting. Circulation 98:2645, 1998.<br />
38. Roe MT, Bowen TE, Topol EJ. Management of non-Q-wave myocardial infarction. New England Journal<br />
of Medicine 339(19):1396-1397, 1998.<br />
39. Topol EJ, Lincoff AM, Sapp S. Coronary stenting and use of abciximab. The Lancet 352:1311-1312,<br />
1998.<br />
40. Harrington RA, Simoons ML, Topol EJ. Eptifibatide in acute coronary syndromes. New England Journal<br />
of Medicine 340:60-61, 1999.<br />
41. Topol EJ. Coronary artery stenting. New England Journal of Medicine 340:1367-68, 1999.<br />
42. Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence of TTP in stented patients treated with ticlopidine.<br />
Journal of the American Medical Association 282:1718-1719, 1999.<br />
43. Brener SB, Topol EJ, Jones AA, Cohn ED, Gainey PC, White HJ, Effron MB, Barr LA, Burchenal JEB,<br />
Katz S, George BS, Cheek HB, Moses JW, Moliterno DJ. RAPPORT Trial. Circulation 99(25):3323-24,<br />
1999.<br />
44. Berger PB, Ellis SG, Holmes Jr. DR, Granger CB, Criger DA, Betriu A, Topol EJ, Califf RM. Relationship<br />
between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute<br />
myocardial infarction. Circulation Website Vol. 102:e29-e30, 2000.<br />
45. Newby KH, Thompson T, Stebbins A, Califf RM, Topol EJ, Natale A. Sustained ventricular arrhythmias in<br />
patients receiving thrombolytic therapy. Circulation WebSite Vol. 101:e237-e238, 2000.<br />
46. Bhatt DL, Topol EJ. GP IIb/IIIa inhibitors and fibrinolysis in myocardial infarction. Journal of the American<br />
Medical Association 284:3124-25, 2000.<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 84
47. Newby LK. Bhapkar MV, Lee KL, Califf RM, Topol EJ on behalf of the SYMPHONY Investigators.<br />
Randomization in the SYMPHONY trial. The Lancet, 356:1521-22, 2000.<br />
48. Topol EJ. Conflict of Interest. The New England Journal of Medicine 344:1017, 2001.<br />
49. Steinhubl SR, Kottke-Marchant K, Moliterno DJ, Rosenthal M, Topol EJ, Lincoff AM, Coller BS.<br />
Attainment and maintenance of platelet inhibition through standard dosing of abciximab in patients<br />
undergoing percutaneous coronary intervention--Response. Circulation 102:e186, 2000.<br />
50. Chew DP, Bhatt DL, Lincoff AM, Moliterno DJ, Brener SJ, Wolski KE, Topol EJ. Optimal activated clotting<br />
time during percutaneous coronary intervention. Circulation 104:e83-e84, 2001.<br />
51. Bhatt DL, Chew DP, Topol EJ, Hirsch AT, Ringleb PA, Hacke W. Superiority of clopidogrel vs aspirin in<br />
patients with prior cardiac surgery. Circulation 104:e76, 2001.<br />
52. Chew DP, Bhatt DL, Sapp S., Topol EJ. Increased mortality with long-term platelet glycoprotein IIb/IIIa<br />
antagonists. Circulation 104:109e, 2001.<br />
53. Topol EJ. Comments on GUSTO V. The Lancet 358:1462, 2001.<br />
54. Mukherjee D, Nissen S, Topol EJ. Counterpoint on COX-2 inhibitor article. We defend our data and<br />
suggest caution. Cleveland Clinic Journal of Medicine 68:963-964, 2001.<br />
55. Mukherjee D, Nissen S, Topol EJ. Cardiovascular events and COX-2 inhibitors. Journal of the American<br />
Medical Association 286:2811-2812, 2001.<br />
56. Chew DP, Bhatt DL, Lincoff AM, Moliterno DJ, Brener SJ, Wolski KE and Topol EJ. Defining the Optimal<br />
Activated Clotting Times During Percutaneous Coronary Intervention: Aggregate Results From Six<br />
Randomized Controlled Trials. Circulation 104:124e., 2001.<br />
57. Jeremias A, Casserly I, Estess M, Smedira N, Topol EJ. Acute myocardial infarction due to coronary<br />
artery compression by an aortic root pseudoaneurysm after aortic valve replacement. American Journal<br />
of Medicine 110:417-418, 2001. [PMID 11294182]<br />
58. Lincoff AM, Topol EJ, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, Frederick B,<br />
Nakada MT. Abciximab suppresses the rise in levels of circulating inflammatory markers after<br />
percutaneous coronary revascularization. Circulation 105:E74, 2002.<br />
59. Mukherjee D, Nissen SE, Topol EJ. Lack of cardioprotective effect of naproxen. Archives of Internal<br />
Medicine 162:2637, 2002. [PMID 12456255]<br />
60. Bhatt DL, Topol EJ. The arterial inflammation hypothesis. Archives of Internal Medicine 162:2249-51,<br />
2002. [PMID 12390076]<br />
61. Aviles RJ, Topol EJ, Lauer MS. Troponin T levels in patients with ACS, with and without renal dysfunction.<br />
New England Journal of Medicine 347:1723, 2002.<br />
62. Moliterno DJ, Bertrand M, Neuman F-J, Topol EJ. TARGET 6 month follow-up. The Lancet 360:2086,<br />
2002. [PMID 12504452]<br />
63. Gibler WB, Armstrong PW, Holroyd B, Topol EJ. Response to articles 114 and 142. Annals of Emergency<br />
Medicine 40:659-660, 2003.<br />
64. Steinhubl SR, Berger PB, Mann JT, Fry ETA, DeLago A, Wilmer C, Topol EJ, for the CREDO<br />
Investigators. Clopidogrel pretreatment in the CREDO trial. Journal of the American Medical Association<br />
289:1926-27, 2003.<br />
65. Topol EJ, Kottke-Marchant K, Gum P. Aspirin resistance and its clinical relevance. Journal of the<br />
American College of Cardiology 42:1336-37, 2003. [PMID 14522509]<br />
66. Lincoff AM, Topol EJ, for the REPLACE-2 Investigators. Glycoprotein IIb/IIIa inhibition in percutaneous<br />
coronary interventions. Journal of the American Medical Association 290:1451, 2003.<br />
67. Topol EJ. Anticoagulation in pregnant patients with heart valves. Summary of the APPCR<br />
(Anticoagulation in Prosthetic Valves and Pregnancy Consensus Report) Panel. Archives of Internal<br />
Medicine 163:2251-52, 2003. [PMID 14557227]<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 85
68. Saw J, Topol EJ. Lack of adverse clopidogrel-atorvastatin clinical interaction. American Journal of<br />
Cardiology 93:669-70, 2004. [PMID 14996608]<br />
69. Vivekananthan D, Penn MS, Topol EJ. Antioxidant vitamins for prevention of cardiovascular disease. The<br />
Lancet 362:920-21, 2003.<br />
70. James SJ, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, Barnathan ES, Califf RM, Topol<br />
EJ, Simoons ML, Wallentin L. Heart-kidney interactions in ischemic syndromes. Circulation 109(5): e31-<br />
32, 2004.<br />
71. Khot UN, Khot MB, Topol EJ. Conventional risk factors in patients with CHD. Journal of the American<br />
Medical Association 291:300-301, 2004.<br />
72. Topol EJ. Natural history of aspirin resistance. Journal of the American College of Cardiology Vol<br />
43(7):1332-33, 2004.<br />
73. Wang Q, Rao S, Topol EJ. Genomewide linkage analysis. American Journal of Human Genetics 75:152-<br />
4, 2004.<br />
74. Casserly I, Topol EJ. Atherosclerosis and Alzheimer's disease. The Lancet 363:2091-92, 2004.<br />
75. Steinhubl SR, Topol EJ. Risk reduction with long-term clopidogrel following percutaneous coronary<br />
intervention. European Heart Journal 25:2169-70, 2004. [PMID 15571836]<br />
76. Topol EJ. Rofecoxib, Merck, and the FDA. New England Journal of Medicine 351:2877-78, 2004.<br />
77. Topol EJ. Arthritis medications and cardiovascular events. Journal of the American Medical Association<br />
293:1976-77, 2005.<br />
78. Wang Q, Rao S, Topol EJ. Miscues on the "lack of MEF2A mutations" in coronary artery disease.<br />
Journal of Clinical Investigation 115:1399-1401, 2005. [PMID 15931371]<br />
79. Topol EJ. Eric Topol responds. Fortune December 27, page 24, 2004.<br />
80. Saw J, Brennan D, Topol EJ, Steinhubl SR, berger PB, Kerieakes DJ, Serebruany VL. CREDO trial.<br />
Circulation 109:e230, 2004.<br />
81. Topol EJ, Blumenthal D. Physicians and investments. Journal of the American Medical Association<br />
294:1897-98, 2005.<br />
82. Topol EJ. Nesiritide--not verified. New England Journal of Medicine 353:1525-27, 2005.<br />
83. Sinnaeve PR, Simes J, Yusuf S, Garg J, Mehta S, Eikelboom J, Bittl JA, Serruys P, Topol EJ, Granger<br />
CB. Direct thrombin inhibitors in acute coronary syndromes. European Heart Journal 22:2354-55, 2005.<br />
84. Mukherjee D, Topol EJ, Moliterno DJ. Are tirofiban and abciximab identical in efficacy? European Heart<br />
Journal 27:120, 2006. [PMID 16107485]<br />
85. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann F-J, Bonizzoni E, Topol EJ,<br />
Chiariello M. Relationship between patient's risl profile and benefits in mortality from adjunctive abciximab<br />
to mechanical revascularization for ST-segment elevation myocardial infarction: A meta-regression<br />
analysis of randomized trials. Journal of the American College of Cardiology Vol 47(3):685-86, 2006.<br />
86. Topol EJ for the CHARISMA Investigators. Clopidogrel for the Prevention of Atherothrombotic Events.<br />
New England Journal of Medicine 355:420-21, 2006.<br />
87. Patay BA, Topol EJ. Is there a genetic basis for acute coronary syndrome? Nature Clinical Practice<br />
Cardiovascular Medicine Epub Sept 18 2007 [PMID 17876345]<br />
88. McCarthy JJ, Topol EJ, Validity of reported genetic risk factoirs for acute coronary syndrome. J American<br />
Medical Association 298(15):1758, 2007 [PMID 17940228]<br />
89. Suhar CJ, Hitchcock TM, Russo RJ, Topol EJ. Is computed tomographic angiography prognostic in<br />
patients with cardiac systems? Journal of the American College Cardiology 51:1510, 2008. [PMID:<br />
18402911]<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 86
Book Reviews<br />
1. Topol EJ. Acute Myocardial Infarction. Gersh B, Rahimtoola S eds. Elsevier, New York, Mayo Clinic<br />
Proceedings, 66:764, 1991.<br />
2. Topol EJ. The Spirit of Enquiry. Glaser Sholem ed., Alan Sutton Publishing Limited, UK, The Lancet<br />
347:381, 1996.<br />
3. Topol EJ. Medical Blunders. Youngson R and Schott I eds., Robinson Publishers, London, England, The<br />
Lancet 349:1403, 1997.<br />
4. Topol EJ. The dawn of risk factors. A Change of Heart: How the People of Framingham Massachusetts,<br />
Helped Unravel the Mysteries of Cardiovascular Disease. Levy D, Brink S eds. Knopf Publishers, USA,<br />
Nature Medicine 11:1043, 2005.<br />
Bibliography | Eric J. Topol, M.D. | June 2011<br />
Page 87